



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 209/12, A61K 31/395, C07D 215/14, 405/04, 413/12, 215/08, 401/12, 413/06		A1	(11) International Publication Number: WO 00/15612 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/GB99/02819			94403 Vitry Sur Seine Cedex (FR). HARRIS, Neil, Victor [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). McCARTHY, Clive [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB).
(22) International Filing Date: 26 August 1999 (26.08.99)			(74) Agent: LER CAFIN; Rhone-Poulenc Rorer Limited, Patent Department, Rainham Road South, Dagenham, Essex RM10 7xs (GB).
(30) Priority Data: 9818641,4 26 August 1998 (26.08.98) GB 60/110,098 25 November 1998 (25.11.98) US			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, IU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TI, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): RHONE-POULENC RORER LIMITED [GB/GB]; RPR House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB).			
(72) Inventors; and			
(73) Inventors/Applicants (for US only): BOURZAT, Jean-Dominique [FR/FR]; Rhône-Poulenc Rorer Recherche Développement, Centre de Recherche de Vitry-Alfortville, 13, quai Jules Guesde, BP14, F-94403 Vitry Sur Seine Cedex (FR). COMMERCON, Alain [FR/FR]; Rhône-Poulenc Rorer Recherche Développement, Centre de Recherche de Vitry-Alfortville, 13 quai Jules Guesde, BP14, F-94403 Vitry Sur Seine Cedex (FR). FILOCHE, Bruno, Jacques, Christophe [FR/FR]; Rhône-Poulenc Rorer Recherche Développement, Centre de Recherche de Vitry-Alfortville, 13 quai Jules Guesde, BP14, F-			
(54) Title: AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION			Published With international search report. With amended claims.
<p>(57) Abstract</p> <p>The invention is directed to physiologically active compounds of formula (I) wherein R¹ represents R²-Z¹, R²-L²-R⁴-Z³, R³-L³-Ar¹-L⁴-Z² or R³-L³-Ar¹-L²-R⁴-Z²; R² represents hydrogen, halogen, lower alkyl or lower alkoxy; Ar¹ represents a straight chain C₁-alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, exo, thioxo, or alkyl substituted by -ZR⁶-, -NY¹Y², -CO₂R⁵ or -C(=O)-NY¹Y²; L¹ represents a direct bond; an alkylene, alkylene, alkyne, cycloalkylene, cycloalkylene, heteroalkylene, heteroarylalkylene, heteroaryl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, -S(O)nR⁹, R¹, -C(=O)-R³, -C(=O)-OR³, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-SO₂-R⁷, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)₂]-C(=O)-NY⁴Y⁵, or by (b) alkyl substituted by an acidic functional group, or by S(O)nR⁹, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵; a -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)₂]- linkage, a -Z²-R¹²- linkage; a -C(=O)-CH₂-C(=O)- linkage; a -R¹³-Z¹-R¹²- linkage; a -C(=O)(R¹³)-[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)₂]- linkage; Z¹ is C(=O)(R¹³), C(=O) or CH(OH); Y is carboxy or an acid bioisostere, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4/β1).</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Greece	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	US	United States of America
BY	Belarus	IS	Iceland	MX	Mexico	UZ	Uzbekistan
CA	Canada	IT	Italy	NE	Niger	VN	Viet Nam
CF	Central African Republic	JP	Japan	NL	Netherlands	YU	Yugoslavia
CG	Congo	KE	Kenya	NO	Norway	ZW	Zimbabwe
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand		
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	KY	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LC	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION

This invention is directed to aza-bicycles, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states 5 capable of being modulated by the inhibition of cell adhesion.

Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localise within the extra-cellular matrix. Many of the cell-cell and cell-extracellular matrix interactions are mediated by protein ligands (e.g. fibronectin, VCAM-1 and vitronectin) 10 and their integrin receptors [e.g. $\alpha 5\beta 1$ (VLA-5), $\alpha 4\beta 1$ (VLA-4) and $\alpha V\beta 3$]. Recent studies have shown these interactions to play an important part in many physiological (e.g. embryonic development and wound healing) and pathological conditions (e.g. tumour-cell invasion and metastasis, inflammation, atherosclerosis and autoimmune disease).

15 A wide variety of proteins serve as ligands for integrin receptors. In general, the proteins recognised by integrins fall into one of three classes: extracellular matrix proteins, plasma proteins and cell surface proteins. Extracellular matrix proteins such as collagen, fibronectin, fibrinogen, laminin, thrombospondin and vitronectin bind to a number of integrins. Many of the adhesive proteins also circulate in plasma and bind to activated blood cells. Additional 20 components in plasma that are ligands for integrins include fibrinogen and factor X. Cell bound complement C3bi and several transmembrane proteins, such as Ig-like cell adhesion molecule (ICAM-1,2,3) and vascular cell adhesion molecule (VCAM-1), which are members of the Ig superfamily, also serve as cell-surface ligands for some integrins.

25 Integrins are heterodimeric cell surface receptors consisting of two subunits called α and β . There are at least fifteen different α -subunits ($\alpha 1\text{-}\alpha 9$, $\alpha\text{-L}$, $\alpha\text{-M}$, $\alpha\text{-X}$, $\alpha\text{-IIb}$, $\alpha\text{-V}$ and $\alpha\text{-E}$) and at least seven different β ($\beta 1\text{-}\beta 7$) subunits. The integrin family can be subdivided into classes based on the β subunits, which can be associated with one or more α -subunits. The most widely distributed integrins belong to the $\beta 1$ class, also known as the very late antigens (VLA). The 30 second class of integrins are leukocyte specific receptors and consist of one of three α -subunits ($\alpha\text{-L}$, $\alpha\text{-M}$ or $\alpha\text{-X}$) complexed with the $\beta 2$ protein. The cytoadhesins $\alpha\text{-IIb}\beta 3$ and $\alpha\text{-V}\beta 3$, constitute the third class of integrins.

The present invention principally relates to agents which modulate the interaction of the ligand 35 VCAM-1 with its integrin receptor $\alpha 4\beta 1$ (VLA-4), which is expressed on numerous


hematopoietic cells and established cell lines, including hematopoietic precursors, peripheral and cytotoxic T lymphocytes, B lymphocytes, monocytes, thymocytes and eosinophils.

The integrin $\alpha 4\beta 1$ mediates both cell-cell and cell-matrix interactions. Cells expressing $\alpha 4\beta 1$ 5 bind to the carboxy-terminal cell binding domain (CS-1) of the extracellular matrix protein fibronectin, to the cytokine-inducible endothelial cell surface protein VCAM-1, and to each other to promote homotypic aggregation. The expression of VCAM-1 by endothelial cells is upregulated by proinflammatory cytokines such as INF- γ , TNF- α , IL-1 β and IL-4.

10 Regulation of $\alpha 4\beta 1$ mediated cell adhesion is important in numerous physiological processes, including T-cell proliferation, B-cell localisation to germinal centres, and adhesion of activated T-cells and eosinophils to endothelial cells. Evidence for the involvement of VLA-4/VCAM-1 interaction in various disease processes such as melanoma cell division in metastasis, T-cell infiltration of synovial membranes in rheumatoid arthritis, autoimmune diabetes, colitis and 15 leukocyte penetration of the blood-brain barrier in experimental autoimmune encephalomyelitis, atherosclerosis, peripheral vascular disease, cardiovascular disease and multiple sclerosis, has been accumulated by investigating the role of the peptide CS-1 (the variable region of fibronectin to which $\alpha 4\beta 1$ binds via the sequence Leu-Asp-Val) and antibodies specific for VLA-4 or VCAM-1 in various in vitro and in vivo experimental models of inflammation. For example, in a 20 Streptococcal cell wall-induced experimental model of arthritis in rats, intravenous administration of CS-1 at the initiation of arthritis suppresses both acute and chronic inflammation (S.M.Wahl et al., J.Clin.Invest., 1994, 94, pages 655-662). In the oxazalone-sensitised model of inflammation (contact hypersensitivity response) in mice, intravenous administration of anti- $\alpha 4$ specific monoclonal antibodies significantly inhibited (50-60% 25 reduction in the ear swelling response) the efferent response (P.L.Chisholm et al. J.Immunol., 1993, 23, pages 682-688). In a sheep model of allergic bronchoconstriction, HP1/2, an anti- $\alpha 4$ monoclonal antibody given intravenously or by aerosol, blocked the late response and the development of airway hyperresponsiveness (W.M. Abramson et al. J. Clin. Invest., 1994, 93 pages 776-787).

30 We have now found a novel group of aza-bicycles which have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 ($\alpha 4\beta 1$).

Thus, in one aspect, the present invention is directed to aza-bicycles of general formula (I):-



5 wherein:-

R¹ represents:

- (i) R³.Z³;;
- (ii) R³.L².R⁴.Z³;;
- (iii) R³.L³.Ar¹.L⁴.Z³; or
- (iv) R³.L³.Ar¹.L².R⁴.Z³;;

10 R² represents hydrogen, halogen, lower alkyl or lower alkoxy;

R³ represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroaryalkyl, heteroaryalkenyl, heteroaryalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

15 R⁴ represents an alkylene chain, an alkenylene chain, or an alkynylene chain;

R⁵ represents hydrogen or lower alkyl;

R⁶ represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl or heteroaryalkyl;

R⁷ and R⁷a are each independently hydrogen or lower alkyl;

20 R⁸ represents hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaryalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R⁹ represents alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or alkyl substituted by aryl, an acidic functional group, cycloalkyl, heteroaryl, heterocycloalkyl, -S(O)_mR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵;

25 R¹⁰ represents hydrogen, R³ or alkyl substituted with alkoxy, cycloalkyl, hydroxy, mercapto, alkylthio or -NY⁴Y⁵;

R¹¹ and R¹³ are each independently selected from hydrogen or a group consisting amino acid side chains, an acidic functional group, R³, -C(=O)-R³, or -C(=O)-NY⁴Y⁵, or alkyl substituted

by an acidic functional group or by R^3 , $-NY^4Y^5$, $-NH-C(=O)-R^3$, $-C(=O)-R^4-NH_2$,

$-C(=O)-Ar^1-NH_2$, $-C(=O)-R^4-CO_2H$, or $-C(=O)-NY^4Y^5$;

or R^{10} and R^{11} or R^{10} and R^{12} together with the atoms to which they attached form a 3- to 6-membered heterocycloalkyl ring;

5 R^{12} represents C_{1-6} alkylene, optionally substituted by R^3 ;

R^{14} represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

A^1 represents a straight chain C_{1-3} alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl

10 substituted by $-ZR^6$, $-NY^1Y^2$, $-CO_2R^6$ or $-C(=O)-NY^1Y^2$;

Ar^1 represents arylene or heteroaryldiyl;

L^1 represents:

- (i) a direct bond;
- (ii) an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, $-S(O)_mR^9$, R^3 , $-C(=O)-R^3$, $-C(=O)-OR^3$, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $-[C(=O)-N(R^{10})-C(R^5)(R^{11})]_p-C(=O)-NY^4Y^5$, or by (b) alkyl substituted by an acidic functional group, or by $S(O)_mR^9$,

20 $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$;

- (iii) a $-[C(=O)-N(R^{10})-C(R^5)(R^{11})]_p$ - linkage;

- (iv) a $-Z^2-R^{12}$ - linkage;

- (v) a $-C(=O)-CH_2-C(=O)-$ linkage;

- (vi) a $-R^{12}-Z^2-R^{12}$ - linkage;

- (vii) a $-C(R^4)(R^{13})-[C(=O)-N(R^{10})-C(R^5)(R^{11})]_p$ - linkage; or

- (viii) a $-L^5-L^6-L^7$ - linkage;

L^2 represents a $-NR^5-C(=Z)-NR^5$, $-C(=Z)-NR^5$, $-C(=O)-$, $-C(=Z)-O-$, $-NR^5-C(=Z)-$, $-Z-$,

$-S(O)_m$, $-NR^5-$, $-SO_2-NR^5$, $-NR^5-SO_2-$, $-NR^5-C(=O)-O-$, $-O-C(=O)-$, or $-O-C(=O)-NR^5$.

linkage;

L^3 represents a heteroaryldiyl, $-NR^5-C(=Z)-NR^5-$, $-C(=Z)-NR^5-$, $-C(=Z)-O-$, $-NR^5-C(=Z)-$, $-Z-$, $-S(O)_m-$, $-NR^5-$, $-SO_2-NR^5-$, $-NR^5-SO_2-$, $-NR^5-C(=O)-O-$, $-O-C(=O)-$, or $-O-C(=O)-NR^5-$.

linkage;

L^4 represents a direct bond, an alkylene, alkenylene or alkynylene chain;

5 L^5 and L^7 each independently represent a direct bond or an alkylene chain;

L^6 represents a cycloalkylene or heterocycloalkylene linkage;

Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group $-NY^1Y^2$ may form a cyclic amine;

Y^4 and Y^5 are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, cycloalkenyl, cycloalkyl,

10 heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, $-NY^1Y^2$, or one or more $-CO_2R^8$ or $-C(=O)-NY^1Y^2$ groups; or the group $-NY^4Y^5$ may form a 5- to 7-membered cyclic amine which (i) may be optionally substituted with one or more substituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5-, 6- or 7-membered cyclic acetal derivative thereof), R^{10} ; (ii) may also contain a

15 further heteroatom selected from O, S, SO_2 , or NY^6 ; and (iii) may also be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system;

Y^6 represents hydrogen, alkyl, aryl, arylalkyl, $-C(=O)-R^{14}$, $-C(=O)-OR^{14}$ or $-SO_2R^{14}$;

Z is an oxygen or sulphur atom;

Z^1 is $C(R^7)(R^{7a})$, $C(=O)$ or $CH(OH)$;

20 Z^2 is O, $S(O)_n$, NR^5 , $SONR^5$, $C(=O)NR^5$ or $C(=O)$;

Z^3 is a direct bond, $C(=O)$, $OC(=O)$, $NR^5C(=O)$, or SO_2 ;

m is an integer 1 or 2;

n is zero or an integer 1 or 2;

p is zero or an integer 1 to 4; and

25 Y is carboxy (or an acid bioisostere);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs, but excluding compounds where an oxygen, nitrogen or sulphur atom is attached directly to a carbon carbon multiple bond of an alkenylene, alkynylene or cycloalkenylene residue.

30

In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (1) as hereinbefore described, which

expression includes the prodrugs, protected derivatives of compounds of formula (I) containing one or more acidic functional groups and/or amino-acid side chains, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace 5 their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above, and throughout the description of the invention, the following terms, unless 10 otherwise indicated, shall be understood to have the following meanings:-

"Patient" includes both human and other mammals.

"Acid bioisostere" means a group which has chemical and physical similarities producing 15 broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986,21,p283 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye, 1993,33,p576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995,p34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug 20 Design"; Graham, Theochem, 1995,343,p105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include: -C(=O)-NHOH, -C(=O)-CH₂OH, -C(=O)-CH₂SH, -C(=O)-NH-CN, sulpho, phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl, heteroarylsulphonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolindyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 25 3-hydroxy-1-methylpyrazolyl.

"Acidic functional group" means a group with an acidic hydrogen within it. The "protected derivatives" are those where the acidic hydrogen atom has been replaced with a suitable protecting group. For suitable protecting groups see T.W. Greene and P.G.M.Wuts in 30 "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. Exemplary acidic functional groups include carboxyl (and acid bioisosteres), hydroxy, mercapto and imidazole. Exemplary protected derivatives include esters of carboxy groups (i.e. -CO₂R¹⁴), ethers of hydroxy groups (i.e. -OR¹⁴), thioethers of mercapto groups (i.e. -SR¹⁴), and N-benzyl derivatives of imidazoles.

"Acy" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.

"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.

5 "Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. "Branched", as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-but enyl, i-but enyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

10 15 "Alkenylene" means an aliphatic bivalent radical derived from a straight or branched alkenyl group, in which the alkenyl group is as described herein. Exemplary alkenylene radicals include vinylene and propylene.

20 "Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

25 30 "Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 15 carbon atoms in the chain optionally substituted by alkoxy or by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulphinyl or lower alkylsulphonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl.

"Alkylene" means an aliphatic bivalent radical derived from a straight or branched C₁-6alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

5 "Alkyleneedioxy" means an -O-alkyl-O- group in which the alkyl group is as defined above. Exemplary alkyleneedioxy groups include methyleneedioxy and ethyleneedioxy.

"Alkylsulphiny!" means an alkyl-SO- group in which the alkyl group is as previously described. Preferred alkylsulphiny! groups are those in which the alkyl group is C₁-4alkyl.

10 "Alkylsulphony!" means an alkyl-SO₂- group in which the alkyl group is as previously described. Preferred alkylsulphony! groups are those in which the alkyl group is C₁-4alkyl.

15 "Alkylsulphonylcarbamoy!" means an alkyl-SO₂-NH-C(=O)- group in which the alkyl group is as previously described. Preferred alkylsulphonylcarbamoy! groups are those in which the alkyl group is C₁-4alkyl.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.

20 "Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

"Alkynylene" means an aliphatic bivalent radical derived from a C₂-6alkynyl group. Exemplary alkynylene radicals include ethynylene and propynylene.

30 "Amino acid side chains" means the substituent found on the carbon between the amino and carboxy groups in α -amino acids. For examples of "protected derivatives" of amino acid side chains, see T.W. Greene and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.

5

"Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a

10 cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Aryl groups may be substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxy carbonyl, alkylene dioxy, alkylsulphanyl, alkylsulphonyl, alkylthio, aroyl, arylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphanyl, arylsulphonyl, 15 arylthio, carboxy, cyano, halo, heteroaryl, heteroaryl, heteroarylalkyloxy, heteroaroylaminio, heteroarylxyloxy, hydroxy, nitro, trifluoromethyl, $Y^1Y^2N^-$, $Y^1Y^2NCO^-$, $Y^1Y^2NSO_2^-$, $Y^1Y^2N-C_2-6$ alkylene-Z⁴, (where Z⁴ is O, NR⁶ or SO_n), alkylC(=O)-Y¹N-, alkylSO₂-Y¹N- or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or $Y^1Y^2N^-$.

20 "Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred arylalkenyls contain a lower alkenyl moiety. Exemplary arylalkenyl groups include styryl and phenylallyl.

25 "Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C₁₋₄ alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl groups is as previously described. Exemplary arylalkyloxy groups include benzylxyloxy and 1- or 2-naphthalenemethoxy.

30

"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described. An exemplary arylalkyloxycarbonyl group is benzylxyocarbonyl.

35

"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.

"Arylalkynyl" means an aryl-alkynyl- group in which the aryl and alkynyl are as previously described. Exemplary arylalkynyl groups include phenylethynyl and 3-phenylbut-2-ynyl.

5 "Arylene" means an optionally substituted bivalent radical derived from an aryl group. Exemplary arylene groups include optionally substituted phenylene, naphthylene and indanylene. When Ar¹ is arylene this may particularly represent an optionally substituted phenylene. Suitable substituents include one or more "aryl group substituents" as defined above, particularly halogen, methyl or methoxy.

10 "Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include optionally substituted phenoxy and naphthoxy.

15 "Aryloxycarbonyl" means an aryl-O-C(=O)- group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxy carbonyl and naphthoxy carbonyl.

20 "Arylsulphinyl" means an aryl-SO- group in which the aryl group is as previously described. "Arylsulphonyl" means an aryl-SO₂- group in which the aryl group is as previously described.

"Arylsulphonylcarbamoyl" means an aryl-SO₂-NH-C(=O)- group in which the aryl group is as previously described.

25 "Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.

30 "Azaheteroaryl" means an aromatic carbocyclic moiety of about 5 to about 10 ring members in which one of the ring members is nitrogen and the other ring members are chosen from carbon, oxygen, sulphur, or nitrogen. Examples of azaheteroaryl groups include pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, imidazolyl, and benzimidazolyl.

"Azaheteroarylidyl" means an optionally substituted bivalent radical derived from a heteroaryl group.

"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system where one of the ring carbon atoms is replaced by nitrogen and which (i) may optionally contain an additional heteroatom selected from O, S or NY³ (where Y³ is hydrogen, alkyl, arylalkyl, and aryl) and (ii) may be fused to additional aryl or heteroaryl ring to form a bicyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline and pyridoline.

5

"Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.

10

"Cycloalkenylalkyl" means a cycloalkenyl-alkyl- group in which the cycloalkenyl and alkyl moieties are as previously described. Exemplary cycloalkenylalkyl groups include cyclopentenylmethyl, cyclohexenylmethyl or cycloheptenylmethyl.

15

"Cycloalkenylene" means a bivalent radical derived from an unsaturated monocyclic hydrocarbon of about 3 to about 10 carbon atoms by removing a hydrogen atom from each of two different carbon atoms of the ring. Exemplary cycloalkenylene radicals include cyclopentenylene and cyclohexenylene.

20

"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C₃-8cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.

25

"Cycloalkylalkenyl" means a cycloalkyl-alkenyl- group in which the cycloalkyl and alkenyl moieties are as previously described. Exemplary monocyclic cycloalkylalkenyl groups include cyclopentylvinylene and cyclohexylvinylene.

30

"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

"Cycloalkylalkynyl" means a cycloalkyl-alkynyl- group in which the cycloalkyl and alkynyl moieties are as previously described. Exemplary monocyclic cycloalkylalkynyl groups include cyclopropylethynyl, cyclopentylethynyl and cyclohexylethynyl.

"Cycloalkylene" means a bivalent radical derived from a saturated monocyclic hydrocarbon of about 3 to about 10 carbon atoms by removing a hydrogen atom from each of two different carbon atoms of the ring. Exemplary cycloalkylene radicals include cyclopentylene and cyclohexylene.

5

"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.

"Heteroaroyl" means a heteroaryl-C(=O)- group in which the heteroaryl group is as described herein. Exemplary groups include pyridylcarbonyl.

10

"Heteroaroylamino" means a heteroaryl-NH- group in which the heteroaryl moiety are as previously described.

"Heteroaryl" as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur (examples of such groups include benzimidazolyl, benzthiazolyl, furyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, 20 thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above); (ii) an optionally substituted partially saturated multicyclic heterocarboecyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure (examples of such groups include pyridanyl groups). Optional substituents include one or more "aryl group substituents" as defined above. When R¹ or L¹ contains an 25 optionally substituted heteroaryl group this may particularly represent an optionally substituted "azaheteroaryl" group.

"Heteroarylalkenyl" means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl moieties are as previously described. Preferred heteroarylalkenyl groups contain a lower 30 alkenyl moiety. Exemplary heteroarylalkenyl groups include pyridylethenyl and pyridylallyl.

"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C₁₋₄alkyl moiety.

Exemplary heteroarylalkyl groups include pyridylmethyl.

"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.

5 "Heteroarylalkynyl" means a heteroaryl-alkynyl- group in which the heteroaryl and alkynyl moieties are as previously described. Exemplary heteroarylalkenyl groups include pyridylethynyl and 3-pyridylbut-2-ynyl.

10 "Heteroaryldiyi" means a bivalent radical derived from an aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur, and optionally substituted by one or more "aryl group substituents" as defined above. When Ar¹ is an 15 optionally substituted heteroaryldiyi group this may particularly represent an optionally substituted "azaheteroaryldiyi" group.

15 "Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

20 "Heteroarylsulphonylcarbamoyl" means a heteroaryl-SO₂-NH-C(=O)- group in which the heteroaryl group is as previously described.

25 "Heterocycloalkyl" means: (i) a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from O, S or NY³ and which may optionally be substituted by oxo; (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl ring) and a heterocycloalkyl group are fused together to form a 30 cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).

35 "Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

40 "Heterocycloalkylene" means a bivalent radical derived from a saturated monocyclic hydrocarbon of about 5 to about 7 atoms, which contains one or more heteroatoms selected from O, S or NY³ and is optionally substituted by oxo, by removing a hydrogen atom from each of two 45 different carbon atoms of the ring, or when NY³ is NH by removing a hydrogen atom from one

carbon atom of the ring and a hydrogen atom from the NH, or when the ring contains two N^{Y^3} heteroatoms and N^{Y^3} is NH by removing a hydrogen atom from both nitrogen atoms. When L^1 is a heterocycloalkylene group this may particularly represent a bivalent radical derived pyrrolidine, especially 3,4-pyrrolidinediyl.

5

"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (I), including N-oxides thereof. For example an ester of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively an ester of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.

10

Suitable esters of compounds of formula (I) containing a hydroxy group, are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- β -hydroxynaphthoates, gentisates, isethionates, 15 di-p-toluoyletartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.

Suitable esters of compounds of formula (I) containing a carboxy group, are for example those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.

20

Suitable esters of compounds of formula (I) containing both a carboxy group and a hydroxy group within the moiety $\text{-L}^1\text{-Y}$, include lactones, formed by loss of water between said carboxy and hydroxy groups. Examples of lactones include caprolactones and butyrolactones.

25

An especially useful class of esters of compounds of formula (I) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et al., J. Med. Chem., 1989, 32, page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

Where the compound of the invention contains a carboxy group, or a sufficiently acidic

35

bioisostere, base addition salts may be formed and are simply a more convenient form for use;

and in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory

5 effects inherent in the free base are not vitiated by side effects ascribable to the cations.

Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-

10 glucamine, lysine, arginine, ornithine, choline,

N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine,

N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

15 Some of the compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid

20 addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as

25 sources of the free base form even if the particular salt, *per se*, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g.

30 hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulphonates, ethanesulphonates, benzencsulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.

As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

5

With reference to formula (I) above, the following are particular and preferred groupings:

R¹ may particularly represent a group R³-Z³, in which Z³ is as defined above, especially C(=O), and R³ is as defined above, especially (i) optionally substituted aryl, such as optionally substituted phenyl [preferred optional substituents include aryloxy, cyano, halo (e.g. chloro or fluoro), lower alkoxy (e.g. methoxy), lower alkyl (e.g. methyl), nitro and perfluoroloweralkyl (e.g. trifluoromethyl)], (ii) optionally substituted heteroaryl, such as isoquinolinyl, isoxazolyl, pyrazolopyrimidinyl, pyridyl, pyrimidinyl, quinolinyl, thiazolyl and triazolyl, each optionally substituted by one or more aryl group substituents as described hereinbefore [preferred optional substituents include alkyl-C(=O)-, aryl, cyano, halo, (e.g. chloro or fluoro), lower alkoxy (e.g. methoxy), lower alkyl (e.g. methyl), lower alkylsulphonyl, lower alkylthio, nitro and perfluoroloweralkyl (e.g. trifluoromethyl)] or (iii) optionally substituted arylalkyl in which the aryl group is optionally substituted by one, or preferably two aryl group substituents (preferred optional substituents include halo, hydroxy and methoxy). R¹ may particularly represent a group R³-C(=O)- in which R³ is a substituted aryl selected from 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl, 2-phenoxyphenyl or an optionally substituted heteroaryl selected from quinolin-4-yl, isoquinolin-2-yl, 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 4-trifluoromethylpyridin-3-yl, 2-phenyl-4-methyl-1,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl, 4-trifluoromethylpyrimidin-5-yl, 4-hydroxybenzyl, 3-chloro-4-hydroxybenzyl, 3-fluoro-4-hydroxybenzyl, and 4-hydroxy-3-methoxybenzyl.


R¹ may also particularly represent a group R³-L³-Ar¹-L⁴-Z³, in which Z³ is as defined above, especially C(=O); L⁴ represents a straight or branched C₁-6alkylene chain, more particularly a straight C₁-4alkylene chain such as methylene or ethylene, preferably methylene; Ar¹ is an optionally substituted phenylene, such as optionally substituted m- or p-phenylene, preferably optionally substituted p-phenylene, more preferably a 3-substituted p-phenylene, in which the

substituent is *ortho* to the R^3 - L^3 - group, (preferred optional substituents include halo, C_1 -*alkyl*, C_1 -*alkoxy*, C_1 -*alkylthio*, C_1 -*alkylsulphiny*l and C_1 -*alkylsulphony*l, especially chloro, methyl, methoxy, methylthio, methylsulphiny and methylsulphonyl), or Ar^1 is an optionally substituted heteroaryl diyl, such as optionally substituted azaheteroaryl diyl, (e.g.

5 optionally substituted pyridinediyl, preferably a *p*-pyridinediyl), where the optional substituents include C_1 -*alkyl* and C_1 -*alkoxy*, especially methyl and methoxy, more preferably a pyridine-2,5-diyl, in which the R^3 - L^3 - group is adjacent to the pyridyl nitrogen atom, and which is substituted in the 4- or 6-position with a methyl or methoxy group; L^3 represents a $-NH-C(=O)-NH-$ linkage; and R^3 is as defined above, particularly an optionally substituted aryl group (such as optionally substituted phenyl) or an optionally substituted heteroaryl (such as optionally substituted pyridyl), and is preferably 2- or 3-methyl(or methoxy)phenyl, more preferably 2-methylphenyl, or 3-methyl-2-pyridyl.

10


Ar^1 may also particularly represent a group R^3 - L^3 - Ar^1 - L^4 - Z^3 - in which: Z^3 is as defined above, especially $C(=O)$; L^4 represents a straight or branched C_1 -*alkylene* chain, more particularly a straight C_1 -*alkylene* chain such as methylene or ethylene, preferably methylene; Ar^1 is an 8 to

10 membered bicyclic system  in which (i) ring  is a 5 or 6 membered

optionally substituted heterocycle, preferably a 5 membered heteroaryl ring, (ii) ring  is

a 5 or 6 membered optionally substituted heterocycle or an optionally substituted benzene ring, preferably a benzene ring, (iii) each ring is optionally substituted by one or more "aryl group substituents" as defined above, (iv) the two rings are joined together by a carbon-carbon linkage

20

or a carbon-nitrogen linkage, and  is preferably optionally substituted

benzoxazolyl or optionally substituted benzimidazolyl, each [more particularly ring ]

optionally substituted by one or more "aryl group substituents" as defined above [examples of particular aryl group substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), amino, halogen, hydroxy, lower alkylthio, lower alkylsulphiny, lower alkylsulphonyl, nitro or trifluoromethyl]; L^3 represents NR^5 , especially NH ; and R^3 is as defined above, particularly

25

optionally substituted aryl, such as a 2-substituted phenyl, [examples of particular aryl group substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), halo (e.g. fluoro or chloro) and $Y^1Y^2N^-$ (e.g. dimethylamino)], and is preferably 2-methylphenyl.

5 R^1 may also particularly represent a group $R^3-L^3-Ar^1-L^4-Z^3$, in which: Z^3 is as defined above, especially $C(=O)$; L^4 represents a straight or branched C_{1-6} alkylene chain, more particularly a straight C_{1-4} alkylene chain such as methylene or ethylene, preferably methylene; Ar^1 is an optionally substituted phenylene, such as optionally substituted m- or p-phenylene, preferably optionally substituted p-phenylene, more preferably a 3-substituted p-phenylene, in which the 10 substituent is ortho to the R^3-L^3 - group, (preferred optional substituents include chloro, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulphanyl and C_{1-4} alkylsulphonyl, especially chloro, methyl, methoxy, methylthio, methylsulphanyl and methylsulphonyl), or Ar^1 is an optionally substituted heteroarylidiyl, such as optionally substituted azaheteroarylidiyl, (e.g. optionally substituted pyridinediyl, preferably a p-pyridinediyl), where the optional substituents 15 include C_{1-4} alkyl and C_{1-4} alkoxy, especially methyl and methoxy, more preferably a pyridine-2,5-diyl, in which the R^3-L^3 - group is adjacent to the pyridyl nitrogen atom, and which is substituted in the 4- or 6-position with a methyl or methoxy group; L^3 represents $-C(=O)-NH-$ and R^3 is heterocycloalkyl, more particularly a bicyclic amine containing 9-10 atoms, especially indolinyl.

20

R^2 may particularly represent hydrogen.

R^2 may also particularly represent lower alkyl, (e.g. methyl).

25 R^2 may also particularly represent lower alkoxy (e.g. methoxy).

A^1 may particularly represent an unsubstituted straight chain C_{1-3} alkylene linkage, i.e. methylene, ethylene and trimethylene, especially methylene or ethylene.

30 Z^1 may particularly represent $C(R^7)(R^{7a})$, especially where R^7 and R^{7a} are both hydrogen.

L^1 may particularly represent an optionally substituted alkylene linkage, especially optionally substituted ethylene or propylene, preferably optionally substituted ethylene. Preferred optional substituents include lower alkyl, aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ and $-(C(=O)-N(R^{10})-C(R^5)(R^{11}))_p-C(=O)-NY^4Y^5$

5 or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$.

In one preferred embodiment L^1 is a group  [where R^5 is hydrogen or lower alkyl (e.g. methyl) and R^{15} represents hydrogen or lower alkyl, or where R^5 is hydrogen and R^{15} represents aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $-(C(=O)-N(R^{10})-C(R^5)(R^{11}))_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$, and is more preferably a group

10 $-(CH_2-CH_2-)$, particularly  [where R^{15} represents hydrogen, lower alkyl, aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$ or $-NY^4Y^5$ or alkyl substituted by carboxy, $-OH$, $-OR^3$ or $-C(=O)-NY^4Y^5$]. In another preferred embodiment L^1 is

a group  [where R^5 is hydrogen or lower alkyl (e.g. methyl) and R^{15a} represents

15 lower alkyl, or where R^5 is hydrogen and R^{15a} represents aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $-(C(=O)-N(R^{10})-C(R^5)(R^{11}))_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$, and is more preferably a group  [where R^{15a} represents $-N(R^8)-C(=O)-R^9$, or $-N(R^8)-SO_2-R^9$].

20

L^1 may also particularly represent an unsubstituted alkenylene linkage, especially vinylene.


L^1 may also particularly represent a $-Z^2-R^{12}-$ linkage, such as $-O-CH_2-$, $-S(O)_n-CH_2-$, $-S(O)_n-CH_2-CH_2-$, or especially $-NH-CH_2-$.

L¹ may also particularly represent a -L⁵.L⁶.L⁷- linkage, in which (i) L⁵ and L⁷ are both a direct bond and L⁶ is optionally substituted heterocyloalkylene, such as pyrrolidinyl, especially 3,4-pyrrolidinyl, or cycloalkylene, such as cyclopentyl, (ii) L⁵ is alkylene, such as methylene, L⁶ is 5 is cycloalkylene, such as cyclopentyl, and L⁷ is a direct bond, or (iii) L⁵ is a direct bond, L⁶ is cycloalkylene, such as cyclopentyl, and L⁷ is alkylene, such as methylene.

Y may particularly represent carboxy.

10 It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

A particular group of compounds of the invention are compounds of formula (Ix):-



wherein:-

R¹ represents a group selected from :

(i)	R ³ .
20	(ii) R ³ .L ² .R ⁴ .
	(iii) R ³ .L ³ .Ar ¹ .L ⁴ .
	(iv) R ³ .L ³ .Ar ¹ .L ² .R ⁴ .

[where:

25 R³ is alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

L² represents a -NR⁵.C(=Z)-NR⁵-, -C(=Z)-NR⁵-, -C(=O)-, -C(=Z)-O-, -NR⁵.C(=Z)-, -Z-, -SO-, -SO₂-, -NR⁵-.SO₂-, -NR⁵-.SO₂-, -NR⁵.C(=O)-O-, -O-C(=O)-, or -O-C(=O)-NR⁵- linkage;

L^3 represents a heteroaryldiyl, heterocycloalkylene, $-NR^5-C(=Z)-NR^5-$, $-C(=Z)-NR^5-$, $-C(=Z)-O-$, $-NR^5-C(=Z)-$, $-Z-$, $-SO-$, $-SO_2-$, $-NR^5-$, $-SO_2-NR^5-$, $-NR^5-SO_2-$, $-NR^5-C(=O)-O-$, $-O-C(=O)-$, or $-O-C(=O)-NR^5-$ linkage;

L^4 is a direct bond, an alkylene, alkenylene or alkynylene chain, or a $-L^5-NR^5-$ linkage;

5 L^5 is a direct bond or an alkylene chain;

R^4 is an alkylene chain, an alkenylene chain, or an alkynylene chain;

R^5 is hydrogen or lower alkyl;

Ar^1 is phenylene or heteroaryldiyl; and

Z represents an oxygen or sulphur atom;

10 but excluding compounds where an oxygen, nitrogen or sulphur atom is attached directly to a carbon carbon multiple bond of an alkenylene or alkynylene residue];

R^2 represents hydrogen, halogen, lower alkyl or lower alkoxy;

A^1 represents a straight chain $C_{1.3}$ alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by $-ZR^6$, $-NY^1Y^2$, $-CO_2R^6$ or $-C(=O)-NY^1Y^2$ [where: R^6 is hydrogen, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl or heteroarylalkyl; and Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group $-NY^1Y^2$ may form a heterocycloalkyl group];

Z^1 represents $C(R^7)(R^{7a})$ or $C(=O)$ {where R^7 and R^{7a} are each independently hydrogen or

20 lower alkyl};

L^1 represents:

- (i) a direct bond;
- (ii) an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group (or corresponding protected derivative), R^3 , $-C(=O)-R^3$, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-[C(=O)-N(R^{10})-C(R^5)(R^{11})]_p-C(=O)-NY^4Y^5$ or $-NY^4Y^5$, or by (b) alkyl substituted by an acidic functional group (or corresponding protected derivative), or by $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$;
- 25 (iii) a $-[C(=O)-N(R^{10})-C(R^5)(R^{11})]_p-$ linkage;
- (iv) a $-Z^2-R^{12}-$ linkage;

- (v) a -C(=O)-CH₂-C(=O)- linkage;
- (vi) a -R¹²-Z²-R¹²- linkage; or
- (vii) a -C(R⁴)(R¹³)-[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p- linkage;

{in which

- 5 R⁸ is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
- R⁹ is alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or alkyl substituted by aryl, an acidic functional group (or corresponding protected derivative), cycloalkyl, heteroaryl, heterocycloalkyl, -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵;
- 10 R¹⁰ is hydrogen, R³ or alkyl substituted with alkoxy, cycloalkyl, hydroxy, mercapto, alkylthio or -NY⁴Y⁵;
- R¹¹ and R¹³ are each independently selected from hydrogen or a group consisting amino acid side chains and corresponding protected derivatives, an acidic functional group (or corresponding protected derivative), R³, -C(=O)-R³, or -C(=O)-NY⁴Y⁵, or alkyl substituted by an acidic functional group (or corresponding protected derivative) or by R³, -NY⁴Y⁵, -NHC(=O)-R³, -C(=O)-R⁴-NH₂, -C(=O)-Ar¹-NH₂, -C(=O)-R⁴-CO₂H, or -C(=O)-NY⁴Y⁵;
- 15 or R¹⁰ and R¹¹ or R¹⁰ and R¹² together with the atoms to which they attached form a 3- to 6-membered heterocycloalkyl ring;
- R¹² is C₁-6alkylene, optionally substituted by R³;
- 20 Y⁴ and Y⁵ are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, -NY¹Y², or one or more -CO₂R⁷ or -C(=O)-NY¹Y² groups; or the group -NY⁴Y⁵ may form a 5- to 7-membered cyclic amine which (i) may be optionally substituted with one or more substituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5-, 6- or 7-membered cyclic acetal derivative thereof), R¹⁰; (ii) may also contain a further heteroatom selected from O, S, SO₂, or NY⁶ [where Y⁶ is hydrogen, alkyl, aryl, arylalkyl, -C(=O)-R¹⁴, -C(=O)-OR¹⁴ or -SO₂R¹⁴ (in which R¹⁴ is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl)]; and (iii) may also be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system;
- 25 Z² is O, S(O)_n, NR⁵, SONR⁵, C(=O)NR⁵ or C(=O); and


p is zero or an integer 1 to 4}; and

Y is carboxy (or an acid bioisostere) or -C(=O)-N(Y⁴Y⁵);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

5

Another particular group of compounds of the invention are compounds of formula (Ia):-



10

in which R², R³, A¹, Ar¹, L¹, L⁴, Y and Z¹ are as hereinbefore defined, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

15 Compounds of formula (Ia) in which R³ represents an optionally substituted aryl group, particularly an optionally substituted phenyl group, such as a 2-substituted phenyl, especially 2-methylphenyl, are preferred.

20 Compounds of formula (Ia) in which R³ represents an optionally substituted heteroaryl group, particularly an optionally substituted pyridyl, such as optionally substituted 2-pyridyl, especially 3-methyl-2-pyridyl, are also preferred.

25 Compounds of formula (Ia) in which Ar¹ represents an optionally substituted phenylene, especially optionally substituted m- or p-phenylene, more especially optionally substituted p-phenylene, are preferred. Compounds of formula (Ia) in which Ar¹ represents 3-substituted p-phenylene, in which the substituent is ortho to the R³-NH-C(=O)-NH- group, are particularly preferred. Preferred optional substituents include halo, C₁-4alkyl, C₁-4alkoxy, C₁-4alkylthio, C₁-4alkylsulphanyl and C₁-4alkylsulphonyl, especially chloro, methyl, methoxy, methylthio, methylsulphanyl and methylsulphonyl.

30

Compounds of formula (Ia) in which Ar¹ is an optionally substituted heteroaryldiyl, such as optionally substituted pyridinediyl, particularly a p-pyridinediyl, more particularly a pyridine-2,5-diyl, in which the R³-NH-C(=O)-NH- group is adjacent to the pyridyl nitrogen atom, and which is substituted in the 4- or 6-position, are also preferred. Preferred optional substituents include C₁₋₄alkyl and C₁₋₄alkoxy, especially methyl and methoxy.

5 Compounds of formula (Ia) in which L⁴ represents a straight or branched C₁₋₆alkylene chain, more particularly a straight C₁₋₄alkylene chain such as methylene or ethylene, especially methylene, are preferred.

10

Compounds of formula (Ia) in which A¹ represents methylene are preferred.

Compounds of formula (Ia) in which A¹ represents ethylene are also preferred.

15 Compounds of formula (Ia) in which Z¹ represents CH₂ are preferred.

Compounds of formula (Ia) in which R² represents hydrogen are preferred.

Compounds of formula (Ia) in which L¹ represents an optionally substituted alkylene linkage, 20 particularly optionally substituted ethylene or optionally substituted propylene, especially ethylene optionally substituted with lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵,

are preferred. In one preferred embodiment L¹ is a group  [where R⁵ is

25 hydrogen or lower alkyl (e.g. methyl) and R¹⁵ represents hydrogen or lower alkyl, or where R⁵ is hydrogen and R¹⁵ represents aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵], and is more

preferably a group $\begin{array}{c} \text{CH}-\text{CH}_2- \\ | \\ \text{R}^{15} \end{array}$, particularly $\begin{array}{c} \text{CH}-\text{CH}_2- \\ | \\ \text{R}^{15} \end{array}$ [where R^{15} represents hydrogen, lower alkyl, aryl, heteroaryl, $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-R}^9$, $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-OR}^9$, $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$ or $-\text{NY}^4\text{Y}^5$ or alkyl substituted by carboxy, $-\text{OH}$, $-\text{OR}^3$ or $-\text{C}(=\text{O})\text{-NY}^4\text{Y}^5$]. In another preferred embodiment L^1 is a group $\begin{array}{c} \text{R}^5 \\ | \\ \text{CH}_2-\text{C}- \\ | \\ \text{R}^{15a} \end{array}$ [where R^5 is hydrogen or lower alkyl (e.g. methyl) and R^{15a} represents lower alkyl, or where R^5 is hydrogen and R^{15a} represents aryl, heteroaryl, $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-R}^9$, $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-OR}^9$, $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$, $-\text{NY}^4\text{Y}^5$ or $-\text{[C}(=\text{O})\text{-N}(\text{R}^{10})\text{-C}(\text{R}^5)(\text{R}^{11})\text{]p-C}(=\text{O})\text{-NY}^4\text{Y}^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-\text{ZH}$, $-\text{ZR}^3$, $-\text{C}(=\text{O})\text{-NY}^4\text{Y}^5$ or $-\text{NY}^4\text{Y}^5$], and is more preferably a group $\begin{array}{c} \text{CH}_2-\text{CH}- \\ | \\ \text{R}^{15a} \end{array}$, particularly $\begin{array}{c} \text{CH}_2-\text{CH}- \\ | \\ \text{R}^{15a} \end{array}$ [where R^{15a} represents $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-R}^9$, or $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$].

Compounds of formula (Ia) in which Y represents carboxy are preferred.

A preferred group of compounds of the invention are compounds of formula (Ia) in which: R^2 is hydrogen; R^3 is a 2-substituted phenyl [especially 2-methyl(or methoxy)phenyl]; A^1 is methylene or ethylene; Ar^1 is optionally substituted m- or p-phenylene (especially 3-chloro-p-phenylene, 3-methyl-p-phenylene, 3-methoxy-p-phenylene, 3-methylthio-p-phenylene, 3-methylsulphonyl-p-phenylene and 3-methylsulphonyl-p-phenylene) or optionally substituted p-pyridinediyl [especially 4(or 6)-methyl(or methoxy)-p-pyridine-2,5-diyl]; L^1 is a $\begin{array}{c} \text{CH}-\text{CH}_2- \\ | \\ \text{R}^{15} \end{array}$ group particularly a $\begin{array}{c} \text{CH}-\text{CH}_2- \\ | \\ \text{R}^{15} \end{array}$ group, where R^{15} represents hydrogen, lower alkyl, aryl, heteroaryl, $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-R}^9$, $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-OR}^9$, $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$ or $-\text{NY}^4\text{Y}^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-\text{OH}$, $-\text{OR}^3$, $-\text{C}(=\text{O})\text{-NY}^4\text{Y}^5$; L^4 represents a straight or branched C_{1-6} alkylene chain, especially methylene; Y represents carboxy; and Z^1


represents CH_2 ; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Another preferred group of compounds of the invention are compounds of formula (Ia) in

5 which:- R^2 is hydrogen; R^3 is a 2-substituted phenyl [especially 2-methyl(or methoxy)phenyl]; A^1 is methylene or ethylene; Ar^1 is optionally substituted m- or p-phenylene (especially 3-chloro-p-phenylene, 3-methyl-p-phenylene, 3-methoxy-p-phenylene, 3-methylthio-p-phenylene, 3-methylsulphonyl-p-phenylene and 3-methylsulphonyl-p-phenylene) or optionally substituted p-pyridinediyl [especially 4(or 6)-methyl(or methoxy)-p-pyridine-2,5-diyl]; L^1 is

10 a $\text{—CH}_2\text{—CH—}$ group, particularly $\text{—CH}_2\text{—CH—}$ [where R^{15a} represents $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—R}^9$, or $\text{—N}(\text{R}^8)\text{—SO}_2\text{—R}^9$]; L^4 represents a straight or branched C_{1-6} alkylene chain, especially methylene; Y represents carboxy; and Z^1 represents CH_2 ; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

15 Another particular group of compounds of the invention are compounds of formula (Ib):-



(Ib)

20 in which R^2 , R^3 , A^1 , L^2 , Y and Z^1 are as hereinbefore defined, X is NR^5 or O , Z^4 represents a direct bond, NR^5 , O or $\text{S}(\text{O})_n$ (where R^5 and n are as hereinbefore defined), and R is hydrogen or an aryl group substituent, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Compounds of formula (Ib) in which R^3 represents optionally substituted aryl, especially 2-substituted phenyl, are preferred. Preferred optional substituents include lower alkyl (e.g.

methyl), lower alkoxy (e.g. methoxy), halo (e.g. fluoro or chloro) and $Y^1Y^2N^-$ (e.g. dimethylamino). R^3 especially represents ortho-tolyl.

Compounds of formula (Ib) in which Z^4 represents NH are preferred.

5

Compounds of formula (Ib) in which R represents hydrogen, halo (e.g. chloro), lower alkyl (e.g. methyl or ethyl) or lower alkoxy (e.g. methoxy) are preferred.

Compounds of formula (Ib) in which L^4 represents a straight or branched C_{1-6} alkylene chain, 10 especially a straight or branched C_{1-4} alkylene chain, more especially methylene, are preferred.

Compounds of formula (Ib) in which A^1 represents methylene are preferred.

Compounds of formula (Ib) in which A^1 represents ethylene are also preferred.

15

Compounds of formula (Ib) in which Z^1 represents CH_2 are preferred.

Compounds of formula (Ib) in which R^2 represents hydrogen are preferred.


20 Compounds of formula (Ib) in which L^1 represents an optionally substituted alkylene linkage, particularly optionally substituted ethylene or optionally substituted propylene, especially ethylene optionally substituted with lower alkyl, aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $-(C(=O)-N(R^{10})-C(R^5)(R^{11})_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$,

25 are preferred. In one preferred embodiment L^1 is a group  [where R^5 is

hydrogen or lower alkyl (e.g. methyl) and R^{15} represents hydrogen or lower alkyl, or where R^5 is hydrogen and R^{15} represents aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $-(C(=O)-N(R^{10})-C(R^5)(R^{11})_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$, and is more

preferably a group $\text{—CH}_2\text{—CH}_2\text{—}$, particularly $\text{—CH}_2\text{—CH}_2\text{—}$ [where R^{15} represents hydrogen, lower alkyl, aryl, heteroaryl, $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—R}^9$, $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—OR}^9$, $\text{—N}(\text{R}^8)\text{—SO}_2\text{—R}^9$ or $\text{—NY}^4\text{Y}^5$ or alkyl substituted by carboxy, —OH , —OR^3 or $\text{—C}(=\text{O})\text{—NY}^4\text{Y}^5$]. In another preferred embodiment L^1 is a group $\text{—CH}_2\text{—C}^{\text{R}}\text{—}$ [where R^5 is hydrogen or lower alkyl (e.g. methyl) and R^{15a} represents lower alkyl, or where R^5 is hydrogen and R^{15a} represents aryl, heteroaryl, $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—R}^9$, $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—OR}^9$, $\text{—N}(\text{R}^8)\text{—SO}_2\text{—R}^9$, $\text{—NY}^4\text{Y}^5$ or $\text{[C}(=\text{O})\text{—N}(\text{R}^{10})\text{—C}(\text{R}^5)\text{—C}(\text{R}^{11})\text{]}_p\text{—C}(=\text{O})\text{—NY}^4\text{Y}^5$, or alkyl substituted by carboxy (or an acid bioisostere), —ZH , —ZR^3 , $\text{—C}(=\text{O})\text{—NY}^4\text{Y}^5$ or $\text{—NY}^4\text{Y}^5$], and is more preferably a group $\text{—CH}_2\text{—CH}_2\text{—}$, particularly $\text{—CH}_2\text{—CH}_2\text{—}$ [where R^{15a} represents $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—R}^9$, or $\text{—N}(\text{R}^8)\text{—SO}_2\text{—R}^9$].

Compounds of formula (Ib) in which Y represents carboxy are preferred.



15 A preferred group of compounds of the invention are compounds of formula (Ib) in which: R is


hydrogen, chloro, methyl, ethyl or methoxy; R^2 is hydrogen; R^3 is optionally substituted aryl

(especially ortho-tolyl); A^1 is methylene or ethylene; L^1 is a $\text{—CH}_2\text{—CH}_2\text{—}$ group particularly

20 a $\text{—CH}_2\text{—CH}_2\text{—}$ group, where R^{15} represents hydrogen, lower alkyl, aryl, heteroaryl,

$\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—R}^9$, $\text{—N}(\text{R}^8)\text{—C}(=\text{O})\text{—OR}^9$, $\text{—N}(\text{R}^8)\text{—SO}_2\text{—R}^9$ or $\text{—NY}^4\text{Y}^5$, or alkyl substituted by

carboxy (or an acid bioisostere), -OH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵; L⁴ is a straight or branched C₁₋₄alkylene chain, especially methylene; X is O; Y is carboxy; Z¹ is CH₂; Z⁴ is NH;



and the group $\text{---L}^4\text{---C(=O)}$ is attached at the ring 6 position; and the

corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates 5 (e.g. hydrates) of such compounds and their N-oxides and prodrugs.


Another preferred group of compounds of the invention are compounds of formula (Ib) in which:- R is hydrogen, chloro, methyl, ethyl or methoxy; R² is hydrogen; R³ is optionally substituted aryl (especially ortho-tolyl); A¹ is methylene or ethylene; L¹ is a $\text{---CH}_2\text{---CH---}$

R^{15a}

10 group, particularly $\text{---CH}_2\text{---CH---}$ [where R^{15a} represents -N(R⁸)-C(=O)-R⁹, or

R^{15a}

-N(R⁸)-SO₂-R⁹]; L⁴ is a straight or branched C₁₋₄alkylene chain, especially methylene; X is O;



is attached at

the ring 6 position; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

15

Another preferred group of compounds of the invention are compounds of formula (Ib) in which:- R² is hydrogen; R³ is optionally substituted aryl (especially ortho-tolyl); A¹ is methylene or ethylene; L¹ is a $\text{---CH---CH}_2\text{---}$ group particularly a $\text{---CH---CH}_2\text{---}$ group, where R¹⁵


R¹⁵

R¹⁵

represents hydrogen, lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹,

20 -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -OH, -OR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵; L⁴ is a straight or branched C₁₋₄alkylene chain, (especially

methylene); X is NR⁵ (especially NH); Y is carboxy; Z¹ is CH₂; Z⁴ is NH; and the group



is attached at the ring 5 or 6 position; and the corresponding

N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.


5

Another preferred group of compounds of the invention are compounds of formula (Ib) in which:- R² is hydrogen; R³ is optionally substituted aryl (especially ortho-tolyl); A¹ is methylene or ethylene; L¹ is a $\text{---CH}_2\text{---CH---}$ group, particularly $\text{---CH}_2\text{---CH---}$ [where R^{15a}

$\text{---CH}_2\text{---CH---}$]

represents $\text{-N}(\text{R}^8)\text{-C}(\text{=O})\text{-R}^9$, or $\text{-N}(\text{R}^8)\text{-SO}_2\text{-R}^9$; L⁴ is a straight or branched C₁₋₄alkylene

10 chain, (especially methylene); X is NR⁵ (especially NH); Y is carboxy; Z¹ is CH₂; Z⁴ is NH; and




is attached at the ring 5 or 6 position; and the

corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

15

Another particular group of compounds of the invention are compounds of formula (Ic):-




(Ic)

in which Ar^1 , L^4 , A^1 , R^2 , L^1 , Y and Z^1 are as hereinbefore defined, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

5 Compounds of formula (Ic) in which Ar^1 represents an optionally substituted phenylene, especially optionally substituted m- or p-phenylene, more especially optionally substituted p-phenylene, are preferred. Compounds of formula (Ic) in which Ar^1 represents 3-substituted

p-phenylene, in which the substituent is ortho to the




particularly preferred. Preferred optional substituents include halo, C₁-4alkyl, C₁-4alkoxy,

10 C₁-4alkylthio, C₁-4alkylsulphinyl and C₁-4alkylsulphonyl, especially chloro, methyl, methoxy, methylthio, methylsulphinyl and methylsulphonyl.

Compounds of formula (Ic) in which Ar^1 is an optionally substituted heteroaryldiyl, such as optionally substituted pyridinediyl, particularly a p-pyridinediyl, more particularly a

15 pyridine-2,5-diyl, in which the



atom, and which is substituted in the 4- or 6-position, , are also preferred. Preferred optional substituents include C₁-4alkyl and C₁-4alkoxy, especially methyl and methoxy.

Compounds of formula (Ic) in which L^4 represents a straight or branched C₁-6alkylene chain, especially a straight or branched C₁-4alkylene chain, more especially methylene, are preferred.

Compounds of formula (Ic) in which A^1 represents methylene are preferred.

Compounds of formula (Ic) in which A^1 represents ethylene are also preferred.

25

Compounds of formula (Ic) in which Z^1 represents CH₂ are preferred.

Compounds of formula (Ic) in which R² represents hydrogen are preferred.

Compounds of formula (Ic) in which L¹ represents an optionally substituted alkylene linkage, particularly optionally substituted ethylene or optionally substituted propylene, especially

5 ethylene optionally substituted with lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵,

or alkyl substituted by carboxy (or an acid bioisostere), -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵,

are preferred. In one preferred embodiment L¹ is a group $\begin{array}{c} R^5 \\ | \\ -C-CH_2- \\ | \\ R^{15} \end{array}$ [where R⁵ is

10 hydrogen or lower alkyl (e.g. methyl) and R¹⁵ represents hydrogen or lower alkyl, or where R⁵ is hydrogen and R¹⁵ represents aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹,

-N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵], and is more

preferably a group $\begin{array}{c} R^{15} \\ | \\ -CH-CH_2- \\ | \\ R^{15} \end{array}$, particularly $\begin{array}{c} R^{15} \\ | \\ -CH-CH_2- \\ | \\ R^{15} \end{array}$ [where R¹⁵ represents

hydrogen, lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵ or alkyl substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵]. In another

15 preferred embodiment L¹ is a group $\begin{array}{c} R^5 \\ | \\ -CH_2-C- \\ | \\ R^{15a} \end{array}$ [where R⁵ is hydrogen or lower alkyl (e.g. methyl) and R^{15a} represents lower alkyl (e.g. methyl), or where R⁵ is hydrogen and R^{15a} represents aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy (or an acid

20 bioisostere), -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵], and is more preferably a group $\begin{array}{c} R^{15a} \\ | \\ -CH_2-CH- \\ | \\ R^{15a} \end{array}$, particularly $\begin{array}{c} R^{15a} \\ | \\ -CH_2-CH- \\ | \\ R^{15a} \end{array}$ [where R^{15a} represents -N(R⁸)-C(=O)-R⁹, or -N(R⁸)-SO₂-R⁹].

Compounds of formula (Ic) in which Y represents carboxy are preferred.


A preferred group of compounds of the invention are compounds of formula (Ic) in which: R^2 is hydrogen; A^1 is methylene or ethylene; Ar^I is optionally substituted m- or p-phenylene

5 phenylene, 3-methylsulphinyl-p-phenylene and 3-methylsulphonyl-p-phenylene) or optionally substituted p-pyridinediyl [especially 4(or 6)-methyl(or methoxy)-p-pyridine-2,5-diyl]; L^1 is a $-\text{CH}_2-\text{CH}_2-$ group particularly a $-\text{CH}_2-\text{CH}_2-$ group, where R^{15} represents hydrogen, R^{15} CH_2-CH_2- R^{15} CH_2-CH_2- R^{15}
 methyl, aryl, heteroaryl, $-\text{N}(\text{R}^8)\text{-C}(\text{=O})\text{-R}^9$, $-\text{N}(\text{R}^8)\text{-C}(\text{=O})\text{-OR}^9$, $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$ or $-\text{NY}^4\text{Y}^5$, or
 10 alkyl substituted by carboxy, $-\text{OH}$, $-\text{OR}^3$ or $-\text{C}(\text{=O})\text{-NY}^4\text{Y}^5$; L^4 is a straight or branched C_{1-4} alkylene chain, (especially methylene); Y is carboxy; and Z^1 is CH_2 ; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Another preferred group of compounds of the invention are compounds of formula (Ic) in

15 which:- R² is hydrogen; A¹ is methylene or ethylene; Ar¹ is optionally substituted m- or p-phenylene (especially 3-chloro-p-phenylene, 3-methyl-p-phenylene, 3-methoxy-p-phenylene, 3-methylthio-p-phenylene, 3-methylsulphinyl-p-phenylene and 3-methylsulphonyl-p-phenylene) or optionally substituted p-pyridinediyl [especially 4(or 6)-methyl(or methoxy)-p-pyridine-2,5-diyl]; L¹ is a $\text{---CH}_2\text{---CH---}$ group, particularly $\text{---CH}_2\text{---CH---}$ [where R^{15a} represents ]; L⁴ is a straight or branched C₁-4alkylene chain, -N(R⁸)-C(=O)-R⁹, or -N(R⁸)-SO₂-R⁹; L⁴ is a straight or branched C₁-4alkylene chain, (especially methylene); Y is carboxy; and Z¹ is CH₂; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Another particular group of compounds of the invention are compounds of formula (Id):-



(Id)

5

in which R^3 , A^1 , R^2 , L^1 , Y and Z^1 are as hereinbefore defined, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

10 Compounds of formula (Id) in which R^3 represents optionally substituted aryl, especially optionally substituted phenyl, are preferred. Preferred optional substituents include aryloxy, cyano, halo (e.g. chloro or fluoro), lower alkoxy (e.g. methoxy), lower alkyl (e.g. methyl), nitro and perfluoroloweralkyl (e.g. trifluoromethyl). R^3 especially represents 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 15 4-fluoro-2-trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl and 2-phenoxyphenyl.

Compounds of formula (Id) in which R^3 represents optionally substituted heteroaryl, especially isoquinolinyl, isoxazolyl, pyrazolopyrimidinyl, pyridyl, pyrimidinyl, quinolinyl, thiazolyl and 20 triazolyl, each optionally substituted by one or more aryl group substituents, are preferred. Preferred optional substituents include alkyl-C(=O)-, aryl, cyano, halo, (e.g. chloro or fluoro), lower alkoxy (e.g. methoxy), lower alkyl (e.g. methyl), lower alkylsulphonyl, lower alkylthio, nitro and perfluoroloweralkyl (e.g. trifluoromethyl). R^3 especially represents quinolin-4-yl, isoquinolin-2-yl, 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 25 4-trifluoromethylpyridin-3-yl, 2-phenyl-4-methyl-1,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazolo[1,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl and 4-trifluoromethylpyrimidin-5-yl.

Compounds of formula (Id) in which R^3 represents arylalkyl in which the aryl is optionally substituted by one or more aryl group substituents (particular optional substituents include halo, hydroxy and methoxy) are also preferred. R^3 especially represents optionally substituted benzyl, 30

particularly 4-hydroxybenzyl, 3-chloro-4-hydroxybenzyl, 3-fluoro-4-hydroxybenzyl and 4-hydroxy-3-methoxybenzyl.

Compounds of formula (Id) in which A^1 represents methylene are preferred.


5


Compounds of formula (Id) in which A^1 represents ethylene are also preferred.


Compounds of formula (Id) in which Z^1 represents CH_2 are preferred.

10 Compounds of formula (Id) in which R^2 represents hydrogen are preferred.

Compounds of formula (Id) in which L^1 represents an optionally substituted alkylene linkage, particularly optionally substituted ethylene or optionally substituted propylene, especially ethylene optionally substituted with lower alkyl (e.g. methyl), aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $15 -N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $[-C(=O)-N(R^{10})-C(R^5)(R^{11})]_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$,

are preferred. In one preferred embodiment L^1 is a group 

hydrogen or lower alkyl (e.g. methyl) and R^{15} represents hydrogen or lower alkyl, or where R^5 is hydrogen and R^{15} represents aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $20 -N(R^8)-SO_2-R^9$, $-NY^4Y^5$ or $[-C(=O)-N(R^{10})-C(R^5)(R^{11})]_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-ZH$, $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$, and is more preferably a group 

hydrogen, lower alkyl, aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$ or $-NY^4Y^5$ or alkyl substituted by carboxy, $-OH$, $-OR^3$ or $-C(=O)-NY^4Y^5$. In another preferred embodiment L^1 is a group 

25 and R^{15a} represents lower alkyl, or where R^5 is hydrogen and R^{15a} represents aryl, heteroaryl,

-N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or
 -{C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy (or an acid
 bioisostere), -ZH₂, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵], and is more preferably a
 group —CH₂—CH—, particularly —CH₂—CH— [where R^{15a} represents -N(R⁸)-C(=O)-R⁹,
 R^{15a} R^{15a}

5 or -N(R⁸)-SO₂-R⁹].

Compounds of formula (Id) in which Y represents carboxy are preferred.

A preferred group of compounds of the invention are compounds of formula (Id) in which:- R² is
 10 hydrogen; R³ is optionally substituted phenyl (especially 2-chlorophenyl, 5-chloro-2-
 cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-
 trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl
 and 2-phenoxyphenyl), optionally substituted heteroaryl (especially quinolin-4-yl, isoquinolin-2-
 yl, 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 4-trifluoromethylpyridin-3-yl,
 15 2-phenyl-4-methyl-1,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazolo-
 [1,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl and 4-trifluoromethylpyrimidin-5-yl) or
 optionally substituted benzyl (especially 4-hydroxybenzyl, 3-chloro-4-hydroxybenzyl, 3-fluoro-4-
 hydroxybenzyl and 4-hydroxy-3-methoxybenzyl); A¹ is methylene or ethylene; L¹ is a
 —CH—CH₂— group particularly a —CH—CH₂— group, where R¹⁵ represents hydrogen,
 R¹⁵ R¹⁵

20 methyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or
 alkyl substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵; Y is carboxy; and Z¹ is CH₂; and
 the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and
 solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

25 Another preferred group of compounds of the invention are compounds of formula (Id) in
 which:- R² is hydrogen; R³ is optionally substituted phenyl (especially 2-chlorophenyl, 5-chloro-
 2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-
 trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl
 and 2-phenoxyphenyl), optionally substituted heteroaryl (especially quinolin-4-yl, isoquinolin-2-
 yl, 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 4-trifluoromethylpyridin-3-yl,
 30

2-phenyl-4-methyl-1,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazolo-[1,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl and 4-trifluoromethylpyrimidin-5-yl) or optionally substituted benzyl (especially 4-hydroxybenzyl, 3-chloro-4-hydroxybenzyl, 3-fluoro-4-hydroxybenzyl and 4-hydroxy-3-methoxybenzyl); A¹ is methylene or ethylene; L¹ is

5 a $-\text{CH}_2-\text{CH}-$ group, particularly $-\text{CH}_2-\text{CH}-$ [where R^{15a} represents

$-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-R}^9$, or $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$; Y is carboxy; and Z¹ is CH₂; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

10 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents hydrogen are preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents lower alkyl (e.g. methyl, ethyl, propyl, butyl) are also preferred.

15 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents aryl (e.g. optionally substituted phenyl) are also preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-R}^9$, especially where R⁸ is hydrogen or lower alkyl (e.g. methyl) and R⁹ is lower alkyl (e.g. methyl),

20 aryl (e.g. optionally substituted phenyl), heteroaryl (e.g. pyridyl, isoxazolyl, triazolyl, pyrimidinyl, thiazolyl, or pyrazolopyrimidinyl each optionally substituted by one or more aryl group substituents), alkyl substituted by alkoxy (e.g. $-\text{CH}_2\text{-O-CH}_2\text{-CH}_2\text{-OCH}_3$), alkyl substituted by carboxy (e.g. $-\text{CH}_2\text{-CH}_2\text{-CO}_2\text{H}$ and $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CO}_2\text{H}$) or alkyl substituted by $-\text{N}^{\text{Y}^4}\text{Y}^5$ (e.g. aminomethyl and morpholin-1-ylmethyl), are preferred.

25 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents $-\text{N}(\text{R}^8)\text{-C}(=\text{O})\text{-OR}^9$, especially where R⁸ is hydrogen or lower alkyl (e.g. methyl) and R⁹ is lower alkyl (e.g. ethyl) or alkyl substituted by aryl (e.g. benzyl), are also preferred.

30 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents $-\text{N}(\text{R}^8)\text{-SO}_2\text{-R}^9$, especially where R⁸ is hydrogen or lower alkyl (e.g. methyl) and R⁹ is lower alkyl (e.g. methyl), aryl [e.g. optionally substituted phenyl or optionally substituted naphthyl (especially

dimethylaminonaphth-1-yl]), heteroaryl (e.g. optionally substituted pyridyl or optionally substituted imidazolyl), are also preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents -NY⁴Y⁵, especially where

5 Y⁴ and Y⁵ represent hydrogen are also preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents -NY⁴Y⁵, especially where

Y⁴ is hydrogen and Y⁵ is or lower alkyl (e.g. propyl), or alkyl substituted by aryl (e.g. -CH₂-Ph or -CH₂-CH₂-Ph), are also preferred.

10 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents -NY⁴Y⁵, especially where

Y⁴ and Y⁵ represent alkyl substituted by aryl (e.g. -CH₂-Ph or -CH(CH₃)-Ph), are also preferred.

15 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents alkyl substituted by carboxy (or an acid bioisostere), especially lower alkyl substituted by carboxy (e.g. carboxymethyl), are also preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents alkyl substituted by -OH,


20 especially lower alkyl substituted by -OH (e.g. hydroxymethyl), are also preferred.


Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents alkyl substituted by -OR³, especially lower alkyl substituted by -OR³ (e.g. methoxymethyl), are also preferred.

25 Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R¹⁵ represents alkyl substituted by -C(=O)-NY⁴Y⁵, especially lower alkyl substituted by -C(=O)-NY⁴Y⁵ (e.g.



Particularly preferred compounds of formula (Ia), (Ib), (Ic) and (Id) are those in which R¹⁵ is





Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R^{15a} represents -N(R⁸)-C(=O)-R⁹,
 5 especially where R⁸ is hydrogen or lower alkyl (e.g. methyl) and R⁹ is lower alkyl (e.g. methyl),
 aryl (e.g. optionally substituted phenyl), heteroaryl (e.g. pyridyl, isoxazolyl, triazolyl,
 pyrimidinyl, thiazolyl, or pyrazolopyrimidinyl each optionally substituted by one or more aryl
 group substituents), alkyl substituted by alkoxy (e.g. -CH₂-O-CH₂-CH₂-OCH₃), alkyl
 substituted by carboxy (e.g. -CH₂-CH₂-CO₂H and -CH₂-CH₂-CH₂-CO₂H) or alkyl substituted
 10 by -NY⁴Y⁵ (e.g. aminomethyl and morpholin-1-ylmethyl), are preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R^{15a} represents -N(R⁸)-C(=O)-R⁹ where
 R⁹ is substituted phenyl selected from 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-
 15 methoxyphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-trifluoromethyl, 2-methyl-4-
 nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl or 2-phenoxyphenyl are
 particularly preferred.

Compounds of formula (Ia), (Ib), (Ic) and (Id) in which R^{15a} represents -N(R⁸)-C(=O)-R⁹
 where R⁹ is an optionally substituted heteroaryl selected from quinolin-4-yl, isoquinolin-2-yl,
 20 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 4-trifluoromethylpyridin-3-yl,
 2-phenyl-4-methyl-1,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazol-
 [1,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl and 4-trifluoromethylpyrimidin-5-yl are
 also particularly preferred.

25 Particular compounds of the invention are selected from the compounds formed by joining the
 acyl carbon atom (C*) of one of the fragments (A1 to A34) shown in Table 1 to the nitrogen atom
 (N*) of one of the aza-bicyclic fragments (B1 to B6) shown in Table 2, and joining the carbon
 atom (C*) of the phenyl ring in one of the aza-bicyclic fragments (B1 to B6) shown in Table 2 to
 the carbon atom (C*) of one of the acidic fragments (C1 to C59) depicted in Table 3.

TABLE I















A1		A2	
A3		A4	
A5		A6	
A7		A8	
A9		A10	
A11		A12	
A13		A14	

TABLE I continued

A15		A16	
A17		A18	
A19		A20	
A21		A22	
A23		A24	
A25		A26	

TABLE 1 continued










A27		A28	
A29		A30	
A31		A32	
A33		A34	
A35			

TABLE 2

B1		B2	
B3		B4	
B5		B6	

TABLE 3

C1	$^*\text{CH}_2\text{---CH}_2\text{---CO}_2\text{H}$	C2	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$ CH ₃
C3	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$ CH ₂ CH ₃	C4	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$ (CH ₂) ₃ CH ₃
C5	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$ CH(CH ₃) ₂	C6	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$ CH ₂ CH(CH ₃) ₂
C7	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$ 	C8	$^*\text{CH}\text{---CH}_2\text{---CO}_2\text{H}$

TABLE 3 continued

C9		C10	
C11		C12	
C13		C14	
C15		C16	
C17		C18	
C19		C20	
C21		C22	

TABLE 3 continued

C23	$\begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{F} \text{---} \text{C}_6\text{H}_3\text{---} \text{CF}_3 \end{array}$	C24	$\begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{H}_3\text{C} \text{---} \text{C}_6\text{H}_3\text{---} \text{CH}_3 \end{array}$
C25	$\begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4\text{---} \text{OMe} \end{array}$	C26	$\begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4\text{---} \text{Cl} \\ \\ \text{HO} \end{array}$
C27	$\begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{F} \text{---} \text{C}_6\text{H}_3\text{---} \text{F} \end{array}$	C28	$\begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_3\text{---} \text{Cl} \\ \\ \text{CH}_3 \end{array}$
C29	$\begin{array}{c} * \text{CH}-\text{CH}_2-\text{CO}_2\text{H} \\ \\ \text{NH}_2 \end{array}$	C30	$\begin{array}{c} * \text{CH}-\text{CH}_2-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_5 \end{array}$
C31	$\begin{array}{c} * \text{CH}-\text{CH}_2-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4\text{---} \text{F} \end{array}$	C32	$\begin{array}{c} * \text{CH}-\text{CH}_2-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_3\text{---} \text{N} \end{array}$








TABLE 3 continued

C33		C34	
C35		C36	
C37		C38	
C39		C40	
C41		C42	

TABLE 3 continued

C43	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4-\text{CMe}_3 \end{array} $	C44	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4-\text{Me} \\ \\ \text{CHMe}_2 \end{array} $
C45	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{Me}-\text{C}_6\text{H}_3-\text{Me} \\ \\ \text{Me} \end{array} $	C46	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{Et}-\text{C}_6\text{H}_3-\text{Me} \end{array} $
C47	$ \begin{array}{c} * \text{CH}_2-\text{CO}_2\text{H} \\ \\ \text{C}_3\text{H}_6\text{O} \end{array} $	C48	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4-\text{Me} \\ \\ \text{C}(=\text{O})-\text{Me} \end{array} $
C49	$ \begin{array}{c} * \text{CH}-\text{CH}_2-\text{CO}_2\text{H} \\ \\ \text{H}_3\text{C} \text{---} \text{C}(=\text{O}) \\ \\ \text{N} \\ \\ \text{C}_3\text{H}_5 \end{array} $	C50	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4-\text{Cl} \end{array} $
C51	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4-\text{Me} \\ \\ \text{Cl} \end{array} $	C52	$ \begin{array}{c} * \text{CH}_2-\text{CH}-\text{CO}_2\text{H} \\ \\ \text{HN} \text{---} \text{C}(=\text{O}) \\ \\ \text{C}_6\text{H}_4-\text{Cl} \\ \\ \text{Cl} \end{array} $

TABLE 3 continued

C53		C54	
C55		C56	
C57		C58	
C59			

Particular compounds of the invention are:-

A1-B1-C1;	A1-B1-C8;	A1-B1-C15;	A1-B1-C22;	A1-B1-C29;
A1-B1-C2;	A1-B1-C9;	A1-B1-C16;	A1-B1-C23;	A1-B1-C30;
5 A1-B1-C3;	A1-B1-C10;	A1-B1-C17;	A1-B1-C24;	A1-B1-C31;
A1-B1-C4;	A1-B1-C11;	A1-B1-C18;	A1-B1-C25;	A1-B1-C32;
A1-B1-C5;	A1-B1-C12;	A1-B1-C19;	A1-B1-C26;	A1-B1-C33;
A1-B1-C6;	A1-B1-C13;	A1-B1-C20;	A1-B1-C27;	A1-B1-C34;
A1-B1-C7;	A1-B1-C14;	A1-B1-C21;	A1-B1-C28;	A1-B1-C35;

	A1-B1-C36;	A2-B1-C12;	A2-B1-C47;	A3-B1-C23;	A3-B1-CS8;
	A1-B1-C37;	A2-B1-C13;	A2-B1-C48;	A3-B1-C24;	A3-B1-C59;
	A1-B1-C38;	A2-B1-C14;	A2-B1-C49;	A3-B1-C25;	A4-B1-C1;
	A1-B1-C39;	A2-B1-C15;	A2-B1-C50;	A3-B1-C26;	A4-B1-C2;
5	A1-B1-C40;	A2-B1-C16;	A2-B1-C51;	A3-B1-C27;	A4-B1-C3;
	A1-B1-C41;	A2-B1-C17;	A2-B1-C52;	A3-B1-C28;	A4-B1-C4;
	A1-B1-C42;	A2-B1-C18;	A2-B1-C53;	A3-B1-C29;	A4-B1-C5;
	A1-B1-C43;	A2-B1-C19;	A2-B1-C54;	A3-B1-C30;	A4-B1-C6;
	A1-B1-C44;	A2-B1-C20;	A2-B1-C55;	A3-B1-C31;	A4-B1-C7;
10	A1-B1-C45;	A2-B1-C21;	A2-B1-C56;	A3-B1-C32;	A4-B1-C8;
	A1-B1-C46;	A2-B1-C22;	A2-B1-C57;	A3-B1-C33;	A4-B1-C9;
	A1-B1-C47;	A2-B1-C23;	A2-B1-C58;	A3-B1-C34;	A4-B1-C10;
	A1-B1-C48;	A2-B1-C24;	A2-B1-C59;	A3-B1-C35;	A4-B1-C11;
	A1-B1-C49;	A2-B1-C25;	A3-B1-C1;	A3-B1-C36;	A4-B1-C12;
15	A1-B1-C50;	A2-B1-C26;	A3-B1-C2;	A3-B1-C37;	A4-B1-C13;
	A1-B1-C51;	A2-B1-C27;	A3-B1-C3;	A3-B1-C38;	A4-B1-C14;
	A1-B1-C52;	A2-B1-C28;	A3-B1-C4;	A3-B1-C39;	A4-B1-C15;
	A1-B1-C53;	A2-B1-C29;	A3-B1-C5;	A3-B1-C40;	A4-B1-C16;
	A1-B1-C54;	A2-B1-C30;	A3-B1-C6;	A3-B1-C41;	A4-B1-C17;
20	A1-B1-C55;	A2-B1-C31;	A3-B1-C7;	A3-B1-C42;	A4-B1-C18;
	A1-B1-C56;	A2-B1-C32;	A3-B1-C8;	A3-B1-C43;	A4-B1-C19;
	A1-B1-C57;	A2-B1-C33;	A3-B1-C9;	A3-B1-C44;	A4-B1-C20;
	A1-B1-C58;	A2-B1-C34;	A3-B1-C10;	A3-B1-C45;	A4-B1-C21;
	A1-B1-C59;	A2-B1-C35;	A3-B1-C11;	A3-B1-C46;	A4-B1-C22;
25	A2-B1-C1;	A2-B1-C36;	A3-B1-C12;	A3-B1-C47;	A4-B1-C23;
	A2-B1-C2;	A2-B1-C37;	A3-B1-C13;	A3-B1-C48;	A4-B1-C24;
	A2-B1-C3;	A2-B1-C38;	A3-B1-C14;	A3-B1-C49;	A4-B1-C25;
	A2-B1-C4;	A2-B1-C39;	A3-B1-C15;	A3-B1-C50;	A4-B1-C26;
	A2-B1-C5;	A2-B1-C40;	A3-B1-C16;	A3-B1-C51;	A4-B1-C27;
30	A2-B1-C6;	A2-B1-C41;	A3-B1-C17;	A3-B1-C52;	A4-B1-C28;
	A2-B1-C7;	A2-B1-C42;	A3-B1-C18;	A3-B1-C53;	A4-B1-C29;
	A2-B1-C8;	A2-B1-C43;	A3-B1-C19;	A3-B1-C54;	A4-B1-C30;
	A2-B1-C9;	A2-B1-C44;	A3-B1-C20;	A3-B1-C55;	A4-B1-C31;
	A2-B1-C10;	A2-B1-C45;	A3-B1-C21;	A3-B1-C56;	A4-B1-C32;
35	A2-B1-C11;	A2-B1-C46;	A3-B1-C22;	A3-B1-C57;	A4-B1-C33;

	A4-B1-C34;	A5-B1-C10;	A5-B1-C45;	A6-B1-C21;	A6-B1-C56;
	A4-B1-C35;	A5-B1-C11;	A5-B1-C46;	A6-B1-C22;	A6-B1-C57;
	A4-B1-C36;	A5-B1-C12;	A5-B1-C47;	A6-B1-C23;	A6-B1-C58;
	A4-B1-C37;	A5-B1-C13;	A5-B1-C48;	A6-B1-C24;	A6-B1-C59;
5	A4-B1-C38;	A5-B1-C14;	A5-B1-C49;	A6-B1-C25;	A7-B1-C1;
	A4-B1-C39;	A5-B1-C15;	A5-B1-C50;	A6-B1-C26;	A7-B1-C2;
	A4-B1-C40;	A5-B1-C16;	A5-B1-C51;	A6-B1-C27;	A7-B1-C3;
	A4-B1-C41;	A5-B1-C17;	A5-B1-C52;	A6-B1-C28;	A7-B1-C4;
	A4-B1-C42;	A5-B1-C18;	A5-B1-C53;	A6-B1-C29;	A7-B1-C5;
10	A4-B1-C43;	A5-B1-C19;	A5-B1-C54;	A6-B1-C30;	A7-B1-C6;
	A4-B1-C44;	A5-B1-C20;	A5-B1-C55;	A6-B1-C31;	A7-B1-C7;
	A4-B1-C45;	A5-B1-C21;	A5-B1-C56;	A6-B1-C32;	A7-B1-C8;
	A4-B1-C46;	A5-B1-C22;	A5-B1-C57;	A6-B1-C33;	A7-B1-C9;
	A4-B1-C47;	A5-B1-C23;	A5-B1-C58;	A6-B1-C34;	A7-B1-C10;
15	A4-B1-C48;	A5-B1-C24;	A5-B1-C59;	A6-B1-C35;	A7-B1-C11;
	A4-B1-C49;	A5-B1-C25;	A6-B1-C1;	A6-B1-C36;	A7-B1-C12;
	A4-B1-C50;	A5-B1-C26;	A6-B1-C2;	A6-B1-C37;	A7-B1-C13;
	A4-B1-C51;	A5-B1-C27;	A6-B1-C3;	A6-B1-C38;	A7-B1-C14;
	A4-B1-C52;	A5-B1-C28;	A6-B1-C4;	A6-B1-C39;	A7-B1-C15;
20	A4-B1-C53;	A5-B1-C29;	A6-B1-C5;	A6-B1-C40;	A7-B1-C16;
	A4-B1-C54;	A5-B1-C30;	A6-B1-C6;	A6-B1-C41;	A7-B1-C17;
	A4-B1-C55;	A5-B1-C31;	A6-B1-C7;	A6-B1-C42;	A7-B1-C18;
	A4-B1-C56;	A5-B1-C32;	A6-B1-C8;	A6-B1-C43;	A7-B1-C19;
	A4-B1-C57;	A5-B1-C33;	A6-B1-C9;	A6-B1-C44;	A7-B1-C20;
25	A4-B1-C58;	A5-B1-C34;	A6-B1-C10;	A6-B1-C45;	A7-B1-C21;
	A4-B1-C59;	A5-B1-C35;	A6-B1-C11;	A6-B1-C46;	A7-B1-C22;
	A5-B1-C1;	A5-B1-C36;	A6-B1-C12;	A6-B1-C47;	A7-B1-C23;
	A5-B1-C2;	A5-B1-C37;	A6-B1-C13;	A6-B1-C48;	A7-B1-C24;
	A5-B1-C3;	A5-B1-C38;	A6-B1-C14;	A6-B1-C49;	A7-B1-C25;
30	A5-B1-C4;	A5-B1-C39;	A6-B1-C15;	A6-B1-C50;	A7-B1-C26;
	A5-B1-C5;	A5-B1-C40;	A6-B1-C16;	A6-B1-C51;	A7-B1-C27;
	A5-B1-C6;	A5-B1-C41;	A6-B1-C17;	A6-B1-C52;	A7-B1-C28;
	A5-B1-C7;	A5-B1-C42;	A6-B1-C18;	A6-B1-C53;	A7-B1-C29;
	A5-B1-C8;	A5-B1-C43;	A6-B1-C19;	A6-B1-C54;	A7-B1-C30;
35	A5-B1-C9;	A5-B1-C44;	A6-B1-C20;	A6-B1-C55;	A7-B1-C31;

	A7-B1-C32;	A8-B1-C8;	A8-B1-C43;	A9-B1-C19;	A9-B1-C54;
	A7-B1-C33;	A8-B1-C9;	A8-B1-C44;	A9-B1-C20;	A9-B1-C55;
	A7-B1-C34;	A8-B1-C10;	A8-B1-C45;	A9-B1-C21;	A9-B1-C56;
	A7-B1-C35;	A8-B1-C11;	A8-B1-C46;	A9-B1-C22;	A9-B1-C57;
5	A7-B1-C36;	A8-B1-C12;	A8-B1-C47;	A9-B1-C23;	A9-B1-C58;
	A7-B1-C37;	A8-B1-C13;	A8-B1-C48;	A9-B1-C24;	A9-B1-C59;
	A7-B1-C38;	A8-B1-C14;	A8-B1-C49;	A9-B1-C25;	A10-B1-C1;
	A7-B1-C39;	A8-B1-C15;	A8-B1-C50;	A9-B1-C26;	A10-B1-C2;
	A7-B1-C40;	A8-B1-C16;	A8-B1-C51;	A9-B1-C27;	A10-B1-C3;
10	A7-B1-C41;	A8-B1-C17;	A8-B1-C52;	A9-B1-C28;	A10-B1-C4;
	A7-B1-C42;	A8-B1-C18;	A8-B1-C53;	A9-B1-C29;	A10-B1-C5;
	A7-B1-C43;	A8-B1-C19;	A8-B1-C54;	A9-B1-C30;	A10-B1-C6;
	A7-B1-C44;	A8-B1-C20;	A8-B1-C55;	A9-B1-C31;	A10-B1-C7;
	A7-B1-C45;	A8-B1-C21;	A8-B1-C56;	A9-B1-C32;	A10-B1-C8;
15	A7-B1-C46;	A8-B1-C22;	A8-B1-C57;	A9-B1-C33;	A10-B1-C9;
	A7-B1-C47;	A8-B1-C23;	A8-B1-C58;	A9-B1-C34;	A10-B1-C10;
	A7-B1-C48;	A8-B1-C24;	A8-B1-C59;	A9-B1-C35;	A10-B1-C11;
	A7-B1-C49;	A8-B1-C25;	A9-B1-C1;	A9-B1-C36;	A10-B1-C12;
	A7-B1-C50;	A8-B1-C26;	A9-B1-C2;	A9-B1-C37;	A10-B1-C13;
20	A7-B1-C51;	A8-B1-C27;	A9-B1-C3;	A9-B1-C38;	A10-B1-C14;
	A7-B1-C52;	A8-B1-C28;	A9-B1-C4;	A9-B1-C39;	A10-B1-C15;
	A7-B1-C53;	A8-B1-C29;	A9-B1-C5;	A9-B1-C40;	A10-B1-C16;
	A7-B1-C54;	A8-B1-C30;	A9-B1-C6;	A9-B1-C41;	A10-B1-C17;
	A7-B1-C55;	A8-B1-C31;	A9-B1-C7;	A9-B1-C42;	A10-B1-C18;
25	A7-B1-C56;	A8-B1-C32;	A9-B1-C8;	A9-B1-C43;	A10-B1-C19;
	A7-B1-C57;	A8-B1-C33;	A9-B1-C9;	A9-B1-C44;	A10-B1-C20;
	A7-B1-C58;	A8-B1-C34;	A9-B1-C10;	A9-B1-C45;	A10-B1-C21;
	A7-B1-C59;	A8-B1-C35;	A9-B1-C11;	A9-B1-C46;	A10-B1-C22;
	A8-B1-C1;	A8-B1-C36;	A9-B1-C12;	A9-B1-C47;	A10-B1-C23;
30	A8-B1-C2;	A8-B1-C37;	A9-B1-C13;	A9-B1-C48;	A10-B1-C24;
	A8-B1-C3;	A8-B1-C38;	A9-B1-C14;	A9-B1-C49;	A10-B1-C25;
	A8-B1-C4;	A8-B1-C39;	A9-B1-C15;	A9-B1-C50;	A10-B1-C26;
	A8-B1-C5;	A8-B1-C40;	A9-B1-C16;	A9-B1-C51;	A10-B1-C27;
	A8-B1-C6;	A8-B1-C41;	A9-B1-C17;	A9-B1-C52;	A10-B1-C28;
35	A8-B1-C7;	A8-B1-C42;	A9-B1-C18;	A9-B1-C53;	A10-B1-C29;

	A10-B1-C30;	A11-B1-C6;	A11-B1-C41;	A12-B1-C17;	A12-B1-C52;
	A10-B1-C31;	A11-B1-C7;	A11-B1-C42;	A12-B1-C18;	A12-B1-C53;
	A10-B1-C32;	A11-B1-C8;	A11-B1-C43;	A12-B1-C19;	A12-B1-C54;
	A10-B1-C33;	A11-B1-C9;	A11-B1-C44;	A12-B1-C20;	A12-B1-C55;
5	A10-B1-C34;	A11-B1-C10;	A11-B1-C45;	A12-B1-C21;	A12-B1-C56;
	A10-B1-C35;	A11-B1-C11;	A11-B1-C46;	A12-B1-C22;	A12-B1-C57;
	A10-B1-C36;	A11-B1-C12;	A11-B1-C47;	A12-B1-C23;	A12-B1-C58;
	A10-B1-C37;	A11-B1-C13;	A11-B1-C48;	A12-B1-C24;	A12-B1-C59;
	A10-B1-C38;	A11-B1-C14;	A11-B1-C49;	A12-B1-C25;	A13-B1-C1;
10	A10-B1-C39;	A11-B1-C15;	A11-B1-C50;	A12-B1-C26;	A13-B1-C2;
	A10-B1-C40;	A11-B1-C16;	A11-B1-C51;	A12-B1-C27;	A13-B1-C3;
	A10-B1-C41;	A11-B1-C17;	A11-B1-C52;	A12-B1-C28;	A13-B1-C4;
	A10-B1-C42;	A11-B1-C18;	A11-B1-C53;	A12-B1-C29;	A13-B1-C5;
	A10-B1-C43;	A11-B1-C19;	A11-B1-C54;	A12-B1-C30;	A13-B1-C6;
15	A10-B1-C44;	A11-B1-C20;	A11-B1-C55;	A12-B1-C31;	A13-B1-C7;
	A10-B1-C45;	A11-B1-C21;	A11-B1-C56;	A12-B1-C32;	A13-B1-C8;
	A10-B1-C46;	A11-B1-C22;	A11-B1-C57;	A12-B1-C33;	A13-B1-C9;
	A10-B1-C47;	A11-B1-C23;	A11-B1-C58;	A12-B1-C34;	A13-B1-C10;
	A10-B1-C48;	A11-B1-C24;	A11-B1-C59;	A12-B1-C35;	A13-B1-C11;
20	A10-B1-C49;	A11-B1-C25;	A12-B1-C1;	A12-B1-C36;	A13-B1-C12;
	A10-B1-C50;	A11-B1-C26;	A12-B1-C2;	A12-B1-C37;	A13-B1-C13;
	A10-B1-C51;	A11-B1-C27;	A12-B1-C3;	A12-B1-C38;	A13-B1-C14;
	A10-B1-C52;	A11-B1-C28;	A12-B1-C4;	A12-B1-C39;	A13-B1-C15;
	A10-B1-C53;	A11-B1-C29;	A12-B1-C5;	A12-B1-C40;	A13-B1-C16;
25	A10-B1-C54;	A11-B1-C30;	A12-B1-C6;	A12-B1-C41;	A13-B1-C17;
	A10-B1-C55;	A11-B1-C31;	A12-B1-C7;	A12-B1-C42;	A13-B1-C18;
	A10-B1-C56;	A11-B1-C32;	A12-B1-C8;	A12-B1-C43;	A13-B1-C19;
	A10-B1-C57;	A11-B1-C33;	A12-B1-C9;	A12-B1-C44;	A13-B1-C20;
	A10-B1-C58;	A11-B1-C34;	A12-B1-C10;	A12-B1-C45;	A13-B1-C21;
30	A10-B1-C59;	A11-B1-C35;	A12-B1-C11;	A12-B1-C46;	A13-B1-C22;
	A11-B1-C1;	A11-B1-C36;	A12-B1-C12;	A12-B1-C47;	A13-B1-C23;
	A11-B1-C2;	A11-B1-C37;	A12-B1-C13;	A12-B1-C48;	A13-B1-C24;
	A11-B1-C3;	A11-B1-C38;	A12-B1-C14;	A12-B1-C49;	A13-B1-C25;
	A11-B1-C4;	A11-B1-C39;	A12-B1-C15;	A12-B1-C50;	A13-B1-C26;
35	A11-B1-C5;	A11-B1-C40;	A12-B1-C16;	A12-B1-C51;	A13-B1-C27;

	A13-B1-C28;	A14-B1-C4;	A14-B1-C39;	A15-B1-C15;	A15-B1-C50;
	A13-B1-C29;	A14-B1-C5;	A14-B1-C40;	A15-B1-C16;	A15-B1-C51;
	A13-B1-C30;	A14-B1-C6;	A14-B1-C41;	A15-B1-C17;	A15-B1-C52;
	A13-B1-C31;	A14-B1-C7;	A14-B1-C42;	A15-B1-C18;	A15-B1-C53;
5	A13-B1-C32;	A14-B1-C8;	A14-B1-C43;	A15-B1-C19;	A15-B1-C54;
	A13-B1-C33;	A14-B1-C9;	A14-B1-C44;	A15-B1-C20;	A15-B1-C55;
	A13-B1-C34;	A14-B1-C10;	A14-B1-C45;	A15-B1-C21;	A15-B1-C56;
	A13-B1-C35;	A14-B1-C11;	A14-B1-C46;	A15-B1-C22;	A15-B1-C57;
	A13-B1-C36;	A14-B1-C12;	A14-B1-C47;	A15-B1-C23;	A15-B1-C58;
10	A13-B1-C37;	A14-B1-C13;	A14-B1-C48;	A15-B1-C24;	A15-B1-C59;
	A13-B1-C38;	A14-B1-C14;	A14-B1-C49;	A15-B1-C25;	A16-B1-C1;
	A13-B1-C39;	A14-B1-C15;	A14-B1-C50;	A15-B1-C26;	A16-B1-C2;
	A13-B1-C40;	A14-B1-C16;	A14-B1-C51;	A15-B1-C27;	A16-B1-C3;
	A13-B1-C41;	A14-B1-C17;	A14-B1-C52;	A15-B1-C28;	A16-B1-C4;
15	A13-B1-C42;	A14-B1-C18;	A14-B1-C53;	A15-B1-C29;	A16-B1-C5;
	A13-B1-C43;	A14-B1-C19;	A14-B1-C54;	A15-B1-C30;	A16-B1-C6;
	A13-B1-C44;	A14-B1-C20;	A14-B1-C55;	A15-B1-C31;	A16-B1-C7;
	A13-B1-C45;	A14-B1-C21;	A14-B1-C56;	A15-B1-C32;	A16-B1-C8;
	A13-B1-C46;	A14-B1-C22;	A14-B1-C57;	A15-B1-C33;	A16-B1-C9;
20	A13-B1-C47;	A14-B1-C23;	A14-B1-C58;	A15-B1-C34;	A16-B1-C10;
	A13-B1-C48;	A14-B1-C24;	A14-B1-C59;	A15-B1-C35;	A16-B1-C11;
	A13-B1-C49;	A14-B1-C25;	A15-B1-C1;	A15-B1-C36;	A16-B1-C12;
	A13-B1-C50;	A14-B1-C26;	A15-B1-C2;	A15-B1-C37;	A16-B1-C13;
	A13-B1-C51;	A14-B1-C27;	A15-B1-C3;	A15-B1-C38;	A16-B1-C14;
25	A13-B1-C52;	A14-B1-C28;	A15-B1-C4;	A15-B1-C39;	A16-B1-C15;
	A13-B1-C53;	A14-B1-C29;	A15-B1-C5;	A15-B1-C40;	A16-B1-C16;
	A13-B1-C54;	A14-B1-C30;	A15-B1-C6;	A15-B1-C41;	A16-B1-C17;
	A13-B1-C55;	A14-B1-C31;	A15-B1-C7;	A15-B1-C42;	A16-B1-C18;
	A13-B1-C56;	A14-B1-C32;	A15-B1-C8;	A15-B1-C43;	A16-B1-C19;
30	A13-B1-C57;	A14-B1-C33;	A15-B1-C9;	A15-B1-C44;	A16-B1-C20;
	A13-B1-C58;	A14-B1-C34;	A15-B1-C10;	A15-B1-C45;	A16-B1-C21;
	A13-B1-C59;	A14-B1-C35;	A15-B1-C11;	A15-B1-C46;	A16-B1-C22;
	A14-B1-C1;	A14-B1-C36;	A15-B1-C12;	A15-B1-C47;	A16-B1-C23;
	A14-B1-C2;	A14-B1-C37;	A15-B1-C13;	A15-B1-C48;	A16-B1-C24;
35	A14-B1-C3;	A14-B1-C38;	A15-B1-C14;	A15-B1-C49;	A16-B1-C25;

	A16-B1-C26;	A17-B1-C2;	A17-B1-C37;	A18-B1-C13;	A18-B1-C48;
	A16-B1-C27;	A17-B1-C3;	A17-B1-C38;	A18-B1-C14;	A18-B1-C49;
	A16-B1-C28;	A17-B1-C4;	A17-B1-C39;	A18-B1-C15;	A18-B1-C50;
	A16-B1-C29;	A17-B1-C5;	A17-B1-C40;	A18-B1-C16;	A18-B1-C51;
5	A16-B1-C30;	A17-B1-C6;	A17-B1-C41;	A18-B1-C17;	A18-B1-C52;
	A16-B1-C31;	A17-B1-C7;	A17-B1-C42;	A18-B1-C18;	A18-B1-C53;
	A16-B1-C32;	A17-B1-C8;	A17-B1-C43;	A18-B1-C19;	A18-B1-C54;
	A16-B1-C33;	A17-B1-C9;	A17-B1-C44;	A18-B1-C20;	A18-B1-C55;
	A16-B1-C34;	A17-B1-C10;	A17-B1-C45;	A18-B1-C21;	A18-B1-C56;
10	A16-B1-C35;	A17-B1-C11;	A17-B1-C46;	A18-B1-C22;	A18-B1-C57;
	A16-B1-C36;	A17-B1-C12;	A17-B1-C47;	A18-B1-C23;	A18-B1-C58;
	A16-B1-C37;	A17-B1-C13;	A17-B1-C48;	A18-B1-C24;	A18-B1-C59;
	A16-B1-C38;	A17-B1-C14;	A17-B1-C49;	A18-B1-C25;	A19-B1-C1;
	A16-B1-C39;	A17-B1-C15;	A17-B1-C50;	A18-B1-C26;	A19-B1-C2;
15	A16-B1-C40;	A17-B1-C16;	A17-B1-C51;	A18-B1-C27;	A19-B1-C3;
	A16-B1-C41;	A17-B1-C17;	A17-B1-C52;	A18-B1-C28;	A19-B1-C4;
	A16-B1-C42;	A17-B1-C18;	A17-B1-C53;	A18-B1-C29;	A19-B1-C5;
	A16-B1-C43;	A17-B1-C19;	A17-B1-C54;	A18-B1-C30;	A19-B1-C6;
	A16-B1-C44;	A17-B1-C20;	A17-B1-C55;	A18-B1-C31;	A19-B1-C7;
20	A16-B1-C45;	A17-B1-C21;	A17-B1-C56;	A18-B1-C32;	A19-B1-C8;
	A16-B1-C46;	A17-B1-C22;	A17-B1-C57;	A18-B1-C33;	A19-B1-C9;
	A16-B1-C47;	A17-B1-C23;	A17-B1-C58;	A18-B1-C34;	A19-B1-C10;
	A16-B1-C48;	A17-B1-C24;	A17-B1-C59;	A18-B1-C35;	A19-B1-C11;
	A16-B1-C49;	A17-B1-C25;	A18-B1-C1;	A18-B1-C36;	A19-B1-C12;
25	A16-B1-C50;	A17-B1-C26;	A18-B1-C2;	A18-B1-C37;	A19-B1-C13;
	A16-B1-C51;	A17-B1-C27;	A18-B1-C3;	A18-B1-C38;	A19-B1-C14;
	A16-B1-C52;	A17-B1-C28;	A18-B1-C4;	A18-B1-C39;	A19-B1-C15;
	A16-B1-C53;	A17-B1-C29;	A18-B1-C5;	A18-B1-C40;	A19-B1-C16;
	A16-B1-C54;	A17-B1-C30;	A18-B1-C6;	A18-B1-C41;	A19-B1-C17;
30	A16-B1-C55;	A17-B1-C31;	A18-B1-C7;	A18-B1-C42;	A19-B1-C18;
	A16-B1-C56;	A17-B1-C32;	A18-B1-C8;	A18-B1-C43;	A19-B1-C19;
	A16-B1-C57;	A17-B1-C33;	A18-B1-C9;	A18-B1-C44;	A19-B1-C20;
	A16-B1-C58;	A17-B1-C34;	A18-B1-C10;	A18-B1-C45;	A19-B1-C21;
	A16-B1-C59;	A17-B1-C35;	A18-B1-C11;	A18-B1-C46;	A19-B1-C22;
35	A17-B1-C1;	A17-B1-C36;	A18-B1-C12;	A18-B1-C47;	A19-B1-C23;

	A19-B1-C24;	A19-B1-C59;	A20-B1-C35;	A21-B1-C11;	A21-B1-C46;
	A19-B1-C25;	A20-B1-C1;	A20-B1-C36;	A21-B1-C12;	A21-B1-C47;
	A19-B1-C26;	A20-B1-C2;	A20-B1-C37;	A21-B1-C13;	A21-B1-C48;
	A19-B1-C27;	A20-B1-C3;	A20-B1-C38;	A21-B1-C14;	A21-B1-C49;
5	A19-B1-C28;	A20-B1-C4;	A20-B1-C39;	A21-B1-C15;	A21-B1-C50;
	A19-B1-C29;	A20-B1-C5;	A20-B1-C40;	A21-B1-C16;	A21-B1-C51;
	A19-B1-C30;	A20-B1-C6;	A20-B1-C41;	A21-B1-C17;	A21-B1-C52;
	A19-B1-C31;	A20-B1-C7;	A20-B1-C42;	A21-B1-C18;	A21-B1-C53;
	A19-B1-C32;	A20-B1-C8;	A20-B1-C43;	A21-B1-C19;	A21-B1-C54;
10	A19-B1-C33;	A20-B1-C9;	A20-B1-C44;	A21-B1-C20;	A21-B1-C55;
	A19-B1-C34;	A20-B1-C10;	A20-B1-C45;	A21-B1-C21;	A21-B1-C56;
	A19-B1-C35;	A20-B1-C11;	A20-B1-C46;	A21-B1-C22;	A21-B1-C57;
	A19-B1-C36;	A20-B1-C12;	A20-B1-C47;	A21-B1-C23;	A21-B1-C58;
	A19-B1-C37;	A20-B1-C13;	A20-B1-C48;	A21-B1-C24;	A21-B1-C59;
15	A19-B1-C38;	A20-B1-C14;	A20-B1-C49;	A21-B1-C25;	A22-B1-C1;
	A19-B1-C39;	A20-B1-C15;	A20-B1-C50;	A21-B1-C26;	A22-B1-C2;
	A19-B1-C40;	A20-B1-C16;	A20-B1-C51;	A21-B1-C27;	A22-B1-C3;
	A19-B1-C41;	A20-B1-C17;	A20-B1-C52;	A21-B1-C28;	A22-B1-C4;
	A19-B1-C42;	A20-B1-C18;	A20-B1-C53;	A21-B1-C29;	A22-B1-C5;
20	A19-B1-C43;	A20-B1-C19;	A20-B1-C54;	A21-B1-C30;	A22-B1-C6;
	A19-B1-C44;	A20-B1-C20;	A20-B1-C55;	A21-B1-C31;	A22-B1-C7;
	A19-B1-C45;	A20-B1-C21;	A20-B1-C56;	A21-B1-C32;	A22-B1-C8;
	A19-B1-C46;	A20-B1-C22;	A20-B1-C57;	A21-B1-C33;	A22-B1-C9;
	A19-B1-C47;	A20-B1-C23;	A20-B1-C58;	A21-B1-C34;	A22-B1-C10;
25	A19-B1-C48;	A20-B1-C24;	A20-B1-C59;	A21-B1-C35;	A22-B1-C11;
	A19-B1-C49;	A20-B1-C25;	A21-B1-C1;	A21-B1-C36;	A22-B1-C12;
	A19-B1-C50;	A20-B1-C26;	A21-B1-C2;	A21-B1-C37;	A22-B1-C13;
	A19-B1-C51;	A20-B1-C27;	A21-B1-C3;	A21-B1-C38;	A22-B1-C14;
	A19-B1-C52;	A20-B1-C28;	A21-B1-C4;	A21-B1-C39;	A22-B1-C15;
30	A19-B1-C53;	A20-B1-C29;	A21-B1-C5;	A21-B1-C40;	A22-B1-C16;
	A19-B1-C54;	A20-B1-C30;	A21-B1-C6;	A21-B1-C41;	A22-B1-C17;
	A19-B1-C55;	A20-B1-C31;	A21-B1-C7;	A21-B1-C42;	A22-B1-C18;
	A19-B1-C56;	A20-B1-C32;	A21-B1-C8;	A21-B1-C43;	A22-B1-C19;
	A19-B1-C57;	A20-B1-C33;	A21-B1-C9;	A21-B1-C44;	A22-B1-C20;
35	A19-B1-C58;	A20-B1-C34;	A21-B1-C10;	A21-B1-C45;	A22-B1-C21;

	A22-B1-C22;	A22-B1-C57;	A23-B1-C33;	A24-B1-C9;	A24-B1-C44;
	A22-B1-C23;	A22-B1-C58;	A23-B1-C34;	A24-B1-C10;	A24-B1-C45;
	A22-B1-C24;	A22-B1-C59;	A23-B1-C35;	A24-B1-C11;	A24-B1-C46;
	A22-B1-C25;	A23-B1-C1;	A23-B1-C36;	A24-B1-C12;	A24-B1-C47;
5	A22-B1-C26;	A23-B1-C2;	A23-B1-C37;	A24-B1-C13;	A24-B1-C48;
	A22-B1-C27;	A23-B1-C3;	A23-B1-C38;	A24-B1-C14;	A24-B1-C49;
	A22-B1-C28;	A23-B1-C4;	A23-B1-C39;	A24-B1-C15;	A24-B1-C50;
	A22-B1-C29;	A23-B1-C5;	A23-B1-C40;	A24-B1-C16;	A24-B1-C51;
	A22-B1-C30;	A23-B1-C6;	A23-B1-C41;	A24-B1-C17;	A24-B1-C52;
10	A22-B1-C31;	A23-B1-C7;	A23-B1-C42;	A24-B1-C18;	A24-B1-C53;
	A22-B1-C32;	A23-B1-C8;	A23-B1-C43;	A24-B1-C19;	A24-B1-C54;
	A22-B1-C33;	A23-B1-C9;	A23-B1-C44;	A24-B1-C20;	A24-B1-C55;
	A22-B1-C34;	A23-B1-C10;	A23-B1-C45;	A24-B1-C21;	A24-B1-C56;
	A22-B1-C35;	A23-B1-C11;	A23-B1-C46;	A24-B1-C22;	A24-B1-C57;
15	A22-B1-C36;	A23-B1-C12;	A23-B1-C47;	A24-B1-C23;	A24-B1-C58;
	A22-B1-C37;	A23-B1-C13;	A23-B1-C48;	A24-B1-C24;	A24-B1-C59;
	A22-B1-C38;	A23-B1-C14;	A23-B1-C49;	A24-B1-C25;	A25-B1-C1;
	A22-B1-C39;	A23-B1-C15;	A23-B1-C50;	A24-B1-C26;	A25-B1-C2;
	A22-B1-C40;	A23-B1-C16;	A23-B1-C51;	A24-B1-C27;	A25-B1-C3;
20	A22-B1-C41;	A23-B1-C17;	A23-B1-C52;	A24-B1-C28;	A25-B1-C4;
	A22-B1-C42;	A23-B1-C18;	A23-B1-C53;	A24-B1-C29;	A25-B1-C5;
	A22-B1-C43;	A23-B1-C19;	A23-B1-C54;	A24-B1-C30;	A25-B1-C6;
	A22-B1-C44;	A23-B1-C20;	A23-B1-C55;	A24-B1-C31;	A25-B1-C7;
	A22-B1-C45;	A23-B1-C21;	A23-B1-C56;	A24-B1-C32;	A25-B1-C8;
25	A22-B1-C46;	A23-B1-C22;	A23-B1-C57;	A24-B1-C33;	A25-B1-C9;
	A22-B1-C47;	A23-B1-C23;	A23-B1-C58;	A24-B1-C34;	A25-B1-C10;
	A22-B1-C48;	A23-B1-C24;	A23-B1-C59;	A24-B1-C35;	A25-B1-C11;
	A22-B1-C49;	A23-B1-C25;	A24-B1-C1;	A24-B1-C36;	A25-B1-C12;
	A22-B1-C50;	A23-B1-C26;	A24-B1-C2;	A24-B1-C37;	A25-B1-C13;
30	A22-B1-C51;	A23-B1-C27;	A24-B1-C3;	A24-B1-C38;	A25-B1-C14;
	A22-B1-C52;	A23-B1-C28;	A24-B1-C4;	A24-B1-C39;	A25-B1-C15;
	A22-B1-C53;	A23-B1-C29;	A24-B1-C5;	A24-B1-C40;	A25-B1-C16;
	A22-B1-C54;	A23-B1-C30;	A24-B1-C6;	A24-B1-C41;	A25-B1-C17;
	A22-B1-C55;	A23-B1-C31;	A24-B1-C7;	A24-B1-C42;	A25-B1-C18;
35	A22-B1-C56;	A23-B1-C32;	A24-B1-C8;	A24-B1-C43;	A25-B1-C19;

	A25-B1-C20;	A25-B1-C55;	A26-B1-C31;	A27-B1-C7;	A27-B1-C42;
	A25-B1-C21;	A25-B1-C56;	A26-B1-C32;	A27-B1-C8;	A27-B1-C43;
	A25-B1-C22;	A25-B1-C57;	A26-B1-C33;	A27-B1-C9;	A27-B1-C44;
	A25-B1-C23;	A25-B1-C58;	A26-B1-C34;	A27-B1-C10;	A27-B1-C45;
5	A25-B1-C24;	A25-B1-C59;	A26-B1-C35;	A27-B1-C11;	A27-B1-C46;
	A25-B1-C25;	A26-B1-C1;	A26-B1-C36;	A27-B1-C12;	A27-B1-C47;
	A25-B1-C26;	A26-B1-C2;	A26-B1-C37;	A27-B1-C13;	A27-B1-C48;
	A25-B1-C27;	A26-B1-C3;	A26-B1-C38;	A27-B1-C14;	A27-B1-C49;
	A25-B1-C28;	A26-B1-C4;	A26-B1-C39;	A27-B1-C15;	A27-B1-C50;
10	A25-B1-C29;	A26-B1-C5;	A26-B1-C40;	A27-B1-C16;	A27-B1-C51;
	A25-B1-C30;	A26-B1-C6;	A26-B1-C41;	A27-B1-C17;	A27-B1-C52;
	A25-B1-C31;	A26-B1-C7;	A26-B1-C42;	A27-B1-C18;	A27-B1-C53;
	A25-B1-C32;	A26-B1-C8;	A26-B1-C43;	A27-B1-C19;	A27-B1-C54;
	A25-B1-C33;	A26-B1-C9;	A26-B1-C44;	A27-B1-C20;	A27-B1-C55;
15	A25-B1-C34;	A26-B1-C10;	A26-B1-C45;	A27-B1-C21;	A27-B1-C56;
	A25-B1-C35;	A26-B1-C11;	A26-B1-C46;	A27-B1-C22;	A27-B1-C57;
	A25-B1-C36;	A26-B1-C12;	A26-B1-C47;	A27-B1-C23;	A27-B1-C58;
	A25-B1-C37;	A26-B1-C13;	A26-B1-C48;	A27-B1-C24;	A27-B1-C59;
	A25-B1-C38;	A26-B1-C14;	A26-B1-C49;	A27-B1-C25;	A28-B1-C1;
20	A25-B1-C39;	A26-B1-C15;	A26-B1-C50;	A27-B1-C26;	A28-B1-C2;
	A25-B1-C40;	A26-B1-C16;	A26-B1-C51;	A27-B1-C27;	A28-B1-C3;
	A25-B1-C41;	A26-B1-C17;	A26-B1-C52;	A27-B1-C28;	A28-B1-C4;
	A25-B1-C42;	A26-B1-C18;	A26-B1-C53;	A27-B1-C29;	A28-B1-C5;
	A25-B1-C43;	A26-B1-C19;	A26-B1-C54;	A27-B1-C30;	A28-B1-C6;
25	A25-B1-C44;	A26-B1-C20;	A26-B1-C55;	A27-B1-C31;	A28-B1-C7;
	A25-B1-C45;	A26-B1-C21;	A26-B1-C56;	A27-B1-C32;	A28-B1-C8;
	A25-B1-C46;	A26-B1-C22;	A26-B1-C57;	A27-B1-C33;	A28-B1-C9;
	A25-B1-C47;	A26-B1-C23;	A26-B1-C58;	A27-B1-C34;	A28-B1-C10;
	A25-B1-C48;	A26-B1-C24;	A26-B1-C59;	A27-B1-C35;	A28-B1-C11;
30	A25-B1-C49;	A26-B1-C25;	A27-B1-C1;	A27-B1-C36;	A28-B1-C12;
	A25-B1-C50;	A26-B1-C26;	A27-B1-C2;	A27-B1-C37;	A28-B1-C13;
	A25-B1-C51;	A26-B1-C27;	A27-B1-C3;	A27-B1-C38;	A28-B1-C14;
	A25-B1-C52;	A26-B1-C28;	A27-B1-C4;	A27-B1-C39;	A28-B1-C15;
	A25-B1-C53;	A26-B1-C29;	A27-B1-C5;	A27-B1-C40;	A28-B1-C16;
35	A25-B1-C54;	A26-B1-C30;	A27-B1-C6;	A27-B1-C41;	A28-B1-C17;

	A28-B1-C18;	A28-B1-C53;	A29-B1-C29;	A30-B1-C5;	A30-B1-C40;
	A28-B1-C19;	A28-B1-C54;	A29-B1-C30;	A30-B1-C6;	A30-B1-C41;
	A28-B1-C20;	A28-B1-C55;	A29-B1-C31;	A30-B1-C7;	A30-B1-C42;
	A28-B1-C21;	A28-B1-C56;	A29-B1-C32;	A30-B1-C8;	A30-B1-C43;
5	A28-B1-C22;	A28-B1-C57;	A29-B1-C33;	A30-B1-C9;	A30-B1-C44;
	A28-B1-C23;	A28-B1-C58;	A29-B1-C34;	A30-B1-C10;	A30-B1-C45;
	A28-B1-C24;	A28-B1-C59;	A29-B1-C35;	A30-B1-C11;	A30-B1-C46;
	A28-B1-C25;	A29-B1-C1;	A29-B1-C36;	A30-B1-C12;	A30-B1-C47;
	A28-B1-C26;	A29-B1-C2;	A29-B1-C37;	A30-B1-C13;	A30-B1-C48;
10	A28-B1-C27;	A29-B1-C3;	A29-B1-C38;	A30-B1-C14;	A30-B1-C49;
	A28-B1-C28;	A29-B1-C4;	A29-B1-C39;	A30-B1-C15;	A30-B1-C50;
	A28-B1-C29;	A29-B1-C5;	A29-B1-C40;	A30-B1-C16;	A30-B1-C51;
	A28-B1-C30;	A29-B1-C6;	A29-B1-C41;	A30-B1-C17;	A30-B1-C52;
	A28-B1-C31;	A29-B1-C7;	A29-B1-C42;	A30-B1-C18;	A30-B1-C53;
15	A28-B1-C32;	A29-B1-C8;	A29-B1-C43;	A30-B1-C19;	A30-B1-C54;
	A28-B1-C33;	A29-B1-C9;	A29-B1-C44;	A30-B1-C20;	A30-B1-C55;
	A28-B1-C34;	A29-B1-C10;	A29-B1-C45;	A30-B1-C21;	A30-B1-C56;
	A28-B1-C35;	A29-B1-C11;	A29-B1-C46;	A30-B1-C22;	A30-B1-C57;
	A28-B1-C36;	A29-B1-C12;	A29-B1-C47;	A30-B1-C23;	A30-B1-C58;
20	A28-B1-C37;	A29-B1-C13;	A29-B1-C48;	A30-B1-C24;	A30-B1-C59;
	A28-B1-C38;	A29-B1-C14;	A29-B1-C49;	A30-B1-C25;	A31-B1-C1;
	A28-B1-C39;	A29-B1-C15;	A29-B1-C50;	A30-B1-C26;	A31-B1-C2;
	A28-B1-C40;	A29-B1-C16;	A29-B1-C51;	A30-B1-C27;	A31-B1-C3;
	A28-B1-C41;	A29-B1-C17;	A29-B1-C52;	A30-B1-C28;	A31-B1-C4;
25	A28-B1-C42;	A29-B1-C18;	A29-B1-C53;	A30-B1-C29;	A31-B1-C5;
	A28-B1-C43;	A29-B1-C19;	A29-B1-C54;	A30-B1-C30;	A31-B1-C6;
	A28-B1-C44;	A29-B1-C20;	A29-B1-C55;	A30-B1-C31;	A31-B1-C7;
	A28-B1-C45;	A29-B1-C21;	A29-B1-C56;	A30-B1-C32;	A31-B1-C8;
	A28-B1-C46;	A29-B1-C22;	A29-B1-C57;	A30-B1-C33;	A31-B1-C9;
30	A28-B1-C47;	A29-B1-C23;	A29-B1-C58;	A30-B1-C34;	A31-B1-C10;
	A28-B1-C48;	A29-B1-C24;	A29-B1-C59;	A30-B1-C35;	A31-B1-C11;
	A28-B1-C49;	A29-B1-C25;	A30-B1-C1;	A30-B1-C36;	A31-B1-C12;
	A28-B1-C50;	A29-B1-C26;	A30-B1-C2;	A30-B1-C37;	A31-B1-C13;
	A28-B1-C51;	A29-B1-C27;	A30-B1-C3;	A30-B1-C38;	A31-B1-C14;
35	A28-B1-C52;	A29-B1-C28;	A30-B1-C4;	A30-B1-C39;	A31-B1-C15;

	A31-B1-C16;	A31-B1-C51;	A32-B1-C27;	A33-B1-C3;	A33-B1-C38;
	A31-B1-C17;	A31-B1-C52;	A32-B1-C28;	A33-B1-C4;	A33-B1-C39;
	A31-B1-C18;	A31-B1-C53;	A32-B1-C29;	A33-B1-C5;	A33-B1-C40;
	A31-B1-C19;	A31-B1-C54;	A32-B1-C30;	A33-B1-C6;	A33-B1-C41;
5	A31-B1-C20;	A31-B1-C55;	A32-B1-C31;	A33-B1-C7;	A33-B1-C42;
	A31-B1-C21;	A31-B1-C56;	A32-B1-C32;	A33-B1-C8;	A33-B1-C43;
	A31-B1-C22;	A31-B1-C57;	A32-B1-C33;	A33-B1-C9;	A33-B1-C44;
	A31-B1-C23;	A31-B1-C58;	A32-B1-C34;	A33-B1-C10;	A33-B1-C45;
	A31-B1-C24;	A31-B1-C59;	A32-B1-C35;	A33-B1-C11;	A33-B1-C46;
10	A31-B1-C25;	A32-B1-C1;	A32-B1-C36;	A33-B1-C12;	A33-B1-C47;
	A31-B1-C26;	A32-B1-C2;	A32-B1-C37;	A33-B1-C13;	A33-B1-C48;
	A31-B1-C27;	A32-B1-C3;	A32-B1-C38;	A33-B1-C14;	A33-B1-C49;
	A31-B1-C28;	A32-B1-C4;	A32-B1-C39;	A33-B1-C15;	A33-B1-C50;
	A31-B1-C29;	A32-B1-C5;	A32-B1-C40;	A33-B1-C16;	A33-B1-C51;
15	A31-B1-C30;	A32-B1-C6;	A32-B1-C41;	A33-B1-C17;	A33-B1-C52;
	A31-B1-C31;	A32-B1-C7;	A32-B1-C42;	A33-B1-C18;	A33-B1-C53;
	A31-B1-C32;	A32-B1-C8;	A32-B1-C43;	A33-B1-C19;	A33-B1-C54;
	A31-B1-C33;	A32-B1-C9;	A32-B1-C44;	A33-B1-C20;	A33-B1-C55;
	A31-B1-C34;	A32-B1-C10;	A32-B1-C45;	A33-B1-C21;	A33-B1-C56;
20	A31-B1-C35;	A32-B1-C11;	A32-B1-C46;	A33-B1-C22;	A33-B1-C57;
	A31-B1-C36;	A32-B1-C12;	A32-B1-C47;	A33-B1-C23;	A33-B1-C58;
	A31-B1-C37;	A32-B1-C13;	A32-B1-C48;	A33-B1-C24;	A33-B1-C59;
	A31-B1-C38;	A32-B1-C14;	A32-B1-C49;	A33-B1-C25;	A34-B1-C1;
	A31-B1-C39;	A32-B1-C15;	A32-B1-C50;	A33-B1-C26;	A34-B1-C2;
25	A31-B1-C40;	A32-B1-C16;	A32-B1-C51;	A33-B1-C27;	A34-B1-C3;
	A31-B1-C41;	A32-B1-C17;	A32-B1-C52;	A33-B1-C28;	A34-B1-C4;
	A31-B1-C42;	A32-B1-C18;	A32-B1-C53;	A33-B1-C29;	A34-B1-C5;
	A31-B1-C43;	A32-B1-C19;	A32-B1-C54;	A33-B1-C30;	A34-B1-C6;
	A31-B1-C44;	A32-B1-C20;	A32-B1-C55;	A33-B1-C31;	A34-B1-C7;
30	A31-B1-C45;	A32-B1-C21;	A32-B1-C56;	A33-B1-C32;	A34-B1-C8;
	A31-B1-C46;	A32-B1-C22;	A32-B1-C57;	A33-B1-C33;	A34-B1-C9;
	A31-B1-C47;	A32-B1-C23;	A32-B1-C58;	A33-B1-C34;	A34-B1-C10;
	A31-B1-C48;	A32-B1-C24;	A32-B1-C59;	A33-B1-C35;	A34-B1-C11;
	A31-B1-C49;	A32-B1-C25;	A33-B1-C1;	A33-B1-C36;	A34-B1-C12;
35	A31-B1-C50;	A32-B1-C26;	A33-B1-C2;	A33-B1-C37;	A34-B1-C13;

	A34-B1-C14;	A34-B1-C49;	A35-B1-C25;	A1-B2-C1;	A1-B2-C36;
	A34-B1-C15;	A34-B1-C50;	A35-B1-C26;	A1-B2-C2;	A1-B2-C37;
	A34-B1-C16;	A34-B1-C51;	A35-B1-C27;	A1-B2-C3;	A1-B2-C38;
	A34-B1-C17;	A34-B1-C52;	A35-B1-C28;	A1-B2-C4;	A1-B2-C39;
5	A34-B1-C18;	A34-B1-C53;	A35-B1-C29;	A1-B2-C5;	A1-B2-C40;
	A34-B1-C19;	A34-B1-C54;	A35-B1-C30;	A1-B2-C6;	A1-B2-C41;
	A34-B1-C20;	A34-B1-C55;	A35-B1-C31;	A1-B2-C7;	A1-B2-C42;
	A34-B1-C21;	A34-B1-C56;	A35-B1-C32;	A1-B2-C8;	A1-B2-C43;
	A34-B1-C22;	A34-B1-C57;	A35-B1-C33;	A1-B2-C9;	A1-B2-C44;
10	A34-B1-C23;	A34-B1-C58;	A35-B1-C34;	A1-B2-C10;	A1-B2-C45;
	A34-B1-C24;	A34-B1-C59;	A35-B1-C35;	A1-B2-C11;	A1-B2-C46;
	A34-B1-C25;	A35-B1-C1;	A35-B1-C36;	A1-B2-C12;	A1-B2-C47;
	A34-B1-C26;	A35-B1-C2;	A35-B1-C37;	A1-B2-C13;	A1-B2-C48;
	A34-B1-C27;	A35-B1-C3;	A35-B1-C38;	A1-B2-C14;	A1-B2-C49;
15	A34-B1-C28;	A35-B1-C4;	A35-B1-C39;	A1-B2-C15;	A1-B2-C50;
	A34-B1-C29;	A35-B1-C5;	A35-B1-C40;	A1-B2-C16;	A1-B2-C51;
	A34-B1-C30;	A35-B1-C6;	A35-B1-C41;	A1-B2-C17;	A1-B2-C52;
	A34-B1-C31;	A35-B1-C7;	A35-B1-C42;	A1-B2-C18;	A1-B2-C53;
	A34-B1-C32;	A35-B1-C8;	A35-B1-C43;	A1-B2-C19;	A1-B2-C54;
20	A34-B1-C33;	A35-B1-C9;	A35-B1-C44;	A1-B2-C20;	A1-B2-C55;
	A34-B1-C34;	A35-B1-C10;	A35-B1-C45;	A1-B2-C21;	A1-B2-C56;
	A34-B1-C35;	A35-B1-C11;	A35-B1-C46;	A1-B2-C22;	A1-B2-C57;
	A34-B1-C36;	A35-B1-C12;	A35-B1-C47;	A1-B2-C23;	A1-B2-C58;
	A34-B1-C37;	A35-B1-C13;	A35-B1-C48;	A1-B2-C24;	A1-B2-C59;
25	A34-B1-C38;	A35-B1-C14;	A35-B1-C49;	A1-B2-C25;	A2-B2-C1;
	A34-B1-C39;	A35-B1-C15;	A35-B1-C50;	A1-B2-C26;	A2-B2-C2;
	A34-B1-C40;	A35-B1-C16;	A35-B1-C51;	A1-B2-C27;	A2-B2-C3;
	A34-B1-C41;	A35-B1-C17;	A35-B1-C52;	A1-B2-C28;	A2-B2-C4;
	A34-B1-C42;	A35-B1-C18;	A35-B1-C53;	A1-B2-C29;	A2-B2-C5;
30	A34-B1-C43;	A35-B1-C19;	A35-B1-C54;	A1-B2-C30;	A2-B2-C6;
	A34-B1-C44;	A35-B1-C20;	A35-B1-C55;	A1-B2-C31;	A2-B2-C7;
	A34-B1-C45;	A35-B1-C21;	A35-B1-C56;	A1-B2-C32;	A2-B2-C8;
	A34-B1-C46;	A35-B1-C22;	A35-B1-C57;	A1-B2-C33;	A2-B2-C9;
	A34-B1-C47;	A35-B1-C23;	A35-B1-C58;	A1-B2-C34;	A2-B2-C10;
35	A34-B1-C48;	A35-B1-C24;	A35-B1-C59;	A1-B2-C35;	A2-B2-C11;

	A2-B2-C12;	A2-B2-C47;	A3-B2-C23;	A3-B2-C58;	A4-B2-C34;
	A2-B2-C13;	A2-B2-C48;	A3-B2-C24;	A3-B2-C59;	A4-B2-C35;
	A2-B2-C14;	A2-B2-C49;	A3-B2-C25;	A4-B2-C1;	A4-B2-C36;
	A2-B2-C15;	A2-B2-C50;	A3-B2-C26;	A4-B2-C2;	A4-B2-C37;
5	A2-B2-C16;	A2-B2-C51;	A3-B2-C27;	A4-B2-C3;	A4-B2-C38;
	A2-B2-C17;	A2-B2-C52;	A3-B2-C28;	A4-B2-C4;	A4-B2-C39;
	A2-B2-C18;	A2-B2-C53;	A3-B2-C29;	A4-B2-C5;	A4-B2-C40;
	A2-B2-C19;	A2-B2-C54;	A3-B2-C30;	A4-B2-C6;	A4-B2-C41;
	A2-B2-C20;	A2-B2-C55;	A3-B2-C31;	A4-B2-C7;	A4-B2-C42;
10	A2-B2-C21;	A2-B2-C56;	A3-B2-C32;	A4-B2-C8;	A4-B2-C43;
	A2-B2-C22;	A2-B2-C57;	A3-B2-C33;	A4-B2-C9;	A4-B2-C44;
	A2-B2-C23;	A2-B2-C58;	A3-B2-C34;	A4-B2-C10;	A4-B2-C45;
	A2-B2-C24;	A2-B2-C59;	A3-B2-C35;	A4-B2-C11;	A4-B2-C46;
	A2-B2-C25;	A3-B2-C1;	A3-B2-C36;	A4-B2-C12;	A4-B2-C47;
15	A2-B2-C26;	A3-B2-C2;	A3-B2-C37;	A4-B2-C13;	A4-B2-C48;
	A2-B2-C27;	A3-B2-C3;	A3-B2-C38;	A4-B2-C14;	A4-B2-C49;
	A2-B2-C28;	A3-B2-C4;	A3-B2-C39;	A4-B2-C15;	A4-B2-C50;
	A2-B2-C29;	A3-B2-C5;	A3-B2-C40;	A4-B2-C16;	A4-B2-C51;
	A2-B2-C30;	A3-B2-C6;	A3-B2-C41;	A4-B2-C17;	A4-B2-C52;
20	A2-B2-C31;	A3-B2-C7;	A3-B2-C42;	A4-B2-C18;	A4-B2-C53;
	A2-B2-C32;	A3-B2-C8;	A3-B2-C43;	A4-B2-C19;	A4-B2-C54;
	A2-B2-C33;	A3-B2-C9;	A3-B2-C44;	A4-B2-C20;	A4-B2-C55;
	A2-B2-C34;	A3-B2-C10;	A3-B2-C45;	A4-B2-C21;	A4-B2-C56;
	A2-B2-C35;	A3-B2-C11;	A3-B2-C46;	A4-B2-C22;	A4-B2-C57;
25	A2-B2-C36;	A3-B2-C12;	A3-B2-C47;	A4-B2-C23;	A4-B2-C58;
	A2-B2-C37;	A3-B2-C13;	A3-B2-C48;	A4-B2-C24;	A4-B2-C59;
	A2-B2-C38;	A3-B2-C14;	A3-B2-C49;	A4-B2-C25;	A5-B2-C1;
	A2-B2-C39;	A3-B2-C15;	A3-B2-C50;	A4-B2-C26;	A5-B2-C2;
	A2-B2-C40;	A3-B2-C16;	A3-B2-C51;	A4-B2-C27;	A5-B2-C3;
30	A2-B2-C41;	A3-B2-C17;	A3-B2-C52;	A4-B2-C28;	A5-B2-C4;
	A2-B2-C42;	A3-B2-C18;	A3-B2-C53;	A4-B2-C29;	A5-B2-C5;
	A2-B2-C43;	A3-B2-C19;	A3-B2-C54;	A4-B2-C30;	A5-B2-C6;
	A2-B2-C44;	A3-B2-C20;	A3-B2-C55;	A4-B2-C31;	A5-B2-C7;
	A2-B2-C45;	A3-B2-C21;	A3-B2-C56;	A4-B2-C32;	A5-B2-C8;
35	A2-B2-C46;	A3-B2-C22;	A3-B2-C57;	A4-B2-C33;	A5-B2-C9;

	A5-B2-C10;	A5-B2-C45;	A6-B2-C21;	A6-B2-C56;	A7-B2-C32;
	A5-B2-C11;	A5-B2-C46;	A6-B2-C22;	A6-B2-C57;	A7-B2-C33;
	A5-B2-C12;	A5-B2-C47;	A6-B2-C23;	A6-B2-C58;	A7-B2-C34;
	A5-B2-C13;	A5-B2-C48;	A6-B2-C24;	A6-B2-C59;	A7-B2-C35;
5	A5-B2-C14;	A5-B2-C49;	A6-B2-C25;	A7-B2-C1;	A7-B2-C36;
	A5-B2-C15;	A5-B2-C50;	A6-B2-C26;	A7-B2-C2;	A7-B2-C37;
	A5-B2-C16;	A5-B2-C51;	A6-B2-C27;	A7-B2-C3;	A7-B2-C38;
	A5-B2-C17;	A5-B2-C52;	A6-B2-C28;	A7-B2-C4;	A7-B2-C39;
	A5-B2-C18;	A5-B2-C53;	A6-B2-C29;	A7-B2-C5;	A7-B2-C40;
10	A5-B2-C19;	A5-B2-C54;	A6-B2-C30;	A7-B2-C6;	A7-B2-C41;
	A5-B2-C20;	A5-B2-C55;	A6-B2-C31;	A7-B2-C7;	A7-B2-C42;
	A5-B2-C21;	A5-B2-C56;	A6-B2-C32;	A7-B2-C8;	A7-B2-C43;
	A5-B2-C22;	A5-B2-C57;	A6-B2-C33;	A7-B2-C9;	A7-B2-C44;
	A5-B2-C23;	A5-B2-C58;	A6-B2-C34;	A7-B2-C10;	A7-B2-C45;
15	A5-B2-C24;	A5-B2-C59;	A6-B2-C35;	A7-B2-C11;	A7-B2-C46;
	A5-B2-C25;	A6-B2-C1;	A6-B2-C36;	A7-B2-C12;	A7-B2-C47;
	A5-B2-C26;	A6-B2-C2;	A6-B2-C37;	A7-B2-C13;	A7-B2-C48;
	A5-B2-C27;	A6-B2-C3;	A6-B2-C38;	A7-B2-C14;	A7-B2-C49;
	A5-B2-C28;	A6-B2-C4;	A6-B2-C39;	A7-B2-C15;	A7-B2-C50;
20	A5-B2-C29;	A6-B2-C5;	A6-B2-C40;	A7-B2-C16;	A7-B2-C51;
	A5-B2-C30;	A6-B2-C6;	A6-B2-C41;	A7-B2-C17;	A7-B2-C52;
	A5-B2-C31;	A6-B2-C7;	A6-B2-C42;	A7-B2-C18;	A7-B2-C53;
	A5-B2-C32;	A6-B2-C8;	A6-B2-C43;	A7-B2-C19;	A7-B2-C54;
	A5-B2-C33;	A6-B2-C9;	A6-B2-C44;	A7-B2-C20;	A7-B2-C55;
25	A5-B2-C34;	A6-B2-C10;	A6-B2-C45;	A7-B2-C21;	A7-B2-C56;
	A5-B2-C35;	A6-B2-C11;	A6-B2-C46;	A7-B2-C22;	A7-B2-C57;
	A5-B2-C36;	A6-B2-C12;	A6-B2-C47;	A7-B2-C23;	A7-B2-C58;
	A5-B2-C37;	A6-B2-C13;	A6-B2-C48;	A7-B2-C24;	A7-B2-C59;
	A5-B2-C38;	A6-B2-C14;	A6-B2-C49;	A7-B2-C25;	A8-B2-C1;
30	A5-B2-C39;	A6-B2-C15;	A6-B2-C50;	A7-B2-C26;	A8-B2-C2;
	A5-B2-C40;	A6-B2-C16;	A6-B2-C51;	A7-B2-C27;	A8-B2-C3;
	A5-B2-C41;	A6-B2-C17;	A6-B2-C52;	A7-B2-C28;	A8-B2-C4;
	A5-B2-C42;	A6-B2-C18;	A6-B2-C53;	A7-B2-C29;	A8-B2-C5;
	A5-B2-C43;	A6-B2-C19;	A6-B2-C54;	A7-B2-C30;	A8-B2-C6;
35	A5-B2-C44;	A6-B2-C20;	A6-B2-C55;	A7-B2-C31;	A8-B2-C7;

	A8-B2-C8;	A8-B2-C43;	A9-B2-C19;	A9-B2-C54;	A10-B2-C30;
	A8-B2-C9;	A8-B2-C44;	A9-B2-C20;	A9-B2-C55;	A10-B2-C31;
	A8-B2-C10;	A8-B2-C45;	A9-B2-C21;	A9-B2-C56;	A10-B2-C32;
	A8-B2-C11;	A8-B2-C46;	A9-B2-C22;	A9-B2-C57;	A10-B2-C33;
5	A8-B2-C12;	A8-B2-C47;	A9-B2-C23;	A9-B2-C58;	A10-B2-C34;
	A8-B2-C13;	A8-B2-C48;	A9-B2-C24;	A9-B2-C59;	A10-B2-C35;
	A8-B2-C14;	A8-B2-C49;	A9-B2-C25;	A10-B2-C1;	A10-B2-C36;
	A8-B2-C15;	A8-B2-C50;	A9-B2-C26;	A10-B2-C2;	A10-B2-C37;
	A8-B2-C16;	A8-B2-C51;	A9-B2-C27;	A10-B2-C3;	A10-B2-C38;
10	A8-B2-C17;	A8-B2-C52;	A9-B2-C28;	A10-B2-C4;	A10-B2-C39;
	A8-B2-C18;	A8-B2-C53;	A9-B2-C29;	A10-B2-C5;	A10-B2-C40;
	A8-B2-C19;	A8-B2-C54;	A9-B2-C30;	A10-B2-C6;	A10-B2-C41;
	A8-B2-C20;	A8-B2-C55;	A9-B2-C31;	A10-B2-C7;	A10-B2-C42;
	A8-B2-C21;	A8-B2-C56;	A9-B2-C32;	A10-B2-C8;	A10-B2-C43;
15	A8-B2-C22;	A8-B2-C57;	A9-B2-C33;	A10-B2-C9;	A10-B2-C44;
	A8-B2-C23;	A8-B2-C58;	A9-B2-C34;	A10-B2-C10;	A10-B2-C45;
	A8-B2-C24;	A8-B2-C59;	A9-B2-C35;	A10-B2-C11;	A10-B2-C46;
	A8-B2-C25;	A9-B2-C1;	A9-B2-C36;	A10-B2-C12;	A10-B2-C47;
	A8-B2-C26;	A9-B2-C2;	A9-B2-C37;	A10-B2-C13;	A10-B2-C48;
20	A8-B2-C27;	A9-B2-C3;	A9-B2-C38;	A10-B2-C14;	A10-B2-C49;
	A8-B2-C28;	A9-B2-C4;	A9-B2-C39;	A10-B2-C15;	A10-B2-C50;
	A8-B2-C29;	A9-B2-C5;	A9-B2-C40;	A10-B2-C16;	A10-B2-C51;
	A8-B2-C30;	A9-B2-C6;	A9-B2-C41;	A10-B2-C17;	A10-B2-C52;
	A8-B2-C31;	A9-B2-C7;	A9-B2-C42;	A10-B2-C18;	A10-B2-C53;
25	A8-B2-C32;	A9-B2-C8;	A9-B2-C43;	A10-B2-C19;	A10-B2-C54;
	A8-B2-C33;	A9-B2-C9;	A9-B2-C44;	A10-B2-C20;	A10-B2-C55;
	A8-B2-C34;	A9-B2-C10;	A9-B2-C45;	A10-B2-C21;	A10-B2-C56;
	A8-B2-C35;	A9-B2-C11;	A9-B2-C46;	A10-B2-C22;	A10-B2-C57;
	A8-B2-C36;	A9-B2-C12;	A9-B2-C47;	A10-B2-C23;	A10-B2-C58;
30	A8-B2-C37;	A9-B2-C13;	A9-B2-C48;	A10-B2-C24;	A10-B2-C59;
	A8-B2-C38;	A9-B2-C14;	A9-B2-C49;	A10-B2-C25;	A11-B2-C1;
	A8-B2-C39;	A9-B2-C15;	A9-B2-C50;	A10-B2-C26;	A11-B2-C2;
	A8-B2-C40;	A9-B2-C16;	A9-B2-C51;	A10-B2-C27;	A11-B2-C3;
	A8-B2-C41;	A9-B2-C17;	A9-B2-C52;	A10-B2-C28;	A11-B2-C4;
35	A8-B2-C42;	A9-B2-C18;	A9-B2-C53;	A10-B2-C29;	A11-B2-C5;

	A11-B2-C6;	A11-B2-C41;	A12-B2-C17;	A12-B2-C52;	A13-B2-C28;
	A11-B2-C7;	A11-B2-C42;	A12-B2-C18;	A12-B2-C53;	A13-B2-C29;
	A11-B2-C8;	A11-B2-C43;	A12-B2-C19;	A12-B2-C54;	A13-B2-C30;
	A11-B2-C9;	A11-B2-C44;	A12-B2-C20;	A12-B2-C55;	A13-B2-C31;
5	A11-B2-C10;	A11-B2-C45;	A12-B2-C21;	A12-B2-C56;	A13-B2-C32;
	A11-B2-C11;	A11-B2-C46;	A12-B2-C22;	A12-B2-C57;	A13-B2-C33;
	A11-B2-C12;	A11-B2-C47;	A12-B2-C23;	A12-B2-C58;	A13-B2-C34;
	A11-B2-C13;	A11-B2-C48;	A12-B2-C24;	A12-B2-C59;	A13-B2-C35;
	A11-B2-C14;	A11-B2-C49;	A12-B2-C25;	A13-B2-C1;	A13-B2-C36;
10	A11-B2-C15;	A11-B2-C50;	A12-B2-C26;	A13-B2-C2;	A13-B2-C37;
	A11-B2-C16;	A11-B2-C51;	A12-B2-C27;	A13-B2-C3;	A13-B2-C38;
	A11-B2-C17;	A11-B2-C52;	A12-B2-C28;	A13-B2-C4;	A13-B2-C39;
	A11-B2-C18;	A11-B2-C53;	A12-B2-C29;	A13-B2-C5;	A13-B2-C40;
	A11-B2-C19;	A11-B2-C54;	A12-B2-C30;	A13-B2-C6;	A13-B2-C41;
15	A11-B2-C20;	A11-B2-C55;	A12-B2-C31;	A13-B2-C7;	A13-B2-C42;
	A11-B2-C21;	A11-B2-C56;	A12-B2-C32;	A13-B2-C8;	A13-B2-C43;
	A11-B2-C22;	A11-B2-C57;	A12-B2-C33;	A13-B2-C9;	A13-B2-C44;
	A11-B2-C23;	A11-B2-C58;	A12-B2-C34;	A13-B2-C10;	A13-B2-C45;
	A11-B2-C24;	A11-B2-C59;	A12-B2-C35;	A13-B2-C11;	A13-B2-C46;
20	A11-B2-C25;	A12-B2-C1;	A12-B2-C36;	A13-B2-C12;	A13-B2-C47;
	A11-B2-C26;	A12-B2-C2;	A12-B2-C37;	A13-B2-C13;	A13-B2-C48;
	A11-B2-C27;	A12-B2-C3;	A12-B2-C38;	A13-B2-C14;	A13-B2-C49;
	A11-B2-C28;	A12-B2-C4;	A12-B2-C39;	A13-B2-C15;	A13-B2-C50;
	A11-B2-C29;	A12-B2-C5;	A12-B2-C40;	A13-B2-C16;	A13-B2-C51;
25	A11-B2-C30;	A12-B2-C6;	A12-B2-C41;	A13-B2-C17;	A13-B2-C52;
	A11-B2-C31;	A12-B2-C7;	A12-B2-C42;	A13-B2-C18;	A13-B2-C53;
	A11-B2-C32;	A12-B2-C8;	A12-B2-C43;	A13-B2-C19;	A13-B2-C54;
	A11-B2-C33;	A12-B2-C9;	A12-B2-C44;	A13-B2-C20;	A13-B2-C55;
	A11-B2-C34;	A12-B2-C10;	A12-B2-C45;	A13-B2-C21;	A13-B2-C56;
30	A11-B2-C35;	A12-B2-C11;	A12-B2-C46;	A13-B2-C22;	A13-B2-C57;
	A11-B2-C36;	A12-B2-C12;	A12-B2-C47;	A13-B2-C23;	A13-B2-C58;
	A11-B2-C37;	A12-B2-C13;	A12-B2-C48;	A13-B2-C24;	A13-B2-C59;
	A11-B2-C38;	A12-B2-C14;	A12-B2-C49;	A13-B2-C25;	A14-B2-C1;
	A11-B2-C39;	A12-B2-C15;	A12-B2-C50;	A13-B2-C26;	A14-B2-C2;
35	A11-B2-C40;	A12-B2-C16;	A12-B2-C51;	A13-B2-C27;	A14-B2-C3;

	A14-B2-C4;	A14-B2-C39;	A15-B2-C15;	A15-B2-C50;	A16-B2-C26;
	A14-B2-C5;	A14-B2-C40;	A15-B2-C16;	A15-B2-C51;	A16-B2-C27;
	A14-B2-C6;	A14-B2-C41;	A15-B2-C17;	A15-B2-C52;	A16-B2-C28;
	A14-B2-C7;	A14-B2-C42;	A15-B2-C18;	A15-B2-C53;	A16-B2-C29;
5	A14-B2-C8;	A14-B2-C43;	A15-B2-C19;	A15-B2-C54;	A16-B2-C30;
	A14-B2-C9;	A14-B2-C44;	A15-B2-C20;	A15-B2-C55;	A16-B2-C31;
	A14-B2-C10;	A14-B2-C45;	A15-B2-C21;	A15-B2-C56;	A16-B2-C32;
	A14-B2-C11;	A14-B2-C46;	A15-B2-C22;	A15-B2-C57;	A16-B2-C33;
	A14-B2-C12;	A14-B2-C47;	A15-B2-C23;	A15-B2-C58;	A16-B2-C34;
10	A14-B2-C13;	A14-B2-C48;	A15-B2-C24;	A15-B2-C59;	A16-B2-C35;
	A14-B2-C14;	A14-B2-C49;	A15-B2-C25;	A16-B2-C1;	A16-B2-C36;
	A14-B2-C15;	A14-B2-C50;	A15-B2-C26;	A16-B2-C2;	A16-B2-C37;
	A14-B2-C16;	A14-B2-C51;	A15-B2-C27;	A16-B2-C3;	A16-B2-C38;
	A14-B2-C17;	A14-B2-C52;	A15-B2-C28;	A16-B2-C4;	A16-B2-C39;
15	A14-B2-C18;	A14-B2-C53;	A15-B2-C29;	A16-B2-C5;	A16-B2-C40;
	A14-B2-C19;	A14-B2-C54;	A15-B2-C30;	A16-B2-C6;	A16-B2-C41;
	A14-B2-C20;	A14-B2-C55;	A15-B2-C31;	A16-B2-C7;	A16-B2-C42;
	A14-B2-C21;	A14-B2-C56;	A15-B2-C32;	A16-B2-C8;	A16-B2-C43;
	A14-B2-C22;	A14-B2-C57;	A15-B2-C33;	A16-B2-C9;	A16-B2-C44;
20	A14-B2-C23;	A14-B2-C58;	A15-B2-C34;	A16-B2-C10;	A16-B2-C45;
	A14-B2-C24;	A14-B2-C59;	A15-B2-C35;	A16-B2-C11;	A16-B2-C46;
	A14-B2-C25;	A15-B2-C1;	A15-B2-C36;	A16-B2-C12;	A16-B2-C47;
	A14-B2-C26;	A15-B2-C2;	A15-B2-C37;	A16-B2-C13;	A16-B2-C48;
	A14-B2-C27;	A15-B2-C3;	A15-B2-C38;	A16-B2-C14;	A16-B2-C49;
25	A14-B2-C28;	A15-B2-C4;	A15-B2-C39;	A16-B2-C15;	A16-B2-C50;
	A14-B2-C29;	A15-B2-C5;	A15-B2-C40;	A16-B2-C16;	A16-B2-C51;
	A14-B2-C30;	A15-B2-C6;	A15-B2-C41;	A16-B2-C17;	A16-B2-C52;
	A14-B2-C31;	A15-B2-C7;	A15-B2-C42;	A16-B2-C18;	A16-B2-C53;
	A14-B2-C32;	A15-B2-C8;	A15-B2-C43;	A16-B2-C19;	A16-B2-C54;
30	A14-B2-C33;	A15-B2-C9;	A15-B2-C44;	A16-B2-C20;	A16-B2-C55;
	A14-B2-C34;	A15-B2-C10;	A15-B2-C45;	A16-B2-C21;	A16-B2-C56;
	A14-B2-C35;	A15-B2-C11;	A15-B2-C46;	A16-B2-C22;	A16-B2-C57;
	A14-B2-C36;	A15-B2-C12;	A15-B2-C47;	A16-B2-C23;	A16-B2-C58;
	A14-B2-C37;	A15-B2-C13;	A15-B2-C48;	A16-B2-C24;	A16-B2-C59;
35	A14-B2-C38;	A15-B2-C14;	A15-B2-C49;	A16-B2-C25;	A17-B2-C1;

	A17-B2-C2;	A17-B2-C37;	A18-B2-C13;	A18-B2-C48;	A19-B2-C24;
	A17-B2-C3;	A17-B2-C38;	A18-B2-C14;	A18-B2-C49;	A19-B2-C25;
	A17-B2-C4;	A17-B2-C39;	A18-B2-C15;	A18-B2-C50;	A19-B2-C26;
	A17-B2-C5;	A17-B2-C40;	A18-B2-C16;	A18-B2-C51;	A19-B2-C27;
5	A17-B2-C6;	A17-B2-C41;	A18-B2-C17;	A18-B2-C52;	A19-B2-C28;
	A17-B2-C7;	A17-B2-C42;	A18-B2-C18;	A18-B2-C53;	A19-B2-C29;
	A17-B2-C8;	A17-B2-C43;	A18-B2-C19;	A18-B2-C54;	A19-B2-C30;
	A17-B2-C9;	A17-B2-C44;	A18-B2-C20;	A18-B2-C55;	A19-B2-C31;
	A17-B2-C10;	A17-B2-C45;	A18-B2-C21;	A18-B2-C56;	A19-B2-C32;
10	A17-B2-C11;	A17-B2-C46;	A18-B2-C22;	A18-B2-C57;	A19-B2-C33;
	A17-B2-C12;	A17-B2-C47;	A18-B2-C23;	A18-B2-C58;	A19-B2-C34;
	A17-B2-C13;	A17-B2-C48;	A18-B2-C24;	A18-B2-C59;	A19-B2-C35;
	A17-B2-C14;	A17-B2-C49;	A18-B2-C25;	A19-B2-C1;	A19-B2-C36;
	A17-B2-C15;	A17-B2-C50;	A18-B2-C26;	A19-B2-C2;	A19-B2-C37;
15	A17-B2-C16;	A17-B2-C51;	A18-B2-C27;	A19-B2-C3;	A19-B2-C38;
	A17-B2-C17;	A17-B2-C52;	A18-B2-C28;	A19-B2-C4;	A19-B2-C39;
	A17-B2-C18;	A17-B2-C53;	A18-B2-C29;	A19-B2-C5;	A19-B2-C40;
	A17-B2-C19;	A17-B2-C54;	A18-B2-C30;	A19-B2-C6;	A19-B2-C41;
	A17-B2-C20;	A17-B2-C55;	A18-B2-C31;	A19-B2-C7;	A19-B2-C42;
20	A17-B2-C21;	A17-B2-C56;	A18-B2-C32;	A19-B2-C8;	A19-B2-C43;
	A17-B2-C22;	A17-B2-C57;	A18-B2-C33;	A19-B2-C9;	A19-B2-C44;
	A17-B2-C23;	A17-B2-C58;	A18-B2-C34;	A19-B2-C10;	A19-B2-C45;
	A17-B2-C24;	A17-B2-C59;	A18-B2-C35;	A19-B2-C11;	A19-B2-C46;
	A17-B2-C25;	A18-B2-C1;	A18-B2-C36;	A19-B2-C12;	A19-B2-C47;
25	A17-B2-C26;	A18-B2-C2;	A18-B2-C37;	A19-B2-C13;	A19-B2-C48;
	A17-B2-C27;	A18-B2-C3;	A18-B2-C38;	A19-B2-C14;	A19-B2-C49;
	A17-B2-C28;	A18-B2-C4;	A18-B2-C39;	A19-B2-C15;	A19-B2-C50;
	A17-B2-C29;	A18-B2-C5;	A18-B2-C40;	A19-B2-C16;	A19-B2-C51;
	A17-B2-C30;	A18-B2-C6;	A18-B2-C41;	A19-B2-C17;	A19-B2-C52;
30	A17-B2-C31;	A18-B2-C7;	A18-B2-C42;	A19-B2-C18;	A19-B2-C53;
	A17-B2-C32;	A18-B2-C8;	A18-B2-C43;	A19-B2-C19;	A19-B2-C54;
	A17-B2-C33;	A18-B2-C9;	A18-B2-C44;	A19-B2-C20;	A19-B2-C55;
	A17-B2-C34;	A18-B2-C10;	A18-B2-C45;	A19-B2-C21;	A19-B2-C56;
	A17-B2-C35;	A18-B2-C11;	A18-B2-C46;	A19-B2-C22;	A19-B2-C57;
35	A17-B2-C36;	A18-B2-C12;	A18-B2-C47;	A19-B2-C23;	A19-B2-C58;

	A19-B2-C59;	A20-B2-C35;	A21-B2-C11;	A21-B2-C46;	A22-B2-C22;
	A20-B2-C1;	A20-B2-C36;	A21-B2-C12;	A21-B2-C47;	A22-B2-C23;
	A20-B2-C2;	A20-B2-C37;	A21-B2-C13;	A21-B2-C48;	A22-B2-C24;
	A20-B2-C3;	A20-B2-C38;	A21-B2-C14;	A21-B2-C49;	A22-B2-C25;
5	A20-B2-C4;	A20-B2-C39;	A21-B2-C15;	A21-B2-C50;	A22-B2-C26;
	A20-B2-C5;	A20-B2-C40;	A21-B2-C16;	A21-B2-C51;	A22-B2-C27;
	A20-B2-C6;	A20-B2-C41;	A21-B2-C17;	A21-B2-C52;	A22-B2-C28;
	A20-B2-C7;	A20-B2-C42;	A21-B2-C18;	A21-B2-C53;	A22-B2-C29;
	A20-B2-C8;	A20-B2-C43;	A21-B2-C19;	A21-B2-C54;	A22-B2-C30;
10	A20-B2-C9;	A20-B2-C44;	A21-B2-C20;	A21-B2-C55;	A22-B2-C31;
	A20-B2-C10;	A20-B2-C45;	A21-B2-C21;	A21-B2-C56;	A22-B2-C32;
	A20-B2-C11;	A20-B2-C46;	A21-B2-C22;	A21-B2-C57;	A22-B2-C33;
	A20-B2-C12;	A20-B2-C47;	A21-B2-C23;	A21-B2-C58;	A22-B2-C34;
	A20-B2-C13;	A20-B2-C48;	A21-B2-C24;	A21-B2-C59;	A22-B2-C35;
15	A20-B2-C14;	A20-B2-C49;	A21-B2-C25;	A22-B2-C1;	A22-B2-C36;
	A20-B2-C15;	A20-B2-C50;	A21-B2-C26;	A22-B2-C2;	A22-B2-C37;
	A20-B2-C16;	A20-B2-C51;	A21-B2-C27;	A22-B2-C3;	A22-B2-C38;
	A20-B2-C17;	A20-B2-C52;	A21-B2-C28;	A22-B2-C4;	A22-B2-C39;
	A20-B2-C18;	A20-B2-C53;	A21-B2-C29;	A22-B2-C5;	A22-B2-C40;
20	A20-B2-C19;	A20-B2-C54;	A21-B2-C30;	A22-B2-C6;	A22-B2-C41;
	A20-B2-C20;	A20-B2-C55;	A21-B2-C31;	A22-B2-C7;	A22-B2-C42;
	A20-B2-C21;	A20-B2-C56;	A21-B2-C32;	A22-B2-C8;	A22-B2-C43;
	A20-B2-C22;	A20-B2-C57;	A21-B2-C33;	A22-B2-C9;	A22-B2-C44;
	A20-B2-C23;	A20-B2-C58;	A21-B2-C34;	A22-B2-C10;	A22-B2-C45;
25	A20-B2-C24;	A20-B2-C59;	A21-B2-C35;	A22-B2-C11;	A22-B2-C46;
	A20-B2-C25;	A21-B2-C1;	A21-B2-C36;	A22-B2-C12;	A22-B2-C47;
	A20-B2-C26;	A21-B2-C2;	A21-B2-C37;	A22-B2-C13;	A22-B2-C48;
	A20-B2-C27;	A21-B2-C3;	A21-B2-C38;	A22-B2-C14;	A22-B2-C49;
	A20-B2-C28;	A21-B2-C4;	A21-B2-C39;	A22-B2-C15;	A22-B2-C50;
30	A20-B2-C29;	A21-B2-C5;	A21-B2-C40;	A22-B2-C16;	A22-B2-C51;
	A20-B2-C30;	A21-B2-C6;	A21-B2-C41;	A22-B2-C17;	A22-B2-C52;
	A20-B2-C31;	A21-B2-C7;	A21-B2-C42;	A22-B2-C18;	A22-B2-C53;
	A20-B2-C32;	A21-B2-C8;	A21-B2-C43;	A22-B2-C19;	A22-B2-C54;
	A20-B2-C33;	A21-B2-C9;	A21-B2-C44;	A22-B2-C20;	A22-B2-C55;
35	A20-B2-C34;	A21-B2-C10;	A21-B2-C45;	A22-B2-C21;	A22-B2-C56;

	A22-B2-C57;	A23-B2-C33;	A24-B2-C9;	A24-B2-C44;	A25-B2-C20;
	A22-B2-C58;	A23-B2-C34;	A24-B2-C10;	A24-B2-C45;	A25-B2-C21;
	A22-B2-C59;	A23-B2-C35;	A24-B2-C11;	A24-B2-C46;	A25-B2-C22;
	A23-B2-C1;	A23-B2-C36;	A24-B2-C12;	A24-B2-C47;	A25-B2-C23;
5	A23-B2-C2;	A23-B2-C37;	A24-B2-C13;	A24-B2-C48;	A25-B2-C24;
	A23-B2-C3;	A23-B2-C38;	A24-B2-C14;	A24-B2-C49;	A25-B2-C25;
	A23-B2-C4;	A23-B2-C39;	A24-B2-C15;	A24-B2-C50;	A25-B2-C26;
	A23-B2-C5;	A23-B2-C40;	A24-B2-C16;	A24-B2-C51;	A25-B2-C27;
	A23-B2-C6;	A23-B2-C41;	A24-B2-C17;	A24-B2-C52;	A25-B2-C28;
10	A23-B2-C7;	A23-B2-C42;	A24-B2-C18;	A24-B2-C53;	A25-B2-C29;
	A23-B2-C8;	A23-B2-C43;	A24-B2-C19;	A24-B2-C54;	A25-B2-C30;
	A23-B2-C9;	A23-B2-C44;	A24-B2-C20;	A24-B2-C55;	A25-B2-C31;
	A23-B2-C10;	A23-B2-C45;	A24-B2-C21;	A24-B2-C56;	A25-B2-C32;
	A23-B2-C11;	A23-B2-C46;	A24-B2-C22;	A24-B2-C57;	A25-B2-C33;
15	A23-B2-C12;	A23-B2-C47;	A24-B2-C23;	A24-B2-C58;	A25-B2-C34;
	A23-B2-C13;	A23-B2-C48;	A24-B2-C24;	A24-B2-C59;	A25-B2-C35;
	A23-B2-C14;	A23-B2-C49;	A24-B2-C25;	A25-B2-C1;	A25-B2-C36;
	A23-B2-C15;	A23-B2-C50;	A24-B2-C26;	A25-B2-C2;	A25-B2-C37;
	A23-B2-C16;	A23-B2-C51;	A24-B2-C27;	A25-B2-C3;	A25-B2-C38;
20	A23-B2-C17;	A23-B2-C52;	A24-B2-C28;	A25-B2-C4;	A25-B2-C39;
	A23-B2-C18;	A23-B2-C53;	A24-B2-C29;	A25-B2-C5;	A25-B2-C40;
	A23-B2-C19;	A23-B2-C54;	A24-B2-C30;	A25-B2-C6;	A25-B2-C41;
	A23-B2-C20;	A23-B2-C55;	A24-B2-C31;	A25-B2-C7;	A25-B2-C42;
	A23-B2-C21;	A23-B2-C56;	A24-B2-C32;	A25-B2-C8;	A25-B2-C43;
25	A23-B2-C22;	A23-B2-C57;	A24-B2-C33;	A25-B2-C9;	A25-B2-C44;
	A23-B2-C23;	A23-B2-C58;	A24-B2-C34;	A25-B2-C10;	A25-B2-C45;
	A23-B2-C24;	A23-B2-C59;	A24-B2-C35;	A25-B2-C11;	A25-B2-C46;
	A23-B2-C25;	A24-B2-C1;	A24-B2-C36;	A25-B2-C12;	A25-B2-C47;
	A23-B2-C26;	A24-B2-C2;	A24-B2-C37;	A25-B2-C13;	A25-B2-C48;
30	A23-B2-C27;	A24-B2-C3;	A24-B2-C38;	A25-B2-C14;	A25-B2-C49;
	A23-B2-C28;	A24-B2-C4;	A24-B2-C39;	A25-B2-C15;	A25-B2-C50;
	A23-B2-C29;	A24-B2-C5;	A24-B2-C40;	A25-B2-C16;	A25-B2-C51;
	A23-B2-C30;	A24-B2-C6;	A24-B2-C41;	A25-B2-C17;	A25-B2-C52;
	A23-B2-C31;	A24-B2-C7;	A24-B2-C42;	A25-B2-C18;	A25-B2-C53;
35	A23-B2-C32;	A24-B2-C8;	A24-B2-C43;	A25-B2-C19;	A25-B2-C54;

	A25-B2-C55;	A26-B2-C31;	A27-B2-C7;	A27-B2-C42;	A28-B2-C18;
	A25-B2-C56;	A26-B2-C32;	A27-B2-C8;	A27-B2-C43;	A28-B2-C19;
	A25-B2-C57;	A26-B2-C33;	A27-B2-C9;	A27-B2-C44;	A28-B2-C20;
	A25-B2-C58;	A26-B2-C34;	A27-B2-C10;	A27-B2-C45;	A28-B2-C21; ~
5	A25-B2-C59;	A26-B2-C35;	A27-B2-C11;	A27-B2-C46;	A28-B2-C22;
	A26-B2-C1;	A26-B2-C36;	A27-B2-C12;	A27-B2-C47;	A28-B2-C23;
	A26-B2-C2;	A26-B2-C37;	A27-B2-C13;	A27-B2-C48;	A28-B2-C24;
	A26-B2-C3;	A26-B2-C38;	A27-B2-C14;	A27-B2-C49;	A28-B2-C25;
	A26-B2-C4;	A26-B2-C39;	A27-B2-C15;	A27-B2-C50;	A28-B2-C26;
10	A26-B2-C5;	A26-B2-C40;	A27-B2-C16;	A27-B2-C51;	A28-B2-C27;
	A26-B2-C6;	A26-B2-C41;	A27-B2-C17;	A27-B2-C52;	A28-B2-C28;
	A26-B2-C7;	A26-B2-C42;	A27-B2-C18;	A27-B2-C53;	A28-B2-C29;
	A26-B2-C8;	A26-B2-C43;	A27-B2-C19;	A27-B2-C54;	A28-B2-C30;
	A26-B2-C9;	A26-B2-C44;	A27-B2-C20;	A27-B2-C55;	A28-B2-C31;
15	A26-B2-C10;	A26-B2-C45;	A27-B2-C21;	A27-B2-C56;	A28-B2-C32;
	A26-B2-C11;	A26-B2-C46;	A27-B2-C22;	A27-B2-C57;	A28-B2-C33;
	A26-B2-C12;	A26-B2-C47;	A27-B2-C23;	A27-B2-C58;	A28-B2-C34;
	A26-B2-C13;	A26-B2-C48;	A27-B2-C24;	A27-B2-C59;	A28-B2-C35;
	A26-B2-C14;	A26-B2-C49;	A27-B2-C25;	A28-B2-C1;	A28-B2-C36;
20	A26-B2-C15;	A26-B2-C50;	A27-B2-C26;	A28-B2-C2;	A28-B2-C37;
	A26-B2-C16;	A26-B2-C51;	A27-B2-C27;	A28-B2-C3;	A28-B2-C38;
	A26-B2-C17;	A26-B2-C52;	A27-B2-C28;	A28-B2-C4;	A28-B2-C39;
	A26-B2-C18;	A26-B2-C53;	A27-B2-C29;	A28-B2-C5;	A28-B2-C40;
	A26-B2-C19;	A26-B2-C54;	A27-B2-C30;	A28-B2-C6;	A28-B2-C41;
25	A26-B2-C20;	A26-B2-C55;	A27-B2-C31;	A28-B2-C7;	A28-B2-C42;
	A26-B2-C21;	A26-B2-C56;	A27-B2-C32;	A28-B2-C8;	A28-B2-C43;
	A26-B2-C22;	A26-B2-C57;	A27-B2-C33;	A28-B2-C9;	A28-B2-C44;
	A26-B2-C23;	A26-B2-C58;	A27-B2-C34;	A28-B2-C10;	A28-B2-C45;
	A26-B2-C24;	A26-B2-C59;	A27-B2-C35;	A28-B2-C11;	A28-B2-C46;
30	A26-B2-C25;	A27-B2-C1;	A27-B2-C36;	A28-B2-C12;	A28-B2-C47;
	A26-B2-C26;	A27-B2-C2;	A27-B2-C37;	A28-B2-C13;	A28-B2-C48;
	A26-B2-C27;	A27-B2-C3;	A27-B2-C38;	A28-B2-C14;	A28-B2-C49;
	A26-B2-C28;	A27-B2-C4;	A27-B2-C39;	A28-B2-C15;	A28-B2-C50;
	A26-B2-C29;	A27-B2-C5;	A27-B2-C40;	A28-B2-C16;	A28-B2-C51;
35	A26-B2-C30;	A27-B2-C6;	A27-B2-C41;	A28-B2-C17;	A28-B2-C52;

	A28-B2-C53;	A29-B2-C29;	A30-B2-C5;	A30-B2-C40;	A31-B2-C16;
	A28-B2-C54;	A29-B2-C30;	A30-B2-C6;	A30-B2-C41;	A31-B2-C17;
	A28-B2-C55;	A29-B2-C31;	A30-B2-C7;	A30-B2-C42;	A31-B2-C18;
	A28-B2-C56;	A29-B2-C32;	A30-B2-C8;	A30-B2-C43;	A31-B2-C19;
5	A28-B2-C57;	A29-B2-C33;	A30-B2-C9;	A30-B2-C44;	A31-B2-C20;
	A28-B2-C58;	A29-B2-C34;	A30-B2-C10;	A30-B2-C45;	A31-B2-C21;
	A28-B2-C59;	A29-B2-C35;	A30-B2-C11;	A30-B2-C46;	A31-B2-C22;
	A29-B2-C1;	A29-B2-C36;	A30-B2-C12;	A30-B2-C47;	A31-B2-C23;
	A29-B2-C2;	A29-B2-C37;	A30-B2-C13;	A30-B2-C48;	A31-B2-C24;
10	A29-B2-C3;	A29-B2-C38;	A30-B2-C14;	A30-B2-C49;	A31-B2-C25;
	A29-B2-C4;	A29-B2-C39;	A30-B2-C15;	A30-B2-C50;	A31-B2-C26;
	A29-B2-C5;	A29-B2-C40;	A30-B2-C16;	A30-B2-C51;	A31-B2-C27;
	A29-B2-C6;	A29-B2-C41;	A30-B2-C17;	A30-B2-C52;	A31-B2-C28;
	A29-B2-C7;	A29-B2-C42;	A30-B2-C18;	A30-B2-C53;	A31-B2-C29;
15	A29-B2-C8;	A29-B2-C43;	A30-B2-C19;	A30-B2-C54;	A31-B2-C30;
	A29-B2-C9;	A29-B2-C44;	A30-B2-C20;	A30-B2-C55;	A31-B2-C31;
	A29-B2-C10;	A29-B2-C45;	A30-B2-C21;	A30-B2-C56;	A31-B2-C32;
	A29-B2-C11;	A29-B2-C46;	A30-B2-C22;	A30-B2-C57;	A31-B2-C33;
	A29-B2-C12;	A29-B2-C47;	A30-B2-C23;	A30-B2-C58;	A31-B2-C34;
20	A29-B2-C13;	A29-B2-C48;	A30-B2-C24;	A30-B2-C59;	A31-B2-C35;
	A29-B2-C14;	A29-B2-C49;	A30-B2-C25;	A31-B2-C1;	A31-B2-C36;
	A29-B2-C15;	A29-B2-C50;	A30-B2-C26;	A31-B2-C2;	A31-B2-C37;
	A29-B2-C16;	A29-B2-C51;	A30-B2-C27;	A31-B2-C3;	A31-B2-C38;
	A29-B2-C17;	A29-B2-C52;	A30-B2-C28;	A31-B2-C4;	A31-B2-C39;
25	A29-B2-C18;	A29-B2-C53;	A30-B2-C29;	A31-B2-C5;	A31-B2-C40;
	A29-B2-C19;	A29-B2-C54;	A30-B2-C30;	A31-B2-C6;	A31-B2-C41;
	A29-B2-C20;	A29-B2-C55;	A30-B2-C31;	A31-B2-C7;	A31-B2-C42;
	A29-B2-C21;	A29-B2-C56;	A30-B2-C32;	A31-B2-C8;	A31-B2-C43;
	A29-B2-C22;	A29-B2-C57;	A30-B2-C33;	A31-B2-C9;	A31-B2-C44;
30	A29-B2-C23;	A29-B2-C58;	A30-B2-C34;	A31-B2-C10;	A31-B2-C45;
	A29-B2-C24;	A29-B2-C59;	A30-B2-C35;	A31-B2-C11;	A31-B2-C46;
	A29-B2-C25;	A30-B2-C1;	A30-B2-C36;	A31-B2-C12;	A31-B2-C47;
	A29-B2-C26;	A30-B2-C2;	A30-B2-C37;	A31-B2-C13;	A31-B2-C48;
	A29-B2-C27;	A30-B2-C3;	A30-B2-C38;	A31-B2-C14;	A31-B2-C49;
35	A29-B2-C28;	A30-B2-C4;	A30-B2-C39;	A31-B2-C15;	A31-B2-C50;

	A31-B2-C51;	A32-B2-C27;	A33-B2-C3;	A33-B2-C38;	A34-B2-C14;
	A31-B2-C52;	A32-B2-C28;	A33-B2-C4;	A33-B2-C39;	A34-B2-C15;
	A31-B2-C53;	A32-B2-C29;	A33-B2-C5;	A33-B2-C40;	A34-B2-C16;
	A31-B2-C54;	A32-B2-C30;	A33-B2-C6;	A33-B2-C41;	A34-B2-C17;.
5	A31-B2-C55;	A32-B2-C31;	A33-B2-C7;	A33-B2-C42;	A34-B2-C18;
	A31-B2-C56;	A32-B2-C32;	A33-B2-C8;	A33-B2-C43;	A34-B2-C19;
	A31-B2-C57;	A32-B2-C33;	A33-B2-C9;	A33-B2-C44;	A34-B2-C20;
	A31-B2-C58;	A32-B2-C34;	A33-B2-C10;	A33-B2-C45;	A34-B2-C21;
	A31-B2-C59;	A32-B2-C35;	A33-B2-C11;	A33-B2-C46;	A34-B2-C22;
10	A32-B2-C1;	A32-B2-C36;	A33-B2-C12;	A33-B2-C47;	A34-B2-C23;
	A32-B2-C2;	A32-B2-C37;	A33-B2-C13;	A33-B2-C48;	A34-B2-C24;
	A32-B2-C3;	A32-B2-C38;	A33-B2-C14;	A33-B2-C49;	A34-B2-C25;
	A32-B2-C4;	A32-B2-C39;	A33-B2-C15;	A33-B2-C50;	A34-B2-C26;
	A32-B2-C5;	A32-B2-C40;	A33-B2-C16;	A33-B2-C51;	A34-B2-C27;
15	A32-B2-C6;	A32-B2-C41;	A33-B2-C17;	A33-B2-C52;	A34-B2-C28;
	A32-B2-C7;	A32-B2-C42;	A33-B2-C18;	A33-B2-C53;	A34-B2-C29;
	A32-B2-C8;	A32-B2-C43;	A33-B2-C19;	A33-B2-C54;	A34-B2-C30;
	A32-B2-C9;	A32-B2-C44;	A33-B2-C20;	A33-B2-C55;	A34-B2-C31;
	A32-B2-C10;	A32-B2-C45;	A33-B2-C21;	A33-B2-C56;	A34-B2-C32;
20	A32-B2-C11;	A32-B2-C46;	A33-B2-C22;	A33-B2-C57;	A34-B2-C33;
	A32-B2-C12;	A32-B2-C47;	A33-B2-C23;	A33-B2-C58;	A34-B2-C34;
	A32-B2-C13;	A32-B2-C48;	A33-B2-C24;	A33-B2-C59;	A34-B2-C35;
	A32-B2-C14;	A32-B2-C49;	A33-B2-C25;	A34-B2-C1;	A34-B2-C36;
	A32-B2-C15;	A32-B2-C50;	A33-B2-C26;	A34-B2-C2;	A34-B2-C37;
25	A32-B2-C16;	A32-B2-C51;	A33-B2-C27;	A34-B2-C3;	A34-B2-C38;
	A32-B2-C17;	A32-B2-C52;	A33-B2-C28;	A34-B2-C4;	A34-B2-C39;
	A32-B2-C18;	A32-B2-C53;	A33-B2-C29;	A34-B2-C5;	A34-B2-C40;
	A32-B2-C19;	A32-B2-C54;	A33-B2-C30;	A34-B2-C6;	A34-B2-C41;
	A32-B2-C20;	A32-B2-C55;	A33-B2-C31;	A34-B2-C7;	A34-B2-C42;
30	A32-B2-C21;	A32-B2-C56;	A33-B2-C32;	A34-B2-C8;	A34-B2-C43;
	A32-B2-C22;	A32-B2-C57;	A33-B2-C33;	A34-B2-C9;	A34-B2-C44;
	A32-B2-C23;	A32-B2-C58;	A33-B2-C34;	A34-B2-C10;	A34-B2-C45;
	A32-B2-C24;	A32-B2-C59;	A33-B2-C35;	A34-B2-C11;	A34-B2-C46;
	A32-B2-C25;	A33-B2-C1;	A33-B2-C36;	A34-B2-C12;	A34-B2-C47;
35	A32-B2-C26;	A33-B2-C2;	A33-B2-C37;	A34-B2-C13;	A34-B2-C48;

	A34-B2-C49;	A35-B2-C25;	A1-B3-C1;	A1-B3-C36;	A2-B3-C12;
	A34-B2-C50;	A35-B2-C26;	A1-B3-C2;	A1-B3-C37;	A2-B3-C13;
	A34-B2-C51;	A35-B2-C27;	A1-B3-C3;	A1-B3-C38;	A2-B3-C14;
	A34-B2-C52;	A35-B2-C28;	A1-B3-C4;	A1-B3-C39;	A2-B3-C15;
5	A34-B2-C53;	A35-B2-C29;	A1-B3-C5;	A1-B3-C40;	A2-B3-C16;
	A34-B2-C54;	A35-B2-C30;	A1-B3-C6;	A1-B3-C41;	A2-B3-C17;
	A34-B2-C55;	A35-B2-C31;	A1-B3-C7;	A1-B3-C42;	A2-B3-C18;
	A34-B2-C56;	A35-B2-C32;	A1-B3-C8;	A1-B3-C43;	A2-B3-C19;
	A34-B2-C57;	A35-B2-C33;	A1-B3-C9;	A1-B3-C44;	A2-B3-C20;
10	A34-B2-C58;	A35-B2-C34;	A1-B3-C10;	A1-B3-C45;	A2-B3-C21;
	A34-B2-C59;	A35-B2-C35;	A1-B3-C11;	A1-B3-C46;	A2-B3-C22;
	A35-B2-C1;	A35-B2-C36;	A1-B3-C12;	A1-B3-C47;	A2-B3-C23;
	A35-B2-C2;	A35-B2-C37;	A1-B3-C13;	A1-B3-C48;	A2-B3-C24;
	A35-B2-C3;	A35-B2-C38;	A1-B3-C14;	A1-B3-C49;	A2-B3-C25;
15	A35-B2-C4;	A35-B2-C39;	A1-B3-C15;	A1-B3-C50;	A2-B3-C26;
	A35-B2-C5;	A35-B2-C40;	A1-B3-C16;	A1-B3-C51;	A2-B3-C27;
	A35-B2-C6;	A35-B2-C41;	A1-B3-C17;	A1-B3-C52;	A2-B3-C28;
	A35-B2-C7;	A35-B2-C42;	A1-B3-C18;	A1-B3-C53;	A2-B3-C29;
	A35-B2-C8;	A35-B2-C43;	A1-B3-C19;	A1-B3-C54;	A2-B3-C30;
20	A35-B2-C9;	A35-B2-C44;	A1-B3-C20;	A1-B3-C55;	A2-B3-C31;
	A35-B2-C10;	A35-B2-C45;	A1-B3-C21;	A1-B3-C56;	A2-B3-C32;
	A35-B2-C11;	A35-B2-C46;	A1-B3-C22;	A1-B3-C57;	A2-B3-C33;
	A35-B2-C12;	A35-B2-C47;	A1-B3-C23;	A1-B3-C58;	A2-B3-C34;
	A35-B2-C13;	A35-B2-C48;	A1-B3-C24;	A1-B3-C59;	A2-B3-C35;
25	A35-B2-C14;	A35-B2-C49;	A1-B3-C25;	A2-B3-C1;	A2-B3-C36;
	A35-B2-C15;	A35-B2-C50;	A1-B3-C26;	A2-B3-C2;	A2-B3-C37;
	A35-B2-C16;	A35-B2-C51;	A1-B3-C27;	A2-B3-C3;	A2-B3-C38;
	A35-B2-C17;	A35-B2-C52;	A1-B3-C28;	A2-B3-C4;	A2-B3-C39;
	A35-B2-C18;	A35-B2-C53;	A1-B3-C29;	A2-B3-C5;	A2-B3-C40;
30	A35-B2-C19;	A35-B2-C54;	A1-B3-C30;	A2-B3-C6;	A2-B3-C41;
	A35-B2-C20;	A35-B2-C55;	A1-B3-C31;	A2-B3-C7;	A2-B3-C42;
	A35-B2-C21;	A35-B2-C56;	A1-B3-C32;	A2-B3-C8;	A2-B3-C43;
	A35-B2-C22;	A35-B2-C57;	A1-B3-C33;	A2-B3-C9;	A2-B3-C44;
	A35-B2-C23;	A35-B2-C58;	A1-B3-C34;	A2-B3-C10;	A2-B3-C45;
35	A35-B2-C24;	A35-B2-C59;	A1-B3-C35;	A2-B3-C11;	A2-B3-C46;

	A2-B3-C47;	A3-B3-C23;	A3-B3-C58;	A4-B3-C34;	A5-B3-C10;
	A2-B3-C48;	A3-B3-C24;	A3-B3-C59;	A4-B3-C35;	A5-B3-C11;
	A2-B3-C49;	A3-B3-C25;	A4-B3-C1;	A4-B3-C36;	A5-B3-C12;
	A2-B3-C50;	A3-B3-C26;	A4-B3-C2;	A4-B3-C37;	A5-B3-C13;
5	A2-B3-C51;	A3-B3-C27;	A4-B3-C3;	A4-B3-C38;	A5-B3-C14;
	A2-B3-C52;	A3-B3-C28;	A4-B3-C4;	A4-B3-C39;	A5-B3-C15;
	A2-B3-C53;	A3-B3-C29;	A4-B3-C5;	A4-B3-C40;	A5-B3-C16;
	A2-B3-C54;	A3-B3-C30;	A4-B3-C6;	A4-B3-C41;	A5-B3-C17;
	A2-B3-C55;	A3-B3-C31;	A4-B3-C7;	A4-B3-C42;	A5-B3-C18;
10	A2-B3-C56;	A3-B3-C32;	A4-B3-C8;	A4-B3-C43;	A5-B3-C19;
	A2-B3-C57;	A3-B3-C33;	A4-B3-C9;	A4-B3-C44;	A5-B3-C20;
	A2-B3-C58;	A3-B3-C34;	A4-B3-C10;	A4-B3-C45;	A5-B3-C21;
	A2-B3-C59;	A3-B3-C35;	A4-B3-C11;	A4-B3-C46;	A5-B3-C22;
	A3-B3-C1;	A3-B3-C36;	A4-B3-C12;	A4-B3-C47;	A5-B3-C23;
15	A3-B3-C2;	A3-B3-C37;	A4-B3-C13;	A4-B3-C48;	A5-B3-C24;
	A3-B3-C3;	A3-B3-C38;	A4-B3-C14;	A4-B3-C49;	A5-B3-C25;
	A3-B3-C4;	A3-B3-C39;	A4-B3-C15;	A4-B3-C50;	A5-B3-C26;
	A3-B3-C5;	A3-B3-C40;	A4-B3-C16;	A4-B3-C51;	A5-B3-C27;
	A3-B3-C6;	A3-B3-C41;	A4-B3-C17;	A4-B3-C52;	A5-B3-C28;
20	A3-B3-C7;	A3-B3-C42;	A4-B3-C18;	A4-B3-C53;	A5-B3-C29;
	A3-B3-C8;	A3-B3-C43;	A4-B3-C19;	A4-B3-C54;	A5-B3-C30;
	A3-B3-C9;	A3-B3-C44;	A4-B3-C20;	A4-B3-C55;	A5-B3-C31;
	A3-B3-C10;	A3-B3-C45;	A4-B3-C21;	A4-B3-C56;	A5-B3-C32;
	A3-B3-C11;	A3-B3-C46;	A4-B3-C22;	A4-B3-C57;	A5-B3-C33;
25	A3-B3-C12;	A3-B3-C47;	A4-B3-C23;	A4-B3-C58;	A5-B3-C34;
	A3-B3-C13;	A3-B3-C48;	A4-B3-C24;	A4-B3-C59;	A5-B3-C35;
	A3-B3-C14;	A3-B3-C49;	A4-B3-C25;	A5-B3-C1;	A5-B3-C36;
	A3-B3-C15;	A3-B3-C50;	A4-B3-C26;	A5-B3-C2;	A5-B3-C37;
	A3-B3-C16;	A3-B3-C51;	A4-B3-C27;	A5-B3-C3;	A5-B3-C38;
30	A3-B3-C17;	A3-B3-C52;	A4-B3-C28;	A5-B3-C4;	A5-B3-C39;
	A3-B3-C18;	A3-B3-C53;	A4-B3-C29;	A5-B3-C5;	A5-B3-C40;
	A3-B3-C19;	A3-B3-C54;	A4-B3-C30;	A5-B3-C6;	A5-B3-C41;
	A3-B3-C20;	A3-B3-C55;	A4-B3-C31;	A5-B3-C7;	A5-B3-C42;
	A3-B3-C21;	A3-B3-C56;	A4-B3-C32;	A5-B3-C8;	A5-B3-C43;
35	A3-B3-C22;	A3-B3-C57;	A4-B3-C33;	A5-B3-C9;	A5-B3-C44;

	A5-B3-C45;	A6-B3-C21;	A6-B3-C56;	A7-B3-C32;	A8-B3-C8;
	A5-B3-C46;	A6-B3-C22;	A6-B3-C57;	A7-B3-C33;	A8-B3-C9;
	A5-B3-C47;	A6-B3-C23;	A6-B3-C58;	A7-B3-C34;	A8-B3-C10;
	A5-B3-C48;	A6-B3-C24;	A6-B3-C59;	A7-B3-C35;	A8-B3-C11;
5	A5-B3-C49;	A6-B3-C25;	A7-B3-C1;	A7-B3-C36;	A8-B3-C12;
	A5-B3-C50;	A6-B3-C26;	A7-B3-C2;	A7-B3-C37;	A8-B3-C13;
	A5-B3-C51;	A6-B3-C27;	A7-B3-C3;	A7-B3-C38;	A8-B3-C14;
	A5-B3-C52;	A6-B3-C28;	A7-B3-C4;	A7-B3-C39;	A8-B3-C15;
	A5-B3-C53;	A6-B3-C29;	A7-B3-C5;	A7-B3-C40;	A8-B3-C16;
10	A5-B3-C54;	A6-B3-C30;	A7-B3-C6;	A7-B3-C41;	A8-B3-C17;
	A5-B3-C55;	A6-B3-C31;	A7-B3-C7;	A7-B3-C42;	A8-B3-C18;
	A5-B3-C56;	A6-B3-C32;	A7-B3-C8;	A7-B3-C43;	A8-B3-C19;
	A5-B3-C57;	A6-B3-C33;	A7-B3-C9;	A7-B3-C44;	A8-B3-C20;
	A5-B3-C58;	A6-B3-C34;	A7-B3-C10;	A7-B3-C45;	A8-B3-C21;
15	A5-B3-C59;	A6-B3-C35;	A7-B3-C11;	A7-B3-C46;	A8-B3-C22;
	A6-B3-C1;	A6-B3-C36;	A7-B3-C12;	A7-B3-C47;	A8-B3-C23;
	A6-B3-C2;	A6-B3-C37;	A7-B3-C13;	A7-B3-C48;	A8-B3-C24;
	A6-B3-C3;	A6-B3-C38;	A7-B3-C14;	A7-B3-C49;	A8-B3-C25;
	A6-B3-C4;	A6-B3-C39;	A7-B3-C15;	A7-B3-C50;	A8-B3-C26;
20	A6-B3-C5;	A6-B3-C40;	A7-B3-C16;	A7-B3-C51;	A8-B3-C27;
	A6-B3-C6;	A6-B3-C41;	A7-B3-C17;	A7-B3-C52;	A8-B3-C28;
	A6-B3-C7;	A6-B3-C42;	A7-B3-C18;	A7-B3-C53;	A8-B3-C29;
	A6-B3-C8;	A6-B3-C43;	A7-B3-C19;	A7-B3-C54;	A8-B3-C30;
	A6-B3-C9;	A6-B3-C44;	A7-B3-C20;	A7-B3-C55;	A8-B3-C31;
25	A6-B3-C10;	A6-B3-C45;	A7-B3-C21;	A7-B3-C56;	A8-B3-C32;
	A6-B3-C11;	A6-B3-C46;	A7-B3-C22;	A7-B3-C57;	A8-B3-C33;
	A6-B3-C12;	A6-B3-C47;	A7-B3-C23;	A7-B3-C58;	A8-B3-C34;
	A6-B3-C13;	A6-B3-C48;	A7-B3-C24;	A7-B3-C59;	A8-B3-C35;
	A6-B3-C14;	A6-B3-C49;	A7-B3-C25;	A8-B3-C1;	A8-B3-C36;
30	A6-B3-C15;	A6-B3-C50;	A7-B3-C26;	A8-B3-C2;	A8-B3-C37;
	A6-B3-C16;	A6-B3-C51;	A7-B3-C27;	A8-B3-C3;	A8-B3-C38;
	A6-B3-C17;	A6-B3-C52;	A7-B3-C28;	A8-B3-C4;	A8-B3-C39;
	A6-B3-C18;	A6-B3-C53;	A7-B3-C29;	A8-B3-C5;	A8-B3-C40;
	A6-B3-C19;	A6-B3-C54;	A7-B3-C30;	A8-B3-C6;	A8-B3-C41;
35	A6-B3-C20;	A6-B3-C55;	A7-B3-C31;	A8-B3-C7;	A8-B3-C42;

	A8-B3-C43;	A9-B3-C19;	A9-B3-CS4;	A10-B3-C30;	A11-B3-C6;
	A8-B3-C44;	A9-B3-C20;	A9-B3-C55;	A10-B3-C31;	A11-B3-C7;
	A8-B3-C45;	A9-B3-C21;	A9-B3-C56;	A10-B3-C32;	A11-B3-C8;
	A8-B3-C46;	A9-B3-C22;	A9-B3-C57;	A10-B3-C33;	A11-B3-C9;
5	A8-B3-C47;	A9-B3-C23;	A9-B3-C58;	A10-B3-C34;	A11-B3-C10;
	A8-B3-C48;	A9-B3-C24;	A9-B3-C59;	A10-B3-C35;	A11-B3-C11;
	A8-B3-C49;	A9-B3-C25;	A10-B3-C1;	A10-B3-C36;	A11-B3-C12;
	A8-B3-C50;	A9-B3-C26;	A10-B3-C2;	A10-B3-C37;	A11-B3-C13;
	A8-B3-C51;	A9-B3-C27;	A10-B3-C3;	A10-B3-C38;	A11-B3-C14;
10	A8-B3-C52;	A9-B3-C28;	A10-B3-C4;	A10-B3-C39;	A11-B3-C15;
	A8-B3-C53;	A9-B3-C29;	A10-B3-C5;	A10-B3-C40;	A11-B3-C16;
	A8-B3-C54;	A9-B3-C30;	A10-B3-C6;	A10-B3-C41;	A11-B3-C17;
	A8-B3-C55;	A9-B3-C31;	A10-B3-C7;	A10-B3-C42;	A11-B3-C18;
	A8-B3-C56;	A9-B3-C32;	A10-B3-C8;	A10-B3-C43;	A11-B3-C19;
15	A8-B3-C57;	A9-B3-C33;	A10-B3-C9;	A10-B3-C44;	A11-B3-C20;
	A8-B3-C58;	A9-B3-C34;	A10-B3-C10;	A10-B3-C45;	A11-B3-C21;
	A8-B3-C59;	A9-B3-C35;	A10-B3-C11;	A10-B3-C46;	A11-B3-C22;
	A9-B3-C1;	A9-B3-C36;	A10-B3-C12;	A10-B3-C47;	A11-B3-C23;
	A9-B3-C2;	A9-B3-C37;	A10-B3-C13;	A10-B3-C48;	A11-B3-C24;
20	A9-B3-C3;	A9-B3-C38;	A10-B3-C14;	A10-B3-C49;	A11-B3-C25;
	A9-B3-C4;	A9-B3-C39;	A10-B3-C15;	A10-B3-C50;	A11-B3-C26;
	A9-B3-C5;	A9-B3-C40;	A10-B3-C16;	A10-B3-C51;	A11-B3-C27;
	A9-B3-C6;	A9-B3-C41;	A10-B3-C17;	A10-B3-C52;	A11-B3-C28;
	A9-B3-C7;	A9-B3-C42;	A10-B3-C18;	A10-B3-C53;	A11-B3-C29;
25	A9-B3-C8;	A9-B3-C43;	A10-B3-C19;	A10-B3-C54;	A11-B3-C30;
	A9-B3-C9;	A9-B3-C44;	A10-B3-C20;	A10-B3-C55;	A11-B3-C31;
	A9-B3-C10;	A9-B3-C45;	A10-B3-C21;	A10-B3-C56;	A11-B3-C32;
	A9-B3-C11;	A9-B3-C46;	A10-B3-C22;	A10-B3-C57;	A11-B3-C33;
	A9-B3-C12;	A9-B3-C47;	A10-B3-C23;	A10-B3-C58;	A11-B3-C34;
30	A9-B3-C13;	A9-B3-C48;	A10-B3-C24;	A10-B3-C59;	A11-B3-C35;
	A9-B3-C14;	A9-B3-C49;	A10-B3-C25;	A11-B3-C1;	A11-B3-C36;
	A9-B3-C15;	A9-B3-C50;	A10-B3-C26;	A11-B3-C2;	A11-B3-C37;
	A9-B3-C16;	A9-B3-C51;	A10-B3-C27;	A11-B3-C3;	A11-B3-C38;
	A9-B3-C17;	A9-B3-C52;	A10-B3-C28;	A11-B3-C4;	A11-B3-C39;
35	A9-B3-C18;	A9-B3-C53;	A10-B3-C29;	A11-B3-C5;	A11-B3-C40;

	A11-B3-C41;	A12-B3-C17;	A12-B3-C52;	A13-B3-C28;	A14-B3-C4;
	A11-B3-C42;	A12-B3-C18;	A12-B3-C53;	A13-B3-C29;	A14-B3-C5;
	A11-B3-C43;	A12-B3-C19;	A12-B3-C54;	A13-B3-C30;	A14-B3-C6;
	A11-B3-C44;	A12-B3-C20;	A12-B3-C55;	A13-B3-C31;	A14-B3-C7;
5	A11-B3-C45;	A12-B3-C21;	A12-B3-C56;	A13-B3-C32;	A14-B3-C8;
	A11-B3-C46;	A12-B3-C22;	A12-B3-C57;	A13-B3-C33;	A14-B3-C9;
	A11-B3-C47;	A12-B3-C23;	A12-B3-C58;	A13-B3-C34;	A14-B3-C10;
	A11-B3-C48;	A12-B3-C24;	A12-B3-C59;	A13-B3-C35;	A14-B3-C11;
	A11-B3-C49;	A12-B3-C25;	A13-B3-C1;	A13-B3-C36;	A14-B3-C12;
10	A11-B3-C50;	A12-B3-C26;	A13-B3-C2;	A13-B3-C37;	A14-B3-C13;
	A11-B3-C51;	A12-B3-C27;	A13-B3-C3;	A13-B3-C38;	A14-B3-C14;
	A11-B3-C52;	A12-B3-C28;	A13-B3-C4;	A13-B3-C39;	A14-B3-C15;
	A11-B3-C53;	A12-B3-C29;	A13-B3-C5;	A13-B3-C40;	A14-B3-C16;
	A11-B3-C54;	A12-B3-C30;	A13-B3-C6;	A13-B3-C41;	A14-B3-C17;
15	A11-B3-C55;	A12-B3-C31;	A13-B3-C7;	A13-B3-C42;	A14-B3-C18;
	A11-B3-C56;	A12-B3-C32;	A13-B3-C8;	A13-B3-C43;	A14-B3-C19;
	A11-B3-C57;	A12-B3-C33;	A13-B3-C9;	A13-B3-C44;	A14-B3-C20;
	A11-B3-C58;	A12-B3-C34;	A13-B3-C10;	A13-B3-C45;	A14-B3-C21;
	A11-B3-C59;	A12-B3-C35;	A13-B3-C11;	A13-B3-C46;	A14-B3-C22;
20	A12-B3-C1;	A12-B3-C36;	A13-B3-C12;	A13-B3-C47;	A14-B3-C23;
	A12-B3-C2;	A12-B3-C37;	A13-B3-C13;	A13-B3-C48;	A14-B3-C24;
	A12-B3-C3;	A12-B3-C38;	A13-B3-C14;	A13-B3-C49;	A14-B3-C25;
	A12-B3-C4;	A12-B3-C39;	A13-B3-C15;	A13-B3-C50;	A14-B3-C26;
	A12-B3-C5;	A12-B3-C40;	A13-B3-C16;	A13-B3-C51;	A14-B3-C27;
25	A12-B3-C6;	A12-B3-C41;	A13-B3-C17;	A13-B3-C52;	A14-B3-C28;
	A12-B3-C7;	A12-B3-C42;	A13-B3-C18;	A13-B3-C53;	A14-B3-C29;
	A12-B3-C8;	A12-B3-C43;	A13-B3-C19;	A13-B3-C54;	A14-B3-C30;
	A12-B3-C9;	A12-B3-C44;	A13-B3-C20;	A13-B3-C55;	A14-B3-C31;
	A12-B3-C10;	A12-B3-C45;	A13-B3-C21;	A13-B3-C56;	A14-B3-C32;
30	A12-B3-C11;	A12-B3-C46;	A13-B3-C22;	A13-B3-C57;	A14-B3-C33;
	A12-B3-C12;	A12-B3-C47;	A13-B3-C23;	A13-B3-C58;	A14-B3-C34;
	A12-B3-C13;	A12-B3-C48;	A13-B3-C24;	A13-B3-C59;	A14-B3-C35;
	A12-B3-C14;	A12-B3-C49;	A13-B3-C25;	A14-B3-C1;	A14-B3-C36;
	A12-B3-C15;	A12-B3-C50;	A13-B3-C26;	A14-B3-C2;	A14-B3-C37;
35	A12-B3-C16;	A12-B3-C51;	A13-B3-C27;	A14-B3-C3;	A14-B3-C38;

	A14-B3-C39;	A15-B3-C15;	A15-B3-C50;	A16-B3-C26;	A17-B3-C2;
	A14-B3-C40;	A15-B3-C16;	A15-B3-C51;	A16-B3-C27;	A17-B3-C3;
	A14-B3-C41;	A15-B3-C17;	A15-B3-C52;	A16-B3-C28;	A17-B3-C4;
	A14-B3-C42;	A15-B3-C18;	A15-B3-C53;	A16-B3-C29;	A17-B3-C5;
5	A14-B3-C43;	A15-B3-C19;	A15-B3-C54;	A16-B3-C30;	A17-B3-C6;
	A14-B3-C44;	A15-B3-C20;	A15-B3-C55;	A16-B3-C31;	A17-B3-C7;
	A14-B3-C45;	A15-B3-C21;	A15-B3-C56;	A16-B3-C32;	A17-B3-C8;
	A14-B3-C46;	A15-B3-C22;	A15-B3-C57;	A16-B3-C33;	A17-B3-C9;
	A14-B3-C47;	A15-B3-C23;	A15-B3-C58;	A16-B3-C34;	A17-B3-C10;
10	A14-B3-C48;	A15-B3-C24;	A15-B3-C59;	A16-B3-C35;	A17-B3-C11;
	A14-B3-C49;	A15-B3-C25;	A16-B3-C1;	A16-B3-C36;	A17-B3-C12;
	A14-B3-C50;	A15-B3-C26;	A16-B3-C2;	A16-B3-C37;	A17-B3-C13;
	A14-B3-C51;	A15-B3-C27;	A16-B3-C3;	A16-B3-C38;	A17-B3-C14;
	A14-B3-C52;	A15-B3-C28;	A16-B3-C4;	A16-B3-C39;	A17-B3-C15;
15	A14-B3-C53;	A15-B3-C29;	A16-B3-C5;	A16-B3-C40;	A17-B3-C16;
	A14-B3-C54;	A15-B3-C30;	A16-B3-C6;	A16-B3-C41;	A17-B3-C17;
	A14-B3-C55;	A15-B3-C31;	A16-B3-C7;	A16-B3-C42;	A17-B3-C18;
	A14-B3-C56;	A15-B3-C32;	A16-B3-C8;	A16-B3-C43;	A17-B3-C19;
	A14-B3-C57;	A15-B3-C33;	A16-B3-C9;	A16-B3-C44;	A17-B3-C20;
20	A14-B3-C58;	A15-B3-C34;	A16-B3-C10;	A16-B3-C45;	A17-B3-C21;
	A14-B3-C59;	A15-B3-C35;	A16-B3-C11;	A16-B3-C46;	A17-B3-C22;
	A15-B3-C1;	A15-B3-C36;	A16-B3-C12;	A16-B3-C47;	A17-B3-C23;
	A15-B3-C2;	A15-B3-C37;	A16-B3-C13;	A16-B3-C48;	A17-B3-C24;
	A15-B3-C3;	A15-B3-C38;	A16-B3-C14;	A16-B3-C49;	A17-B3-C25;
25	A15-B3-C4;	A15-B3-C39;	A16-B3-C15;	A16-B3-C50;	A17-B3-C26;
	A15-B3-C5;	A15-B3-C40;	A16-B3-C16;	A16-B3-C51;	A17-B3-C27;
	A15-B3-C6;	A15-B3-C41;	A16-B3-C17;	A16-B3-C52;	A17-B3-C28;
	A15-B3-C7;	A15-B3-C42;	A16-B3-C18;	A16-B3-C53;	A17-B3-C29;
	A15-B3-C8;	A15-B3-C43;	A16-B3-C19;	A16-B3-C54;	A17-B3-C30;
30	A15-B3-C9;	A15-B3-C44;	A16-B3-C20;	A16-B3-C55;	A17-B3-C31;
	A15-B3-C10;	A15-B3-C45;	A16-B3-C21;	A16-B3-C56;	A17-B3-C32;
	A15-B3-C11;	A15-B3-C46;	A16-B3-C22;	A16-B3-C57;	A17-B3-C33;
	A15-B3-C12;	A15-B3-C47;	A16-B3-C23;	A16-B3-C58;	A17-B3-C34;
	A15-B3-C13;	A15-B3-C48;	A16-B3-C24;	A16-B3-C59;	A17-B3-C35;
35	A15-B3-C14;	A15-B3-C49;	A16-B3-C25;	A17-B3-C1;	A17-B3-C36;

	A17-B3-C37;	A18-B3-C13;	A18-B3-C48;	A19-B3-C24;	A19-B3-C59;
	A17-B3-C38;	A18-B3-C14;	A18-B3-C49;	A19-B3-C25;	A20-B3-C1;
	A17-B3-C39;	A18-B3-C15;	A18-B3-C50;	A19-B3-C26;	A20-B3-C2;
	A17-B3-C40;	A18-B3-C16;	A18-B3-C51;	A19-B3-C27;	A20-B3-C3;
5	A17-B3-C41;	A18-B3-C17;	A18-B3-C52;	A19-B3-C28;	A20-B3-C4;
	A17-B3-C42;	A18-B3-C18;	A18-B3-C53;	A19-B3-C29;	A20-B3-C5;
	A17-B3-C43;	A18-B3-C19;	A18-B3-C54;	A19-B3-C30;	A20-B3-C6;
	A17-B3-C44;	A18-B3-C20;	A18-B3-C55;	A19-B3-C31;	A20-B3-C7;
	A17-B3-C45;	A18-B3-C21;	A18-B3-C56;	A19-B3-C32;	A20-B3-C8;
10	A17-B3-C46;	A18-B3-C22;	A18-B3-C57;	A19-B3-C33;	A20-B3-C9;
	A17-B3-C47;	A18-B3-C23;	A18-B3-C58;	A19-B3-C34;	A20-B3-C10;
	A17-B3-C48;	A18-B3-C24;	A18-B3-C59;	A19-B3-C35;	A20-B3-C11;
	A17-B3-C49;	A18-B3-C25;	A19-B3-C1;	A19-B3-C36;	A20-B3-C12;
	A17-B3-C50;	A18-B3-C26;	A19-B3-C2;	A19-B3-C37;	A20-B3-C13;
15	A17-B3-C51;	A18-B3-C27;	A19-B3-C3;	A19-B3-C38;	A20-B3-C14;
	A17-B3-C52;	A18-B3-C28;	A19-B3-C4;	A19-B3-C39;	A20-B3-C15;
	A17-B3-C53;	A18-B3-C29;	A19-B3-C5;	A19-B3-C40;	A20-B3-C16;
	A17-B3-C54;	A18-B3-C30;	A19-B3-C6;	A19-B3-C41;	A20-B3-C17;
	A17-B3-C55;	A18-B3-C31;	A19-B3-C7;	A19-B3-C42;	A20-B3-C18;
20	A17-B3-C56;	A18-B3-C32;	A19-B3-C8;	A19-B3-C43;	A20-B3-C19;
	A17-B3-C57;	A18-B3-C33;	A19-B3-C9;	A19-B3-C44;	A20-B3-C20;
	A17-B3-C58;	A18-B3-C34;	A19-B3-C10;	A19-B3-C45;	A20-B3-C21;
	A17-B3-C59;	A18-B3-C35;	A19-B3-C11;	A19-B3-C46;	A20-B3-C22;
	A18-B3-C1;	A18-B3-C36;	A19-B3-C12;	A19-B3-C47;	A20-B3-C23;
25	A18-B3-C2;	A18-B3-C37;	A19-B3-C13;	A19-B3-C48;	A20-B3-C24;
	A18-B3-C3;	A18-B3-C38;	A19-B3-C14;	A19-B3-C49;	A20-B3-C25;
	A18-B3-C4;	A18-B3-C39;	A19-B3-C15;	A19-B3-C50;	A20-B3-C26;
	A18-B3-C5;	A18-B3-C40;	A19-B3-C16;	A19-B3-C51;	A20-B3-C27;
	A18-B3-C6;	A18-B3-C41;	A19-B3-C17;	A19-B3-C52;	A20-B3-C28;
30	A18-B3-C7;	A18-B3-C42;	A19-B3-C18;	A19-B3-C53;	A20-B3-C29;
	A18-B3-C8;	A18-B3-C43;	A19-B3-C19;	A19-B3-C54;	A20-B3-C30;
	A18-B3-C9;	A18-B3-C44;	A19-B3-C20;	A19-B3-C55;	A20-B3-C31;
	A18-B3-C10;	A18-B3-C45;	A19-B3-C21;	A19-B3-C56;	A20-B3-C32;
	A18-B3-C11;	A18-B3-C46;	A19-B3-C22;	A19-B3-C57;	A20-B3-C33;
35	A18-B3-C12;	A18-B3-C47;	A19-B3-C23;	A19-B3-C58;	A20-B3-C34;

	A20-B3-C35;	A21-B3-C11;	A21-B3-C46;	A22-B3-C22;	A22-B3-C57;
	A20-B3-C36;	A21-B3-C12;	A21-B3-C47;	A22-B3-C23;	A22-B3-C58;
	A20-B3-C37;	A21-B3-C13;	A21-B3-C48;	A22-B3-C24;	A22-B3-C59;
	A20-B3-C38;	A21-B3-C14;	A21-B3-C49;	A22-B3-C25;	A23-B3-C1;
5	A20-B3-C39;	A21-B3-C15;	A21-B3-C50;	A22-B3-C26;	A23-B3-C2;
	A20-B3-C40;	A21-B3-C16;	A21-B3-C51;	A22-B3-C27;	A23-B3-C3;
	A20-B3-C41;	A21-B3-C17;	A21-B3-C52;	A22-B3-C28;	A23-B3-C4;
	A20-B3-C42;	A21-B3-C18;	A21-B3-C53;	A22-B3-C29;	A23-B3-C5;
	A20-B3-C43;	A21-B3-C19;	A21-B3-C54;	A22-B3-C30;	A23-B3-C6;
10	A20-B3-C44;	A21-B3-C20;	A21-B3-C55;	A22-B3-C31;	A23-B3-C7;
	A20-B3-C45;	A21-B3-C21;	A21-B3-C56;	A22-B3-C32;	A23-B3-C8;
	A20-B3-C46;	A21-B3-C22;	A21-B3-C57;	A22-B3-C33;	A23-B3-C9;
	A20-B3-C47;	A21-B3-C23;	A21-B3-C58;	A22-B3-C34;	A23-B3-C10;
	A20-B3-C48;	A21-B3-C24;	A21-B3-C59;	A22-B3-C35;	A23-B3-C11;
15	A20-B3-C49;	A21-B3-C25;	A22-B3-C1;	A22-B3-C36;	A23-B3-C12;
	A20-B3-C50;	A21-B3-C26;	A22-B3-C2;	A22-B3-C37;	A23-B3-C13;
	A20-B3-C51;	A21-B3-C27;	A22-B3-C3;	A22-B3-C38;	A23-B3-C14;
	A20-B3-C52;	A21-B3-C28;	A22-B3-C4;	A22-B3-C39;	A23-B3-C15;
	A20-B3-C53;	A21-B3-C29;	A22-B3-C5;	A22-B3-C40;	A23-B3-C16;
20	A20-B3-C54;	A21-B3-C30;	A22-B3-C6;	A22-B3-C41;	A23-B3-C17;
	A20-B3-C55;	A21-B3-C31;	A22-B3-C7;	A22-B3-C42;	A23-B3-C18;
	A20-B3-C56;	A21-B3-C32;	A22-B3-C8;	A22-B3-C43;	A23-B3-C19;
	A20-B3-C57;	A21-B3-C33;	A22-B3-C9;	A22-B3-C44;	A23-B3-C20;
	A20-B3-C58;	A21-B3-C34;	A22-B3-C10;	A22-B3-C45;	A23-B3-C21;
25	A20-B3-C59;	A21-B3-C35;	A22-B3-C11;	A22-B3-C46;	A23-B3-C22;
	A21-B3-C1;	A21-B3-C36;	A22-B3-C12;	A22-B3-C47;	A23-B3-C23;
	A21-B3-C2;	A21-B3-C37;	A22-B3-C13;	A22-B3-C48;	A23-B3-C24;
	A21-B3-C3;	A21-B3-C38;	A22-B3-C14;	A22-B3-C49;	A23-B3-C25;
	A21-B3-C4;	A21-B3-C39;	A22-B3-C15;	A22-B3-C50;	A23-B3-C26;
30	A21-B3-C5;	A21-B3-C40;	A22-B3-C16;	A22-B3-C51;	A23-B3-C27;
	A21-B3-C6;	A21-B3-C41;	A22-B3-C17;	A22-B3-C52;	A23-B3-C28;
	A21-B3-C7;	A21-B3-C42;	A22-B3-C18;	A22-B3-C53;	A23-B3-C29;
	A21-B3-C8;	A21-B3-C43;	A22-B3-C19;	A22-B3-C54;	A23-B3-C30;
	A21-B3-C9;	A21-B3-C44;	A22-B3-C20;	A22-B3-C55;	A23-B3-C31;
35	A21-B3-C10;	A21-B3-C45;	A22-B3-C21;	A22-B3-C56;	A23-B3-C32;

	A23-B3-C33;	A24-B3-C9;	A24-B3-C44;	A25-B3-C20;	A25-B3-C55;
	A23-B3-C34;	A24-B3-C10;	A24-B3-C45;	A25-B3-C21;	A25-B3-C56;
	A23-B3-C35;	A24-B3-C11;	A24-B3-C46;	A25-B3-C22;	A25-B3-C57;
	A23-B3-C36;	A24-B3-C12;	A24-B3-C47;	A25-B3-C23;	A25-B3-C58;
5	A23-B3-C37;	A24-B3-C13;	A24-B3-C48;	A25-B3-C24;	A25-B3-C59;
	A23-B3-C38;	A24-B3-C14;	A24-B3-C49;	A25-B3-C25;	A26-B3-C1;
	A23-B3-C39;	A24-B3-C15;	A24-B3-C50;	A25-B3-C26;	A26-B3-C2;
	A23-B3-C40;	A24-B3-C16;	A24-B3-C51;	A25-B3-C27;	A26-B3-C3;
	A23-B3-C41;	A24-B3-C17;	A24-B3-C52;	A25-B3-C28;	A26-B3-C4;
10	A23-B3-C42;	A24-B3-C18;	A24-B3-C53;	A25-B3-C29;	A26-B3-C5;
	A23-B3-C43;	A24-B3-C19;	A24-B3-C54;	A25-B3-C30;	A26-B3-C6;
	A23-B3-C44;	A24-B3-C20;	A24-B3-C55;	A25-B3-C31;	A26-B3-C7;
	A23-B3-C45;	A24-B3-C21;	A24-B3-C56;	A25-B3-C32;	A26-B3-C8;
	A23-B3-C46;	A24-B3-C22;	A24-B3-C57;	A25-B3-C33;	A26-B3-C9;
15	A23-B3-C47;	A24-B3-C23;	A24-B3-C58;	A25-B3-C34;	A26-B3-C10;
	A23-B3-C48;	A24-B3-C24;	A24-B3-C59;	A25-B3-C35;	A26-B3-C11;
	A23-B3-C49;	A24-B3-C25;	A25-B3-C1;	A25-B3-C36;	A26-B3-C12;
	A23-B3-C50;	A24-B3-C26;	A25-B3-C2;	A25-B3-C37;	A26-B3-C13;
	A23-B3-C51;	A24-B3-C27;	A25-B3-C3;	A25-B3-C38;	A26-B3-C14;
20	A23-B3-C52;	A24-B3-C28;	A25-B3-C4;	A25-B3-C39;	A26-B3-C15;
	A23-B3-C53;	A24-B3-C29;	A25-B3-C5;	A25-B3-C40;	A26-B3-C16;
	A23-B3-C54;	A24-B3-C30;	A25-B3-C6;	A25-B3-C41;	A26-B3-C17;
	A23-B3-C55;	A24-B3-C31;	A25-B3-C7;	A25-B3-C42;	A26-B3-C18;
	A23-B3-C56;	A24-B3-C32;	A25-B3-C8;	A25-B3-C43;	A26-B3-C19;
25	A23-B3-C57;	A24-B3-C33;	A25-B3-C9;	A25-B3-C44;	A26-B3-C20;
	A23-B3-C58;	A24-B3-C34;	A25-B3-C10;	A25-B3-C45;	A26-B3-C21;
	A23-B3-C59;	A24-B3-C35;	A25-B3-C11;	A25-B3-C46;	A26-B3-C22;
	A24-B3-C1;	A24-B3-C36;	A25-B3-C12;	A25-B3-C47;	A26-B3-C23;
	A24-B3-C2;	A24-B3-C37;	A25-B3-C13;	A25-B3-C48;	A26-B3-C24;
30	A24-B3-C3;	A24-B3-C38;	A25-B3-C14;	A25-B3-C49;	A26-B3-C25;
	A24-B3-C4;	A24-B3-C39;	A25-B3-C15;	A25-B3-C50;	A26-B3-C26;
	A24-B3-C5;	A24-B3-C40;	A25-B3-C16;	A25-B3-C51;	A26-B3-C27;
	A24-B3-C6;	A24-B3-C41;	A25-B3-C17;	A25-B3-C52;	A26-B3-C28;
	A24-B3-C7;	A24-B3-C42;	A25-B3-C18;	A25-B3-C53;	A26-B3-C29;
35	A24-B3-C8;	A24-B3-C43;	A25-B3-C19;	A25-B3-C54;	A26-B3-C30;

	A26-B3-C31;	A27-B3-C7;	A27-B3-C42;	A28-B3-C18;	A28-B3-C53;
	A26-B3-C32;	A27-B3-C8;	A27-B3-C43;	A28-B3-C19;	A28-B3-C54;
	A26-B3-C33;	A27-B3-C9;	A27-B3-C44;	A28-B3-C20;	A28-B3-C55;
	A26-B3-C34;	A27-B3-C10;	A27-B3-C45;	A28-B3-C21;	A28-B3-C56;
5	A26-B3-C35;	A27-B3-C11;	A27-B3-C46;	A28-B3-C22;	A28-B3-C57;
	A26-B3-C36;	A27-B3-C12;	A27-B3-C47;	A28-B3-C23;	A28-B3-C58;
	A26-B3-C37;	A27-B3-C13;	A27-B3-C48;	A28-B3-C24;	A28-B3-C59;
	A26-B3-C38;	A27-B3-C14;	A27-B3-C49;	A28-B3-C25;	A29-B3-C1;
	A26-B3-C39;	A27-B3-C15;	A27-B3-C50;	A28-B3-C26;	A29-B3-C2;
10	A26-B3-C40;	A27-B3-C16;	A27-B3-C51;	A28-B3-C27;	A29-B3-C3;
	A26-B3-C41;	A27-B3-C17;	A27-B3-C52;	A28-B3-C28;	A29-B3-C4;
	A26-B3-C42;	A27-B3-C18;	A27-B3-C53;	A28-B3-C29;	A29-B3-C5;
	A26-B3-C43;	A27-B3-C19;	A27-B3-C54;	A28-B3-C30;	A29-B3-C6;
	A26-B3-C44;	A27-B3-C20;	A27-B3-C55;	A28-B3-C31;	A29-B3-C7;
15	A26-B3-C45;	A27-B3-C21;	A27-B3-C56;	A28-B3-C32;	A29-B3-C8;
	A26-B3-C46;	A27-B3-C22;	A27-B3-C57;	A28-B3-C33;	A29-B3-C9;
	A26-B3-C47;	A27-B3-C23;	A27-B3-C58;	A28-B3-C34;	A29-B3-C10;
	A26-B3-C48;	A27-B3-C24;	A27-B3-C59;	A28-B3-C35;	A29-B3-C11;
	A26-B3-C49;	A27-B3-C25;	A28-B3-C1;	A28-B3-C36;	A29-B3-C12;
20	A26-B3-C50;	A27-B3-C26;	A28-B3-C2;	A28-B3-C37;	A29-B3-C13;
	A26-B3-C51;	A27-B3-C27;	A28-B3-C3;	A28-B3-C38;	A29-B3-C14;
	A26-B3-C52;	A27-B3-C28;	A28-B3-C4;	A28-B3-C39;	A29-B3-C15;
	A26-B3-C53;	A27-B3-C29;	A28-B3-C5;	A28-B3-C40;	A29-B3-C16;
	A26-B3-C54;	A27-B3-C30;	A28-B3-C6;	A28-B3-C41;	A29-B3-C17;
25	A26-B3-C55;	A27-B3-C31;	A28-B3-C7;	A28-B3-C42;	A29-B3-C18;
	A26-B3-C56;	A27-B3-C32;	A28-B3-C8;	A28-B3-C43;	A29-B3-C19;
	A26-B3-C57;	A27-B3-C33;	A28-B3-C9;	A28-B3-C44;	A29-B3-C20;
	A26-B3-C58;	A27-B3-C34;	A28-B3-C10;	A28-B3-C45;	A29-B3-C21;
	A26-B3-C59;	A27-B3-C35;	A28-B3-C11;	A28-B3-C46;	A29-B3-C22;
30	A27-B3-C1;	A27-B3-C36;	A28-B3-C12;	A28-B3-C47;	A29-B3-C23;
	A27-B3-C2;	A27-B3-C37;	A28-B3-C13;	A28-B3-C48;	A29-B3-C24;
	A27-B3-C3;	A27-B3-C38;	A28-B3-C14;	A28-B3-C49;	A29-B3-C25;
	A27-B3-C4;	A27-B3-C39;	A28-B3-C15;	A28-B3-C50;	A29-B3-C26;
	A27-B3-C5;	A27-B3-C40;	A28-B3-C16;	A28-B3-C51;	A29-B3-C27;
35	A27-B3-C6;	A27-B3-C41;	A28-B3-C17;	A28-B3-C52;	A29-B3-C28;

	A29-B3-C29;	A30-B3-C5;	A30-B3-C40;	A31-B3-C16;	A31-B3-C51;
	A29-B3-C30;	A30-B3-C6;	A30-B3-C41;	A31-B3-C17;	A31-B3-C52;
	A29-B3-C31;	A30-B3-C7;	A30-B3-C42;	A31-B3-C18;	A31-B3-C53;
	A29-B3-C32;	A30-B3-C8;	A30-B3-C43;	A31-B3-C19;	A31-B3-C54;
5	A29-B3-C33;	A30-B3-C9;	A30-B3-C44;	A31-B3-C20;	A31-B3-C55;
	A29-B3-C34;	A30-B3-C10;	A30-B3-C45;	A31-B3-C21;	A31-B3-C56;
	A29-B3-C35;	A30-B3-C11;	A30-B3-C46;	A31-B3-C22;	A31-B3-C57;
	A29-B3-C36;	A30-B3-C12;	A30-B3-C47;	A31-B3-C23;	A31-B3-C58;
	A29-B3-C37;	A30-B3-C13;	A30-B3-C48;	A31-B3-C24;	A31-B3-C59;
10	A29-B3-C38;	A30-B3-C14;	A30-B3-C49;	A31-B3-C25;	A32-B3-C1;
	A29-B3-C39;	A30-B3-C15;	A30-B3-C50;	A31-B3-C26;	A32-B3-C2;
	A29-B3-C40;	A30-B3-C16;	A30-B3-C51;	A31-B3-C27;	A32-B3-C3;
	A29-B3-C41;	A30-B3-C17;	A30-B3-C52;	A31-B3-C28;	A32-B3-C4;
	A29-B3-C42;	A30-B3-C18;	A30-B3-C53;	A31-B3-C29;	A32-B3-C5;
15	A29-B3-C43;	A30-B3-C19;	A30-B3-C54;	A31-B3-C30;	A32-B3-C6;
	A29-B3-C44;	A30-B3-C20;	A30-B3-C55;	A31-B3-C31;	A32-B3-C7;
	A29-B3-C45;	A30-B3-C21;	A30-B3-C56;	A31-B3-C32;	A32-B3-C8;
	A29-B3-C46;	A30-B3-C22;	A30-B3-C57;	A31-B3-C33;	A32-B3-C9;
	A29-B3-C47;	A30-B3-C23;	A30-B3-C58;	A31-B3-C34;	A32-B3-C10;
20	A29-B3-C48;	A30-B3-C24;	A30-B3-C59;	A31-B3-C35;	A32-B3-C11;
	A29-B3-C49;	A30-B3-C25;	A31-B3-C1;	A31-B3-C36;	A32-B3-C12;
	A29-B3-C50;	A30-B3-C26;	A31-B3-C2;	A31-B3-C37;	A32-B3-C13;
	A29-B3-C51;	A30-B3-C27;	A31-B3-C3;	A31-B3-C38;	A32-B3-C14;
	A29-B3-C52;	A30-B3-C28;	A31-B3-C4;	A31-B3-C39;	A32-B3-C15;
25	A29-B3-C53;	A30-B3-C29;	A31-B3-C5;	A31-B3-C40;	A32-B3-C16;
	A29-B3-C54;	A30-B3-C30;	A31-B3-C6;	A31-B3-C41;	A32-B3-C17;
	A29-B3-C55;	A30-B3-C31;	A31-B3-C7;	A31-B3-C42;	A32-B3-C18;
	A29-B3-C56;	A30-B3-C32;	A31-B3-C8;	A31-B3-C43;	A32-B3-C19;
	A29-B3-C57;	A30-B3-C33;	A31-B3-C9;	A31-B3-C44;	A32-B3-C20;
30	A29-B3-C58;	A30-B3-C34;	A31-B3-C10;	A31-B3-C45;	A32-B3-C21;
	A29-B3-C59;	A30-B3-C35;	A31-B3-C11;	A31-B3-C46;	A32-B3-C22;
	A30-B3-C1;	A30-B3-C36;	A31-B3-C12;	A31-B3-C47;	A32-B3-C23;
	A30-B3-C2;	A30-B3-C37;	A31-B3-C13;	A31-B3-C48;	A32-B3-C24;
	A30-B3-C3;	A30-B3-C38;	A31-B3-C14;	A31-B3-C49;	A32-B3-C25;
35	A30-B3-C4;	A30-B3-C39;	A31-B3-C15;	A31-B3-C50;	A32-B3-C26;

	A32-B3-C27;	A33-B3-C3;	A33-B3-C38;	A34-B3-C14;	A34-B3-C49;
	A32-B3-C28;	A33-B3-C4;	A33-B3-C39;	A34-B3-C15;	A34-B3-C50;
	A32-B3-C29;	A33-B3-C5;	A33-B3-C40;	A34-B3-C16;	A34-B3-C51;
	A32-B3-C30;	A33-B3-C6;	A33-B3-C41;	A34-B3-C17;	A34-B3-C52;
b	A32-B3-C31;	A33-B3-C7;	A33-B3-C42;	A34-B3-C18;	A34-B3-C53;
	A32-B3-C32;	A33-B3-C8;	A33-B3-C43;	A34-B3-C19;	A34-B3-C54;
	A32-B3-C33;	A33-B3-C9;	A33-B3-C44;	A34-B3-C20;	A34-B3-C55;
	A32-B3-C34;	A33-B3-C10;	A33-B3-C45;	A34-B3-C21;	A34-B3-C56;
	A32-B3-C35;	A33-B3-C11;	A33-B3-C46;	A34-B3-C22;	A34-B3-C57;
10	A32-B3-C36;	A33-B3-C12;	A33-B3-C47;	A34-B3-C23;	A34-B3-C58;
	A32-B3-C37;	A33-B3-C13;	A33-B3-C48;	A34-B3-C24;	A34-B3-C59;
	A32-B3-C38;	A33-B3-C14;	A33-B3-C49;	A34-B3-C25;	A35-B3-C1;
	A32-B3-C39;	A33-B3-C15;	A33-B3-C50;	A34-B3-C26;	A35-B3-C2;
	A32-B3-C40;	A33-B3-C16;	A33-B3-C51;	A34-B3-C27;	A35-B3-C3;
15	A32-B3-C41;	A33-B3-C17;	A33-B3-C52;	A34-B3-C28;	A35-B3-C4;
	A32-B3-C42;	A33-B3-C18;	A33-B3-C53;	A34-B3-C29;	A35-B3-C5;
	A32-B3-C43;	A33-B3-C19;	A33-B3-C54;	A34-B3-C30;	A35-B3-C6;
	A32-B3-C44;	A33-B3-C20;	A33-B3-C55;	A34-B3-C31;	A35-B3-C7;
	A32-B3-C45;	A33-B3-C21;	A33-B3-C56;	A34-B3-C32;	A35-B3-C8;
20	A32-B3-C46;	A33-B3-C22;	A33-B3-C57;	A34-B3-C33;	A35-B3-C9;
	A32-B3-C47;	A33-B3-C23;	A33-B3-C58;	A34-B3-C34;	A35-B3-C10;
	A32-B3-C48;	A33-B3-C24;	A33-B3-C59;	A34-B3-C35;	A35-B3-C11;
	A32-B3-C49;	A33-B3-C25;	A34-B3-C1;	A34-B3-C36;	A35-B3-C12;
	A32-B3-C50;	A33-B3-C26;	A34-B3-C2;	A34-B3-C37;	A35-B3-C13;
25	A32-B3-C51;	A33-B3-C27;	A34-B3-C3;	A34-B3-C38;	A35-B3-C14;
	A32-B3-C52;	A33-B3-C28;	A34-B3-C4;	A34-B3-C39;	A35-B3-C15;
	A32-B3-C53;	A33-B3-C29;	A34-B3-C5;	A34-B3-C40;	A35-B3-C16;
	A32-B3-C54;	A33-B3-C30;	A34-B3-C6;	A34-B3-C41;	A35-B3-C17;
	A32-B3-C55;	A33-B3-C31;	A34-B3-C7;	A34-B3-C42;	A35-B3-C18;
30	A32-B3-C56;	A33-B3-C32;	A34-B3-C8;	A34-B3-C43;	A35-B3-C19;
	A32-B3-C57;	A33-B3-C33;	A34-B3-C9;	A34-B3-C44;	A35-B3-C20;
	A32-B3-C58;	A33-B3-C34;	A34-B3-C10;	A34-B3-C45;	A35-B3-C21;
	A32-B3-C59;	A33-B3-C35;	A34-B3-C11;	A34-B3-C46;	A35-B3-C22;
	A33-B3-C1;	A33-B3-C36;	A34-B3-C12;	A34-B3-C47;	A35-B3-C23;
35	A33-B3-C2;	A33-B3-C37;	A34-B3-C13;	A34-B3-C48;	A35-B3-C24;

	A35-B3-C25;	A1-B4-C1;	A1-B4-C36;	A2-B4-C12;	A2-B4-C47;
	A35-B3-C26;	A1-B4-C2;	A1-B4-C37;	A2-B4-C13;	A2-B4-C48;
	A35-B3-C27;	A1-B4-C3;	A1-B4-C38;	A2-B4-C14;	A2-B4-C49;
	A35-B3-C28;	A1-B4-C4;	A1-B4-C39;	A2-B4-C15;	A2-B4-C50;
5	A35-B3-C29;	A1-B4-C5;	A1-B4-C40;	A2-B4-C16;	A2-B4-C51;
	A35-B3-C30;	A1-B4-C6;	A1-B4-C41;	A2-B4-C17;	A2-B4-C52;
	A35-B3-C31;	A1-B4-C7;	A1-B4-C42;	A2-B4-C18;	A2-B4-C53;
	A35-B3-C32;	A1-B4-C8;	A1-B4-C43;	A2-B4-C19;	A2-B4-C54;
	A35-B3-C33;	A1-B4-C9;	A1-B4-C44;	A2-B4-C20;	A2-B4-C55;
10	A35-B3-C34;	A1-B4-C10;	A1-B4-C45;	A2-B4-C21;	A2-B4-C56;
	A35-B3-C35;	A1-B4-C11;	A1-B4-C46;	A2-B4-C22;	A2-B4-C57;
	A35-B3-C36;	A1-B4-C12;	A1-B4-C47;	A2-B4-C23;	A2-B4-C58;
	A35-B3-C37;	A1-B4-C13;	A1-B4-C48;	A2-B4-C24;	A2-B4-C59;
	A35-B3-C38;	A1-B4-C14;	A1-B4-C49;	A2-B4-C25;	A3-B4-C1;
15	A35-B3-C39;	A1-B4-C15;	A1-B4-C50;	A2-B4-C26;	A3-B4-C2;
	A35-B3-C40;	A1-B4-C16;	A1-B4-C51;	A2-B4-C27;	A3-B4-C3;
	A35-B3-C41;	A1-B4-C17;	A1-B4-C52;	A2-B4-C28;	A3-B4-C4;
	A35-B3-C42;	A1-B4-C18;	A1-B4-C53;	A2-B4-C29;	A3-B4-C5;
	A35-B3-C43;	A1-B4-C19;	A1-B4-C54;	A2-B4-C30;	A3-B4-C6;
20	A35-B3-C44;	A1-B4-C20;	A1-B4-C55;	A2-B4-C31;	A3-B4-C7;
	A35-B3-C45;	A1-B4-C21;	A1-B4-C56;	A2-B4-C32;	A3-B4-C8;
	A35-B3-C46;	A1-B4-C22;	A1-B4-C57;	A2-B4-C33;	A3-B4-C9;
	A35-B3-C47;	A1-B4-C23;	A1-B4-C58;	A2-B4-C34;	A3-B4-C10;
	A35-B3-C48;	A1-B4-C24;	A1-B4-C59;	A2-B4-C35;	A3-B4-C11;
25	A35-B3-C49;	A1-B4-C25;	A2-B4-C1;	A2-B4-C36;	A3-B4-C12;
	A35-B3-C50;	A1-B4-C26;	A2-B4-C2;	A2-B4-C37;	A3-B4-C13;
	A35-B3-C51;	A1-B4-C27;	A2-B4-C3;	A2-B4-C38;	A3-B4-C14;
	A35-B3-C52;	A1-B4-C28;	A2-B4-C4;	A2-B4-C39;	A3-B4-C15;
	A35-B3-C53;	A1-B4-C29;	A2-B4-C5;	A2-B4-C40;	A3-B4-C16;
30	A35-B3-C54;	A1-B4-C30;	A2-B4-C6;	A2-B4-C41;	A3-B4-C17;
	A35-B3-C55;	A1-B4-C31;	A2-B4-C7;	A2-B4-C42;	A3-B4-C18;
	A35-B3-C56;	A1-B4-C32;	A2-B4-C8;	A2-B4-C43;	A3-B4-C19;
	A35-B3-C57;	A1-B4-C33;	A2-B4-C9;	A2-B4-C44;	A3-B4-C20;
	A35-B3-C58;	A1-B4-C34;	A2-B4-C10;	A2-B4-C45;	A3-B4-C21;
35	A35-B3-C59;	A1-B4-C35;	A2-B4-C11;	A2-B4-C46;	A3-B4-C22;

	A3-B4-C23;	A3-B4-C58;	A4-B4-C34;	A5-B4-C10;	A5-B4-C45;
	A3-B4-C24;	A3-B4-C59;	A4-B4-C35;	A5-B4-C11;	A5-B4-C46;
	A3-B4-C25;	A4-B4-C1;	A4-B4-C36;	A5-B4-C12;	A5-B4-C47;
	A3-B4-C26;	A4-B4-C2;	A4-B4-C37;	A5-B4-C13;	A5-B4-C48;
5	A3-B4-C27;	A4-B4-C3;	A4-B4-C38;	A5-B4-C14;	A5-B4-C49;
	A3-B4-C28;	A4-B4-C4;	A4-B4-C39;	A5-B4-C15;	A5-B4-C50;
	A3-B4-C29;	A4-B4-C5;	A4-B4-C40;	A5-B4-C16;	A5-B4-C51;
	A3-B4-C30;	A4-B4-C6;	A4-B4-C41;	A5-B4-C17;	A5-B4-C52;
	A3-B4-C31;	A4-B4-C7;	A4-B4-C42;	A5-B4-C18;	A5-B4-C53;
10	A3-B4-C32;	A4-B4-C8;	A4-B4-C43;	A5-B4-C19;	A5-B4-C54;
	A3-B4-C33;	A4-B4-C9;	A4-B4-C44;	A5-B4-C20;	A5-B4-C55;
	A3-B4-C34;	A4-B4-C10;	A4-B4-C45;	A5-B4-C21;	A5-B4-C56;
	A3-B4-C35;	A4-B4-C11;	A4-B4-C46;	A5-B4-C22;	A5-B4-C57;
	A3-B4-C36;	A4-B4-C12;	A4-B4-C47;	A5-B4-C23;	A5-B4-C58;
15	A3-B4-C37;	A4-B4-C13;	A4-B4-C48;	A5-B4-C24;	A5-B4-C59;
	A3-B4-C38;	A4-B4-C14;	A4-B4-C49;	A5-B4-C25;	A6-B4-C1;
	A3-B4-C39;	A4-B4-C15;	A4-B4-C50;	A5-B4-C26;	A6-B4-C2;
	A3-B4-C40;	A4-B4-C16;	A4-B4-C51;	A5-B4-C27;	A6-B4-C3;
	A3-B4-C41;	A4-B4-C17;	A4-B4-C52;	A5-B4-C28;	A6-B4-C4;
20	A3-B4-C42;	A4-B4-C18;	A4-B4-C53;	A5-B4-C29;	A6-B4-C5;
	A3-B4-C43;	A4-B4-C19;	A4-B4-C54;	A5-B4-C30;	A6-B4-C6;
	A3-B4-C44;	A4-B4-C20;	A4-B4-C55;	A5-B4-C31;	A6-B4-C7;
	A3-B4-C45;	A4-B4-C21;	A4-B4-C56;	A5-B4-C32;	A6-B4-C8;;
	A3-B4-C46;	A4-B4-C22;	A4-B4-C57;	A5-B4-C33;	A6-B4-C9;
25	A3-B4-C47;	A4-B4-C23;	A4-B4-C58;	A5-B4-C34;	A6-B4-C10;
	A3-B4-C48;	A4-B4-C24;	A4-B4-C59;	A5-B4-C35;	A6-B4-C11;
	A3-B4-C49;	A4-B4-C25;	A5-B4-C1;	A5-B4-C36;	A6-B4-C12;
	A3-B4-C50;	A4-B4-C26;	A5-B4-C2;	A5-B4-C37;	A6-B4-C13;
	A3-B4-C51;	A4-B4-C27;	A5-B4-C3;	A5-B4-C38;	A6-B4-C14;
30	A3-B4-C52;	A4-B4-C28;	A5-B4-C4;	A5-B4-C39;	A6-B4-C15;
	A3-B4-C53;	A4-B4-C29;	A5-B4-C5;	A5-B4-C40;	A6-B4-C16;
	A3-B4-C54;	A4-B4-C30;	A5-B4-C6;	A5-B4-C41;	A6-B4-C17;
	A3-B4-C55;	A4-B4-C31;	A5-B4-C7;	A5-B4-C42;	A6-B4-C18;
	A3-B4-C56;	A4-B4-C32;	A5-B4-C8;	A5-B4-C43;	A6-B4-C19;
35	A3-B4-C57;	A4-B4-C33;	A5-B4-C9;	A5-B4-C44;	A6-B4-C20;

	A6-B4-C21;	A6-B4-C56;	A7-B4-C32;	A8-B4-C8;	A8-B4-C43;
	A6-B4-C22;	A6-B4-C57;	A7-B4-C33;	A8-B4-C9;	A8-B4-C44;
	A6-B4-C23;	A6-B4-C58;	A7-B4-C34;	A8-B4-C10;	A8-B4-C45;
	A6-B4-C24;	A6-B4-C59;	A7-B4-C35;	A8-B4-C11;	A8-B4-C46;
5	A6-B4-C25;	A7-B4-C1;	A7-B4-C36;	A8-B4-C12;	A8-B4-C47;
	A6-B4-C26;	A7-B4-C2;	A7-B4-C37;	A8-B4-C13;	A8-B4-C48;
	A6-B4-C27;	A7-B4-C3;	A7-B4-C38;	A8-B4-C14;	A8-B4-C49;
	A6-B4-C28;	A7-B4-C4;	A7-B4-C39;	A8-B4-C15;	A8-B4-C50;
	A6-B4-C29;	A7-B4-C5;	A7-B4-C40;	A8-B4-C16;	A8-B4-C51;
10	A6-B4-C30;	A7-B4-C6;	A7-B4-C41;	A8-B4-C17;	A8-B4-C52;
	A6-B4-C31;	A7-B4-C7;	A7-B4-C42;	A8-B4-C18;	A8-B4-C53;
	A6-B4-C32;	A7-B4-C8;	A7-B4-C43;	A8-B4-C19;	A8-B4-C54;
	A6-B4-C33;	A7-B4-C9;	A7-B4-C44;	A8-B4-C20;	A8-B4-C55;
	A6-B4-C34;	A7-B4-C10;	A7-B4-C45;	A8-B4-C21;	A8-B4-C56;
15	A6-B4-C35;	A7-B4-C11;	A7-B4-C46;	A8-B4-C22;	A8-B4-C57;
	A6-B4-C36;	A7-B4-C12;	A7-B4-C47;	A8-B4-C23;	A8-B4-C58;
	A6-B4-C37;	A7-B4-C13;	A7-B4-C48;	A8-B4-C24;	A8-B4-C59;
	A6-B4-C38;	A7-B4-C14;	A7-B4-C49;	A8-B4-C25;	A9-B4-C1;
	A6-B4-C39;	A7-B4-C15;	A7-B4-C50;	A8-B4-C26;	A9-B4-C2;
20	A6-B4-C40;	A7-B4-C16;	A7-B4-C51;	A8-B4-C27;	A9-B4-C3;
	A6-B4-C41;	A7-B4-C17;	A7-B4-C52;	A8-B4-C28;	A9-B4-C4;
	A6-B4-C42;	A7-B4-C18;	A7-B4-C53;	A8-B4-C29;	A9-B4-C5;
	A6-B4-C43;	A7-B4-C19;	A7-B4-C54;	A8-B4-C30;	A9-B4-C6;
	A6-B4-C44;	A7-B4-C20;	A7-B4-C55;	A8-B4-C31;	A9-B4-C7;
25	A6-B4-C45;	A7-B4-C21;	A7-B4-C56;	A8-B4-C32;	A9-B4-C8;
	A6-B4-C46;	A7-B4-C22;	A7-B4-C57;	A8-B4-C33;	A9-B4-C9;
	A6-B4-C47;	A7-B4-C23;	A7-B4-C58;	A8-B4-C34;	A9-B4-C10;
	A6-B4-C48;	A7-B4-C24;	A7-B4-C59;	A8-B4-C35;	A9-B4-C11;
	A6-B4-C49;	A7-B4-C25;	A8-B4-C1;	A8-B4-C36;	A9-B4-C12;
30	A6-B4-C50;	A7-B4-C26;	A8-B4-C2;	A8-B4-C37;	A9-B4-C13;
	A6-B4-C51;	A7-B4-C27;	A8-B4-C3;	A8-B4-C38;	A9-B4-C14;
	A6-B4-C52;	A7-B4-C28;	A8-B4-C4;	A8-B4-C39;	A9-B4-C15;
	A6-B4-C53;	A7-B4-C29;	A8-B4-C5;	A8-B4-C40;	A9-B4-C16;
	A6-B4-C54;	A7-B4-C30;	A8-B4-C6;	A8-B4-C41;	A9-B4-C17;
35	A6-B4-C55;	A7-B4-C31;	A8-B4-C7;	A8-B4-C42;	A9-B4-C18;

	A9-B4-C19;	A9-B4-CS4;	A10-B4-C30;	A11-B4-C6;	A11-B4-C41;
	A9-B4-C20;	A9-B4-C55;	A10-B4-C31;	A11-B4-C7;	A11-B4-C42;
	A9-B4-C21;	A9-B4-C56;	A10-B4-C32;	A11-B4-C8;	A11-B4-C43;
	A9-B4-C22;	A9-B4-C57;	A10-B4-C33;	A11-B4-C9;	A11-B4-C44;
5	A9-B4-C23;	A9-B4-CS8;	A10-B4-C34;	A11-B4-C10;	A11-B4-C45;
	A9-B4-C24;	A9-B4-C59;	A10-B4-C35;	A11-B4-C11;	A11-B4-C46;
	A9-B4-C25;	A10-B4-C1;	A10-B4-C36;	A11-B4-C12;	A11-B4-C47;
	A9-B4-C26;	A10-B4-C2;	A10-B4-C37;	A11-B4-C13;	A11-B4-C48;
	A9-B4-C27;	A10-B4-C3;	A10-B4-C38;	A11-B4-C14;	A11-B4-C49;
10	A9-B4-C28;	A10-B4-C4;	A10-B4-C39;	A11-B4-C15;	A11-B4-C50;
	A9-B4-C29;	A10-B4-C5;	A10-B4-C40;	A11-B4-C16;	A11-B4-C51;
	A9-B4-C30;	A10-B4-C6;	A10-B4-C41;	A11-B4-C17;	A11-B4-C52;
	A9-B4-C31;	A10-B4-C7;	A10-B4-C42;	A11-B4-C18;	A11-B4-C53;
	A9-B4-C32;	A10-B4-C8;	A10-B4-C43;	A11-B4-C19;	A11-B4-C54;
15	A9-B4-C33;	A10-B4-C9;	A10-B4-C44;	A11-B4-C20;	A11-B4-C55;
	A9-B4-C34;	A10-B4-C10;	A10-B4-C45;	A11-B4-C21;	A11-B4-C56;
	A9-B4-C35;	A10-B4-C11;	A10-B4-C46;	A11-B4-C22;	A11-B4-C57;
	A9-B4-C36;	A10-B4-C12;	A10-B4-C47;	A11-B4-C23;	A11-B4-C58;
	A9-B4-C37;	A10-B4-C13;	A10-B4-C48;	A11-B4-C24;	A11-B4-C59;
20	A9-B4-C38;	A10-B4-C14;	A10-B4-C49;	A11-B4-C25;	A12-B4-C1;
	A9-B4-C39;	A10-B4-C15;	A10-B4-C50;	A11-B4-C26;	A12-B4-C2;
	A9-B4-C40;	A10-B4-C16;	A10-B4-C51;	A11-B4-C27;	A12-B4-C3;
	A9-B4-C41;	A10-B4-C17;	A10-B4-C52;	A11-B4-C28;	A12-B4-C4;
	A9-B4-C42;	A10-B4-C18;	A10-B4-C53;	A11-B4-C29;	A12-B4-C5;
25	A9-B4-C43;	A10-B4-C19;	A10-B4-C54;	A11-B4-C30;	A12-B4-C6;
	A9-B4-C44;	A10-B4-C20;	A10-B4-C55;	A11-B4-C31;	A12-B4-C7;
	A9-B4-C45;	A10-B4-C21;	A10-B4-C56;	A11-B4-C32;	A12-B4-C8;
	A9-B4-C46;	A10-B4-C22;	A10-B4-C57;	A11-B4-C33;	A12-B4-C9;
	A9-B4-C47;	A10-B4-C23;	A10-B4-C58;	A11-B4-C34;	A12-B4-C10;
30	A9-B4-C48;	A10-B4-C24;	A10-B4-C59;	A11-B4-C35;	A12-B4-C11;
	A9-B4-C49;	A10-B4-C25;	A11-B4-C1;	A11-B4-C36;	A12-B4-C12;
	A9-B4-C50;	A10-B4-C26;	A11-B4-C2;	A11-B4-C37;	A12-B4-C13;
	A9-B4-C51;	A10-B4-C27;	A11-B4-C3;	A11-B4-C38;	A12-B4-C14;
	A9-B4-C52;	A10-B4-C28;	A11-B4-C4;	A11-B4-C39;	A12-B4-C15;
35	A9-B4-C53;	A10-B4-C29;	A11-B4-C5;	A11-B4-C40;	A12-B4-C16;

	A12-B4-C17;	A12-B4-CS2;	A13-B4-C28;	A14-B4-C4;	A14-B4-C39;
	A12-B4-C18;	A12-B4-CS3;	A13-B4-C29;	A14-B4-C5;	A14-B4-C40;
	A12-B4-C19;	A12-B4-CS4;	A13-B4-C30;	A14-B4-C6;	A14-B4-C41;
	A12-B4-C20;	A12-B4-CS5;	A13-B4-C31;	A14-B4-C7;	A14-B4-C42;
5	A12-B4-C21;	A12-B4-CS6;	A13-B4-C32;	A14-B4-C8;	A14-B4-C43;
	A12-B4-C22;	A12-B4-CS7;	A13-B4-C33;	A14-B4-C9;	A14-B4-C44;
	A12-B4-C23;	A12-B4-CS8;	A13-B4-C34;	A14-B4-C10;	A14-B4-C45;
	A12-B4-C24;	A12-B4-CS9;	A13-B4-C35;	A14-B4-C11;	A14-B4-C46;
	A12-B4-C25;	A13-B4-C1;	A13-B4-C36;	A14-B4-C12;	A14-B4-C47;
10	A12-B4-C26;	A13-B4-C2;	A13-B4-C37;	A14-B4-C13;	A14-B4-C48;
	A12-B4-C27;	A13-B4-C3;	A13-B4-C38;	A14-B4-C14;	A14-B4-C49;
	A12-B4-C28;	A13-B4-C4;	A13-B4-C39;	A14-B4-C15;	A14-B4-C50;
	A12-B4-C29;	A13-B4-C5;	A13-B4-C40;	A14-B4-C16;	A14-B4-C51;
	A12-B4-C30;	A13-B4-C6;	A13-B4-C41;	A14-B4-C17;	A14-B4-C52;
15	A12-B4-C31;	A13-B4-C7;	A13-B4-C42;	A14-B4-C18;	A14-B4-C53;
	A12-B4-C32;	A13-B4-C8;	A13-B4-C43;	A14-B4-C19;	A14-B4-C54;
	A12-B4-C33;	A13-B4-C9;	A13-B4-C44;	A14-B4-C20;	A14-B4-C55;
	A12-B4-C34;	A13-B4-C10;	A13-B4-C45;	A14-B4-C21;	A14-B4-C56;
	A12-B4-C35;	A13-B4-C11;	A13-B4-C46;	A14-B4-C22;	A14-B4-C57;
20	A12-B4-C36;	A13-B4-C12;	A13-B4-C47;	A14-B4-C23;	A14-B4-C58;
	A12-B4-C37;	A13-B4-C13;	A13-B4-C48;	A14-B4-C24;	A14-B4-C59;
	A12-B4-C38;	A13-B4-C14;	A13-B4-C49;	A14-B4-C25;	A15-B4-C1;
	A12-B4-C39;	A13-B4-C15;	A13-B4-C50;	A14-B4-C26;	A15-B4-C2;
	A12-B4-C40;	A13-B4-C16;	A13-B4-C51;	A14-B4-C27;	A15-B4-C3;
25	A12-B4-C41;	A13-B4-C17;	A13-B4-C52;	A14-B4-C28;	A15-B4-C4;
	A12-B4-C42;	A13-B4-C18;	A13-B4-C53;	A14-B4-C29;	A15-B4-C5;
	A12-B4-C43;	A13-B4-C19;	A13-B4-C54;	A14-B4-C30;	A15-B4-C6;
	A12-B4-C44;	A13-B4-C20;	A13-B4-CS5;	A14-B4-C31;	A15-B4-C7;
	A12-B4-C45;	A13-B4-C21;	A13-B4-CS6;	A14-B4-C32;	A15-B4-C8;
30	A12-B4-C46;	A13-B4-C22;	A13-B4-CS7;	A14-B4-C33;	A15-B4-C9;
	A12-B4-C47;	A13-B4-C23;	A13-B4-CS8;	A14-B4-C34;	A15-B4-C10;
	A12-B4-C48;	A13-B4-C24;	A13-B4-CS9;	A14-B4-C35;	A15-B4-C11;
	A12-B4-C49;	A13-B4-C25;	A14-B4-C1;	A14-B4-C36;	A15-B4-C12;
	A12-B4-C50;	A13-B4-C26;	A14-B4-C2;	A14-B4-C37;	A15-B4-C13;
35	A12-B4-C51;	A13-B4-C27;	A14-B4-C3;	A14-B4-C38;	A15-B4-C14;

	A15-B4-C15;	A15-B4-C50;	A16-B4-C26;	A17-B4-C2;	A17-B4-C37;
	A15-B4-C16;	A15-B4-C51;	A16-B4-C27;	A17-B4-C3;	A17-B4-C38;
	A15-B4-C17;	A15-B4-C52;	A16-B4-C28;	A17-B4-C4;	A17-B4-C39;
	A15-B4-C18;	A15-B4-C53;	A16-B4-C29;	A17-B4-C5;	A17-B4-C40;
5	A15-B4-C19;	A15-B4-C54;	A16-B4-C30;	A17-B4-C6;	A17-B4-C41;
	A15-B4-C20;	A15-B4-C55;	A16-B4-C31;	A17-B4-C7;	A17-B4-C42;
	A15-B4-C21;	A15-B4-C56;	A16-B4-C32;	A17-B4-C8;	A17-B4-C43;
	A15-B4-C22;	A15-B4-C57;	A16-B4-C33;	A17-B4-C9;	A17-B4-C44;
	A15-B4-C23;	A15-B4-C58;	A16-B4-C34;	A17-B4-C10;	A17-B4-C45;
10	A15-B4-C24;	A15-B4-C59;	A16-B4-C35;	A17-B4-C11;	A17-B4-C46;
	A15-B4-C25;	A16-B4-C1;	A16-B4-C36;	A17-B4-C12;	A17-B4-C47;
	A15-B4-C26;	A16-B4-C2;	A16-B4-C37;	A17-B4-C13;	A17-B4-C48;
	A15-B4-C27;	A16-B4-C3;	A16-B4-C38;	A17-B4-C14;	A17-B4-C49;
	A15-B4-C28;	A16-B4-C4;	A16-B4-C39;	A17-B4-C15;	A17-B4-C50;
15	A15-B4-C29;	A16-B4-C5;	A16-B4-C40;	A17-B4-C16;	A17-B4-C51;
	A15-B4-C30;	A16-B4-C6;	A16-B4-C41;	A17-B4-C17;	A17-B4-C52;
	A15-B4-C31;	A16-B4-C7;	A16-B4-C42;	A17-B4-C18;	A17-B4-C53;
	A15-B4-C32;	A16-B4-C8;	A16-B4-C43;	A17-B4-C19;	A17-B4-C54;
	A15-B4-C33;	A16-B4-C9;	A16-B4-C44;	A17-B4-C20;	A17-B4-C55;
20	A15-B4-C34;	A16-B4-C10;	A16-B4-C45;	A17-B4-C21;	A17-B4-C56;
	A15-B4-C35;	A16-B4-C11;	A16-B4-C46;	A17-B4-C22;	A17-B4-C57;
	A15-B4-C36;	A16-B4-C12;	A16-B4-C47;	A17-B4-C23;	A17-B4-C58;
	A15-B4-C37;	A16-B4-C13;	A16-B4-C48;	A17-B4-C24;	A17-B4-C59;
	A15-B4-C38;	A16-B4-C14;	A16-B4-C49;	A17-B4-C25;	A18-B4-C1;
25	A15-B4-C39;	A16-B4-C15;	A16-B4-C50;	A17-B4-C26;	A18-B4-C2;
	A15-B4-C40;	A16-B4-C16;	A16-B4-C51;	A17-B4-C27;	A18-B4-C3;
	A15-B4-C41;	A16-B4-C17;	A16-B4-C52;	A17-B4-C28;	A18-B4-C4;
	A15-B4-C42;	A16-B4-C18;	A16-B4-C53;	A17-B4-C29;	A18-B4-C5;
	A15-B4-C43;	A16-B4-C19;	A16-B4-C54;	A17-B4-C30;	A18-B4-C6;
30	A15-B4-C44;	A16-B4-C20;	A16-B4-C55;	A17-B4-C31;	A18-B4-C7;
	A15-B4-C45;	A16-B4-C21;	A16-B4-C56;	A17-B4-C32;	A18-B4-C8;
	A15-B4-C46;	A16-B4-C22;	A16-B4-C57;	A17-B4-C33;	A18-B4-C9;
	A15-B4-C47;	A16-B4-C23;	A16-B4-C58;	A17-B4-C34;	A18-B4-C10;
	A15-B4-C48;	A16-B4-C24;	A16-B4-C59;	A17-B4-C35;	A18-B4-C11;
35	A15-B4-C49;	A16-B4-C25;	A17-B4-C1;	A17-B4-C36;	A18-B4-C12;

	A18-B4-C13;	A18-B4-C48;	A19-B4-C24;	A19-B4-C59;	A20-B4-C35;
	A18-B4-C14;	A18-B4-C49;	A19-B4-C25;	A20-B4-C1;	A20-B4-C36;
	A18-B4-C15;	A18-B4-C50;	A19-B4-C26;	A20-B4-C2;	A20-B4-C37;
	A18-B4-C16;	A18-B4-C51;	A19-B4-C27;	A20-B4-C3;	A20-B4-C38;
5	A18-B4-C17;	A18-B4-C52;	A19-B4-C28;	A20-B4-C4;	A20-B4-C39;
	A18-B4-C18;	A18-B4-C53;	A19-B4-C29;	A20-B4-C5;	A20-B4-C40;
	A18-B4-C19;	A18-B4-C54;	A19-B4-C30;	A20-B4-C6;	A20-B4-C41;
	A18-B4-C20;	A18-B4-C55;	A19-B4-C31;	A20-B4-C7;	A20-B4-C42;
	A18-B4-C21;	A18-B4-C56;	A19-B4-C32;	A20-B4-C8;	A20-B4-C43;
10	A18-B4-C22;	A18-B4-C57;	A19-B4-C33;	A20-B4-C9;	A20-B4-C44;
	A18-B4-C23;	A18-B4-C58;	A19-B4-C34;	A20-B4-C10;	A20-B4-C45;
	A18-B4-C24;	A18-B4-C59;	A19-B4-C35;	A20-B4-C11;	A20-B4-C46;
	A18-B4-C25;	A19-B4-C1;	A19-B4-C36;	A20-B4-C12;	A20-B4-C47;
	A18-B4-C26;	A19-B4-C2;	A19-B4-C37;	A20-B4-C13;	A20-B4-C48;
15	A18-B4-C27;	A19-B4-C3;	A19-B4-C38;	A20-B4-C14;	A20-B4-C49;
	A18-B4-C28;	A19-B4-C4;	A19-B4-C39;	A20-B4-C15;	A20-B4-C50;
	A18-B4-C29;	A19-B4-C5;	A19-B4-C40;	A20-B4-C16;	A20-B4-C51;
	A18-B4-C30;	A19-B4-C6;	A19-B4-C41;	A20-B4-C17;	A20-B4-C52;
	A18-B4-C31;	A19-B4-C7;	A19-B4-C42;	A20-B4-C18;	A20-B4-C53;
20	A18-B4-C32;	A19-B4-C8;	A19-B4-C43;	A20-B4-C19;	A20-B4-C54;
	A18-B4-C33;	A19-B4-C9;	A19-B4-C44;	A20-B4-C20;	A20-B4-C55;
	A18-B4-C34;	A19-B4-C10;	A19-B4-C45;	A20-B4-C21;	A20-B4-C56;
	A18-B4-C35;	A19-B4-C11;	A19-B4-C46;	A20-B4-C22;	A20-B4-C57;
	A18-B4-C36;	A19-B4-C12;	A19-B4-C47;	A20-B4-C23;	A20-B4-C58;
25	A18-B4-C37;	A19-B4-C13;	A19-B4-C48;	A20-B4-C24;	A20-B4-C59;
	A18-B4-C38;	A19-B4-C14;	A19-B4-C49;	A20-B4-C25;	A21-B4-C1;
	A18-B4-C39;	A19-B4-C15;	A19-B4-C50;	A20-B4-C26;	A21-B4-C2;
	A18-B4-C40;	A19-B4-C16;	A19-B4-C51;	A20-B4-C27;	A21-B4-C3;
	A18-B4-C41;	A19-B4-C17;	A19-B4-C52;	A20-B4-C28;	A21-B4-C4;
30	A18-B4-C42;	A19-B4-C18;	A19-B4-C53;	A20-B4-C29;	A21-B4-C5;
	A18-B4-C43;	A19-B4-C19;	A19-B4-C54;	A20-B4-C30;	A21-B4-C6;
	A18-B4-C44;	A19-B4-C20;	A19-B4-C55;	A20-B4-C31;	A21-B4-C7;
	A18-B4-C45;	A19-B4-C21;	A19-B4-C56;	A20-B4-C32;	A21-B4-C8;
	A18-B4-C46;	A19-B4-C22;	A19-B4-C57;	A20-B4-C33;	A21-B4-C9;
35	A18-B4-C47;	A19-B4-C23;	A19-B4-C58;	A20-B4-C34;	A21-B4-C10;

	A21-B4-C11;	A21-B4-C46;	A22-B4-C22;	A22-B4-C57;	A23-B4-C33;
	A21-B4-C12;	A21-B4-C47;	A22-B4-C23;	A22-B4-C58;	A23-B4-C34;
	A21-B4-C13;	A21-B4-C48;	A22-B4-C24;	A22-B4-C59;	A23-B4-C35;
	A21-B4-C14;	A21-B4-C49;	A22-B4-C25;	A23-B4-C1;	A23-B4-C36;
5	A21-B4-C15;	A21-B4-C50;	A22-B4-C26;	A23-B4-C2;	A23-B4-C37;
	A21-B4-C16;	A21-B4-C51;	A22-B4-C27;	A23-B4-C3;	A23-B4-C38;
	A21-B4-C17;	A21-B4-C52;	A22-B4-C28;	A23-B4-C4;	A23-B4-C39;
	A21-B4-C18;	A21-B4-C53;	A22-B4-C29;	A23-B4-C5;	A23-B4-C40;
	A21-B4-C19;	A21-B4-C54;	A22-B4-C30;	A23-B4-C6;	A23-B4-C41;
10	A21-B4-C20;	A21-B4-C55;	A22-B4-C31;	A23-B4-C7;	A23-B4-C42;
	A21-B4-C21;	A21-B4-C56;	A22-B4-C32;	A23-B4-C8;	A23-B4-C43;
	A21-B4-C22;	A21-B4-C57;	A22-B4-C33;	A23-B4-C9;	A23-B4-C44;
	A21-B4-C23;	A21-B4-C58;	A22-B4-C34;	A23-B4-C10;	A23-B4-C45;
	A21-B4-C24;	A21-B4-C59;	A22-B4-C35;	A23-B4-C11;	A23-B4-C46;
15	A21-B4-C25;	A22-B4-C1;	A22-B4-C36;	A23-B4-C12;	A23-B4-C47;
	A21-B4-C26;	A22-B4-C2;	A22-B4-C37;	A23-B4-C13;	A23-B4-C48;
	A21-B4-C27;	A22-B4-C3;	A22-B4-C38;	A23-B4-C14;	A23-B4-C49;
	A21-B4-C28;	A22-B4-C4;	A22-B4-C39;	A23-B4-C15;	A23-B4-C50;
	A21-B4-C29;	A22-B4-C5;	A22-B4-C40;	A23-B4-C16;	A23-B4-C51;
20	A21-B4-C30;	A22-B4-C6;	A22-B4-C41;	A23-B4-C17;	A23-B4-C52;
	A21-B4-C31;	A22-B4-C7;	A22-B4-C42;	A23-B4-C18;	A23-B4-C53;
	A21-B4-C32;	A22-B4-C8;	A22-B4-C43;	A23-B4-C19;	A23-B4-C54;
	A21-B4-C33;	A22-B4-C9;	A22-B4-C44;	A23-B4-C20;	A23-B4-C55;
	A21-B4-C34;	A22-B4-C10;	A22-B4-C45;	A23-B4-C21;	A23-B4-C56;
25	A21-B4-C35;	A22-B4-C11;	A22-B4-C46;	A23-B4-C22;	A23-B4-C57;
	A21-B4-C36;	A22-B4-C12;	A22-B4-C47;	A23-B4-C23;	A23-B4-C58;
	A21-B4-C37;	A22-B4-C13;	A22-B4-C48;	A23-B4-C24;	A23-B4-C59;
	A21-B4-C38;	A22-B4-C14;	A22-B4-C49;	A23-B4-C25;	A24-B4-C1;
	A21-B4-C39;	A22-B4-C15;	A22-B4-C50;	A23-B4-C26;	A24-B4-C2;
30	A21-B4-C40;	A22-B4-C16;	A22-B4-C51;	A23-B4-C27;	A24-B4-C3;
	A21-B4-C41;	A22-B4-C17;	A22-B4-C52;	A23-B4-C28;	A24-B4-C4;
	A21-B4-C42;	A22-B4-C18;	A22-B4-C53;	A23-B4-C29;	A24-B4-C5;
	A21-B4-C43;	A22-B4-C19;	A22-B4-C54;	A23-B4-C30;	A24-B4-C6;
	A21-B4-C44;	A22-B4-C20;	A22-B4-C55;	A23-B4-C31;	A24-B4-C7;
35	A21-B4-C45;	A22-B4-C21;	A22-B4-C56;	A23-B4-C32;	A24-B4-C8;

	A24-B4-C9;	A24-B4-C44;	A25-B4-C20;	A25-B4-C55;	A26-B4-C31;
	A24-B4-C10;	A24-B4-C45;	A25-B4-C21;	A25-B4-C56;	A26-B4-C32;
	A24-B4-C11;	A24-B4-C46;	A25-B4-C22;	A25-B4-C57;	A26-B4-C33;
	A24-B4-C12;	A24-B4-C47;	A25-B4-C23;	A25-B4-C58;	A26-B4-C34;
5	A24-B4-C13;	A24-B4-C48;	A25-B4-C24;	A25-B4-C59;	A26-B4-C35;
	A24-B4-C14;	A24-B4-C49;	A25-B4-C25;	A26-B4-C1;	A26-B4-C36;
	A24-B4-C15;	A24-B4-C50;	A25-B4-C26;	A26-B4-C2;	A26-B4-C37;
	A24-B4-C16;	A24-B4-C51;	A25-B4-C27;	A26-B4-C3;	A26-B4-C38;
	A24-B4-C17;	A24-B4-C52;	A25-B4-C28;	A26-B4-C4;	A26-B4-C39;
10	A24-B4-C18;	A24-B4-C53;	A25-B4-C29;	A26-B4-C5;	A26-B4-C40;
	A24-B4-C19;	A24-B4-C54;	A25-B4-C30;	A26-B4-C6;	A26-B4-C41;
	A24-B4-C20;	A24-B4-C55;	A25-B4-C31;	A26-B4-C7;	A26-B4-C42;
	A24-B4-C21;	A24-B4-C56;	A25-B4-C32;	A26-B4-C8;	A26-B4-C43;
	A24-B4-C22;	A24-B4-C57;	A25-B4-C33;	A26-B4-C9;	A26-B4-C44;
15	A24-B4-C23;	A24-B4-C58;	A25-B4-C34;	A26-B4-C10;	A26-B4-C45;
	A24-B4-C24;	A24-B4-C59;	A25-B4-C35;	A26-B4-C11;	A26-B4-C46;
	A24-B4-C25;	A25-B4-C1;	A25-B4-C36;	A26-B4-C12;	A26-B4-C47;
	A24-B4-C26;	A25-B4-C2;	A25-B4-C37;	A26-B4-C13;	A26-B4-C48;
	A24-B4-C27;	A25-B4-C3;	A25-B4-C38;	A26-B4-C14;	A26-B4-C49;
20	A24-B4-C28;	A25-B4-C4;	A25-B4-C39;	A26-B4-C15;	A26-B4-C50;
	A24-B4-C29;	A25-B4-C5;	A25-B4-C40;	A26-B4-C16;	A26-B4-C51;
	A24-B4-C30;	A25-B4-C6;	A25-B4-C41;	A26-B4-C17;	A26-B4-C52;
	A24-B4-C31;	A25-B4-C7;	A25-B4-C42;	A26-B4-C18;	A26-B4-C53;
	A24-B4-C32;	A25-B4-C8;	A25-B4-C43;	A26-B4-C19;	A26-B4-C54;
25	A24-B4-C33;	A25-B4-C9;	A25-B4-C44;	A26-B4-C20;	A26-B4-C55;
	A24-B4-C34;	A25-B4-C10;	A25-B4-C45;	A26-B4-C21;	A26-B4-C56;
	A24-B4-C35;	A25-B4-C11;	A25-B4-C46;	A26-B4-C22;	A26-B4-C57;
	A24-B4-C36;	A25-B4-C12;	A25-B4-C47;	A26-B4-C23;	A26-B4-C58;
	A24-B4-C37;	A25-B4-C13;	A25-B4-C48;	A26-B4-C24;	A26-B4-C59;
30	A24-B4-C38;	A25-B4-C14;	A25-B4-C49;	A26-B4-C25;	A27-B4-C1;
	A24-B4-C39;	A25-B4-C15;	A25-B4-C50;	A26-B4-C26;	A27-B4-C2;
	A24-B4-C40;	A25-B4-C16;	A25-B4-C51;	A26-B4-C27;	A27-B4-C3;
	A24-B4-C41;	A25-B4-C17;	A25-B4-C52;	A26-B4-C28;	A27-B4-C4;
	A24-B4-C42;	A25-B4-C18;	A25-B4-C53;	A26-B4-C29;	A27-B4-C5;
35	A24-B4-C43;	A25-B4-C19;	A25-B4-C54;	A26-B4-C30;	A27-B4-C6;

	A27-B4-C7;	A27-B4-C42;	A28-B4-C18;	A28-B4-C53;	A29-B4-C29;
	A27-B4-C8;	A27-B4-C43;	A28-B4-C19;	A28-B4-C54;	A29-B4-C30;
	A27-B4-C9;	A27-B4-C44;	A28-B4-C20;	A28-B4-C55;	A29-B4-C31;
	A27-B4-C10;	A27-B4-C45;	A28-B4-C21;	A28-B4-C56;	A29-B4-C32;
5	A27-B4-C11;	A27-B4-C46;	A28-B4-C22;	A28-B4-C57;	A29-B4-C33;
	A27-B4-C12;	A27-B4-C47;	A28-B4-C23;	A28-B4-C58;	A29-B4-C34;
	A27-B4-C13;	A27-B4-C48;	A28-B4-C24;	A28-B4-C59;	A29-B4-C35;
	A27-B4-C14;	A27-B4-C49;	A28-B4-C25;	A29-B4-C1;	A29-B4-C36;
	A27-B4-C15;	A27-B4-C50;	A28-B4-C26;	A29-B4-C2;	A29-B4-C37;
10	A27-B4-C16;	A27-B4-C51;	A28-B4-C27;	A29-B4-C3;	A29-B4-C38;
	A27-B4-C17;	A27-B4-C52;	A28-B4-C28;	A29-B4-C4;	A29-B4-C39;
	A27-B4-C18;	A27-B4-C53;	A28-B4-C29;	A29-B4-C5;	A29-B4-C40;
	A27-B4-C19;	A27-B4-C54;	A28-B4-C30;	A29-B4-C6;	A29-B4-C41;
	A27-B4-C20;	A27-B4-C55;	A28-B4-C31;	A29-B4-C7;	A29-B4-C42;
15	A27-B4-C21;	A27-B4-C56;	A28-B4-C32;	A29-B4-C8;	A29-B4-C43;
	A27-B4-C22;	A27-B4-C57;	A28-B4-C33;	A29-B4-C9;	A29-B4-C44;
	A27-B4-C23;	A27-B4-C58;	A28-B4-C34;	A29-B4-C10;	A29-B4-C45;
	A27-B4-C24;	A27-B4-C59;	A28-B4-C35;	A29-B4-C11;	A29-B4-C46;
	A27-B4-C25;	A28-B4-C1;	A28-B4-C36;	A29-B4-C12;	A29-B4-C47;
20	A27-B4-C26;	A28-B4-C2;	A28-B4-C37;	A29-B4-C13;	A29-B4-C48;
	A27-B4-C27;	A28-B4-C3;	A28-B4-C38;	A29-B4-C14;	A29-B4-C49;
	A27-B4-C28;	A28-B4-C4;	A28-B4-C39;	A29-B4-C15;	A29-B4-C50;
	A27-B4-C29;	A28-B4-C5;	A28-B4-C40;	A29-B4-C16;	A29-B4-C51;
	A27-B4-C30;	A28-B4-C6;	A28-B4-C41;	A29-B4-C17;	A29-B4-C52;
25	A27-B4-C31;	A28-B4-C7;	A28-B4-C42;	A29-B4-C18;	A29-B4-C53;
	A27-B4-C32;	A28-B4-C8;	A28-B4-C43;	A29-B4-C19;	A29-B4-C54;
	A27-B4-C33;	A28-B4-C9;	A28-B4-C44;	A29-B4-C20;	A29-B4-C55;
	A27-B4-C34;	A28-B4-C10;	A28-B4-C45;	A29-B4-C21;	A29-B4-C56;
	A27-B4-C35;	A28-B4-C11;	A28-B4-C46;	A29-B4-C22;	A29-B4-C57;
30	A27-B4-C36;	A28-B4-C12;	A28-B4-C47;	A29-B4-C23;	A29-B4-C58;
	A27-B4-C37;	A28-B4-C13;	A28-B4-C48;	A29-B4-C24;	A29-B4-C59;
	A27-B4-C38;	A28-B4-C14;	A28-B4-C49;	A29-B4-C25;	A30-B4-C1;
	A27-B4-C39;	A28-B4-C15;	A28-B4-C50;	A29-B4-C26;	A30-B4-C2;
	A27-B4-C40;	A28-B4-C16;	A28-B4-C51;	A29-B4-C27;	A30-B4-C3;
35	A27-B4-C41;	A28-B4-C17;	A28-B4-C52;	A29-B4-C28;	A30-B4-C4;

	A30-B4-C5;	A30-B4-C40;	A31-B4-C16;	A31-B4-C51;	A32-B4-C27;
	A30-B4-C6;	A30-B4-C41;	A31-B4-C17;	A31-B4-C52;	A32-B4-C28;
	A30-B4-C7;	A30-B4-C42;	A31-B4-C18;	A31-B4-C53;	A32-B4-C29;
	A30-B4-C8;	A30-B4-C43;	A31-B4-C19;	A31-B4-C54;	A32-B4-C30;
5	A30-B4-C9;	A30-B4-C44;	A31-B4-C20;	A31-B4-C55;	A32-B4-C31;
	A30-B4-C10;	A30-B4-C45;	A31-B4-C21;	A31-B4-C56;	A32-B4-C32;
	A30-B4-C11;	A30-B4-C46;	A31-B4-C22;	A31-B4-C57;	A32-B4-C33;
	A30-B4-C12;	A30-B4-C47;	A31-B4-C23;	A31-B4-C58;	A32-B4-C34;
	A30-B4-C13;	A30-B4-C48;	A31-B4-C24;	A31-B4-C59;	A32-B4-C35;
10	A30-B4-C14;	A30-B4-C49;	A31-B4-C25;	A32-B4-C1;	A32-B4-C36;
	A30-B4-C15;	A30-B4-C50;	A31-B4-C26;	A32-B4-C2;	A32-B4-C37;
	A30-B4-C16;	A30-B4-C51;	A31-B4-C27;	A32-B4-C3;	A32-B4-C38;
	A30-B4-C17;	A30-B4-C52;	A31-B4-C28;	A32-B4-C4;	A32-B4-C39;
	A30-B4-C18;	A30-B4-C53;	A31-B4-C29;	A32-B4-C5;	A32-B4-C40;
15	A30-B4-C19;	A30-B4-C54;	A31-B4-C30;	A32-B4-C6;	A32-B4-C41;
	A30-B4-C20;	A30-B4-C55;	A31-B4-C31;	A32-B4-C7;	A32-B4-C42;
	A30-B4-C21;	A30-B4-C56;	A31-B4-C32;	A32-B4-C8;	A32-B4-C43;
	A30-B4-C22;	A30-B4-C57;	A31-B4-C33;	A32-B4-C9;	A32-B4-C44;
	A30-B4-C23;	A30-B4-C58;	A31-B4-C34;	A32-B4-C10;	A32-B4-C45;
20	A30-B4-C24;	A30-B4-C59;	A31-B4-C35;	A32-B4-C11;	A32-B4-C46;
	A30-B4-C25;	A31-B4-C1;	A31-B4-C36;	A32-B4-C12;	A32-B4-C47;
	A30-B4-C26;	A31-B4-C2;	A31-B4-C37;	A32-B4-C13;	A32-B4-C48;
	A30-B4-C27;	A31-B4-C3;	A31-B4-C38;	A32-B4-C14;	A32-B4-C49;
	A30-B4-C28;	A31-B4-C4;	A31-B4-C39;	A32-B4-C15;	A32-B4-C50;
25	A30-B4-C29;	A31-B4-C5;	A31-B4-C40;	A32-B4-C16;	A32-B4-C51;
	A30-B4-C30;	A31-B4-C6;	A31-B4-C41;	A32-B4-C17;	A32-B4-C52;
	A30-B4-C31;	A31-B4-C7;	A31-B4-C42;	A32-B4-C18;	A32-B4-C53;
	A30-B4-C32;	A31-B4-C8;	A31-B4-C43;	A32-B4-C19;	A32-B4-C54;
	A30-B4-C33;	A31-B4-C9;	A31-B4-C44;	A32-B4-C20;	A32-B4-C55;
30	A30-B4-C34;	A31-B4-C10;	A31-B4-C45;	A32-B4-C21;	A32-B4-C56;
	A30-B4-C35;	A31-B4-C11;	A31-B4-C46;	A32-B4-C22;	A32-B4-C57;
	A30-B4-C36;	A31-B4-C12;	A31-B4-C47;	A32-B4-C23;	A32-B4-C58;
	A30-B4-C37;	A31-B4-C13;	A31-B4-C48;	A32-B4-C24;	A32-B4-C59;
	A30-B4-C38;	A31-B4-C14;	A31-B4-C49;	A32-B4-C25;	A33-B4-C1;
35	A30-B4-C39;	A31-B4-C15;	A31-B4-C50;	A32-B4-C26;	A33-B4-C2;

	A33-B4-C3;	A33-B4-C38;	A34-B4-C14;	A34-B4-C49;	A35-B4-C25;
	A33-B4-C4;	A33-B4-C39;	A34-B4-C15;	A34-B4-C50;	A35-B4-C26;
	A33-B4-C5;	A33-B4-C40;	A34-B4-C16;	A34-B4-C51;	A35-B4-C27;
	A33-B4-C6;	A33-B4-C41;	A34-B4-C17;	A34-B4-C52;	A35-B4-C28;
5	A33-B4-C7;	A33-B4-C42;	A34-B4-C18;	A34-B4-C53;	A35-B4-C29;
	A33-B4-C8;	A33-B4-C43;	A34-B4-C19;	A34-B4-C54;	A35-B4-C30;
	A33-B4-C9;	A33-B4-C44;	A34-B4-C20;	A34-B4-C55;	A35-B4-C31;
	A33-B4-C10;	A33-B4-C45;	A34-B4-C21;	A34-B4-C56;	A35-B4-C32;
	A33-B4-C11;	A33-B4-C46;	A34-B4-C22;	A34-B4-C57;	A35-B4-C33;
10	A33-B4-C12;	A33-B4-C47;	A34-B4-C23;	A34-B4-C58;	A35-B4-C34;
	A33-B4-C13;	A33-B4-C48;	A34-B4-C24;	A34-B4-C59;	A35-B4-C35;
	A33-B4-C14;	A33-B4-C49;	A34-B4-C25;	A35-B4-C1;	A35-B4-C36;
	A33-B4-C15;	A33-B4-C50;	A34-B4-C26;	A35-B4-C2;	A35-B4-C37;
	A33-B4-C16;	A33-B4-C51;	A34-B4-C27;	A35-B4-C3;	A35-B4-C38;
15	A33-B4-C17;	A33-B4-C52;	A34-B4-C28;	A35-B4-C4;	A35-B4-C39;
	A33-B4-C18;	A33-B4-C53;	A34-B4-C29;	A35-B4-C5;	A35-B4-C40;
	A33-B4-C19;	A33-B4-C54;	A34-B4-C30;	A35-B4-C6;	A35-B4-C41;
	A33-B4-C20;	A33-B4-C55;	A34-B4-C31;	A35-B4-C7;	A35-B4-C42;
	A33-B4-C21;	A33-B4-C56;	A34-B4-C32;	A35-B4-C8;	A35-B4-C43;
20	A33-B4-C22;	A33-B4-C57;	A34-B4-C33;	A35-B4-C9;	A35-B4-C44;
	A33-B4-C23;	A33-B4-C58;	A34-B4-C34;	A35-B4-C10;	A35-B4-C45;
	A33-B4-C24;	A33-B4-C59;	A34-B4-C35;	A35-B4-C11;	A35-B4-C46;
	A33-B4-C25;	A34-B4-C1;	A34-B4-C36;	A35-B4-C12;	A35-B4-C47;
	A33-B4-C26;	A34-B4-C2;	A34-B4-C37;	A35-B4-C13;	A35-B4-C48;
25	A33-B4-C27;	A34-B4-C3;	A34-B4-C38;	A35-B4-C14;	A35-B4-C49;
	A33-B4-C28;	A34-B4-C4;	A34-B4-C39;	A35-B4-C15;	A35-B4-C50;
	A33-B4-C29;	A34-B4-C5;	A34-B4-C40;	A35-B4-C16;	A35-B4-C51;
	A33-B4-C30;	A34-B4-C6;	A34-B4-C41;	A35-B4-C17;	A35-B4-C52;
	A33-B4-C31;	A34-B4-C7;	A34-B4-C42;	A35-B4-C18;	A35-B4-C53;
30	A33-B4-C32;	A34-B4-C8;	A34-B4-C43;	A35-B4-C19;	A35-B4-C54;
	A33-B4-C33;	A34-B4-C9;	A34-B4-C44;	A35-B4-C20;	A35-B4-C55;
	A33-B4-C34;	A34-B4-C10;	A34-B4-C45;	A35-B4-C21;	A35-B4-C56;
	A33-B4-C35;	A34-B4-C11;	A34-B4-C46;	A35-B4-C22;	A35-B4-C57;
	A33-B4-C36;	A34-B4-C12;	A34-B4-C47;	A35-B4-C23;	A35-B4-C58;
35	A33-B4-C37;	A34-B4-C13;	A34-B4-C48;	A35-B4-C24;	A35-B4-C59;

	A1-B5-C1;	A1-B5-C36;	A2-B5-C12;	A2-B5-C47;	A3-B5-C23;
	A1-B5-C2;	A1-B5-C37;	A2-B5-C13;	A2-B5-C48;	A3-B5-C24;
	A1-B5-C3;	A1-B5-C38;	A2-B5-C14;	A2-B5-C49;	A3-B5-C25;
	A1-B5-C4;	A1-B5-C39;	A2-B5-C15;	A2-B5-C50;	A3-B5-C26;
5	A1-B5-C5;	A1-B5-C40;	A2-B5-C16;	A2-B5-C51;	A3-B5-C27;
	A1-B5-C6;	A1-B5-C41;	A2-B5-C17;	A2-B5-C52;	A3-B5-C28;
	A1-B5-C7;	A1-B5-C42;	A2-B5-C18;	A2-B5-C53;	A3-B5-C29;
	A1-B5-C8;	A1-B5-C43;	A2-B5-C19;	A2-B5-C54;	A3-B5-C30;
	A1-B5-C9;	A1-B5-C44;	A2-B5-C20;	A2-B5-C55;	A3-B5-C31;
10	A1-B5-C10;	A1-B5-C45;	A2-B5-C21;	A2-B5-C56;	A3-B5-C32;
	A1-B5-C11;	A1-B5-C46;	A2-B5-C22;	A2-B5-C57;	A3-B5-C33;
	A1-B5-C12;	A1-B5-C47;	A2-B5-C23;	A2-B5-C58;	A3-B5-C34;
	A1-B5-C13;	A1-B5-C48;	A2-B5-C24;	A2-B5-C59;	A3-B5-C35;
	A1-B5-C14;	A1-B5-C49;	A2-B5-C25;	A3-B5-C1;	A3-B5-C36;
15	A1-B5-C15;	A1-B5-C50;	A2-B5-C26;	A3-B5-C2;	A3-B5-C37;
	A1-B5-C16;	A1-B5-C51;	A2-B5-C27;	A3-B5-C3;	A3-B5-C38;
	A1-B5-C17;	A1-B5-C52;	A2-B5-C28;	A3-B5-C4;	A3-B5-C39;
	A1-B5-C18;	A1-B5-C53;	A2-B5-C29;	A3-B5-C5;	A3-B5-C40;
	A1-B5-C19;	A1-B5-C54;	A2-B5-C30;	A3-B5-C6;	A3-B5-C41;
20	A1-B5-C20;	A1-B5-C55;	A2-B5-C31;	A3-B5-C7;	A3-B5-C42;
	A1-B5-C21;	A1-B5-C56;	A2-B5-C32;	A3-B5-C8;	A3-B5-C43;
	A1-B5-C22;	A1-B5-C57;	A2-B5-C33;	A3-B5-C9;	A3-B5-C44;
	A1-B5-C23;	A1-B5-C58;	A2-B5-C34;	A3-B5-C10;	A3-B5-C45;
	A1-B5-C24;	A1-B5-C59;	A2-B5-C35;	A3-B5-C11;	A3-B5-C46;
25	A1-B5-C25;	A2-B5-C1;	A2-B5-C36;	A3-B5-C12;	A3-B5-C47;
	A1-B5-C26;	A2-B5-C2;	A2-B5-C37;	A3-B5-C13;	A3-B5-C48;
	A1-B5-C27;	A2-B5-C3;	A2-B5-C38;	A3-B5-C14;	A3-B5-C49;
	A1-B5-C28;	A2-B5-C4;	A2-B5-C39;	A3-B5-C15;	A3-B5-C50;
	A1-B5-C29;	A2-B5-C5;	A2-B5-C40;	A3-B5-C16;	A3-B5-C51;
30	A1-B5-C30;	A2-B5-C6;	A2-B5-C41;	A3-B5-C17;	A3-B5-C52;
	A1-B5-C31;	A2-B5-C7;	A2-B5-C42;	A3-B5-C18;	A3-B5-C53;
	A1-B5-C32;	A2-B5-C8;	A2-B5-C43;	A3-B5-C19;	A3-B5-C54;
	A1-B5-C33;	A2-B5-C9;	A2-B5-C44;	A3-B5-C20;	A3-B5-C55;
	A1-B5-C34;	A2-B5-C10;	A2-B5-C45;	A3-B5-C21;	A3-B5-C56;
35	A1-B5-C35;	A2-B5-C11;	A2-B5-C46;	A3-B5-C22;	A3-B5-C57;

	A3-B5-C58;	A4-B5-C34;	A5-B5-C10;	A5-B5-C45;	A6-B5-C21;
	A3-B5-C59;	A4-B5-C35;	A5-B5-C11;	A5-B5-C46;	A6-B5-C22;
	A4-B5-C1;	A4-B5-C36;	A5-B5-C12;	A5-B5-C47;	A6-B5-C23;
	A4-B5-C2;	A4-B5-C37;	A5-B5-C13;	A5-B5-C48;	A6-B5-C24;
5	A4-B5-C3;	A4-B5-C38;	A5-B5-C14;	A5-B5-C49;	A6-B5-C25;
	A4-B5-C4;	A4-B5-C39;	A5-B5-C15;	A5-B5-C50;	A6-B5-C26;
	A4-B5-C5;	A4-B5-C40;	A5-B5-C16;	A5-B5-C51;	A6-B5-C27;
	A4-B5-C6;	A4-B5-C41;	A5-B5-C17;	A5-B5-C52;	A6-B5-C28;
	A4-B5-C7;	A4-B5-C42;	A5-B5-C18;	A5-B5-C53;	A6-B5-C29;
10	A4-B5-C8;	A4-B5-C43;	A5-B5-C19;	A5-B5-C54;	A6-B5-C30;
	A4-B5-C9;	A4-B5-C44;	A5-B5-C20;	A5-B5-C55;	A6-B5-C31;
	A4-B5-C10;	A4-B5-C45;	A5-B5-C21;	A5-B5-C56;	A6-B5-C32;
	A4-B5-C11;	A4-B5-C46;	A5-B5-C22;	A5-B5-C57;	A6-B5-C33;
	A4-B5-C12;	A4-B5-C47;	A5-B5-C23;	A5-B5-C58;	A6-B5-C34;
15	A4-B5-C13;	A4-B5-C48;	A5-B5-C24;	A5-B5-C59;	A6-B5-C35;
	A4-B5-C14;	A4-B5-C49;	A5-B5-C25;	A6-B5-C1;	A6-B5-C36;
	A4-B5-C15;	A4-B5-C50;	A5-B5-C26;	A6-B5-C2;	A6-B5-C37;
	A4-B5-C16;	A4-B5-C51;	A5-B5-C27;	A6-B5-C3;	A6-B5-C38;
	A4-B5-C17;	A4-B5-C52;	A5-B5-C28;	A6-B5-C4;	A6-B5-C39;
20	A4-B5-C18;	A4-B5-C53;	A5-B5-C29;	A6-B5-C5;	A6-B5-C40;
	A4-B5-C19;	A4-B5-C54;	A5-B5-C30;	A6-B5-C6;	A6-B5-C41;
	A4-B5-C20;	A4-B5-C55;	A5-B5-C31;	A6-B5-C7;	A6-B5-C42;
	A4-B5-C21;	A4-B5-C56;	A5-B5-C32;	A6-B5-C8;;	A6-B5-C43;
	A4-B5-C22;	A4-B5-C57;	A5-B5-C33;	A6-B5-C9;	A6-B5-C44;
25	A4-B5-C23;	A4-B5-C58;	A5-B5-C34;	A6-B5-C10;	A6-B5-C45;
	A4-B5-C24;	A4-B5-C59;	A5-B5-C35;	A6-B5-C11;	A6-B5-C46;
	A4-B5-C25;	A5-B5-C1;	A5-B5-C36;	A6-B5-C12;	A6-B5-C47;
	A4-B5-C26;	A5-B5-C2;	A5-B5-C37;	A6-B5-C13;	A6-B5-C48;
	A4-B5-C27;	A5-B5-C3;	A5-B5-C38;	A6-B5-C14;	A6-B5-C49;
30	A4-B5-C28;	A5-B5-C4;	A5-B5-C39;	A6-B5-C15;	A6-B5-C50;
	A4-B5-C29;	A5-B5-C5;	A5-B5-C40;	A6-B5-C16;	A6-B5-C51;
	A4-B5-C30;	A5-B5-C6;	A5-B5-C41;	A6-B5-C17;	A6-B5-C52;
	A4-B5-C31;	A5-B5-C7;	A5-B5-C42;	A6-B5-C18;	A6-B5-C53;
	A4-B5-C32;	A5-B5-C8;	A5-B5-C43;	A6-B5-C19;	A6-B5-C54;
35	A4-B5-C33;	A5-B5-C9;	A5-B5-C44;	A6-B5-C20;	A6-B5-C55;

	A6-B5-C56;	A7-B5-C32;	A8-B5-C8;	A8-B5-C43;	A9-B5-C19;
	A6-B5-C57;	A7-B5-C33;	A8-B5-C9;	A8-B5-C44;	A9-B5-C20;
	A6-B5-C58;	A7-B5-C34;	A8-B5-C10;	A8-B5-C45;	A9-B5-C21;
	A6-B5-C59;	A7-B5-C35;	A8-B5-C11;	A8-B5-C46;	A9-B5-C22;
5	A7-B5-C1;	A7-B5-C36;	A8-B5-C12;	A8-B5-C47;	A9-B5-C23;
	A7-B5-C2;	A7-B5-C37;	A8-B5-C13;	A8-B5-C48;	A9-B5-C24;
	A7-B5-C3;	A7-B5-C38;	A8-B5-C14;	A8-B5-C49;	A9-B5-C25;
	A7-B5-C4;	A7-B5-C39;	A8-B5-C15;	A8-B5-C50;	A9-B5-C26;
	A7-B5-C5;	A7-B5-C40;	A8-B5-C16;	A8-B5-C51;	A9-B5-C27;
10	A7-B5-C6;	A7-B5-C41;	A8-B5-C17;	A8-B5-C52;	A9-B5-C28;
	A7-B5-C7;	A7-B5-C42;	A8-B5-C18;	A8-B5-C53;	A9-B5-C29;
	A7-B5-C8;	A7-B5-C43;	A8-B5-C19;	A8-B5-C54;	A9-B5-C30;
	A7-B5-C9;	A7-B5-C44;	A8-B5-C20;	A8-B5-C55;	A9-B5-C31;
	A7-B5-C10;	A7-B5-C45;	A8-B5-C21;	A8-B5-C56;	A9-B5-C32;
15	A7-B5-C11;	A7-B5-C46;	A8-B5-C22;	A8-B5-C57;	A9-B5-C33;
	A7-B5-C12;	A7-B5-C47;	A8-B5-C23;	A8-B5-C58;	A9-B5-C34;
	A7-B5-C13;	A7-B5-C48;	A8-B5-C24;	A8-B5-C59;	A9-B5-C35;
	A7-B5-C14;	A7-B5-C49;	A8-B5-C25;	A9-B5-C1;	A9-B5-C36;
	A7-B5-C15;	A7-B5-C50;	A8-B5-C26;	A9-B5-C2;	A9-B5-C37;
20	A7-B5-C16;	A7-B5-C51;	A8-B5-C27;	A9-B5-C3;	A9-B5-C38;
	A7-B5-C17;	A7-B5-C52;	A8-B5-C28;	A9-B5-C4;	A9-B5-C39;
	A7-B5-C18;	A7-B5-C53;	A8-B5-C29;	A9-B5-C5;	A9-B5-C40;
	A7-B5-C19;	A7-B5-C54;	A8-B5-C30;	A9-B5-C6;	A9-B5-C41;
	A7-B5-C20;	A7-B5-C55;	A8-B5-C31;	A9-B5-C7;	A9-B5-C42;
25	A7-B5-C21;	A7-B5-C56;	A8-B5-C32;	A9-B5-C8;	A9-B5-C43;
	A7-B5-C22;	A7-B5-C57;	A8-B5-C33;	A9-B5-C9;	A9-B5-C44;
	A7-B5-C23;	A7-B5-C58;	A8-B5-C34;	A9-B5-C10;	A9-B5-C45;
	A7-B5-C24;	A7-B5-C59;	A8-B5-C35;	A9-B5-C11;	A9-B5-C46;
	A7-B5-C25;	A8-B5-C1;	A8-B5-C36;	A9-B5-C12;	A9-B5-C47;
30	A7-B5-C26;	A8-B5-C2;	A8-B5-C37;	A9-B5-C13;	A9-B5-C48;
	A7-B5-C27;	A8-B5-C3;	A8-B5-C38;	A9-B5-C14;	A9-B5-C49;
	A7-B5-C28;	A8-B5-C4;	A8-B5-C39;	A9-B5-C15;	A9-B5-C50;
	A7-B5-C29;	A8-B5-C5;	A8-B5-C40;	A9-B5-C16;	A9-B5-C51;
	A7-B5-C30;	A8-B5-C6;	A8-B5-C41;	A9-B5-C17;	A9-B5-C52;
35	A7-B5-C31;	A8-B5-C7;	A8-B5-C42;	A9-B5-C18;	A9-B5-C53;

	A9-B5-C54;	A10-B5-C30;	A11-B5-C6;	A11-B5-C41;	A12-B5-C17;
	A9-B5-C55;	A10-B5-C31;	A11-B5-C7;	A11-B5-C42;	A12-B5-C18;
	A9-B5-C56;	A10-B5-C32;	A11-B5-C8;	A11-B5-C43;	A12-B5-C19;
	A9-B5-C57;	A10-B5-C33;	A11-B5-C9;	A11-B5-C44;	A12-B5-C20;
5	A9-B5-C58;	A10-B5-C34;	A11-B5-C10;	A11-B5-C45;	A12-B5-C21;
	A9-B5-C59;	A10-B5-C35;	A11-B5-C11;	A11-B5-C46;	A12-B5-C22;
	A10-B5-C1;	A10-B5-C36;	A11-B5-C12;	A11-B5-C47;	A12-B5-C23;
	A10-B5-C2;	A10-B5-C37;	A11-B5-C13;	A11-B5-C48;	A12-B5-C24;
	A10-B5-C3;	A10-B5-C38;	A11-B5-C14;	A11-B5-C49;	A12-B5-C25;
10	A10-B5-C4;	A10-B5-C39;	A11-B5-C15;	A11-B5-C50;	A12-B5-C26;
	A10-B5-C5;	A10-B5-C40;	A11-B5-C16;	A11-B5-C51;	A12-B5-C27;
	A10-B5-C6;	A10-B5-C41;	A11-B5-C17;	A11-B5-C52;	A12-B5-C28;
	A10-B5-C7;	A10-B5-C42;	A11-B5-C18;	A11-B5-C53;	A12-B5-C29;
	A10-B5-C8;	A10-B5-C43;	A11-B5-C19;	A11-B5-C54;	A12-B5-C30;
15	A10-B5-C9;	A10-B5-C44;	A11-B5-C20;	A11-B5-C55;	A12-B5-C31;
	A10-B5-C10;	A10-B5-C45;	A11-B5-C21;	A11-B5-C56;	A12-B5-C32;
	A10-B5-C11;	A10-B5-C46;	A11-B5-C22;	A11-B5-C57;	A12-B5-C33;
	A10-B5-C12;	A10-B5-C47;	A11-B5-C23;	A11-B5-C58;	A12-B5-C34;
	A10-B5-C13;	A10-B5-C48;	A11-B5-C24;	A11-B5-C59;	A12-B5-C35;
20	A10-B5-C14;	A10-B5-C49;	A11-B5-C25;	A12-B5-C1;	A12-B5-C36;
	A10-B5-C15;	A10-B5-C50;	A11-B5-C26;	A12-B5-C2;	A12-B5-C37;
	A10-B5-C16;	A10-B5-C51;	A11-B5-C27;	A12-B5-C3;	A12-B5-C38;
	A10-B5-C17;	A10-B5-C52;	A11-B5-C28;	A12-B5-C4;	A12-B5-C39;
	A10-B5-C18;	A10-B5-C53;	A11-B5-C29;	A12-B5-C5;	A12-B5-C40;
25	A10-B5-C19;	A10-B5-C54;	A11-B5-C30;	A12-B5-C6;	A12-B5-C41;
	A10-B5-C20;	A10-B5-C55;	A11-B5-C31;	A12-B5-C7;	A12-B5-C42;
	A10-B5-C21;	A10-B5-C56;	A11-B5-C32;	A12-B5-C8;	A12-B5-C43;
	A10-B5-C22;	A10-B5-C57;	A11-B5-C33;	A12-B5-C9;	A12-B5-C44;
	A10-B5-C23;	A10-B5-C58;	A11-B5-C34;	A12-B5-C10;	A12-B5-C45;
30	A10-B5-C24;	A10-B5-C59;	A11-B5-C35;	A12-B5-C11;	A12-B5-C46;
	A10-B5-C25;	A11-B5-C1;	A11-B5-C36;	A12-B5-C12;	A12-B5-C47;
	A10-B5-C26;	A11-B5-C2;	A11-B5-C37;	A12-B5-C13;	A12-B5-C48;
	A10-B5-C27;	A11-B5-C3;	A11-B5-C38;	A12-B5-C14;	A12-B5-C49;
	A10-B5-C28;	A11-B5-C4;	A11-B5-C39;	A12-B5-C15;	A12-B5-C50;
35	A10-B5-C29;	A11-B5-C5;	A11-B5-C40;	A12-B5-C16;	A12-B5-C51;

	A12-B5-C52;	A13-B5-C28;	A14-B5-C4;	A14-B5-C39;	A15-B5-C15;
	A12-B5-C53;	A13-B5-C29;	A14-B5-C5;	A14-B5-C40;	A15-B5-C16;
	A12-B5-C54;	A13-B5-C30;	A14-B5-C6;	A14-B5-C41;	A15-B5-C17;
	A12-B5-C55;	A13-B5-C31;	A14-B5-C7;	A14-B5-C42;	A15-B5-C18;
5	A12-B5-C56;	A13-B5-C32;	A14-B5-C8;	A14-B5-C43;	A15-B5-C19;
	A12-B5-C57;	A13-B5-C33;	A14-B5-C9;	A14-B5-C44;	A15-B5-C20;
	A12-B5-C58;	A13-B5-C34;	A14-B5-C10;	A14-B5-C45;	A15-B5-C21;
	A12-B5-C59;	A13-B5-C35;	A14-B5-C11;	A14-B5-C46;	A15-B5-C22;
	A13-B5-C1;	A13-B5-C36;	A14-B5-C12;	A14-B5-C47;	A15-B5-C23;
10	A13-B5-C2;	A13-B5-C37;	A14-B5-C13;	A14-B5-C48;	A15-B5-C24;
	A13-B5-C3;	A13-B5-C38;	A14-B5-C14;	A14-B5-C49;	A15-B5-C25;
	A13-B5-C4;	A13-B5-C39;	A14-B5-C15;	A14-B5-C50;	A15-B5-C26;
	A13-B5-C5;	A13-B5-C40;	A14-B5-C16;	A14-B5-C51;	A15-B5-C27;
	A13-B5-C6;	A13-B5-C41;	A14-B5-C17;	A14-B5-C52;	A15-B5-C28;
15	A13-B5-C7;	A13-B5-C42;	A14-B5-C18;	A14-B5-C53;	A15-B5-C29;
	A13-B5-C8;	A13-B5-C43;	A14-B5-C19;	A14-B5-C54;	A15-B5-C30;
	A13-B5-C9;	A13-B5-C44;	A14-B5-C20;	A14-B5-C55;	A15-B5-C31;
	A13-B5-C10;	A13-B5-C45;	A14-B5-C21;	A14-B5-C56;	A15-B5-C32;
	A13-B5-C11;	A13-B5-C46;	A14-B5-C22;	A14-B5-C57;	A15-B5-C33;
20	A13-B5-C12;	A13-B5-C47;	A14-B5-C23;	A14-B5-C58;	A15-B5-C34;
	A13-B5-C13;	A13-B5-C48;	A14-B5-C24;	A14-B5-C59;	A15-B5-C35;
	A13-B5-C14;	A13-B5-C49;	A14-B5-C25;	A15-B5-C1;	A15-B5-C36;
	A13-B5-C15;	A13-B5-C50;	A14-B5-C26;	A15-B5-C2;	A15-B5-C37;
	A13-B5-C16;	A13-B5-C51;	A14-B5-C27;	A15-B5-C3;	A15-B5-C38;
25	A13-B5-C17;	A13-B5-C52;	A14-B5-C28;	A15-B5-C4;	A15-B5-C39;
	A13-B5-C18;	A13-B5-C53;	A14-B5-C29;	A15-B5-C5;	A15-B5-C40;
	A13-B5-C19;	A13-B5-C54;	A14-B5-C30;	A15-B5-C6;	A15-B5-C41;
	A13-B5-C20;	A13-B5-C55;	A14-B5-C31;	A15-B5-C7;	A15-B5-C42;
	A13-B5-C21;	A13-B5-C56;	A14-B5-C32;	A15-B5-C8;	A15-B5-C43;
30	A13-B5-C22;	A13-B5-C57;	A14-B5-C33;	A15-B5-C9;	A15-B5-C44;
	A13-B5-C23;	A13-B5-C58;	A14-B5-C34;	A15-B5-C10;	A15-B5-C45;
	A13-B5-C24;	A13-B5-C59;	A14-B5-C35;	A15-B5-C11;	A15-B5-C46;
	A13-B5-C25;	A14-B5-C1;	A14-B5-C36;	A15-B5-C12;	A15-B5-C47;
	A13-B5-C26;	A14-B5-C2;	A14-B5-C37;	A15-B5-C13;	A15-B5-C48;
35	A13-B5-C27;	A14-B5-C3;	A14-B5-C38;	A15-B5-C14;	A15-B5-C49;

	A15-B5-C50;	A16-B5-C26;	A17-B5-C2;	A17-B5-C37;	A18-B5-C13;
	A15-B5-C51;	A16-B5-C27;	A17-B5-C3;	A17-B5-C38;	A18-B5-C14;
	A15-B5-C52;	A16-B5-C28;	A17-B5-C4;	A17-B5-C39;	A18-B5-C15;
	A15-B5-C53;	A16-B5-C29;	A17-B5-C5;	A17-B5-C40;	A18-B5-C16;
5	A15-B5-C54;	A16-B5-C30;	A17-B5-C6;	A17-B5-C41;	A18-B5-C17;
	A15-B5-C55;	A16-B5-C31;	A17-B5-C7;	A17-B5-C42;	A18-B5-C18;
	A15-B5-C56;	A16-B5-C32;	A17-B5-C8;	A17-B5-C43;	A18-B5-C19;
	A15-B5-C57;	A16-B5-C33;	A17-B5-C9;	A17-B5-C44;	A18-B5-C20;
	A15-B5-C58;	A16-B5-C34;	A17-B5-C10;	A17-B5-C45;	A18-B5-C21;
10	A15-B5-C59;	A16-B5-C35;	A17-B5-C11;	A17-B5-C46;	A18-B5-C22;
	A16-B5-C1;	A16-B5-C36;	A17-B5-C12;	A17-B5-C47;	A18-B5-C23;
	A16-B5-C2;	A16-B5-C37;	A17-B5-C13;	A17-B5-C48;	A18-B5-C24;
	A16-B5-C3;	A16-B5-C38;	A17-B5-C14;	A17-B5-C49;	A18-B5-C25;
	A16-B5-C4;	A16-B5-C39;	A17-B5-C15;	A17-B5-C50;	A18-B5-C26;
15	A16-B5-C5;	A16-B5-C40;	A17-B5-C16;	A17-B5-C51;	A18-B5-C27;
	A16-B5-C6;	A16-B5-C41;	A17-B5-C17;	A17-B5-C52;	A18-B5-C28;
	A16-B5-C7;	A16-B5-C42;	A17-B5-C18;	A17-B5-C53;	A18-B5-C29;
	A16-B5-C8;	A16-B5-C43;	A17-B5-C19;	A17-B5-C54;	A18-B5-C30;
	A16-B5-C9;	A16-B5-C44;	A17-B5-C20;	A17-B5-C55;	A18-B5-C31;
20	A16-B5-C10;	A16-B5-C45;	A17-B5-C21;	A17-B5-C56;	A18-B5-C32;
	A16-B5-C11;	A16-B5-C46;	A17-B5-C22;	A17-B5-C57;	A18-B5-C33;
	A16-B5-C12;	A16-B5-C47;	A17-B5-C23;	A17-B5-C58;	A18-B5-C34;
	A16-B5-C13;	A16-B5-C48;	A17-B5-C24;	A17-B5-C59;	A18-B5-C35;
	A16-B5-C14;	A16-B5-C49;	A17-B5-C25;	A18-B5-C1;	A18-B5-C36;
25	A16-B5-C15;	A16-B5-C50;	A17-B5-C26;	A18-B5-C2;	A18-B5-C37;
	A16-B5-C16;	A16-B5-C51;	A17-B5-C27;	A18-B5-C3;	A18-B5-C38;
	A16-B5-C17;	A16-B5-C52;	A17-B5-C28;	A18-B5-C4;	A18-B5-C39;
	A16-B5-C18;	A16-B5-C53;	A17-B5-C29;	A18-B5-C5;	A18-B5-C40;
	A16-B5-C19;	A16-B5-C54;	A17-B5-C30;	A18-B5-C6;	A18-B5-C41;
30	A16-B5-C20;	A16-B5-C55;	A17-B5-C31;	A18-B5-C7;	A18-B5-C42;
	A16-B5-C21;	A16-B5-C56;	A17-B5-C32;	A18-B5-C8;	A18-B5-C43;
	A16-B5-C22;	A16-B5-C57;	A17-B5-C33;	A18-B5-C9;	A18-B5-C44;
	A16-B5-C23;	A16-B5-C58;	A17-B5-C34;	A18-B5-C10;	A18-B5-C45;
	A16-B5-C24;	A16-B5-C59;	A17-B5-C35;	A18-B5-C11;	A18-B5-C46;
35	A16-B5-C25;	A17-B5-C1;	A17-B5-C36;	A18-B5-C12;	A18-B5-C47;

	A18-B5-C48;	A19-B5-C24;	A19-B5-C59;	A20-B5-C35;	A21-B5-C11;
	A18-B5-C49;	A19-B5-C25;	A20-B5-C1;	A20-B5-C36;	A21-B5-C12;
	A18-B5-C50;	A19-B5-C26;	A20-B5-C2;	A20-B5-C37;	A21-B5-C13;
	A18-B5-C51;	A19-B5-C27;	A20-B5-C3;	A20-B5-C38;	A21-B5-C14;
5	A18-B5-C52;	A19-B5-C28;	A20-B5-C4;	A20-B5-C39;	A21-B5-C15;
	A18-B5-C53;	A19-B5-C29;	A20-B5-C5;	A20-B5-C40;	A21-B5-C16;
	A18-B5-C54;	A19-B5-C30;	A20-B5-C6;	A20-B5-C41;	A21-B5-C17;
	A18-B5-C55;	A19-B5-C31;	A20-B5-C7;	A20-B5-C42;	A21-B5-C18;
	A18-B5-C56;	A19-B5-C32;	A20-B5-C8;	A20-B5-C43;	A21-B5-C19;
10	A18-B5-C57;	A19-B5-C33;	A20-B5-C9;	A20-B5-C44;	A21-B5-C20;
	A18-B5-C58;	A19-B5-C34;	A20-B5-C10;	A20-B5-C45;	A21-B5-C21;
	A18-B5-C59;	A19-B5-C35;	A20-B5-C11;	A20-B5-C46;	A21-B5-C22;
	A19-B5-C1;	A19-B5-C36;	A20-B5-C12;	A20-B5-C47;	A21-B5-C23;
	A19-B5-C2;	A19-B5-C37;	A20-B5-C13;	A20-B5-C48;	A21-B5-C24;
15	A19-B5-C3;	A19-B5-C38;	A20-B5-C14;	A20-B5-C49;	A21-B5-C25;
	A19-B5-C4;	A19-B5-C39;	A20-B5-C15;	A20-B5-C50;	A21-B5-C26;
	A19-B5-C5;	A19-B5-C40;	A20-B5-C16;	A20-B5-C51;	A21-B5-C27;
	A19-B5-C6;	A19-B5-C41;	A20-B5-C17;	A20-B5-C52;	A21-B5-C28;
	A19-B5-C7;	A19-B5-C42;	A20-B5-C18;	A20-B5-C53;	A21-B5-C29;
20	A19-B5-C8;	A19-B5-C43;	A20-B5-C19;	A20-B5-C54;	A21-B5-C30;
	A19-B5-C9;	A19-B5-C44;	A20-B5-C20;	A20-B5-C55;	A21-B5-C31;
	A19-B5-C10;	A19-B5-C45;	A20-B5-C21;	A20-B5-C56;	A21-B5-C32;
	A19-B5-C11;	A19-B5-C46;	A20-B5-C22;	A20-B5-C57;	A21-B5-C33;
	A19-B5-C12;	A19-B5-C47;	A20-B5-C23;	A20-B5-C58;	A21-B5-C34;
25	A19-B5-C13;	A19-B5-C48;	A20-B5-C24;	A20-B5-C59;	A21-B5-C35;
	A19-B5-C14;	A19-B5-C49;	A20-B5-C25;	A21-B5-C1;	A21-B5-C36;
	A19-B5-C15;	A19-B5-C50;	A20-B5-C26;	A21-B5-C2;	A21-B5-C37;
	A19-B5-C16;	A19-B5-C51;	A20-B5-C27;	A21-B5-C3;	A21-B5-C38;
	A19-B5-C17;	A19-B5-C52;	A20-B5-C28;	A21-B5-C4;	A21-B5-C39;
30	A19-B5-C18;	A19-B5-C53;	A20-B5-C29;	A21-B5-C5;	A21-B5-C40;
	A19-B5-C19;	A19-B5-C54;	A20-B5-C30;	A21-B5-C6;	A21-B5-C41;
	A19-B5-C20;	A19-B5-C55;	A20-B5-C31;	A21-B5-C7;	A21-B5-C42;
	A19-B5-C21;	A19-B5-C56;	A20-B5-C32;	A21-B5-C8;	A21-B5-C43;
	A19-B5-C22;	A19-B5-C57;	A20-B5-C33;	A21-B5-C9;	A21-B5-C44;
35	A19-B5-C23;	A19-B5-C58;	A20-B5-C34;	A21-B5-C10;	A21-B5-C45;

	A21-B5-C46;	A22-B5-C22;	A22-B5-C57;	A23-B5-C33;	A24-B5-C9;
	A21-B5-C47;	A22-B5-C23;	A22-B5-C58;	A23-B5-C34;	A24-B5-C10;
	A21-B5-C48;	A22-B5-C24;	A22-B5-C59;	A23-B5-C35;	A24-B5-C11;
	A21-B5-C49;	A22-B5-C25;	A23-B5-C1;	A23-B5-C36;	A24-B5-C12;
5	A21-B5-C50;	A22-B5-C26;	A23-B5-C2;	A23-B5-C37;	A24-B5-C13;
	A21-B5-C51;	A22-B5-C27;	A23-B5-C3;	A23-B5-C38;	A24-B5-C14;
	A21-B5-C52;	A22-B5-C28;	A23-B5-C4;	A23-B5-C39;	A24-B5-C15;
	A21-B5-C53;	A22-B5-C29;	A23-B5-C5;	A23-B5-C40;	A24-B5-C16;
	A21-B5-C54;	A22-B5-C30;	A23-B5-C6;	A23-B5-C41;	A24-B5-C17;
10	A21-B5-C55;	A22-B5-C31;	A23-B5-C7;	A23-B5-C42;	A24-B5-C18;
	A21-B5-C56;	A22-B5-C32;	A23-B5-C8;	A23-B5-C43;	A24-B5-C19;
	A21-B5-C57;	A22-B5-C33;	A23-B5-C9;	A23-B5-C44;	A24-B5-C20;
	A21-B5-C58;	A22-B5-C34;	A23-B5-C10;	A23-B5-C45;	A24-B5-C21;
	A21-B5-C59;	A22-B5-C35;	A23-B5-C11;	A23-B5-C46;	A24-B5-C22;
15	A22-B5-C1;	A22-B5-C36;	A23-B5-C12;	A23-B5-C47;	A24-B5-C23;
	A22-B5-C2;	A22-B5-C37;	A23-B5-C13;	A23-B5-C48;	A24-B5-C24;
	A22-B5-C3;	A22-B5-C38;	A23-B5-C14;	A23-B5-C49;	A24-B5-C25;
	A22-B5-C4;	A22-B5-C39;	A23-B5-C15;	A23-B5-C50;	A24-B5-C26;
	A22-B5-C5;	A22-B5-C40;	A23-B5-C16;	A23-B5-C51;	A24-B5-C27;
20	A22-B5-C6;	A22-B5-C41;	A23-B5-C17;	A23-B5-C52;	A24-B5-C28;
	A22-B5-C7;	A22-B5-C42;	A23-B5-C18;	A23-B5-C53;	A24-B5-C29;
	A22-B5-C8;	A22-B5-C43;	A23-B5-C19;	A23-B5-C54;	A24-B5-C30;
	A22-B5-C9;	A22-B5-C44;	A23-B5-C20;	A23-B5-C55;	A24-B5-C31;
	A22-B5-C10;	A22-B5-C45;	A23-B5-C21;	A23-B5-C56;	A24-B5-C32;
25	A22-B5-C11;	A22-B5-C46;	A23-B5-C22;	A23-B5-C57;	A24-B5-C33;
	A22-B5-C12;	A22-B5-C47;	A23-B5-C23;	A23-B5-C58;	A24-B5-C34;
	A22-B5-C13;	A22-B5-C48;	A23-B5-C24;	A23-B5-C59;	A24-B5-C35;
	A22-B5-C14;	A22-B5-C49;	A23-B5-C25;	A24-B5-C1;	A24-B5-C36;
	A22-B5-C15;	A22-B5-C50;	A23-B5-C26;	A24-B5-C2;	A24-B5-C37;
30	A22-B5-C16;	A22-B5-C51;	A23-B5-C27;	A24-B5-C3;	A24-B5-C38;
	A22-B5-C17;	A22-B5-C52;	A23-B5-C28;	A24-B5-C4;	A24-B5-C39;
	A22-B5-C18;	A22-B5-C53;	A23-B5-C29;	A24-B5-C5;	A24-B5-C40;
	A22-B5-C19;	A22-B5-C54;	A23-B5-C30;	A24-B5-C6;	A24-B5-C41;
	A22-B5-C20;	A22-B5-C55;	A23-B5-C31;	A24-B5-C7;	A24-B5-C42;
35	A22-B5-C21;	A22-B5-C56;	A23-B5-C32;	A24-B5-C8;	A24-B5-C43;

	A24-B5-C44;	A25-B5-C20;	A25-B5-C55;	A26-B5-C31;	A27-B5-C7;
	A24-B5-C45;	A25-B5-C21;	A25-B5-C56;	A26-B5-C32;	A27-B5-C8;
	A24-B5-C46;	A25-B5-C22;	A25-B5-C57;	A26-B5-C33;	A27-B5-C9;
	A24-B5-C47;	A25-B5-C23;	A25-B5-C58;	A26-B5-C34;	A27-B5-C10;
5	A24-B5-C48;	A25-B5-C24;	A25-B5-C59;	A26-B5-C35;	A27-B5-C11;
	A24-B5-C49;	A25-B5-C25;	A26-B5-C1;	A26-B5-C36;	A27-B5-C12;
	A24-B5-C50;	A25-B5-C26;	A26-B5-C2;	A26-B5-C37;	A27-B5-C13;
	A24-B5-C51;	A25-B5-C27;	A26-B5-C3;	A26-B5-C38;	A27-B5-C14;
	A24-B5-C52;	A25-B5-C28;	A26-B5-C4;	A26-B5-C39;	A27-B5-C15;
10	A24-B5-C53;	A25-B5-C29;	A26-B5-C5;	A26-B5-C40;	A27-B5-C16;
	A24-B5-C54;	A25-B5-C30;	A26-B5-C6;	A26-B5-C41;	A27-B5-C17;
	A24-B5-C55;	A25-B5-C31;	A26-B5-C7;	A26-B5-C42;	A27-B5-C18;
	A24-B5-C56;	A25-B5-C32;	A26-B5-C8;	A26-B5-C43;	A27-B5-C19;
	A24-B5-C57;	A25-B5-C33;	A26-B5-C9;	A26-B5-C44;	A27-B5-C20;
15	A24-B5-C58;	A25-B5-C34;	A26-B5-C10;	A26-B5-C45;	A27-B5-C21;
	A24-B5-C59;	A25-B5-C35;	A26-B5-C11;	A26-B5-C46;	A27-B5-C22;
	A25-B5-C1;	A25-B5-C36;	A26-B5-C12;	A26-B5-C47;	A27-B5-C23;
	A25-B5-C2;	A25-B5-C37;	A26-B5-C13;	A26-B5-C48;	A27-B5-C24;
	A25-B5-C3;	A25-B5-C38;	A26-B5-C14;	A26-B5-C49;	A27-B5-C25;
20	A25-B5-C4;	A25-B5-C39;	A26-B5-C15;	A26-B5-C50;	A27-B5-C26;
	A25-B5-C5;	A25-B5-C40;	A26-B5-C16;	A26-B5-C51;	A27-B5-C27;
	A25-B5-C6;	A25-B5-C41;	A26-B5-C17;	A26-B5-C52;	A27-B5-C28;
	A25-B5-C7;	A25-B5-C42;	A26-B5-C18;	A26-B5-C53;	A27-B5-C29;
	A25-B5-C8;	A25-B5-C43;	A26-B5-C19;	A26-B5-C54;	A27-B5-C30;
25	A25-B5-C9;	A25-B5-C44;	A26-B5-C20;	A26-B5-C55;	A27-B5-C31;
	A25-B5-C10;	A25-B5-C45;	A26-B5-C21;	A26-B5-C56;	A27-B5-C32;
	A25-B5-C11;	A25-B5-C46;	A26-B5-C22;	A26-B5-C57;	A27-B5-C33;
	A25-B5-C12;	A25-B5-C47;	A26-B5-C23;	A26-B5-C58;	A27-B5-C34;
	A25-B5-C13;	A25-B5-C48;	A26-B5-C24;	A26-B5-C59;	A27-B5-C35;
30	A25-B5-C14;	A25-B5-C49;	A26-B5-C25;	A27-B5-C1;	A27-B5-C36;
	A25-B5-C15;	A25-B5-C50;	A26-B5-C26;	A27-B5-C2;	A27-B5-C37;
	A25-B5-C16;	A25-B5-C51;	A26-B5-C27;	A27-B5-C3;	A27-B5-C38;
	A25-B5-C17;	A25-B5-C52;	A26-B5-C28;	A27-B5-C4;	A27-B5-C39;
	A25-B5-C18;	A25-B5-C53;	A26-B5-C29;	A27-B5-C5;	A27-B5-C40;
35	A25-B5-C19;	A25-B5-C54;	A26-B5-C30;	A27-B5-C6;	A27-B5-C41;

	A27-B5-C42;	A28-B5-C18;	A28-B5-C53;	A29-B5-C29;	A30-B5-C5;
	A27-B5-C43;	A28-B5-C19;	A28-B5-C54;	A29-B5-C30;	A30-B5-C6;
	A27-B5-C44;	A28-B5-C20;	A28-B5-C55;	A29-B5-C31;	A30-B5-C7;
	A27-B5-C45;	A28-B5-C21;	A28-B5-C56;	A29-B5-C32;	A30-B5-C8;
5	A27-B5-C46;	A28-B5-C22;	A28-B5-C57;	A29-B5-C33;	A30-B5-C9;
	A27-B5-C47;	A28-B5-C23;	A28-B5-C58;	A29-B5-C34;	A30-B5-C10;
	A27-B5-C48;	A28-B5-C24;	A28-B5-C59;	A29-B5-C35;	A30-B5-C11;
	A27-B5-C49;	A28-B5-C25;	A29-B5-C1;	A29-B5-C36;	A30-B5-C12;
	A27-B5-C50;	A28-B5-C26;	A29-B5-C2;	A29-B5-C37;	A30-B5-C13;
10	A27-B5-C51;	A28-B5-C27;	A29-B5-C3;	A29-B5-C38;	A30-B5-C14;
	A27-B5-C52;	A28-B5-C28;	A29-B5-C4;	A29-B5-C39;	A30-B5-C15;
	A27-B5-C53;	A28-B5-C29;	A29-B5-C5;	A29-B5-C40;	A30-B5-C16;
	A27-B5-C54;	A28-B5-C30;	A29-B5-C6;	A29-B5-C41;	A30-B5-C17;
	A27-B5-C55;	A28-B5-C31;	A29-B5-C7;	A29-B5-C42;	A30-B5-C18;
15	A27-B5-C56;	A28-B5-C32;	A29-B5-C8;	A29-B5-C43;	A30-B5-C19;
	A27-B5-C57;	A28-B5-C33;	A29-B5-C9;	A29-B5-C44;	A30-B5-C20;
	A27-B5-C58;	A28-B5-C34;	A29-B5-C10;	A29-B5-C45;	A30-B5-C21;
	A27-B5-C59;	A28-B5-C35;	A29-B5-C11;	A29-B5-C46;	A30-B5-C22;
	A28-B5-C1;	A28-B5-C36;	A29-B5-C12;	A29-B5-C47;	A30-B5-C23;
20	A28-B5-C2;	A28-B5-C37;	A29-B5-C13;	A29-B5-C48;	A30-B5-C24;
	A28-B5-C3;	A28-B5-C38;	A29-B5-C14;	A29-B5-C49;	A30-B5-C25;
	A28-B5-C4;	A28-B5-C39;	A29-B5-C15;	A29-B5-C50;	A30-B5-C26;
	A28-B5-C5;	A28-B5-C40;	A29-B5-C16;	A29-B5-C51;	A30-B5-C27;
	A28-B5-C6;	A28-B5-C41;	A29-B5-C17;	A29-B5-C52;	A30-B5-C28;
25	A28-B5-C7;	A28-B5-C42;	A29-B5-C18;	A29-B5-C53;	A30-B5-C29;
	A28-B5-C8;	A28-B5-C43;	A29-B5-C19;	A29-B5-C54;	A30-B5-C30;
	A28-B5-C9;	A28-B5-C44;	A29-B5-C20;	A29-B5-C55;	A30-B5-C31;
	A28-B5-C10;	A28-B5-C45;	A29-B5-C21;	A29-B5-C56;	A30-B5-C32;
	A28-B5-C11;	A28-B5-C46;	A29-B5-C22;	A29-B5-C57;	A30-B5-C33;
30	A28-B5-C12;	A28-B5-C47;	A29-B5-C23;	A29-B5-C58;	A30-B5-C34;
	A28-B5-C13;	A28-B5-C48;	A29-B5-C24;	A29-B5-C59;	A30-B5-C35;
	A28-B5-C14;	A28-B5-C49;	A29-B5-C25;	A30-B5-C1;	A30-B5-C36;
	A28-B5-C15;	A28-B5-C50;	A29-B5-C26;	A30-B5-C2;	A30-B5-C37;
	A28-B5-C16;	A28-B5-C51;	A29-B5-C27;	A30-B5-C3;	A30-B5-C38;
35	A28-B5-C17;	A28-B5-C52;	A29-B5-C28;	A30-B5-C4;	A30-B5-C39;

	A30-B5-C40;	A31-B5-C16;	A31-B5-C51;	A32-B5-C27;	A33-B5-C3;
	A30-B5-C41;	A31-B5-C17;	A31-B5-C52;	A32-B5-C28;	A33-B5-C4;
	A30-B5-C42;	A31-B5-C18;	A31-B5-C53;	A32-B5-C29;	A33-B5-C5;
	A30-B5-C43;	A31-B5-C19;	A31-B5-C54;	A32-B5-C30;	A33-B5-C6;
5	A30-B5-C44;	A31-B5-C20;	A31-B5-C55;	A32-B5-C31;	A33-B5-C7;
	A30-B5-C45;	A31-B5-C21;	A31-B5-C56;	A32-B5-C32;	A33-B5-C8;
	A30-B5-C46;	A31-B5-C22;	A31-B5-C57;	A32-B5-C33;	A33-B5-C9;
	A30-B5-C47;	A31-B5-C23;	A31-B5-C58;	A32-B5-C34;	A33-B5-C10;
	A30-B5-C48;	A31-R5-C24;	A31-B5-C59;	A32-B5-C35;	A33-B5-C11;
10	A30-B5-C49;	A31-B5-C25;	A32-B5-C1;	A32-B5-C36;	A33-B5-C12;
	A30-B5-C50;	A31-B5-C26;	A32-B5-C2;	A32-B5-C37;	A33-B5-C13;
	A30-B5-C51;	A31-B5-C27;	A32-B5-C3;	A32-B5-C38;	A33-B5-C14;
	A30-B5-C52;	A31-B5-C28;	A32-B5-C4;	A32-B5-C39;	A33-B5-C15;
	A30-B5-C53;	A31-B5-C29;	A32-B5-C5;	A32-B5-C40;	A33-B5-C16;
15	A30-B5-C54;	A31-B5-C30;	A32-B5-C6;	A32-B5-C41;	A33-B5-C17;
	A30-B5-C55;	A31-B5-C31;	A32-B5-C7;	A32-B5-C42;	A33-B5-C18;
	A30-B5-C56;	A31-B5-C32;	A32-B5-C8;	A32-B5-C43;	A33-B5-C19;
	A30-B5-C57;	A31-B5-C33;	A32-B5-C9;	A32-B5-C44;	A33-B5-C20;
	A30-B5-C58;	A31-B5-C34;	A32-B5-C10;	A32-B5-C45;	A33-B5-C21;
20	A30-B5-C59;	A31-B5-C35;	A32-B5-C11;	A32-B5-C46;	A33-B5-C22;
	A31-B5-C1;	A31-B5-C36;	A32-B5-C12;	A32-B5-C47;	A33-B5-C23;
	A31-B5-C2;	A31-B5-C37;	A32-B5-C13;	A32-B5-C48;	A33-B5-C24;
	A31-B5-C3;	A31-B5-C38;	A32-B5-C14;	A32-B5-C49;	A33-B5-C25;
	A31-B5-C4;	A31-B5-C39;	A32-B5-C15;	A32-B5-C50;	A33-B5-C26;
25	A31-B5-C5;	A31-B5-C40;	A32-B5-C16;	A32-B5-C51;	A33-B5-C27;
	A31-B5-C6;	A31-B5-C41;	A32-B5-C17;	A32-B5-C52;	A33-B5-C28;
	A31-B5-C7;	A31-B5-C42;	A32-B5-C18;	A32-B5-C53;	A33-B5-C29;
	A31-B5-C8;	A31-B5-C43;	A32-B5-C19;	A32-B5-C54;	A33-B5-C30;
	A31-B5-C9;	A31-B5-C44;	A32-B5-C20;	A32-B5-C55;	A33-B5-C31;
30	A31-B5-C10;	A31-B5-C45;	A32-B5-C21;	A32-B5-C56;	A33-B5-C32;
	A31-B5-C11;	A31-B5-C46;	A32-B5-C22;	A32-B5-C57;	A33-B5-C33;
	A31-B5-C12;	A31-B5-C47;	A32-B5-C23;	A32-B5-C58;	A33-B5-C34;
	A31-B5-C13;	A31-B5-C48;	A32-B5-C24;	A32-B5-C59;	A33-B5-C35;
	A31-B5-C14;	A31-B5-C49;	A32-B5-C25;	A33-B5-C1;	A33-B5-C36;
35	A31-B5-C15;	A31-B5-C50;	A32-B5-C26;	A33-B5-C2;	A33-B5-C37;

	A33-B5-C38;	A34-B5-C14;	A34-B5-C49;	A35-B5-C25;	A1-B6-C1;
	A33-B5-C39;	A34-B5-C15;	A34-B5-C50;	A35-B5-C26;	A1-B6-C2;
	A33-B5-C40;	A34-B5-C16;	A34-B5-C51;	A35-B5-C27;	A1-B6-C3;
	A33-B5-C41;	A34-B5-C17;	A34-B5-C52;	A35-B5-C28;	A1-B6-C4;
5	A33-B5-C42;	A34-B5-C18;	A34-B5-C53;	A35-B5-C29;	A1-B6-C5;
	A33-B5-C43;	A34-B5-C19;	A34-B5-C54;	A35-B5-C30;	A1-B6-C6;
	A33-B5-C44;	A34-B5-C20;	A34-B5-C55;	A35-B5-C31;	A1-B6-C7;
	A33-B5-C45;	A34-B5-C21;	A34-B5-C56;	A35-B5-C32;	A1-B6-C8;
	A33-B5-C46;	A34-B5-C22;	A34-B5-C57;	A35-B5-C33;	A1-B6-C9;
10	A33-B5-C47;	A34-B5-C23;	A34-B5-C58;	A35-B5-C34;	A1-B6-C10;
	A33-B5-C48;	A34-B5-C24;	A34-B5-C59;	A35-B5-C35;	A1-B6-C11;
	A33-B5-C49;	A34-B5-C25;	A35-B5-C1;	A35-B5-C36;	A1-B6-C12;
	A33-B5-C50;	A34-B5-C26;	A35-B5-C2;	A35-B5-C37;	A1-B6-C13;
	A33-B5-C51;	A34-B5-C27;	A35-B5-C3;	A35-B5-C38;	A1-B6-C14;
15	A33-B5-C52;	A34-B5-C28;	A35-B5-C4;	A35-B5-C39;	A1-B6-C15;
	A33-B5-C53;	A34-B5-C29;	A35-B5-C5;	A35-B5-C40;	A1-B6-C16;
	A33-B5-C54;	A34-B5-C30;	A35-B5-C6;	A35-B5-C41;	A1-B6-C17;
	A33-B5-C55;	A34-B5-C31;	A35-B5-C7;	A35-B5-C42;	A1-B6-C18;
	A33-B5-C56;	A34-B5-C32;	A35-B5-C8;	A35-B5-C43;	A1-B6-C19;
20	A33-B5-C57;	A34-B5-C33;	A35-B5-C9;	A35-B5-C44;	A1-B6-C20;
	A33-B5-C58;	A34-B5-C34;	A35-B5-C10;	A35-B5-C45;	A1-B6-C21;
	A33-B5-C59;	A34-B5-C35;	A35-B5-C11;	A35-B5-C46;	A1-B6-C22;
	A34-B5-C1;	A34-B5-C36;	A35-B5-C12;	A35-B5-C47;	A1-B6-C23;
	A34-B5-C2;	A34-B5-C37;	A35-B5-C13;	A35-B5-C48;	A1-B6-C24;
25	A34-B5-C3;	A34-B5-C38;	A35-B5-C14;	A35-B5-C49;	A1-B6-C25;
	A34-B5-C4;	A34-B5-C39;	A35-B5-C15;	A35-B5-C50;	A1-B6-C26;
	A34-B5-C5;	A34-B5-C40;	A35-B5-C16;	A35-B5-C51;	A1-B6-C27;
	A34-B5-C6;	A34-B5-C41;	A35-B5-C17;	A35-B5-C52;	A1-B6-C28;
	A34-B5-C7;	A34-B5-C42;	A35-B5-C18;	A35-B5-C53;	A1-B6-C29;
30	A34-B5-C8;	A34-B5-C43;	A35-B5-C19;	A35-B5-C54;	A1-B6-C30;
	A34-B5-C9;	A34-B5-C44;	A35-B5-C20;	A35-B5-C55;	A1-B6-C31;
	A34-B5-C10;	A34-B5-C45;	A35-B5-C21;	A35-B5-C56;	A1-B6-C32;
	A34-B5-C11;	A34-B5-C46;	A35-B5-C22;	A35-B5-C57;	A1-B6-C33;
	A34-B5-C12;	A34-B5-C47;	A35-B5-C23;	A35-B5-C58;	A1-B6-C34;
35	A34-B5-C13;	A34-B5-C48;	A35-B5-C24;	A35-B5-C59;	A1-B6-C35;

	A1-B6-C36;	A2-B6-C12;	A2-B6-C47;	A3-B6-C23;	A3-B6-C58;
	A1-B6-C37;	A2-B6-C13;	A2-B6-C48;	A3-B6-C24;	A3-B6-C59;
	A1-B6-C38;	A2-B6-C14;	A2-B6-C49;	A3-B6-C25;	A4-B6-C1;
	A1-B6-C39;	A2-B6-C15;	A2-B6-C50;	A3-B6-C26;	A4-B6-C2;
5	A1-B6-C40;	A2-B6-C16;	A2-B6-C51;	A3-B6-C27;	A4-B6-C3;
	A1-B6-C41;	A2-B6-C17;	A2-B6-C52;	A3-B6-C28;	A4-B6-C4;
	A1-B6-C42;	A2-B6-C18;	A2-B6-C53;	A3-B6-C29;	A4-B6-C5;
	A1-B6-C43;	A2-B6-C19;	A2-B6-C54;	A3-B6-C30;	A4-B6-C6;
	A1-B6-C44;	A2-B6-C20;	A2-B6-C55;	A3-B6-C31;	A4-B6-C7;
10	A1-B6-C45;	A2-B6-C21;	A2-B6-C56;	A3-B6-C32;	A4-B6-C8;
	A1-B6-C46;	A2-B6-C22;	A2-B6-C57;	A3-B6-C33;	A4-B6-C9;
	A1-B6-C47;	A2-B6-C23;	A2-B6-C58;	A3-B6-C34;	A4-B6-C10;
	A1-B6-C48;	A2-B6-C24;	A2-B6-C59;	A3-B6-C35;	A4-B6-C11;
	A1-B6-C49;	A2-B6-C25;	A3-B6-C1;	A3-B6-C36;	A4-B6-C12;
15	A1-B6-C50;	A2-B6-C26;	A3-B6-C2;	A3-B6-C37;	A4-B6-C13;
	A1-B6-C51;	A2-B6-C27;	A3-B6-C3;	A3-B6-C38;	A4-B6-C14;
	A1-B6-C52;	A2-B6-C28;	A3-B6-C4;	A3-B6-C39;	A4-B6-C15;
	A1-B6-C53;	A2-B6-C29;	A3-B6-C5;	A3-B6-C40;	A4-B6-C16;
	A1-B6-C54;	A2-B6-C30;	A3-B6-C6;	A3-B6-C41;	A4-B6-C17;
20	A1-B6-C55;	A2-B6-C31;	A3-B6-C7;	A3-B6-C42;	A4-B6-C18;
	A1-B6-C56;	A2-B6-C32;	A3-B6-C8;	A3-B6-C43;	A4-B6-C19;
	A1-B6-C57;	A2-B6-C33;	A3-B6-C9;	A3-B6-C44;	A4-B6-C20;
	A1-B6-C58;	A2-B6-C34;	A3-B6-C10;	A3-B6-C45;	A4-B6-C21;
	A1-B6-C59;	A2-B6-C35;	A3-B6-C11;	A3-B6-C46;	A4-B6-C22;
25	A2-B6-C1;	A2-B6-C36;	A3-B6-C12;	A3-B6-C47;	A4-B6-C23;
	A2-B6-C2;	A2-B6-C37;	A3-B6-C13;	A3-B6-C48;	A4-B6-C24;
	A2-B6-C3;	A2-B6-C38;	A3-B6-C14;	A3-B6-C49;	A4-B6-C25;
	A2-B6-C4;	A2-B6-C39;	A3-B6-C15;	A3-B6-C50;	A4-B6-C26;
	A2-B6-C5;	A2-B6-C40;	A3-B6-C16;	A3-B6-C51;	A4-B6-C27;
30	A2-B6-C6;	A2-B6-C41;	A3-B6-C17;	A3-B6-C52;	A4-B6-C28;
	A2-B6-C7;	A2-B6-C42;	A3-B6-C18;	A3-B6-C53;	A4-B6-C29;
	A2-B6-C8;	A2-B6-C43;	A3-B6-C19;	A3-B6-C54;	A4-B6-C30;
	A2-B6-C9;	A2-B6-C44;	A3-B6-C20;	A3-B6-C55;	A4-B6-C31;
	A2-B6-C10;	A2-B6-C45;	A3-B6-C21;	A3-B6-C56;	A4-B6-C32;
35	A2-B6-C11;	A2-B6-C46;	A3-B6-C22;	A3-B6-C57;	A4-B6-C33;

	A4-B6-C34;	A5-B6-C10;	A5-B6-C45;	A6-B6-C21;	A6-B6-C56;
	A4-B6-C35;	A5-B6-C11;	A5-B6-C46;	A6-B6-C22;	A6-B6-C57;
	A4-B6-C36;	A5-B6-C12;	A5-B6-C47;	A6-B6-C23;	A6-B6-C58;
	A4-B6-C37;	A5-B6-C13;	A5-B6-C48;	A6-B6-C24;	A6-B6-C59;
5	A4-B6-C38;	A5-B6-C14;	A5-B6-C49;	A6-B6-C25;	A7-B6-C1;
	A4-B6-C39;	A5-B6-C15;	A5-B6-C50;	A6-B6-C26;	A7-B6-C2;
	A4-B6-C40;	A5-B6-C16;	A5-B6-C51;	A6-B6-C27;	A7-B6-C3;
	A4-B6-C41;	A5-B6-C17;	A5-B6-C52;	A6-B6-C28;	A7-B6-C4;
	A4-B6-C42;	A5-B6-C18;	A5-B6-C53;	A6-B6-C29;	A7-B6-C5;
10	A4-B6-C43;	A5-B6-C19;	A5-B6-C54;	A6-B6-C30;	A7-B6-C6;
	A4-B6-C44;	A5-B6-C20;	A5-B6-C55;	A6-B6-C31;	A7-B6-C7;
	A4-B6-C45;	A5-B6-C21;	A5-B6-C56;	A6-B6-C32;	A7-B6-C8;
	A4-B6-C46;	A5-B6-C22;	A5-B6-C57;	A6-B6-C33;	A7-B6-C9;
	A4-B6-C47;	A5-B6-C23;	A5-B6-C58;	A6-B6-C34;	A7-B6-C10;
15	A4-B6-C48;	A5-B6-C24;	A5-B6-C59;	A6-B6-C35;	A7-B6-C11;
	A4-B6-C49;	A5-B6-C25;	A6-B6-C1;	A6-B6-C36;	A7-B6-C12;
	A4-B6-C50;	A5-B6-C26;	A6-B6-C2;	A6-B6-C37;	A7-B6-C13;
	A4-B6-C51;	A5-B6-C27;	A6-B6-C3;	A6-B6-C38;	A7-B6-C14;
	A4-B6-C52;	A5-B6-C28;	A6-B6-C4;	A6-B6-C39;	A7-B6-C15;
20	A4-B6-C53;	A5-B6-C29;	A6-B6-C5;	A6-B6-C40;	A7-B6-C16;
	A4-B6-C54;	A5-B6-C30;	A6-B6-C6;	A6-B6-C41;	A7-B6-C17;
	A4-B6-C55;	A5-B6-C31;	A6-B6-C7;	A6-B6-C42;	A7-B6-C18;
	A4-B6-C56;	A5-B6-C32;	A6-B6-C8;;	A6-B6-C43;	A7-B6-C19;
	A4-B6-C57;	A5-B6-C33;	A6-B6-C9;	A6-B6-C44;	A7-B6-C20;
25	A4-B6-C58;	A5-B6-C34;	A6-B6-C10;	A6-B6-C45;	A7-B6-C21;
	A4-B6-C59;	A5-B6-C35;	A6-B6-C11;	A6-B6-C46;	A7-B6-C22;
	A5-B6-C1;	A5-B6-C36;	A6-B6-C12;	A6-B6-C47;	A7-B6-C23;
	A5-B6-C2;	A5-B6-C37;	A6-B6-C13;	A6-B6-C48;	A7-B6-C24;
	A5-B6-C3;	A5-B6-C38;	A6-B6-C14;	A6-B6-C49;	A7-B6-C25;
30	A5-B6-C4;	A5-B6-C39;	A6-B6-C15;	A6-B6-C50;	A7-B6-C26;
	A5-B6-C5;	A5-B6-C40;	A6-B6-C16;	A6-B6-C51;	A7-B6-C27;
	A5-B6-C6;	A5-B6-C41;	A6-B6-C17;	A6-B6-C52;	A7-B6-C28;
	A5-B6-C7;	A5-B6-C42;	A6-B6-C18;	A6-B6-C53;	A7-B6-C29;
	A5-B6-C8;	A5-B6-C43;	A6-B6-C19;	A6-B6-C54;	A7-B6-C30;
35	A5-B6-C9;	A5-B6-C44;	A6-B6-C20;	A6-B6-C55;	A7-B6-C31;

	A7-B6-C32;	A8-B6-C8;	A8-B6-C43;	A9-B6-C19;	A9-B6-C54;
	A7-B6-C33;	A8-B6-C9;	A8-B6-C44;	A9-B6-C20;	A9-B6-C55;
	A7-B6-C34;	A8-B6-C10;	A8-B6-C45;	A9-B6-C21;	A9-B6-C56;
	A7-B6-C35;	A8-B6-C11;	A8-B6-C46;	A9-B6-C22;	A9-B6-C57;
5	A7-B6-C36;	A8-B6-C12;	A8-B6-C47;	A9-B6-C23;	A9-B6-C58;
	A7-B6-C37;	A8-B6-C13;	A8-B6-C48;	A9-B6-C24;	A9-B6-C59;
	A7-B6-C38;	A8-B6-C14;	A8-B6-C49;	A9-B6-C25;	A10-B6-C1;
	A7-B6-C39;	A8-B6-C15;	A8-B6-C50;	A9-B6-C26;	A10-B6-C2;
	A7-B6-C40;	A8-B6-C16;	A8-B6-C51;	A9-B6-C27;	A10-B6-C3;
10	A7-B6-C41;	A8-B6-C17;	A8-B6-C52;	A9-B6-C28;	A10-B6-C4;
	A7-B6-C42;	A8-B6-C18;	A8-B6-C53;	A9-B6-C29;	A10-B6-C5;
	A7-B6-C43;	A8-B6-C19;	A8-B6-C54;	A9-B6-C30;	A10-B6-C6;
	A7-B6-C44;	A8-B6-C20;	A8-B6-C55;	A9-B6-C31;	A10-B6-C7;
	A7-B6-C45;	A8-B6-C21;	A8-B6-C56;	A9-B6-C32;	A10-B6-C8;
15	A7-B6-C46;	A8-B6-C22;	A8-B6-C57;	A9-B6-C33;	A10-B6-C9;
	A7-B6-C47;	A8-B6-C23;	A8-B6-C58;	A9-B6-C34;	A10-B6-C10;
	A7-B6-C48;	A8-B6-C24;	A8-B6-C59;	A9-B6-C35;	A10-B6-C11;
	A7-B6-C49;	A8-B6-C25;	A9-B6-C1;	A9-B6-C36;	A10-B6-C12;
	A7-B6-C50;	A8-B6-C26;	A9-B6-C2;	A9-B6-C37;	A10-B6-C13;
20	A7-B6-C51;	A8-B6-C27;	A9-B6-C3;	A9-B6-C38;	A10-B6-C14;
	A7-B6-C52;	A8-B6-C28;	A9-B6-C4;	A9-B6-C39;	A10-B6-C15;
	A7-B6-C53;	A8-B6-C29;	A9-B6-C5;	A9-B6-C40;	A10-B6-C16;
	A7-B6-C54;	A8-B6-C30;	A9-B6-C6;	A9-B6-C41;	A10-B6-C17;
	A7-B6-C55;	A8-B6-C31;	A9-B6-C7;	A9-B6-C42;	A10-B6-C18;
25	A7-B6-C56;	A8-B6-C32;	A9-B6-C8;	A9-B6-C43;	A10-B6-C19;
	A7-B6-C57;	A8-B6-C33;	A9-B6-C9;	A9-B6-C44;	A10-B6-C20;
	A7-B6-C58;	A8-B6-C34;	A9-B6-C10;	A9-B6-C45;	A10-B6-C21;
	A7-B6-C59;	A8-B6-C35;	A9-B6-C11;	A9-B6-C46;	A10-B6-C22;
	A8-B6-C1;	A8-B6-C36;	A9-B6-C12;	A9-B6-C47;	A10-B6-C23;
30	A8-B6-C2;	A8-B6-C37;	A9-B6-C13;	A9-B6-C48;	A10-B6-C24;
	A8-B6-C3;	A8-B6-C38;	A9-B6-C14;	A9-B6-C49;	A10-B6-C25;
	A8-B6-C4;	A8-B6-C39;	A9-B6-C15;	A9-B6-C50;	A10-B6-C26;
	A8-B6-C5;	A8-B6-C40;	A9-B6-C16;	A9-B6-C51;	A10-B6-C27;
	A8-B6-C6;	A8-B6-C41;	A9-B6-C17;	A9-B6-C52;	A10-B6-C28;
35	A8-B6-C7;	A8-B6-C42;	A9-B6-C18;	A9-B6-C53;	A10-B6-C29;

	A10-B6-C30;	A11-B6-C6;	A11-B6-C41;	A12-B6-C17;	A12-B6-C52;
	A10-B6-C31;	A11-B6-C7;	A11-B6-C42;	A12-B6-C18;	A12-B6-C53;
	A10-B6-C32;	A11-B6-C8;	A11-B6-C43;	A12-B6-C19;	A12-B6-C54;
	A10-B6-C33;	A11-B6-C9;	A11-B6-C44;	A12-B6-C20;	A12-B6-C55;
5	A10-B6-C34;	A11-B6-C10;	A11-B6-C45;	A12-B6-C21;	A12-B6-C56;
	A10-B6-C35;	A11-B6-C11;	A11-B6-C46;	A12-B6-C22;	A12-B6-C57;
	A10-B6-C36;	A11-B6-C12;	A11-B6-C47;	A12-B6-C23;	A12-B6-C58;
	A10-B6-C37;	A11-B6-C13;	A11-B6-C48;	A12-B6-C24;	A12-B6-C59;
	A10-B6-C38;	A11-B6-C14;	A11-B6-C49;	A12-B6-C25;	A13-B6-C1;
10	A10-B6-C39;	A11-B6-C15;	A11-B6-C50;	A12-B6-C26;	A13-B6-C2;
	A10-B6-C40;	A11-B6-C16;	A11-B6-C51;	A12-B6-C27;	A13-B6-C3;
	A10-B6-C41;	A11-B6-C17;	A11-B6-C52;	A12-B6-C28;	A13-B6-C4;
	A10-B6-C42;	A11-B6-C18;	A11-B6-C53;	A12-B6-C29;	A13-B6-C5;
	A10-B6-C43;	A11-B6-C19;	A11-B6-C54;	A12-B6-C30;	A13-B6-C6;
15	A10-B6-C44;	A11-B6-C20;	A11-B6-C55;	A12-B6-C31;	A13-B6-C7;
	A10-B6-C45;	A11-B6-C21;	A11-B6-C56;	A12-B6-C32;	A13-B6-C8;
	A10-B6-C46;	A11-B6-C22;	A11-B6-C57;	A12-B6-C33;	A13-B6-C9;
	A10-B6-C47;	A11-B6-C23;	A11-B6-C58;	A12-B6-C34;	A13-B6-C10;
	A10-B6-C48;	A11-B6-C24;	A11-B6-C59;	A12-B6-C35;	A13-B6-C11;
20	A10-B6-C49;	A11-B6-C25;	A12-B6-C1;	A12-B6-C36;	A13-B6-C12;
	A10-B6-C50;	A11-B6-C26;	A12-B6-C2;	A12-B6-C37;	A13-B6-C13;
	A10-B6-C51;	A11-B6-C27;	A12-B6-C3;	A12-B6-C38;	A13-B6-C14;
	A10-B6-C52;	A11-B6-C28;	A12-B6-C4;	A12-B6-C39;	A13-B6-C15;
	A10-B6-C53;	A11-B6-C29;	A12-B6-C5;	A12-B6-C40;	A13-B6-C16;
25	A10-B6-C54;	A11-B6-C30;	A12-B6-C6;	A12-B6-C41;	A13-B6-C17;
	A10-B6-C55;	A11-B6-C31;	A12-B6-C7;	A12-B6-C42;	A13-B6-C18;
	A10-B6-C56;	A11-B6-C32;	A12-B6-C8;	A12-B6-C43;	A13-B6-C19;
	A10-B6-C57;	A11-B6-C33;	A12-B6-C9;	A12-B6-C44;	A13-B6-C20;
	A10-B6-C58;	A11-B6-C34;	A12-B6-C10;	A12-B6-C45;	A13-B6-C21;
30	A10-B6-C59;	A11-B6-C35;	A12-B6-C11;	A12-B6-C46;	A13-B6-C22;
	A11-B6-C1;	A11-B6-C36;	A12-B6-C12;	A12-B6-C47;	A13-B6-C23;
	A11-B6-C2;	A11-B6-C37;	A12-B6-C13;	A12-B6-C48;	A13-B6-C24;
	A11-B6-C3;	A11-B6-C38;	A12-B6-C14;	A12-B6-C49;	A13-B6-C25;
	A11-B6-C4;	A11-B6-C39;	A12-B6-C15;	A12-B6-C50;	A13-B6-C26;
35	A11-B6-C5;	A11-B6-C40;	A12-B6-C16;	A12-B6-C51;	A13-B6-C27;

	A13-B6-C28;	A14-B6-C4;	A14-B6-C39;	A15-B6-C15;	A15-B6-C50;
	A13-B6-C29;	A14-B6-C5;	A14-B6-C40;	A15-B6-C16;	A15-B6-C51;
	A13-B6-C30;	A14-B6-C6;	A14-B6-C41;	A15-B6-C17;	A15-B6-C52;
	A13-B6-C31;	A14-B6-C7;	A14-B6-C42;	A15-B6-C18;	A15-B6-C53;
5	A13-B6-C32;	A14-B6-C8;	A14-B6-C43;	A15-B6-C19;	A15-B6-C54;
	A13-B6-C33;	A14-B6-C9;	A14-B6-C44;	A15-B6-C20;	A15-B6-C55;
	A13-B6-C34;	A14-B6-C10;	A14-B6-C45;	A15-B6-C21;	A15-B6-C56;
	A13-B6-C35;	A14-B6-C11;	A14-B6-C46;	A15-B6-C22;	A15-B6-C57;
	A13-B6-C36;	A14-B6-C12;	A14-B6-C47;	A15-B6-C23;	A15-B6-C58;
10	A13-B6-C37;	A14-B6-C13;	A14-B6-C48;	A15-B6-C24;	A15-B6-C59;
	A13-B6-C38;	A14-B6-C14;	A14-B6-C49;	A15-B6-C25;	A16-B6-C1;
	A13-B6-C39;	A14-B6-C15;	A14-B6-C50;	A15-B6-C26;	A16-B6-C2;
	A13-B6-C40;	A14-B6-C16;	A14-B6-C51;	A15-B6-C27;	A16-B6-C3;
	A13-B6-C41;	A14-B6-C17;	A14-B6-C52;	A15-B6-C28;	A16-B6-C4;
15	A13-B6-C42;	A14-B6-C18;	A14-B6-C53;	A15-B6-C29;	A16-B6-C5;
	A13-B6-C43;	A14-B6-C19;	A14-B6-C54;	A15-B6-C30;	A16-B6-C6;
	A13-B6-C44;	A14-B6-C20;	A14-B6-C55;	A15-B6-C31;	A16-B6-C7;
	A13-B6-C45;	A14-B6-C21;	A14-B6-C56;	A15-B6-C32;	A16-B6-C8;
	A13-B6-C46;	A14-B6-C22;	A14-B6-C57;	A15-B6-C33;	A16-B6-C9;
20	A13-B6-C47;	A14-B6-C23;	A14-B6-C58;	A15-B6-C34;	A16-B6-C10;
	A13-B6-C48;	A14-B6-C24;	A14-B6-C59;	A15-B6-C35;	A16-B6-C11;
	A13-B6-C49;	A14-B6-C25;	A15-B6-C1;	A15-B6-C36;	A16-B6-C12;
	A13-B6-C50;	A14-B6-C26;	A15-B6-C2;	A15-B6-C37;	A16-B6-C13;
	A13-B6-C51;	A14-B6-C27;	A15-B6-C3;	A15-B6-C38;	A16-B6-C14;
25	A13-B6-C52;	A14-B6-C28;	A15-B6-C4;	A15-B6-C39;	A16-B6-C15;
	A13-B6-C53;	A14-B6-C29;	A15-B6-C5;	A15-B6-C40;	A16-B6-C16;
	A13-B6-C54;	A14-B6-C30;	A15-B6-C6;	A15-B6-C41;	A16-B6-C17;
	A13-B6-C55;	A14-B6-C31;	A15-B6-C7;	A15-B6-C42;	A16-B6-C18;
	A13-B6-C56;	A14-B6-C32;	A15-B6-C8;	A15-B6-C43;	A16-B6-C19;
30	A13-B6-C57;	A14-B6-C33;	A15-B6-C9;	A15-B6-C44;	A16-B6-C20;
	A13-B6-C58;	A14-B6-C34;	A15-B6-C10;	A15-B6-C45;	A16-B6-C21;
	A13-B6-C59;	A14-B6-C35;	A15-B6-C11;	A15-B6-C46;	A16-B6-C22;
	A14-B6-C1;	A14-B6-C36;	A15-B6-C12;	A15-B6-C47;	A16-B6-C23;
	A14-B6-C2;	A14-B6-C37;	A15-B6-C13;	A15-B6-C48;	A16-B6-C24;
35	A14-B6-C3;	A14-B6-C38;	A15-B6-C14;	A15-B6-C49;	A16-B6-C25;

	A16-B6-C26;	A17-B6-C2;	A17-B6-C37;	A18-B6-C13;	A18-B6-C48;
	A16-B6-C27;	A17-B6-C3;	A17-B6-C38;	A18-B6-C14;	A18-B6-C49;
	A16-B6-C28;	A17-B6-C4;	A17-B6-C39;	A18-B6-C15;	A18-B6-C50;
	A16-B6-C29;	A17-B6-C5;	A17-B6-C40;	A18-B6-C16;	A18-B6-C51;
5	A16-B6-C30;	A17-B6-C6;	A17-B6-C41;	A18-B6-C17;	A18-B6-C52;
	A16-B6-C31;	A17-B6-C7;	A17-B6-C42;	A18-B6-C18;	A18-B6-C53;
	A16-B6-C32;	A17-B6-C8;	A17-B6-C43;	A18-B6-C19;	A18-B6-C54;
	A16-B6-C33;	A17-B6-C9;	A17-B6-C44;	A18-B6-C20;	A18-B6-C55;
	A16-B6-C34;	A17-B6-C10;	A17-B6-C45;	A18-B6-C21;	A18-B6-C56;
10	A16-B6-C35;	A17-B6-C11;	A17-B6-C46;	A18-B6-C22;	A18-B6-C57;
	A16-B6-C36;	A17-B6-C12;	A17-B6-C47;	A18-B6-C23;	A18-B6-C58;
	A16-B6-C37;	A17-B6-C13;	A17-B6-C48;	A18-B6-C24;	A18-B6-C59;
	A16-B6-C38;	A17-B6-C14;	A17-B6-C49;	A18-B6-C25;	A19-B6-C1;
	A16-B6-C39;	A17-B6-C15;	A17-B6-C50;	A18-B6-C26;	A19-B6-C2;
15	A16-B6-C40;	A17-B6-C16;	A17-B6-C51;	A18-B6-C27;	A19-B6-C3;
	A16-B6-C41;	A17-B6-C17;	A17-B6-C52;	A18-B6-C28;	A19-B6-C4;
	A16-B6-C42;	A17-B6-C18;	A17-B6-C53;	A18-B6-C29;	A19-B6-C5;
	A16-B6-C43;	A17-B6-C19;	A17-B6-C54;	A18-B6-C30;	A19-B6-C6;
	A16-B6-C44;	A17-B6-C20;	A17-B6-C55;	A18-B6-C31;	A19-B6-C7;
20	A16-B6-C45;	A17-B6-C21;	A17-B6-C56;	A18-B6-C32;	A19-B6-C8;
	A16-B6-C46;	A17-B6-C22;	A17-B6-C57;	A18-B6-C33;	A19-B6-C9;
	A16-B6-C47;	A17-B6-C23;	A17-B6-C58;	A18-B6-C34;	A19-B6-C10;
	A16-B6-C48;	A17-B6-C24;	A17-B6-C59;	A18-B6-C35;	A19-B6-C11;
	A16-B6-C49;	A17-B6-C25;	A18-B6-C1;	A18-B6-C36;	A19-B6-C12;
25	A16-B6-C50;	A17-B6-C26;	A18-B6-C2;	A18-B6-C37;	A19-B6-C13;
	A16-B6-C51;	A17-B6-C27;	A18-B6-C3;	A18-B6-C38;	A19-B6-C14;
	A16-B6-C52;	A17-B6-C28;	A18-B6-C4;	A18-B6-C39;	A19-B6-C15;
	A16-B6-C53;	A17-B6-C29;	A18-B6-C5;	A18-B6-C40;	A19-B6-C16;
	A16-B6-C54;	A17-B6-C30;	A18-B6-C6;	A18-B6-C41;	A19-B6-C17;
30	A16-B6-C55;	A17-B6-C31;	A18-B6-C7;	A18-B6-C42;	A19-B6-C18;
	A16-B6-C56;	A17-B6-C32;	A18-B6-C8;	A18-B6-C43;	A19-B6-C19;
	A16-B6-C57;	A17-B6-C33;	A18-B6-C9;	A18-B6-C44;	A19-B6-C20;
	A16-B6-C58;	A17-B6-C34;	A18-B6-C10;	A18-B6-C45;	A19-B6-C21;
	A16-B6-C59;	A17-B6-C35;	A18-B6-C11;	A18-B6-C46;	A19-B6-C22;
35	A17-B6-C1;	A17-B6-C36;	A18-B6-C12;	A18-B6-C47;	A19-B6-C23;

	A19-B6-C24;	A19-B6-C59;	A20-B6-C35;	A21-B6-C11;	A21-B6-C46;
	A19-B6-C25;	A20-B6-C1;	A20-B6-C36;	A21-B6-C12;	A21-B6-C47;
	A19-B6-C26;	A20-B6-C2;	A20-B6-C37;	A21-B6-C13;	A21-B6-C48;
	A19-B6-C27;	A20-B6-C3;	A20-B6-C38;	A21-B6-C14;	A21-B6-C49;
5	A19-B6-C28;	A20-B6-C4;	A20-B6-C39;	A21-B6-C15;	A21-B6-C50;
	A19-B6-C29;	A20-B6-C5;	A20-B6-C40;	A21-B6-C16;	A21-B6-C51;
	A19-B6-C30;	A20-B6-C6;	A20-B6-C41;	A21-B6-C17;	A21-B6-C52;
	A19-B6-C31;	A20-B6-C7;	A20-B6-C42;	A21-B6-C18;	A21-B6-C53;
	A19-B6-C32;	A20-B6-C8;	A20-B6-C43;	A21-B6-C19;	A21-B6-C54;
10	A19-B6-C33;	A20-B6-C9;	A20-B6-C44;	A21-B6-C20;	A21-B6-C55;
	A19-B6-C34;	A20-B6-C10;	A20-B6-C45;	A21-B6-C21;	A21-B6-C56;
	A19-B6-C35;	A20-B6-C11;	A20-B6-C46;	A21-B6-C22;	A21-B6-C57;
	A19-B6-C36;	A20-B6-C12;	A20-B6-C47;	A21-B6-C23;	A21-B6-C58;
	A19-B6-C37;	A20-B6-C13;	A20-B6-C48;	A21-B6-C24;	A21-B6-C59;
15	A19-B6-C38;	A20-B6-C14;	A20-B6-C49;	A21-B6-C25;	A22-B6-C1;
	A19-B6-C39;	A20-B6-C15;	A20-B6-C50;	A21-B6-C26;	A22-B6-C2;
	A19-B6-C40;	A20-B6-C16;	A20-B6-C51;	A21-B6-C27;	A22-B6-C3;
	A19-B6-C41;	A20-B6-C17;	A20-B6-C52;	A21-B6-C28;	A22-B6-C4;
	A19-B6-C42;	A20-B6-C18;	A20-B6-C53;	A21-B6-C29;	A22-B6-C5;
20	A19-B6-C43;	A20-B6-C19;	A20-B6-C54;	A21-B6-C30;	A22-B6-C6;
	A19-B6-C44;	A20-B6-C20;	A20-B6-C55;	A21-B6-C31;	A22-B6-C7;
	A19-B6-C45;	A20-B6-C21;	A20-B6-C56;	A21-B6-C32;	A22-B6-C8;
	A19-B6-C46;	A20-B6-C22;	A20-B6-C57;	A21-B6-C33;	A22-B6-C9;
	A19-B6-C47;	A20-B6-C23;	A20-B6-C58;	A21-B6-C34;	A22-B6-C10;
25	A19-B6-C48;	A20-B6-C24;	A20-B6-C59;	A21-B6-C35;	A22-B6-C11;
	A19-B6-C49;	A20-B6-C25;	A21-B6-C1;	A21-B6-C36;	A22-B6-C12;
	A19-B6-C50;	A20-B6-C26;	A21-B6-C2;	A21-B6-C37;	A22-B6-C13;
	A19-B6-C51;	A20-B6-C27;	A21-B6-C3;	A21-B6-C38;	A22-B6-C14;
	A19-B6-C52;	A20-B6-C28;	A21-B6-C4;	A21-B6-C39;	A22-B6-C15;
30	A19-B6-C53;	A20-B6-C29;	A21-B6-C5;	A21-B6-C40;	A22-B6-C16;
	A19-B6-C54;	A20-B6-C30;	A21-B6-C6;	A21-B6-C41;	A22-B6-C17;
	A19-B6-C55;	A20-B6-C31;	A21-B6-C7;	A21-B6-C42;	A22-B6-C18;
	A19-B6-C56;	A20-B6-C32;	A21-B6-C8;	A21-B6-C43;	A22-B6-C19;
	A19-B6-C57;	A20-B6-C33;	A21-B6-C9;	A21-B6-C44;	A22-B6-C20;
35	A19-B6-C58;	A20-B6-C34;	A21-B6-C10;	A21-B6-C45;	A22-B6-C21;

	A22-B6-C22;	A22-B6-C57;	A23-B6-C33;	A24-B6-C9;	A24-B6-C44;
	A22-B6-C23;	A22-B6-C58;	A23-B6-C34;	A24-B6-C10;	A24-B6-C45;
	A22-B6-C24;	A22-B6-C59;	A23-B6-C35;	A24-B6-C11;	A24-B6-C46;
	A22-B6-C25;	A23-B6-C1;	A23-B6-C36;	A24-B6-C12;	A24-B6-C47;
5	A22-B6-C26;	A23-B6-C2;	A23-B6-C37;	A24-B6-C13;	A24-B6-C48;
	A22-B6-C27;	A23-B6-C3;	A23-B6-C38;	A24-B6-C14;	A24-B6-C49;
	A22-B6-C28;	A23-B6-C4;	A23-B6-C39;	A24-B6-C15;	A24-B6-C50;
	A22-B6-C29;	A23-B6-C5;	A23-B6-C40;	A24-B6-C16;	A24-B6-C51;
	A22-B6-C30;	A23-B6-C6;	A23-B6-C41;	A24-B6-C17;	A24-B6-C52;
10	A22-B6-C31;	A23-B6-C7;	A23-B6-C42;	A24-B6-C18;	A24-B6-C53;
	A22-B6-C32;	A23-B6-C8;	A23-B6-C43;	A24-B6-C19;	A24-B6-C54;
	A22-B6-C33;	A23-B6-C9;	A23-B6-C44;	A24-B6-C20;	A24-B6-C55;
	A22-B6-C34;	A23-B6-C10;	A23-B6-C45;	A24-B6-C21;	A24-B6-C56;
	A22-B6-C35;	A23-B6-C11;	A23-B6-C46;	A24-B6-C22;	A24-B6-C57;
15	A22-B6-C36;	A23-B6-C12;	A23-B6-C47;	A24-B6-C23;	A24-B6-C58;
	A22-B6-C37;	A23-B6-C13;	A23-B6-C48;	A24-B6-C24;	A24-B6-C59;
	A22-B6-C38;	A23-B6-C14;	A23-B6-C49;	A24-B6-C25;	A25-B6-C1;
	A22-B6-C39;	A23-B6-C15;	A23-B6-C50;	A24-B6-C26;	A25-B6-C2;
	A22-B6-C40;	A23-B6-C16;	A23-B6-C51;	A24-B6-C27;	A25-B6-C3;
20	A22-B6-C41;	A23-B6-C17;	A23-B6-C52;	A24-B6-C28;	A25-B6-C4;
	A22-B6-C42;	A23-B6-C18;	A23-B6-C53;	A24-B6-C29;	A25-B6-C5;
	A22-B6-C43;	A23-B6-C19;	A23-B6-C54;	A24-B6-C30;	A25-B6-C6;
	A22-B6-C44;	A23-B6-C20;	A23-B6-C55;	A24-B6-C31;	A25-B6-C7;
	A22-B6-C45;	A23-B6-C21;	A23-B6-C56;	A24-B6-C32;	A25-B6-C8;
25	A22-B6-C46;	A23-B6-C22;	A23-B6-C57;	A24-B6-C33;	A25-B6-C9;
	A22-B6-C47;	A23-B6-C23;	A23-B6-C58;	A24-B6-C34;	A25-B6-C10;
	A22-B6-C48;	A23-B6-C24;	A23-B6-C59;	A24-B6-C35;	A25-B6-C11;
	A22-B6-C49;	A23-B6-C25;	A24-B6-C1;	A24-B6-C36;	A25-B6-C12;
	A22-B6-C50;	A23-B6-C26;	A24-B6-C2;	A24-B6-C37;	A25-B6-C13;
30	A22-B6-C51;	A23-B6-C27;	A24-B6-C3;	A24-B6-C38;	A25-B6-C14;
	A22-B6-C52;	A23-B6-C28;	A24-B6-C4;	A24-B6-C39;	A25-B6-C15;
	A22-B6-C53;	A23-B6-C29;	A24-B6-C5;	A24-B6-C40;	A25-B6-C16;
	A22-B6-C54;	A23-B6-C30;	A24-B6-C6;	A24-B6-C41;	A25-B6-C17;
	A22-B6-C55;	A23-B6-C31;	A24-B6-C7;	A24-B6-C42;	A25-B6-C18;
35	A22-B6-C56;	A23-B6-C32;	A24-B6-C8;	A24-B6-C43;	A25-B6-C19;

	A25-B6-C20;	A25-B6-C55;	A26-B6-C31;	A27-B6-C7;	A27-B6-C42;
	A25-B6-C21;	A25-B6-C56;	A26-B6-C32;	A27-B6-C8;	A27-B6-C43;
	A25-B6-C22;	A25-B6-C57;	A26-B6-C33;	A27-B6-C9;	A27-B6-C44;
	A25-B6-C23;	A25-B6-C58;	A26-B6-C34;	A27-B6-C10;	A27-B6-C45;
5	A25-B6-C24;	A25-B6-C59;	A26-B6-C35;	A27-B6-C11;	A27-B6-C46;
	A25-B6-C25;	A26-B6-C1;	A26-B6-C36;	A27-B6-C12;	A27-B6-C47;
	A25-B6-C26;	A26-B6-C2;	A26-B6-C37;	A27-B6-C13;	A27-B6-C48;
	A25-B6-C27;	A26-B6-C3;	A26-B6-C38;	A27-B6-C14;	A27-B6-C49;
	A25-B6-C28;	A26-B6-C4;	A26-B6-C39;	A27-B6-C15;	A27-B6-C50;
10	A25-B6-C29;	A26-B6-C5;	A26-B6-C40;	A27-B6-C16;	A27-B6-C51;
	A25-B6-C30;	A26-B6-C6;	A26-B6-C41;	A27-B6-C17;	A27-B6-C52;
	A25-B6-C31;	A26-B6-C7;	A26-B6-C42;	A27-B6-C18;	A27-B6-C53;
	A25-B6-C32;	A26-B6-C8;	A26-B6-C43;	A27-B6-C19;	A27-B6-C54;
	A25-B6-C33;	A26-B6-C9;	A26-B6-C44;	A27-B6-C20;	A27-B6-C55;
15	A25-B6-C34;	A26-B6-C10;	A26-B6-C45;	A27-B6-C21;	A27-B6-C56;
	A25-B6-C35;	A26-B6-C11;	A26-B6-C46;	A27-B6-C22;	A27-B6-C57;
	A25-B6-C36;	A26-B6-C12;	A26-B6-C47;	A27-B6-C23;	A27-B6-C58;
	A25-B6-C37;	A26-B6-C13;	A26-B6-C48;	A27-B6-C24;	A27-B6-C59;
	A25-B6-C38;	A26-B6-C14;	A26-B6-C49;	A27-B6-C25;	A28-B6-C1;
20	A25-B6-C39;	A26-B6-C15;	A26-B6-C50;	A27-B6-C26;	A28-B6-C2;
	A25-B6-C40;	A26-B6-C16;	A26-B6-C51;	A27-B6-C27;	A28-B6-C3;
	A25-B6-C41;	A26-B6-C17;	A26-B6-C52;	A27-B6-C28;	A28-B6-C4;
	A25-B6-C42;	A26-B6-C18;	A26-B6-C53;	A27-B6-C29;	A28-B6-C5;
	A25-B6-C43;	A26-B6-C19;	A26-B6-C54;	A27-B6-C30;	A28-B6-C6;
25	A25-B6-C44;	A26-B6-C20;	A26-B6-C55;	A27-B6-C31;	A28-B6-C7;
	A25-B6-C45;	A26-B6-C21;	A26-B6-C56;	A27-B6-C32;	A28-B6-C8;
	A25-B6-C46;	A26-B6-C22;	A26-B6-C57;	A27-B6-C33;	A28-B6-C9;
	A25-B6-C47;	A26-B6-C23;	A26-B6-C58;	A27-B6-C34;	A28-B6-C10;
	A25-B6-C48;	A26-B6-C24;	A26-B6-C59;	A27-B6-C35;	A28-B6-C11;
30	A25-B6-C49;	A26-B6-C25;	A27-B6-C1;	A27-B6-C36;	A28-B6-C12;
	A25-B6-C50;	A26-B6-C26;	A27-B6-C2;	A27-B6-C37;	A28-B6-C13;
	A25-B6-C51;	A26-B6-C27;	A27-B6-C3;	A27-B6-C38;	A28-B6-C14;
	A25-B6-C52;	A26-B6-C28;	A27-B6-C4;	A27-B6-C39;	A28-B6-C15;
	A25-B6-C53;	A26-B6-C29;	A27-B6-C5;	A27-B6-C40;	A28-B6-C16;
35	A25-B6-C54;	A26-B6-C30;	A27-B6-C6;	A27-B6-C41;	A28-B6-C17;


	A28-B6-C18;	A28-B6-C53;	A29-B6-C29;	A30-B6-C5;	A30-B6-C40;
	A28-B6-C19;	A28-B6-C54;	A29-B6-C30;	A30-B6-C6;	A30-B6-C41;
	A28-B6-C20;	A28-B6-C55;	A29-B6-C31;	A30-B6-C7;	A30-B6-C42;
	A28-B6-C21;	A28-B6-C56;	A29-B6-C32;	A30-B6-C8;	A30-B6-C43;
5	A28-B6-C22;	A28-B6-C57;	A29-B6-C33;	A30-B6-C9;	A30-B6-C44;
	A28-B6-C23;	A28-B6-C58;	A29-B6-C34;	A30-B6-C10;	A30-B6-C45;
	A28-B6-C24;	A28-B6-C59;	A29-B6-C35;	A30-B6-C11;	A30-B6-C46;
	A28-B6-C25;	A29-B6-C1;	A29-B6-C36;	A30-B6-C12;	A30-B6-C47;
	A28-B6-C26;	A29-B6-C2;	A29-B6-C37;	A30-B6-C13;	A30-B6-C48;
10	A28-B6-C27;	A29-B6-C3;	A29-B6-C38;	A30-B6-C14;	A30-B6-C49;
	A28-B6-C28;	A29-B6-C4;	A29-B6-C39;	A30-B6-C15;	A30-B6-C50;
	A28-B6-C29;	A29-B6-C5;	A29-B6-C40;	A30-B6-C16;	A30-B6-C51;
	A28-B6-C30;	A29-B6-C6;	A29-B6-C41;	A30-B6-C17;	A30-B6-C52;
	A28-B6-C31;	A29-B6-C7;	A29-B6-C42;	A30-B6-C18;	A30-B6-C53;
15	A28-B6-C32;	A29-B6-C8;	A29-B6-C43;	A30-B6-C19;	A30-B6-C54;
	A28-B6-C33;	A29-B6-C9;	A29-B6-C44;	A30-B6-C20;	A30-B6-C55;
	A28-B6-C34;	A29-B6-C10;	A29-B6-C45;	A30-B6-C21;	A30-B6-C56;
	A28-B6-C35;	A29-B6-C11;	A29-B6-C46;	A30-B6-C22;	A30-B6-C57;
	A28-B6-C36;	A29-B6-C12;	A29-B6-C47;	A30-B6-C23;	A30-B6-C58;
20	A28-B6-C37;	A29-B6-C13;	A29-B6-C48;	A30-B6-C24;	A30-B6-C59;
	A28-B6-C38;	A29-B6-C14;	A29-B6-C49;	A30-B6-C25;	A31-B6-C1;
	A28-B6-C39;	A29-B6-C15;	A29-B6-C50;	A30-B6-C26;	A31-B6-C2;
	A28-B6-C40;	A29-B6-C16;	A29-B6-C51;	A30-B6-C27;	A31-B6-C3;
	A28-B6-C41;	A29-B6-C17;	A29-B6-C52;	A30-B6-C28;	A31-B6-C4;
25	A28-B6-C42;	A29-B6-C18;	A29-B6-C53;	A30-B6-C29;	A31-B6-C5;
	A28-B6-C43;	A29-B6-C19;	A29-B6-C54;	A30-B6-C30;	A31-B6-C6;
	A28-B6-C44;	A29-B6-C20;	A29-B6-C55;	A30-B6-C31;	A31-B6-C7;
	A28-B6-C45;	A29-B6-C21;	A29-B6-C56;	A30-B6-C32;	A31-B6-C8;
	A28-B6-C46;	A29-B6-C22;	A29-B6-C57;	A30-B6-C33;	A31-B6-C9;
30	A28-B6-C47;	A29-B6-C23;	A29-B6-C58;	A30-B6-C34;	A31-B6-C10;
	A28-B6-C48;	A29-B6-C24;	A29-B6-C59;	A30-B6-C35;	A31-B6-C11;
	A28-B6-C49;	A29-B6-C25;	A30-B6-C1;	A30-B6-C36;	A31-B6-C12;
	A28-B6-C50;	A29-B6-C26;	A30-B6-C2;	A30-B6-C37;	A31-B6-C13;
	A28-B6-C51;	A29-B6-C27;	A30-B6-C3;	A30-B6-C38;	A31-B6-C14;
35	A28-B6-C52;	A29-B6-C28;	A30-B6-C4;	A30-B6-C39;	A31-B6-C15;

	A31-B6-C16;	A31-B6-C51;	A32-B6-C27;	A33-B6-C3;	A33-B6-C38;
	A31-B6-C17;	A31-B6-C52;	A32-B6-C28;	A33-B6-C4;	A33-B6-C39;
	A31-B6-C18;	A31-B6-C53;	A32-B6-C29;	A33-B6-C5;	A33-B6-C40;
	A31-B6-C19;	A31-B6-C54;	A32-B6-C30;	A33-B6-C6;	A33-B6-C41;
5	A31-B6-C20;	A31-B6-C55;	A32-B6-C31;	A33-B6-C7;	A33-B6-C42;
	A31-B6-C21;	A31-B6-C56;	A32-B6-C32;	A33-B6-C8;	A33-B6-C43;
	A31-B6-C22;	A31-B6-C57;	A32-B6-C33;	A33-B6-C9;	A33-B6-C44;
	A31-B6-C23;	A31-B6-C58;	A32-B6-C34;	A33-B6-C10;	A33-B6-C45;
	A31-B6-C24;	A31-B6-C59;	A32-B6-C35;	A33-B6-C11;	A33-B6-C46;
10	A31-B6-C25;	A32-B6-C1;	A32-B6-C36;	A33-B6-C12;	A33-B6-C47;
	A31-B6-C26;	A32-B6-C2;	A32-B6-C37;	A33-B6-C13;	A33-B6-C48;
	A31-B6-C27;	A32-B6-C3;	A32-B6-C38;	A33-B6-C14;	A33-B6-C49;
	A31-B6-C28;	A32-B6-C4;	A32-B6-C39;	A33-B6-C15;	A33-B6-C50;
	A31-B6-C29;	A32-B6-C5;	A32-B6-C40;	A33-B6-C16;	A33-B6-C51;
15	A31-B6-C30;	A32-B6-C6;	A32-B6-C41;	A33-B6-C17;	A33-B6-C52;
	A31-B6-C31;	A32-B6-C7;	A32-B6-C42;	A33-B6-C18;	A33-B6-C53;
	A31-B6-C32;	A32-B6-C8;	A32-B6-C43;	A33-B6-C19;	A33-B6-C54;
	A31-B6-C33;	A32-B6-C9;	A32-B6-C44;	A33-B6-C20;	A33-B6-C55;
	A31-B6-C34;	A32-B6-C10;	A32-B6-C45;	A33-B6-C21;	A33-B6-C56;
20	A31-B6-C35;	A32-B6-C11;	A32-B6-C46;	A33-B6-C22;	A33-B6-C57;
	A31-B6-C36;	A32-B6-C12;	A32-B6-C47;	A33-B6-C23;	A33-B6-C58;
	A31-B6-C37;	A32-B6-C13;	A32-B6-C48;	A33-B6-C24;	A33-B6-C59;
	A31-B6-C38;	A32-B6-C14;	A32-B6-C49;	A33-B6-C25;	A34-B6-C1;
	A31-B6-C39;	A32-B6-C15;	A32-B6-C50;	A33-B6-C26;	A34-B6-C2;
25	A31-B6-C40;	A32-B6-C16;	A32-B6-C51;	A33-B6-C27;	A34-B6-C3;
	A31-B6-C41;	A32-B6-C17;	A32-B6-C52;	A33-B6-C28;	A34-B6-C4;
	A31-B6-C42;	A32-B6-C18;	A32-B6-C53;	A33-B6-C29;	A34-B6-C5;
	A31-B6-C43;	A32-B6-C19;	A32-B6-C54;	A33-B6-C30;	A34-B6-C6;
	A31-B6-C44;	A32-B6-C20;	A32-B6-C55;	A33-B6-C31;	A34-B6-C7;
30	A31-B6-C45;	A32-B6-C21;	A32-B6-C56;	A33-B6-C32;	A34-B6-C8;
	A31-B6-C46;	A32-B6-C22;	A32-B6-C57;	A33-B6-C33;	A34-B6-C9;
	A31-B6-C47;	A32-B6-C23;	A32-B6-C58;	A33-B6-C34;	A34-B6-C10;
	A31-B6-C48;	A32-B6-C24;	A32-B6-C59;	A33-B6-C35;	A34-B6-C11;
	A31-B6-C49;	A32-B6-C25;	A33-B6-C1;	A33-B6-C36;	A34-B6-C12;
35	A31-B6-C50;	A32-B6-C26;	A33-B6-C2;	A33-B6-C37;	A34-B6-C13;

	A34-B6-C14;	A34-B6-C49;	A35-B6-C25;
	A34-B6-C15;	A34-B6-C50;	A35-B6-C26;
	A34-B6-C16;	A34-B6-C51;	A35-B6-C27;
	A34-B6-C17;	A34-B6-C52;	A35-B6-C28;
5	A34-B6-C18;	A34-B6-C53;	A35-B6-C29;
	A34-B6-C19;	A34-B6-C54;	A35-B6-C30;
	A34-B6-C20;	A34-B6-C55;	A35-B6-C31;
	A34-B6-C21;	A34-B6-C56;	A35-B6-C32;
	A34-B6-C22;	A34-B6-C57;	A35-B6-C33;
10	A34-B6-C23;	A34-B6-C58;	A35-B6-C34;
	A34-B6-C24;	A34-B6-C59;	A35-B6-C35;
	A34-B6-C25;	A35-B6-C1;	A35-B6-C36;
	A34-B6-C26;	A35-B6-C2;	A35-B6-C37;
	A34-B6-C27;	A35-B6-C3;	A35-B6-C38;
15	A34-B6-C28;	A35-B6-C4;	A35-B6-C39;
	A34-B6-C29;	A35-B6-C5;	A35-B6-C40;
	A34-B6-C30;	A35-B6-C6;	A35-B6-C41;
	A34-B6-C31;	A35-B6-C7;	A35-B6-C42;
	A34-B6-C32;	A35-B6-C8;	A35-B6-C43;
20	A34-B6-C33;	A35-B6-C9;	A35-B6-C44;
	A34-B6-C34;	A35-B6-C10;	A35-B6-C45;
	A34-B6-C35;	A35-B6-C11;	A35-B6-C46;
	A34-B6-C36;	A35-B6-C12;	A35-B6-C47;
	A34-B6-C37;	A35-B6-C13;	A35-B6-C48;
25	A34-B6-C38;	A35-B6-C14;	A35-B6-C49;
	A34-B6-C39;	A35-B6-C15;	
	A34-B6-C40;	A35-B6-C16;	
	A34-B6-C41;	A35-B6-C17;	
	A34-B6-C42;	A35-B6-C18;	
30	A34-B6-C43;	A35-B6-C19;	
	A34-B6-C44;	A35-B6-C20;	
	A34-B6-C45;	A35-B6-C21;	
	A34-B6-C46;	A35-B6-C22;	
	A34-B6-C47;	A35-B6-C23;	
35	A34-B6-C48;	A35-B6-C24;	

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

5 Thus, for example, in the above list the compound denoted as A1-B1-C1 is the product of the combination of group A1 in Table 1 and B1 in Table 2 and C1 in Table 3, namely



Preferred compounds of the invention are:-

10 3-(1-[(3-methoxy-4-(3-[2-methylphenyl]-ureido)-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl)-propionic acid;
 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-butyric acid;
 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl)-butyric acid;
 15 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-pentanedioic acid;
 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl)-pentanedioic acid;
 4-[2-carboxy-1-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethylcarbamoyl]-butyric acid;
 20 N-[2-carboxy-1-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethyl]-succinamic acid;
 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl)-3-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionic acid;
 25 2-(2-chloro-6-methyl-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid;
 2-(2,6-dichloro-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid;
 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-3-phenyl-
 30 propionic acid;

3-(1-[(3-methoxy-4-(3-*o*-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1*H*-indol-5-yl)-pentanoic acid; and the corresponding N-oxide, and its prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

5 The compounds of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of the invention and compositions containing compounds of the invention for use in therapy.

10 Compounds within the scope of the present invention block the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$) according to tests described in the literature and described in vitro and in vivo procedures hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further 15 embodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion. For example, compounds of the present invention are useful in the treatment of inflammatory diseases, for example joint inflammation, including arthritis, 20 rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. Additionally, the compounds may be useful in the treatment of acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, colitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, multiple sclerosis, asthma, psoriasis restenosis, myocarditis, 25 inflammatory bowel disease and melanoma cell division in metastasis.

A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

30 Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$), for example conditions as hereinbefore described, which comprises the

5 administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. "Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$), and thus producing the desired therapeutic effect.

10

References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.

15 The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or excipient.

20 Compounds of the invention may be administered by any suitable means. In practice compounds of the present invention may generally be administered parenterally, topically, rectally, orally or by inhalation, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents.

25 The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and

30 chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets. To prepare a capsule, it is

35 advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension.

Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to
5 the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or
aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as
ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are
used. The solutions of the salts of the products according to the invention are especially useful
for administration by intramuscular or subcutaneous injection. The aqueous solutions, also
10 comprising solutions of the salts in pure distilled water, may be used for intravenous
administration with the proviso that their pH is suitably adjusted, that they are judiciously
buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that
they are sterilised by heating, irradiation or microfiltration.

15 For topical administration, gels (water or alcohol based), creams or ointments containing
compounds of the invention may be used. Compounds of the invention may also be incorporated
in a gel or matrix base for application in a patch, which would allow a controlled release of
compound through the transdermal barrier.

20 For administration by inhalation compounds of the invention may be dissolved or suspended in a
suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or
adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with
25 known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being
necessary that it should constitute a proportion such that a suitable dosage shall be obtained.
Obviously, several unit dosage forms may be administered at about the same time. The dose
30 employed will be determined by the physician, and depends upon the desired therapeutic effect,
the route of administration and the duration of the treatment, and the condition of the patient.
In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to
about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1
to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from
35 about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous
administration. In each particular case, the doses will be determined in accordance with the

factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

10 Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH publishers, 15 1989.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups 20 may be used in accordance with standard practice, for examples see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

25 Compounds of formula (I), wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined, and where Y is carboxy, may be prepared by hydrolysis of esters of formula (I), wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined and Y is a -CO₂R¹⁶ group (in which R¹⁶ is alkyl, alkenyl 30 or arylalkyl). The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide, e.g. sodium hydroxide or lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient temperature to about reflux temperature. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50°C to about 80°C.


As another example compounds of formula (I), wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined, and where Y is carboxy, may be prepared by acid catalysed removal of the tert-butyl group of tert-butyl esters of formula (I), wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined and Y is a -CO₂R¹⁶ group (in which R¹⁶ is tert-butyl), using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.

As another example compounds of formula (I), wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined, and where Y is carboxy, may be prepared by hydrogenation of compounds of formula (I) wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined and Y is a -CO₂R¹⁶ group (in which R¹⁶ is arylmethyl, e.g. benzyl). The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol. This reaction is most suitable for compounds of formula (I) where L¹ does not contain carbon-carbon multiple bonds.

In a process A compounds of formula (I), containing an amide bond may be prepared by coupling of an acid (or an acid halide) with an amine to give an amide bond using standard peptide coupling procedures as described hereinafter.

As an example of process A, compounds of formula (I) wherein R², A¹, L¹, Y and Z¹ are as hereinbefore defined and R¹ is a group selected from R³-Z³, R³-L²-R⁴-Z³, R³-L³-Ar¹-L⁴-Z³ or R³-L³-Ar¹-L²-R⁴-Z³ [in which R³, R⁴, L², L³, L⁴ and Ar¹ are as hereinbefore defined and Z³ is C(=O)] may be prepared by:-

(i) treating bromo-Wang resin (4-bromomethylphenoxylated styrene/divinylbenzene copolymer) with an acid of formula (II) wherein A¹, Z¹, R², and L¹ are as hereinbefore defined and R¹⁷ is a suitable imino-protecting group, such as 9H-fluoren-9-ylmethoxycarbonyl, in the presence of a tertiary amine, such as diisopropylethylamine, and cesium iodide, in an inert solvent, such as dimethylformamide, at a temperature at about room temperature, to give Resin A;




where  represents the polymeric core comprising polystyrene

crosslinked with 1% to 2% divinylbenzene;

5


(ii) treatment of Resin A with piperidine in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature to give Resin B:-



(Resin B)

wherein A^1 , Z^1 , R^2 , L^1 and  are as hereinbefore defined;

5 (iii) Reaction of Resin B with compounds of formula (III) wherein R^{18} is R^3 ,
 R^3 . L^2 . R^4 , R^3 . L^3 . Ar^1 . L^4 , or R^3 . L^3 . Ar^1 . L^2 . R^4 . (in which R^3 , R^4 , L^2 , L^3 , Ar^1
and L^4 are as hereinbefore defined) and X^1 is a hydroxy group or a halogen,
preferably chlorine, atom to give Resin C wherein R^2 , R^{18} , A^1 , Z^1 , L^1 and
 are as hereinbefore defined [When X^1 is a hydroxy group the reaction
10 may be carried out using standard peptide coupling procedures for example
coupling in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate and triethylamine (or diisopropylethylamine) in
tetrahydrofuran (or dimethylformamide), at room temperature. When X^1 is a
halogen atom the acylation reaction may be carried out with the aid of a base,
15 such pyridine, preferably in a solvent such as tetrahydrofuran and at a
temperature at about room temperature];



(iv) treatment of Resin C with trifluoroacetic acid in an inert solvent, such as dichloromethane, and at a temperature at about room temperature.

5


As another example of process A, compounds of formula (I) wherein R^1 , R^2 , A^1 , Y and Z^1 are as hereinbefore defined and L^1 contains a $-N(R^8)-C(=O)-R^9$ group (in which R^8 and R^9 are as hereinbefore defined) may be prepared by reaction of the corresponding compounds of formula (I) wherein R^1 , R^2 , A^1 , Y and Z^1 are as hereinbefore defined and L^1 contains a $-NH(R^8)$ group (in which R^8 is as hereinbefore defined) with acids (or acid chlorides) of formula $R^9-C(=O)-X^1$ 10 wherein R^9 and X^1 are as hereinbefore defined, using standard coupling conditions, for example those described hereinbefore.

15 Esters of formula (I), wherein R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined, Y is a $-CO_2R^{16}$ group (in which R^{16} is as hereinbefore defined) and L^1 contains a $-N(R^8)-C(=O)-R^9$ group (in which R^8 and R^9 are as hereinbefore defined) may be similarly prepared from the corresponding esters of formula (I) where L^1 contains a $-NHR^8$ group (in which R^8 is as hereinbefore defined) by reaction with a compound of formula $R^9-C(=O)-X^1$ wherein R^9 and X^1 are as hereinbefore defined.

20

Esters of formula (I), wherein R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined, R^1 is a group selected from R^3-Z^3 , $R^3-L^2-R^4-Z^3$, $R^3-L^3-Ar^1-L^4-Z^3$, or $R^3-L^3-Ar^1-L^2-R^4-Z^3$ [in which R^3 ,

R^4 , L^2 , L^3 , L^4 and Ar^1 are as hereinbefore defined and Z^3 is $C(=O)$] and Y is a $-CO_2R^{16}$ group (in which R^{16} is as hereinbefore defined), may be prepared by reacting a compound of formula (III) wherein R^{18} is R^3 , R^3 - L^2 - R^4 , R^3 - L^3 - Ar^1 - L^4 , or R^3 - L^3 - Ar^1 - L^2 - R^4 , (in which R^3 , R^4 , L^2 , L^3 , Ar^1 and L^4 are as hereinbefore defined) and X^1 is a hydroxy group, a halogen, preferably 5 chlorine, atom with an amine of formula (IV):-



wherein R^2 , A^1 , L^1 , Z^1 and R^{16} are as hereinbefore defined, using standard coupling conditions, 10 for example those described hereinbefore.

Esters of formula (I), wherein R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined, R^1 is a group selected from R^3 - Z^3 , R^3 - L^2 - R^4 - Z^3 , R^3 - L^3 - Ar^1 - L^4 - Z^3 , or R^3 - L^3 - Ar^1 - L^2 - R^4 - Z^3 , (in which R^3 , R^4 , L^2 , L^3 , L^4 and Ar^1 are as hereinbefore defined and Z^3 is SO_2) and Y is a $-CO_2R^{16}$ group 15 (in which R^{16} is as hereinbefore defined), may be prepared by sulphonylation of a compound of formula (IV), wherein R^2 , A^1 , L^1 , Z^1 and R^{16} are as hereinbefore defined, using a sulphonyl chloride of formula (V):-




20 wherein R^{18} is as defined hereinabove. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as tetrahydrofuran and at a temperature from about 0°C to about room temperature.

25 Esters of formula (I), wherein R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined, Y is a $-CO_2R^{16}$ group (in which R^{16} is as hereinbefore defined) and L^1 contains a $-N(R^8)-SO_2-R^9$ group (in which R^8 and R^9 are as hereinbefore defined), may be similarly prepared from the corresponding esters of formula (I) where L^1 contains a $-NHR^8$ group (in which R^8 is as

hereinbefore defined) by reaction with sulphonyl chlorides of formula $R^9\text{-SO}_2\text{Cl}$ wherein R^9 is as hereinbefore defined.


5 Esters of formula (I), wherein R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined, R^1 is $R^3\text{-L}^3\text{-Ar}^1\text{-L}^4\text{-Z}^3$. (in which R^3 , L^3 , L^4 and Ar^1 are as hereinbefore defined, Z^3 is $NHC(=O)$ and Y is a -CO_2R^{16} group (in which R^{16} is as hereinbefore defined), may be prepared by reacting a compound of formula (IV), wherein R^2 , A^1 , L^1 , Z^1 and R^{16} are as hereinbefore defined, with an isocyanate of formula (VI):-



wherein R^3 , L^3 , L^4 and Ar^1 are as hereinbefore defined. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as dichloromethane, and at a temperature at about room temperature.

15 Esters of formula (I), wherein R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined, R^1 is $R^3\text{-Z}^3$. (in which R^3 is as hereinbefore defined and Z^3 is $NHC(=O)$) may be similarly prepared by reacting a compound of formula (IV), wherein R^2 , A^1 , L^1 , Z^1 and R^{16} are as hereinbefore defined, with an isocyanate of formula $R^3\text{-NCO}$ wherein R^3 is as hereinbefore defined.

20 Esters of formula (I), wherein R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined, R^1 is a group selected from $R^3\text{-Z}^3$. (in which R^3 is as hereinbefore defined [except aryl and heteroaryl] and Z^3 is a direct bond), $R^3\text{-L}^2\text{-R}^4\text{-Z}^3$, $R^3\text{-L}^3\text{-Ar}^1\text{-L}^4\text{-Z}^3$, or $R^3\text{-L}^3\text{-Ar}^1\text{-L}^2\text{-R}^4\text{-Z}^3$. (in which R^3 , L^3 , L^4 and Ar^1 are as hereinbefore defined, and Z^3 is a direct bond) and Y is a -CO_2R^{16} group (in which R^{16} is as hereinbefore defined), may be prepared by alkylation of a compound of formula (IV), wherein R^2 , A^1 , L^1 , Z^1 and R^{16} are as hereinbefore defined, with a compound of formula (VII):-




30 wherein R^3 is as immediately hereinbefore defined and X^2 is a halogen, preferably bromine, atom. The alkylation may for example be carried out in the presence of a base, such as an alkali

metal hydride, e.g. sodium hydride, in dimethylformamide, or dimethyl sulphoxide, at a temperature from about 0°C to about 100°C.

5 Esters of formula (I), wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ contains a -NHR⁸ group (in which R⁸ is alkyl, arylalkyl, cycloalkylalkyl, heteroaryalkyl or heterocycloalkylalkyl), may be similarly prepared by alkylation of the corresponding derivatives of formula (I) where L¹ contains a -NH₂ group, with the appropriate alkyl (or arylalkyl, cycloalkylalkyl, heteroaryalkyl or heterocycloalkylalkyl) halide.

10 Esters of formula (I), wherein R², A¹, L¹ and Z¹ are as hereinbefore defined, R¹ is a group selected from R³-Z³ [in which R³ is as herein defined and Z³ is OC(=O)] may be prepared by reaction of a compound of formula (IV), wherein R², A¹, L¹, Z¹ and R¹⁶ are as hereinbefore defined, with a compound of formula (VIII):-




wherein R³ is as hereinbefore defined and X³ is a halogen, preferably chlorine atom, in the presence of a suitable base, such as triethylamine or pyridine, and at a temperature from about 20 0°C to about room temperature.

Esters of formula (I), wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ contains a -N(R⁸)-C(=O)-OR⁹ group (in which R⁸ and R⁹ are as hereinbefore defined), may be similarly prepared from the corresponding derivatives of formula (I) where L¹ contains a -NHR⁸ group (in which R⁸ is as hereinbefore defined) by reaction with compounds of formula R⁹O-C(=O)-X³ wherein R⁹ and X³ are as hereinbefore defined.

30 Esters of formula (I), wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ is
$$\begin{array}{c} \text{---CH---CH}_2 \\ | \\ \text{NH}_2 \end{array}$$
 (or

$\text{---CH---CH}_2\text{---}$) may be prepared by hydrogenation of the corresponding derivatives of $\text{---CH---CH}_2\text{---}$ NH_2

formula (I), where L^1 is $\text{---CH---CH}_2\text{---}$ (or $\text{N}(\text{CH}_2\text{Ph})_2$) $\text{---CH---CH}_2\text{---}$ (or $\text{CH}_3\text{---CH---CH}_2\text{---}$ $\text{N}(\text{CH}_2\text{Ph})_2$).



carried out in the presence of formic acid and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, at a temperature at about 60°C. The reaction may

5 conveniently be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

Esters of formula (I), wherein R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined, Y is a $\text{-CO}_2\text{R}^{16}$

10 group (in which R^{16} is as hereinbefore defined) and L^1 is a $\text{---CH---CH}_2\text{---}$ (or NH_2)

$\text{---CH---CH}_2\text{---}$ linkage, may also be obtained from the racemic mixture following standard $\text{---CH---CH}_2\text{---}$ NH_2

recrystallisation of a suitable salt (for example recrystallisation of the tartrate salt), or by the application of standard enzymatic resolution procedures (for example those described by Soloshonok, V. A., et. al., *Tetrahedron: Asymmetry* 6 (1995) 7, 1601-1610).

15 Esters of formula (I), wherein R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined, Y is a $\text{-CO}_2\text{R}^{16}$ group (in which R^{16} is as hereinbefore defined) and L^1 is a $\text{---CH---CH}_2\text{---}$ or $\text{N}(\text{CH}_2\text{Ph})_2$


$\text{---CH---CH}_2\text{---}$ linkage, may be prepared by reacting an ester of formula (I), wherein $\text{---CH---CH}_2\text{---}$ NH_2 $\text{---CH---CH}_2\text{---}$ $\text{N}(\text{CH}_2\text{Ph})_2$

R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined, Y is a $\text{-CO}_2\text{R}^{16}$ group (in which R^{16} is as

20 hereinbefore defined) and L^1 is a -CH=CH- linkage, with an alkali metal hydride, such as sodium hydride, in an inert solvent, e.g. tetrahydrofuran, and at a temperature at about room

temperature, and subsequent reaction with the anion derived from treating dibenzylamine, or (S)-N-benzyl- α -methylbenzylamine, with butyllithium, at a temperature at about -78°C.

Esters of formula (I), wherein R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined, Y is a $-CO_2R^{16}$ group (in which R^{16} is as hereinbefore defined) and L^1 contains an alkenylene, alkynylene or cycloalkenylene in which the aliphatic carbon-carbon multiple bond is attached directly to the phenyl moiety in formula (I), may be prepared by coupling of compounds of formula (IX):-



wherein R^1 , R^2 , A^1 and Z^1 are as hereinbefore defined and X^4 is a halogen, preferably bromine or iodine, atom with a compound of formula (X):-



wherein R^{16} is as hereinbefore defined and R^{19} is alkenyl, alkynyl or cycloalkenyl. When X^4 is a bromine or iodine atom the reaction may be conveniently carried out in the presence of palladium acetate, a triarylphosphine, such as tri-*o*-tolylphosphine, and a tertiary amine, such as tributylamine, at a temperature up to about 110°C. This reaction is particularly suitable for the preparation of esters of formula (I) in which L^1 is vinylene. When X^4 is a chlorine atom the reaction may be conveniently carried out in the presence of sodium iodide, nickel bromide, palladium(0) bis(dibenzylideneacetone), a triarylphosphine, such as tri-*o*-tolylphosphine, and a tertiary amine, such as tributylamine, at a temperature up to about 110°C.

According to a further feature of the present invention, compounds of the invention may be prepared by interconversion of other compounds of the invention.

For example compounds of formula (I), wherein R^1 , R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined and Y is a group $-C(=O)-NHOH$, may be prepared by reacting compounds of formula

(I), wherein R^1 , R^2 , A^1 , L^1 and Z^1 are as hereinbefore defined and Y is carboxy, with hydroxylamine using standard peptide coupling procedures such as treatment with carbodiimide, for example dicyclohexylcarbodiimide, in the presence of triethylamine, in an inert solvent such as dichloromethane or tetrahydrofuran and at a temperature at about room

5 temperature. The coupling may also be carried out using 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in dichloromethane at room temperature. The preparation may also be carried out using an O-protected hydroxylamine such as O-(trimethylsilyl)hydroxylamine, O-(t-butyldimethylsilyl)-hydroxylamine, or O-(tetrahydropyranyl)hydroxylamine followed by treatment with acid.

10

As another example of the interconversion process, compounds of formula (I) containing sulphoxide linkages may be prepared by the oxidation of corresponding compounds containing -S- linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulphate in a medium such as aqueous methanol, buffered to about pH5, at temperatures between about 0°C and room temperature. This latter method is preferred for compounds containing an acid-labile group.

20

As another example of the interconversion process, compounds of formula (I) containing sulphone linkages may be prepared by the oxidation of corresponding compounds containing -S- or sulphoxide linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.

25

As another example of the interconversion process, compounds of formula (I), wherein R^1 , R^2 , A^1 , Z^1 and Y are as hereinbefore defined, and L^1 is optionally substituted alkylene, may be prepared by hydrogenation of the corresponding compounds of formula (I) in which L^1 is the corresponding optionally substituted alkenylene. The hydrogenation may be carried out using 30 hydrogen (optionally under pressure) in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (I), wherein R^1 , R^2 ,

35 A^1 , L^1 and Z^1 are as hereinbefore defined, L^1 is an alkylene linkage substituted by -CON Y^4 Y 5

and Y is carboxy, may be prepared by reacting compounds of formula (I), wherein R¹, R², A¹, L¹ and Z¹ are as hereinbefore defined, L¹ is an alkylene linkage substituted by -CO₂H and Y is carboxy, with an anhydride, such as trifluoroacetic anhydride, in an inert solvent e.g. tetrahydrofuran, followed by treatment with an amine HNY⁴Y⁵.

5

As another example of the interconversion process, compounds of formula (I), wherein R¹, R², A¹, L¹ and Y are as hereinbefore defined, and Z¹ is C(=O) may be prepared by oxidation of compounds of formula (I), wherein R¹, R², A¹, L¹ and Y are as hereinbefore defined, and Z¹ is CH₂. For example the oxidation may conveniently be carried out by reaction with potassium

10 permanganate.

As another example of the interconversion process, compounds of formula (I), wherein R¹, R², A¹, L¹ and Y are as hereinbefore defined, and Z¹ is CH(OH) may be prepared by reduction of compounds of formula (I), wherein R¹, R², A¹, L¹ and Y are as hereinbefore defined, and Z¹ is C(=O). For example the reduction may conveniently be carried out by reaction with sodium 15 borohydride in aqueous ethanol at a temperature at about room temperature.

As another example of the interconversion process, compounds of the invention containing a heterocyclic group wherein the hetero atom is a nitrogen atom may be oxidised to their corresponding N-oxides. The oxidation may conveniently be carried out by means of reaction 20 with a mixture of hydrogen peroxide and an organic acid, e.g. acetic acid, preferably at or above room temperature, for example at a temperature of about 60-90°C. Alternatively, the oxidation may be carried out by reaction with a peracid, for example peracetic acid or m-chloroperoxybenzoic acid, in an inert solvent such as chloroform or dichloromethane, at a 25 temperature from about room temperature to reflux, preferably at elevated temperature. The oxidation may alternatively be carried out by reaction with hydrogen peroxide in the presence of sodium tungstate at temperatures between room temperature and about 60°C.

It will be appreciated that compounds of the present invention may contain asymmetric centres. 30 These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) hereinabove. Such isomers can be separated from their mixtures, by

the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates.

- 5 According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
- 10

The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the

- 15 invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be

- 20 regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.



- 25
- 30

According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.


5 Compounds of formula (III) wherein R^{18} is $R^3\text{-}L^3\text{-}Ar^1\text{-}L^4$ - group (in which R^3 , R^4 , L^2 , L^3 , L^4 and Ar^1 are as hereinbefore defined) may be prepared by the application or adaptation of methods described in the specification of International Patent Application Publication No. WO 96/22966.

10 Acids of formula (III) wherein R^{18} is $R^3\text{-}L^3\text{-}Ar^1\text{-}L^4$ - (in which R^3 and L^4 are as defined above,



15 wherein R and L^4 are as hereinbefore defined, R^{16} is lower alkyl and X is O, with isocyanates of formula $R^3\text{-}N=C=O$ (in which R^3 is as hereinbefore defined) in ethanol and at room temperature, followed by reaction with a carbodiimide, such as dicyclohexylcarbodiimide or diisopropylcarbodiimide in ethanol and at a temperature from about room temperature to about reflux temperature, and subsequent hydrolysis using standard conditions, for example those described hereinbefore.


20 Acids of formula (III) wherein R^{18} is $R^3\text{-}L^3\text{-}Ar^1\text{-}L^4$ - (in which R^3 and L^4 are as hereinbefore

defined, Ar^1 is  (in which R is as hereinbefore defined), L^3 is NH and X^1 is

25 hydroxy may be similarly prepared from compounds of formula (I) wherein R, L^4 and R^{16} are as hereinbefore defined and X is NH.


Acid chlorides of formula (III) wherein R¹⁸ is as hereinbefore defined and X¹ is a chlorine atom may be prepared from the corresponding acids of formula (II) wherein R¹⁸ is as hereinbefore defined and X¹ is hydroxy, by the application of standard procedures for the conversion of acids to acid chlorides for example by reaction with oxalyl chloride.

Compounds of formula (IV) wherein R² and R¹⁶ are as hereinbefore defined, Z¹ is CH₂, L¹ is as defined hereinbefore (except where L¹ contains a non-aromatic carbon-carbon multiple bond) and A¹ is an ethylene linkage, may be prepared by hydrogenation of the corresponding quinoline analogues of formula (2):-



wherein R² and R¹⁶ are as hereinbefore defined and L¹ is as defined immediately hereinbefore, in the presence of a suitable metal catalyst. The reduction may conveniently be carried out at a pressure of 50 bars of hydrogen, in the presence of 5% rhodium in carbon powder as catalyst, in hydrochloric acid, and at a temperature at about room temperature.

Compounds of formula (2), wherein R² and R¹⁶ are as hereinbefore defined and L¹ is alkylene may be prepared by an electrochemical coupling reaction between a compound of formula (3):-



wherein R² is as hereinbefore defined and X⁵ is iodo, or preferably bromo, and an alkenoic ester of formula (X) wherein R¹⁶ is as hereinbefore defined and R²⁰ is alkenyl. The reaction may


conveniently be carried out in the presence of nickel salt catalyst, such as nickel bromide trihydrate, tetrabutylammonium bromide, tetrabutylammonium iodide and 1,2-dibromoethane, in an inert solvent, or a mixture of inert solvents, such as dimethylformamide and pyridine, and at a temperature at about 60°C. This reaction is particularly suitable for the preparation of

5 compounds of formula (1) in which L¹ is ethylene.

Compounds of formula (2), wherein R² and R¹⁶ are as defined hereinbefore and L¹ is an alkylene linkage substituted by -CH₂OR³ (for example -CH₂OCH₃) may be prepared from compounds of formula (2), wherein R² and R¹⁶ are as defined hereinbefore and L¹ is an alkenylene linkage where the carbon-carbon double bond is substituted by a methyl group, using the following standard reaction procedures:- (i) allylic bromination with N-bromosuccinimide; 10 (ii) displacement of the allylic bromo with OR³ by reaction with an alkali metal salt of formula R³O⁻M⁺ (for example sodium methoxide); (iii) hydrogenation.

15 Compounds of formula (2), wherein R² and R¹⁶ are as defined hereinbefore and L¹ is alkenylene, alkynylene or cycloalkenylene in which the carbon-carbon multiple bond is attached directly to the phenyl moiety in formula (1), may be prepared by reacting a compound of formula (3) wherein R² is as hereinbefore defined and X⁵ is an iodine, or preferably a bromine, atom with a compound of formula (X) wherein R¹⁶ and R¹⁹ are as hereinbefore defined using 20 standard Heck coupling reaction conditions, for example reaction in the presence of palladium acetate, triphenylphosphine and tributylamine at a temperature up to about 120°C.

Compounds of formula (2), wherein R² and R¹⁶ are as defined hereinbefore and L¹ is an optionally substituted arylene or an optionally substituted heteroaryldiy linkage, may be 25 prepared by reacting a compound of formula (3) wherein R² is as hereinbefore defined and X⁵ is iodo or bromo with a compound of formula (4):-



30 wherein R¹⁶ are as defined hereinbefore and L¹ is an optionally substituted arylene or an optionally substituted heteroaryldiy linkage in the presence of a complex metal catalyst such as tetrakis(triphenylphosphine)palladium(0), using standard reaction conditions, for example those described by Trecourt et al, *Tetrahedron*, 51 (1995) 43, pages 11743-11750.


Compounds of formula (IV) or (2) wherein R^2 and R^{16} are as defined hereinbefore and L^1 is
 $\text{---CH}_2\text{---CH---}$ may be prepared by standard methodology for the preparation of α -amino-



acids for example those described in **Organic Syntheses Based On Name Reactions and Unnamed Reactions**, A.Hassner and C.Stumer, Pergamon, pages 275 and 374.

Compounds of formula (2) wherein R^2 and R^{16} are as defined hereinbefore and L^1 is

$\text{---CH}_2\text{---CH---}$ may be prepared by reaction of compounds of formula (5):-




10

(5)

wherein R^2 is as hereinbefore defined and X^6 is a bromine or chlorine atom with the anion derived from reaction of (2R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine with butyllithium according to the method described by D. L. Boger and D. Yohannes, *J. Org. Chem.* 15 [JOCEAH], 1990, 55, for the preparation of compound 31 on page 6010.

Compounds of formula (IV) wherein R^2 , R^{16} , A^1 and Z^1 are as hereinbefore defined and L^1 is

$\text{---CH}_2\text{---CH---}$ may be similarly prepared from compounds of formula (6):-



20

(6)


wherein R^2 , A^1 , X^6 and Z^1 are as hereinbefore defined.

Compounds of formula (6) wherein R^2 , A^1 , X^6 are as hereinbefore defined and Z^1 is CH_2 may be prepared by the application or adaptation of methodologies described in US Patent

5 Application No. 4156734, for example the preparation of the N-protected dihydroindole, 1-benzoyl-5-chloromethyl-2,3-dihydro-1H-indole from 1-benzoyl-2,3-dihydro-1H-indole (Beilstein, 20, 257) is described as Example 23A.

Compounds of formula (IV) wherein R^2 , R^{16} and L^1 are as hereinbefore defined, Z^1 is CH_2 , A^1

10 is a straight chain C_{1-3} alkylene linkage and L^1 contains an alkenylene, alkynylene or cycloalkenylene group in which the aliphatic carbon-carbon multiple bond is attached directly to the phenyl moiety in formula (IV), may be prepared by coupling of compounds of formula (7):-



(7)

15 wherein R^2 is as hereinbefore defined, A^1 is a straight chain C_{1-3} alkylene linkage, X^7 is a halogen, preferably bromine or iodine, atom and Z^1 is CH_2 with a compound of formula (X) wherein R^{16} is as hereinbefore defined and R^{19} is alkenyl, alkynyl or cycloalkenyl. The cross-coupling reaction may conveniently be carried out in the presence of palladium acetate and tris(*o*-tolyl)phosphine using standard coupling conditions such as those described hereinbefore. In this reaction a suitable protecting group for the NH group is for example a tertiary-butoxycarbonyl group.

Compounds of formula (IV) wherein R^2 , R^{16} and L^1 are as hereinbefore defined, Z^1 is CH_2 , A^1

25 is a straight chain C_{1-3} alkylene linkage and L^1 contains an alkylene or cycloalkylene group may be prepared by hydrogenation of the corresponding compounds of formula (IV) in which L^1 contains an alkenylene, alkynylene or cycloalkenylene group using standard hydrogenation procedures for example those described hereinbefore.

Compounds of formula (7) wherein R² is hydrogen, A¹ is ethylene, Z¹ is CH₂ and X⁶ is an iodine atom attached to the 6 position of the tetrahydroquinoline ring may be prepared by iodination of 1,2,3,4-tetrahydroquinoline with iodine monochloride in acetic acid at a temperature at about 5 room temperature.

2,3-Dihydro-4(1H)-quinolones of formula (7) wherein R² is hydrogen, A¹ is ethylene, Z¹ is C(=O) and X⁶ is a halogen atom attached to the 6 position of the tetrahydroquinoline ring may be prepared by the application or adaptation of the Fries-type acid catalysed rearrangement of 10 1-arylazetidin-2-ones described by S.Kano et. al. J. Chem. Soc., Perkin Trans. 1 1998, 10 pages 2105-2111.

Compounds of formula (IV) wherein R², R¹⁶, L¹ and A¹ are as hereinbefore defined and Z¹ is CH₂, and L¹ is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{CH}_2\text{CO}_2\text{Me} \end{array}$ linkage, may be prepared by reacting an ester of formula (I), 15 wherein R¹, R² and A¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined), Z¹ is CH₂, and L¹ is a -CH=CH- linkage, with dimethyl malonate, in the presence of an alkali metal alkoxide, such as sodium methoxide, in methanol and at a temperature at about reflux temperature.

20 Compounds of formula (IV) wherein R², R¹⁶ and A¹ are as hereinbefore defined and Z¹ is CH₂,

and the moiety -L²-Y is  , may be prepared coupling of compounds of formula

(8) wherein R² and A¹ are as hereinbefore defined, and X⁶ is a halogen, preferably bromine or iodine, atom with 5,6-dihydropyran-2-one in the presence of tetrakis(triphenylphosphine)palladium (0) and triethylamine in an inert solvent, such as 25 dimethylformamide, at a temperature at about 95°C and in a sealed vessel.

Compounds of formula (IV) wherein R², R¹⁶, L¹ and A¹ are as hereinbefore defined and Z¹ is CH₂, and L¹ contains a -N(R⁸)-C(=O)-R⁹ group (in which R⁸ and R⁹ are as hereinbefore defined) may be prepared from the corresponding compounds of formula (IV) where L¹ contains

a -NHR⁸ group (in which R⁸ is as hereinbefore defined) by reaction with a compound of formula R⁹-C(=O)-X¹ wherein R⁹ and X¹ are as hereinbefore defined, using standard peptide coupling procedures for example those described hereinbefore.

5 Compounds of formula (IV) wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ is ---CH---CH_2 (or



$\begin{array}{c} | \\ \text{---CH---CH}_2 \end{array}$) may be prepared by hydrogenation of the corresponding derivatives of $\begin{array}{c} | \\ \text{NH}_2 \end{array}$

formula (IV), where L¹ is ---CH---CH_2 (or $\begin{array}{c} | \\ \text{N}(\text{CH}_2\text{Ph})_2 \end{array}$ or $\begin{array}{c} | \\ \text{CH}_3\text{---} \\ \text{---} \end{array} \begin{array}{c} | \\ \text{N} \\ \text{---} \\ \text{CH}_2 \\ \text{---} \\ \text{CH} \\ \text{---} \\ \text{Ph} \end{array}$). The reaction may be

10 carried out in the presence of formic acid and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, at a temperature at about 60°C. The reaction may conveniently be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

15 Compounds of formula (IV) wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ is a ---CH---CH_2 (or



$\begin{array}{c} | \\ \text{---CH---CH}_2 \end{array}$) linkage, may also be obtained from the racemic mixture following standard




recrystallisation of a suitable salt (for example recrystallisation of the tartrate salt), or by the application of standard enzymatic resolution procedures (for example those described by

20 Soloshonok, V. A., et. al., *Tetrahedron: Asymmetry* 6 (1995) 7, 1601-1610).

Compounds of formula (IV) wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ is a ---CH---CH_2 or





5 wherein R¹, R², A¹ and Z¹ are as hereinbefore defined, Y is a -CO₂R¹⁶ group (in which R¹⁶ is as hereinbefore defined) and L¹ is a -CH=CH- linkage, with an alkali metal hydride, such as sodium hydride, in an inert solvent, e.g. tetrahydrofuran, and at a temperature at about room temperature, and subsequent reaction with the anion derived from treating dibenzylamine, or (S)-N-benzyl- α -methylbenzylamine, with butyllithium, at a temperature at about -78°C.

10 Compounds of formula (IX) wherein R¹, R² and X⁴ are as described hereinbefore, A¹ is methylene and Z¹ is C(=O) may be prepared by the application or adaptation of methods described by Bourlot, A. S. et. al., *Synthesis*, 1994, 4, 411-416.

15 Compounds of formula (IX) wherein R¹, R² and X⁴ are as described hereinbefore, A¹ is ethylene and Z¹ is C(=O) may be prepared by the application or adaptation of methods described in United States Patent Application No. US4421918.

20 Intermediates of formulae (IV), (IX) and (2) are novel compounds and, as such, they and processes described herein for their preparation constitute further features of the present invention.

25 The present invention is further Exemplified but not limited by the following illustrative Examples and Reference Examples.

In the nuclear magnetic resonance spectra (NMR) the chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: s = singlet; d =

25 doublet; t = triplet; m = multiplet.

30 Mass spectra (MS) for Example 4(b) and for the Reference Examples (unless otherwise indicated) were recorded on a Micromass Platform II mass spectrometer fitted with an Electrospray source and an HP1100 liquid chromatograph; using a mixture of acetonitrile and water (1:1, v/v) as the mobile phase, a flow rate of 0.3 ml/minute, an injection volume of 20 μ l, a

run time of 2.0 minutes, a scan range of 150 - 850 Daltons Positive/Negative, a scan time of 2.0 seconds, an ESI voltage of 3.5Kv, an ESI pressure of 20n/m² Nitrogen.

Mass spectra [MS(ES⁺)] for the Examples 1 - 12 were recorded on a Micromass LCT Mass Spectrometer (Orthogonal Acceleration Time of Flight Mass Spectrometer), with the Z-Flow

5 Atmospheric pressure ionisation source operating in positive ion electrospray mode (ES⁺), connected to an HP1100 liquid chromatograph. The conditions used were as follows: 3 micron Luna C18 HPLC column (30mm x 4.6mm) operated under gradient elution conditions with a mixture of acetonitrile and water as the mobile phase gradient : 0.00 minutes, 95% water:5% acetonitrile; 0.50 minutes, 95% water:5% acetonitrile; 4.50 minutes, 5% water:95% acetonitrile;

10 5.00 minutes, 5% water :95% acetonitrile; 5.50 minutes, 95% water :5% acetonitrile; flow rate 2ml/minute with approximately 200ml/minute split to the Mass Spectrometer; injection volume 10-40ml; in line Diode Array detection (220-450nm), in line Evaporative light scattering (ELS) detection ELS - temperature 50°C, Gain 8 - 1.8ml/minute; Source temperature 150°C.

15 **EXAMPLE 1**

3-(1-[(3-Methoxy-4-(3-[2-methylphenyl]-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid

A solution of ethyl 3-(1-[(3-methoxy-4-(2-toluidinocarbonyl)amino)phenyl]acetyl)-1,2,3,4-tetrahydroquinolin-6-yl)-propanoate (0.24g, Reference Example 1) in anhydrous ethanol (4ml), 20 at 20°C, was treated dropwise with a solution of lithium hydroxide monohydrate (33mg) in distilled water (1ml). After stirring for 3 hours at 20°C the reaction mixture was evaporated under reduced pressure (2.7 kPa) at 40°C. The residue was treated with distilled water (35ml) and the resulting solution was washed twice with diethyl ether (20ml), then acidified to pH 3 by addition of hydrochloric acid (0.8ml, 1N) and then extracted twice with ethyl acetate (25ml). The 25 combined organic extracts were washed twice with water (5ml), then dried over magnesium sulfate and then evaporated under reduced pressure (2.7 kPa) at 40°C. The resulting white foamy solid (191mg) was subjected to chromatography on silica gel plates (4 plates, 20x20cm, thickness = 0.5mm), eluting with a mixture of dichloromethane and methanol (9:1, v/v) to give the title compound (148mg) as a white foamy solid. ¹H NMR (300 MHz, (CD₃)₂SO): δ 1.81 (m, 2H); 2.27 (s, 3H); from 2.45-2.70 (m, 4H), 2.82 (t, J=7.5Hz, 2H); 3.72 (t, J=6.5Hz, 2H); 3.82 (s, 2H); 3.87 (s, 3H); 6.60-7.50 (m, 8H); 7.82 (d, J= 8 Hz, 1H); 8.05 (d, J= 8 Hz, 1H); 8.50 (s, 1H); 8.60 (s, 1H). MS (Electron Impact recorded on a Finnigan SSQ 7000 spectrometer at 70eV) 501(M⁺).

EXAMPLE 2

(a) (R/S) 3-(1-[[3-Methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-butyric acid
 A solution of ethyl (R/S) 3-(1-[[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-butyrate [2.8g, Reference Example 4(a)] in methanol (about 150ml) was treated with aqueous sodium hydroxide solution (15ml, 1M). The mixture was warmed at about 50°C for 3 hours, then treated with a further aliquot of aqueous sodium hydroxide solution (7.5ml). After a further 2-3 hours at 50°C TLC analysis indicated complete reaction. The bulk of the methanol was removed by evaporation and the residue was diluted with hydrochloric acid (about 200ml, 1M). The resulting mixture was stirred for about 30 minutes, then the solid was collected by filtration, washed with water, and dried to give the title compound (2.3g) as a very light orange powder. LC-MS: R_T = 3.84 minutes (100% total area by ELS); MS(ES^+) 502 (MH^+), 524 (MNa^+).

15 (b) By proceeding in a similar manner to Example 2(a) but using ethyl (R/S) 3-[(2-o-tolylamino-3H-benzimidazol-5-yl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl)-butyrate [Reference Example 4(k)] and carrying out the hydrolysis at room temperature there was prepared (R/S) 3-[(1-[(2-o-tolylamino-3H-benzimidazol-5-yl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl)-butyric acid as a white solid. [Elemental analysis: - C, 71.11; H, 6.55; N, 8.66%. Calculated for
 20 $C_{30}H_{31}N_3O_4 \cdot 0.5H_2O$: - C, 71.15; H, 6.32; N, 8.30%]. MS (ES^+) 498 (MH^+).

25 (c) By proceeding in a similar manner to Example 2(a) but using a suspension of ethyl (R/S) 3-(1-[[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-heptanoate [Reference Example 4(p)] in industrial methylated spirits and carrying out the reaction at 80°C for 45 minutes there was prepared (R/S) 3-[(1-[[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-heptanoic acid as a white solid. LC-MS (using 0.1 v/v formic acid in acetonitrile to replace acetonitrile for the gradient elution): R_T =4.31 minutes (100% total area by ELS); MS(ES^+) 544(MH^+), 566(MNa^+).

30 (d) By proceeding in a similar manner to Example 2(a) but using ethyl (R/S) 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-heptanoate [Reference Example 4(q)] in industrial methylated spirits and carrying out the reaction at 80°C for 45 minutes there was prepared (R/S) 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-heptanoic acid as a

white powder. LC-MS (using 0.1 v/v formic acid in acetonitrile to replace acetonitrile for the gradient elution): $R_T=4.47$ minutes (100% total area by ELS); MS(ES^+) 556(MH^+), 578(MNa^+).

(e) By proceeding in a similar manner to Example 2(a) but using ethyl (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-pentanoate [Reference Example 4(r)] and carrying out the reaction at reflux temperature for 1 hour there was prepared (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-pentanoic acid as a pale fawn solid. LC-MS: $R_T=3.01$ minutes; MS(ES^+) 538 (MNa^+).

(f) By proceeding in a similar manner to Example 2(a) but using ethyl (R/S) 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-pentanoate [Reference Example 4(s)] in industrial methylated spirits and carrying out the reaction at 80°C for 45 minutes there was prepared (R/S) 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-pentanoic acid as a white powder. LC-MS (using 0.1 v/v formic acid in acetonitrile to replace acetonitrile for the gradient elution): $R_T=4.17$ minutes (100% total area by ELS); MS(ES^+) 528(MH^+), 550(MNa^+).

(g) By proceeding in a similar manner to Example 2(a) but using ethyl (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate [Reference Example 4(s)] and carrying out the reaction at reflux temperature for 1 hour there was prepared (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionic acid as an off-white solid. LC-MS: $R_T=3.17$ minutes; MS(ES^+) 564 (MH^+), 586 (MNa^+).

(h) By proceeding in a similar manner to Example 2(a) but using R/S ethyl 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl]-3-phenyl-propionate [Reference Example 4(u)] in industrial methylated spirits and carrying out the reaction at 80°C for 90 minutes there was prepared (R/S) 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl]-3-phenyl-propionic acid as an off-white powder. LC-MS (using 0.1 v/v formic acid in acetonitrile to replace acetonitrile for the gradient elution): $R_T=4.27$ minutes (100% total area by ELS); MS(ES^+) 576(MH^+), 598(MNa^+).

EXAMPLE 3

(a) (R/S) 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-vl)-butyric acid

A mixture of ethyl (R/S) 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-butyrate [0.55g, Reference Example 4(b)], aqueous sodium hydroxide solution (5.5ml, 1M),

5 methanol (5.5ml) and tetrahydrofuran (11ml) was stirred at room temperature overnight then evaporated to low bulk. The residue was diluted with water and the mixture was acidified by the addition of hydrochloric acid. The precipitate was collected by filtration, washed with water and then dried to give the title compound (0.41g) as a white powder. LC-MS: R_T = 3.77 minutes (100% total area by ELS); MS(ES⁺) 472 (MH⁺), 494 (MNa⁺).

10

(b) By proceeding in a similar manner to Example 3(a) but using ethyl (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl)-butyrate [Reference Example 4(e)] there was prepared (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-vl)-butyric acid as a white powder. LC-MS: R_T =

15 3.89 minutes (100% total area by ELS); MS(ES⁺) 516(MH⁺), 538 (MNa⁺).

(c) By proceeding in a similar manner to Example 3(a) but using ethyl (R/S) 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl)-butyrate [Reference Example 4(f)] there was prepared (R/S) 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-vl)-butyric acid as a white solid. LC-MS: R_T = 2.92 minutes (100% total area by ELS);

MS(ES⁺) 508 (MNa⁺).

(d) By proceeding in a similar manner to Example 3(a) but using ethyl (R/S) 3-(1-[(2-o-tolylamino-benzoxazol-6-yl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl)-butyrate [Reference

25 Example 4(g)] there was prepared (R/S) 3-[1-[(2-o-tolylamino-benzoxazol-6-vl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-vl]-butyric acid as a colourless foam. LC-MS: R_T = 3.01 minutes (100% total area by ELS); MS(ES⁺) 484 (MH⁺), 506 (MNa⁺).

EXAMPLE 4

30 (a) 3-(1-[(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-vl)-pentanedioic acid

A stirred suspension of dimethyl 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-pentanedioate [270mg, Reference Example 4(c)] in ethanol (10ml) was treated with a solution of sodium hydroxide (190mg) in water (2ml) and the mixture stirred at

reflux for 3 hours. After cooling to room temperature the mixture was treated with water (10ml) and then carefully acidified to pH1 by the addition of hydrochloric acid (3M) with ice cooling. The resultant precipitate was collected by filtration, then dried and then recrystallised from ethyl acetate to give the title compound (60mg) as a white crystalline solid. LC-MS: $R_T = 2.44$

5 minutes (100% total area by ELS); MS(ES^+) 568 (M Na^+).

(b) By proceeding in a similar manner to Example 4(a) but using dimethyl 3-(1-[4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-pentanedioate [Reference Example 4(d)] there was prepared 3-(1-[4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl-pentanedioic acid as a white solid. MS (ES^-) 514 (M $^-$).

10

(c) By proceeding in a similar manner to Example 4(a) but using dimethyl 3-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl)-pentanedioate [Reference Example 4(h)] and subjecting the product to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:9, v/v) there was prepared 3-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl-pentanedioic acid as a white foam. LC-MS: $R_T = 2.40$ minutes (100% total area by ELS); MS(ES^+) 582 (M Na^+).

15

(d) By proceeding in a similar manner to Example 4(a) but using methyl (R) 4-[2-methoxycarbonyl-1-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethylcarbamoyl]-butyrate [Reference Example 4(i)] and subjecting the product to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:9, v/v) there was prepared (R) 4-[2-carboxy-1-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethylcarbamoyl]-butyric acid as a white powder. LC-MS: $R_T = 2.43$ minutes (100% total area by ELS); MS(ES^+) 653 (M Na^+).

25

(e) By proceeding in a similar manner to Example 4(a) but using methyl (R) N-[2-methoxycarbonyl-1-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethyl]-succinamate [Reference Example 4(j)] and subjecting the product to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:9, v/v) there was prepared (R) N-[2-carboxy-1-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethyl]-succinamic acid as a colourless gum. LC-MS: $R_T = 2.44$ minutes (100% total area by ELS); MS(ES^+) 639 (M Na^+).

EXAMPLE 5(R/S) 1-(4-[2-Oxo-2-*l*6-(2-oxo-tetrahydro-pyran-4-yl)-3,4-dihydro-2H-quinolin-1-yl]-ethyl)-phenyl)-3-*o*-tolyl-urea

A solution of [4-(3-*o*-tolyl-ureido)-phenyl]-acetic acid (310mg) and diisopropylethylamine (310mg) dimethylformamide (5ml) was treated successively with O-(7-azabenzotriazol-1-yl)-⁵ N,N,N',N'-tetramethyluronium hexafluorophosphate (450mg), then (R/S) 4-(1,2,3,4-tetrahydro-quinolin-6-yl)-tetrahydro-pyran-2-one (250mg, Reference Example 5(c)). After standing at room temperature for 2 hours the mixture was partitioned between ethyl acetate (100ml) and dilute hydrochloric acid (100ml). The layers were separated and the organic layer was washed with water, dried and evaporated. The residue was subjected to flash chromatography on silica eluting with ethyl acetate to give a yellow gum. This was dissolved in the minimum volume of ethanol and the solution was then treated with ether to yield a yellow solid, which was collected by filtration and dried to give the title compound (80mg) as a yellow solid. LC-MS: R_T = 3.74 minutes (100% total area by ELS); MS(ES⁺) 520 (MNa⁺).

15

EXAMPLE 6

(R) 3-(1-[(3-Methoxy-4-(3-*o*-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl)-3-[⁵-methyl-isoxazole-3-carbonyl]-amino-1-propionic acid

Methyl (R) 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-3-[⁵-methyl-isoxazole-3-carbonyl]-amino-²⁰ propionate (310mg, Reference Example 17) was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:3, v/v) and the clear solution allowed to stand at room temperature for 2 hours. The residue obtained on evaporation of this solution was added to a mixture of [3-methoxy-4-(3-*o*-tolyl-ureido)-phenyl]-acetic acid (280mg), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (340mg) and diisopropylethylamine (1ml) in dimethylformamide (30ml). The resultant mixture was stirred at room temperature for 3 hours and then allowed to stand overnight. The mixture was evaporated to low bulk and the residue was partitioned between ethyl acetate and dilute hydrochloric acid. The layers were separated and the organic layer was washed with sodium carbonate solution, dried and evaporated to give 580mg of an orange oil. Purification by flash chromatography eluting with 1:1 ethyl acetate and dichloromethane gave an orange foam. This product was dissolved in methanol (20ml) and the solution treated with 1.0 M sodium hydroxide solution. After refluxing for 2 hours the mixture was evaporated to low bulk and the residue diluted with water. Acidification with dilute hydrochloric acid gave a gummy product which was extracted into ethyl acetate solution. This solution was dried and evaporated to give the title compound (110mg) as a light yellow foam.

LC-MS: R_T = 2.94 minutes (100% total area by ELS); MS(ES⁺) 648 (MNa⁺).

EXAMPLE 7

(a) (S) 2-(2-Chloro-6-methyl-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid

5 A mixture of methyl (S) 2-amino-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate (200mg, Reference Example 18), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (200mg) and 2-chloro-6-methylbenzoic acid (90mg) in dimethylformamide was treated with diisopropylethylamine (150mg) and the clear solution allowed to stand at room temperature overnight. The reaction mixture was partitioned between

10 ethyl acetate (50ml) and dilute hydrochloric acid (50ml). The organic phase was washed with sodium bicarbonate solution, then dried and then evaporated. The residue was examined by Thin Layer Chromatography on silica using a mixture of ethyl acetate and dichloromethane (1:9, v/v) and showed two very close spots, of approximately equal intensity. The product was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (1:9, v/v); the bulk of the fractions contained mixed spots, but separate fractions containing each of the pure components was obtained. On standing in solution for more than about one hour, each pure component reverted to an identical mixture of the two components, suggesting that the two spots represented stable rotamers. Accordingly, all fractions containing either or both spots were combined and evaporated to give a colourless oil

15

20 (160mg). This material was dissolved in methanol (10ml) and treated with lithium hydroxide solution (4ml, 1M). After standing at room temperature for 30 minutes the mixture was evaporated to low bulk and the residue dissolved in water (10ml). Acidification with dilute hydrochloric acid afforded a white precipitate, which was collected by filtration, washed with water and then dried to give the title compound (105mg) as a white solid. LC-MS: (indicated a mixture of two stable rotamers): rotamer 1, $R_T = 2.79$ minutes (57% total area by ELS), MS (ES $^+$) 567, 569 (MNa $^+$); rotamer 2, $R_T = 3.96$ minutes (43% total area by ELS), MS (ES $^+$) 567, 569 (MNa $^+$).

25

25 (b) By proceeding in a similar manner to Example 7(a) but using tetrahydro-pyran-4-carboxylic acid there was prepared (S) 3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-2-[tetrahydro-pyran-4-carbonyl]-aminol-propionic acid as a white powder. LC-MS: (indicated a mixture of two stable rotamers): rotamer 1, $R_T = 2.47$ minutes (52% total area by ELSD), MS (ES $^+$) 527 and 529 (MNa $^+$); rotamer 2, $R_T = 2.66$ minutes (48% total area by ELS), MS (ES $^+$) 527 and 529 (MNa $^+$).

EXAMPLE 8(S) 2-(2,6-Dichloro-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid

5 A solution of methyl (S) 2-amino-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate (180mg, reference Example 18) in dichloromethane (10ml) was treated with diisopropylethylamine (150mg) then with 2,6-dichlorobenzoyl chloride (130mg). After standing at room temperature overnight the mixture was partitioned between ethyl acetate (50ml) and dilute hydrochloric acid (50ml). The organic phase was washed with sodium bicarbonate

10 solution, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (1:9, v/v) to give a colourless oil (160mg). This material was treated with methanol (10ml) and then with lithium hydroxide solution (4ml, 1M). After standing at room temperature for one hour the mixture was evaporated to low bulk and the residue was dissolved in water (10ml). The solution was

15 acidification by addition of dilute hydrochloric. The resulting white precipitate was filtered then washed with water and then dried to give the title compound (120mg) as a white solid. LC-MS (indicated a mixture of stable rotamers): rotamer 1, $R_T = 2.79$ minutes (48% total area by ELS), MS (ES $^+$) 587, 599 (MNa $^+$); rotamer 2, $R_T = 3.74$ minutes (10 total area by ELS), MS (ES $^+$) 587, 589 (MNa $^+$); rotamer 3, $R_T = 3.96$ minutes (46% total area by ELS), MS (ES $^+$) 587, 599 (MNa $^+$).

20

EXAMPLE 9(R/S) 3-[1-[(4-[2,3-Dihydro-indole-1-carbonyl]-amino)-3-methoxy-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-butyric acid

Step 1. Bromo-Wang resin (1g, nominal loading of 1 mmol/g, Novabiochem) was suspended in

25 dimethylformamide (15ml) and treated successively with a solution of (R/S) 6-(2-carboxy-1-methyl-ethyl)-3,4-dihydro-2H-quinoline-1-carboxylic acid 9H-fluoren-9-ylmethyl ester (880mg, Reference Example 28) in dimethylformamide (5ml), diisopropylethylamine (0.35ml) and cesium iodide (270mg). The mixture was allowed to stand at room temperature with occasional shaking overnight. The resin was drained then washed (i) five times with dimethylformamide, (ii) three

30 times with water, (iii) three times with dimethylformamide, (iv) three times with methanol, (v) four times with dichloromethane, and (vi) twice with ether, and then dried.

Step 2. The resin from Step 1 was then suspended in a mixture of piperidine and dimethylformamide (20ml, 1:4, v/v) and the mixture was kept at room temperature with occasional shaking for about 2 hours. The resin was drained then washed (i) five times with

35

dimethylformamide, (ii) three times with methanol, (iii) four times with dimethylformamide, and (vi) twice with ether, and then dried.

Step 3. The resin from Step 2 was then suspended in dimethylformamide (15ml) and treated 5 successively with O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (570mg), {4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl}-acetic acid (490mg) and diisopropylethylamine (0.52ml) and the mixture allowed to stand at room temperature with occasional shaking overnight. The resin was drained washed then washed (i) five times with dimethylformamide, (ii) three times with methanol, (iii) four times 10 with dimethylformamide, and (vi) twice with ether, and then dried.

Step 4. The resin from Step 3 was treated with a mixture of trifluoroacetic acid and dichloromethane (about 10ml, 1:1, v/v) and the mixture kept at room temperature with 15 occasional shaking for about 1 hour. The resin was drained and then washed with a mixture of trifluoroacetic acid and dichloromethane (about 1ml, 1:1, v/v). The combined filtrates were evaporated and the residual brown oil was treated with dilute sodium hydroxide solution. The resulting aqueous solution was washed with ether, then with dichloromethane, and then acidified by addition of hydrochloric acid. The precipitated product was extracted four times with dichloromethane. The combined extracts were dried and then evaporated. The residue was 20 triturated with ether to give the title compound (120mg) as a cream solid. LC-MS: R_T = 3.16 minutes (100% total area by ELS); MS(ES⁺) 550 (MNa⁺).

EXAMPLE 10

(S) 2-Acetylamino-3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-25 quinolin-6-yl]-propionic acid

A solution of methyl (S) 2-acetylamino-3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate [220mg, Reference Example 4(l)] in dioxane (3ml) was treated with a solution of lithium hydroxide hydrate (50mg) in water (1ml). The mixture was stirred at room temperature for 3 hours, then treated with water (5ml), then acidified to pH 30 1-2 by the addition of dilute hydrochloric acid (with ice cooling). The resulting precipitate was extracted three times with ethyl acetate and the combined extracts were washed with water, then with brine, then dried and then evaporated. The residue was recrystallised from ethyl acetate to give the title compound (21mg) as a white powder. LC-MS: R_T = 2.77 minutes (100% total area by ELS); MS(ES⁺) 581 (MNa⁺).

EXAMPLE 11(R/S) 3-(1-[3-Methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-butyric acid, sodium salt.

A solution of (R/S) 3-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-butyric acid (2.1g) in methanol (about 150ml) was treated with exactly one equivalent of 0.1M sodium hydroxide solution. The methanol was evaporated off and the residue diluted with water (about 120ml) and lyophilised. The lyophilate was triturated with ether and the insoluble material was then washed with ether, then with pentane and then dried to give the title compound (1.9g) as an off-white, free-flowing powder. MS(ES⁺) 525 (MH⁺). [Elemental analysis : Found: C, 60.01; H, 6.13; N, 7.28; H₂O, 8.25%. Calculated for C₂₉H₃₀N₃O₅•0.3H₂O: C, 60.25; H, 6.20; N, 7.27; H₂O, 9.3 %].

EXAMPLE 12(a) (S) 2-(2,6-Dichloro-benzoylamino)-3-[1-(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid

Methyl (S) 2-(N-boc-amino)-3-[1-(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate [200mg, Reference Example 4(m)] was treated with trifluoroacetic acid (3ml) and the resulting solution was left at room temperature for 15 minutes then evaporated. The residue was dissolved in dichloromethane (20ml) and treated with diisopropylethylamine (260 mg) and then with 2,6-dichlorobenzoyl chloride (140mg). After standing at room temperature overnight the mixture was evaporated to low bulk and the residue partitioned between ethyl acetate (50ml) and dilute hydrochloric acid. The organic phase was washed with sodium bicarbonate solution, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (15:85 .v/v). The resulting colourless gum was treated with methanol (10ml) and then with lithium hydroxide solution (2ml,1M). After standing at room temperature for 2 hours the mixture was evaporated to low bulk, the residue was treated with water (10ml) and the mixture acidified by addition of dilute hydrochloric acid. The resulting white precipitate was filtered, then washed with water, and then dried to give the title compound (90mg) as a white powder. LC-MS: R_T = 2.97 minutes (100% total area by ELS); MS(ES⁺) 657 and 659 (MH⁺), 679 and 681 (MNa⁺).

(b) By proceeding in a similar manner to Example 12(a) but using methyl (S) 3-[1-(2-chlorobenzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-2-(N-boc-amino)-propionate [Reference Example 4(n)]

35 and 2-chloro-6-methylbenzoyl chloride there was prepared (S) 3-[1-(2-chloro-benzoyl)-1,2,3,4-

tetrahydro-quinolin-6-yl]-2-(2-chloro-6-methyl-benzoylamino)-propionic acid as a white powder.

LC-MS: $R_T = 2.76$ minutes (100% total area by ELS); MS (ES $^+$) 533 and 535 (MNa $^+$).

(c) By proceeding in a similar manner to Example 12(a) but using methyl (S) 3-[1-(4-acetoxy-3-chloro-phenyl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-2-(N-boc-amino)-propionate [Reference Example 4(o)] and 2-chloro-6-methylbenzoyl chloride there was prepared (S) 3-[1-(3-chloro-4-hydroxy-phenyl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-2-(2-chloro-6-methyl-benzoylamino)-propionic acid. LC-MS: $R_T = 2.67$ minutes (100% total area by ELS); MS (ES $^+$) 563 and 565 (MNa $^+$).

10

REFERENCE EXAMPLE 1

Ethyl 3-[1-(2-{3-methoxy-4-[(2-toluidinocarbonyl)amino]phenyl}acetyl)-1,2,3,4-tetrahydro-6-quinolinyl]propanoate

A stirred solution of 3-methoxy-4-[3-(2-methylphenyl)ureido]phenylacetic acid (0.232g, prepared 15 as described in Example 52B of International Patent Application Publication No. WO 96/22966) in anhydrous tetrahydrofuran (5ml), under an atmosphere of argon and at 20°C, was treated with powdered molecular sieves 4Å (2g), ethyl 3-(1,2,3,4-tetrahydro-6-quinolinyl)propanoate (0.115g, Reference Example 2), triethylamine (0.275ml), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.223g) and 4-dimethylaminopyridine (6mg). After 20 stirring at 20°C for 1 hour the reaction mixture was filtered through a pad of celite. The filtrate was evaporated under reduced pressure (2.7 kPa) at 40°C and the residue was treated with ethyl acetate (25ml). The solution obtained was washed twice with saturated aqueous ammonium chloride solution (5ml), then with water (5ml), then dried over magnesium sulfate, and then evaporated under reduced pressure (2.7 kPa) at 40°C. The resulting white foamy solid (0.457g) 25 was subjected to flash chromatography on silica (0.040-0.063mm) eluting with a mixture of cyclohexane and ethyl acetate (250ml, 9:1, then 500ml, 7:3, then 1000ml, 4:6; v/v) to give the title compound (0.244g) as a white foamy solid.

REFERENCE EXAMPLE 2

30 Ethyl 3-(1,2,3,4-tetrahydro-6-quinolinyl)propanoate

A stirred mixture of ethyl 3-(6-quinolinyl)propanoate (0.3g, Reference Example 3) in hydrochloric acid (3ml, 0.1N) and 5% rhodium in carbon powder (33mg) was hydrogenated in a 22 cm³ stainless steel pressure reactor at a pressure of 50 bars of hydrogen. After stirring for 4 hours at 25°C a further portion of 30 mg of 5% rhodium in carbon powder (33mg) was added 35 and the hydrogenation was continued under a pressure of 50 bars at 25°C for 1 hour. The

reaction mixture was filtered through a pad of celite and the filter pad was washed with hydrochloric acid (3ml, 0.1N) then with ethyl acetate (25ml). The combined filtrate and washings were combined and the aqueous phase was decanted from the organic phase. The aqueous phase was extracted twice with ethyl acetate (25ml) and combined with the aforementioned organic 5 phase. The combined solutions were dried over magnesium sulfate then evaporated under reduced pressure (2. kPa) at 40°C to give the title compound (0.121g) as a brown oil.

REFERENCE EXAMPLE 3

Ethyl 3-(6-quinoliny)propanoate

10 Into the electrochemical apparatus described below were introduced successively, dimethylformamide (45ml), pyridine (5ml), tetrabutylammonium bromide (250mg), tetrabutylammonium iodide (18.8mg) and 1,2-dibromoethane (0.15ml). The solution was deoxygenated by bubbling argon through the solution for about 10 minutes. After carrying out a pre-electrolysis, constant current of 125mA during 30 minutes, the stirred mixture was treated 15 with nickel bromide trihydrate (341mg), 6-bromoquinoline (2.6g), and ethyl acrylate (3.12g). Stirring was continued until complete dissolution. The reaction medium was heated to 60°C and then electrolysis was carried out using a constant current of 250mA whilst maintaining the temperature at 60°C. After 3 hours and the passage of 2810 coulombs (i.e. 2.33 Faradays per mole of 6-bromoquinoline) the electrolysis was stopped. The electrolysed solution plus 20 dimethylformamide washings (20ml) from the electrochemical apparatus and the electrodes was treated with water (250ml) and then extracted three times with heptane (70ml), ethyl acetate (50ml) and diethyl ether (50ml). The combined extracts were evaporated under reduced pressure (2.7 kPa) at 40°C. The residual yellow oil (2.78g) was subjected to Pressure Column Chromatography on silica [40 mm diameter column containing 100 g of silica 60 Merck (0.040 - 25 0.063 mm)] eluting with a mixture of cyclohexane, ethyl acetate and 2-propanol (90:8:2 then 85/12/3; v/v/v) under a slight pressure of argon (approximately 30 Kpa) to give the title compound (1.92g) as a yellowish oil.

The electrochemical apparatus is made up of: a cylindrical body (50ml volume) which contains 30 the reaction medium and into which is plunged a 10 mm diameter soft iron bar (the consumable anode) and a cylindrical nickel foam grid (diameter 30mm, height 42.5mm, surfaces connect approximately 40ml) concentrically laid out around the anode; a glass lid provided with 5 threaded outputs; a central output for the electrical contact of the anode; four peripheral outputs for the electrical contact of the cathode, thermometer, tubing for argon arrival and a cooling agent with water. The two parts of the electrolyser are associated by the intermediate of 35

a 60 mm interior diameter flat grinding, ensuring the sealing. The reaction medium is maintained under an inert atmosphere by continuously bubbling argon through the electrolysed solution. The electrodes are connected to a stabilized power supply or an intentiostat. Moreover, in the circuit of the anode, a current integrator is connected in series. The reaction medium is stirred by a Teflon[®] covered magnet bar. The body of the electrochemical apparatus can be plunged in an oil bath at the required temperature for the reaction.

REFERENCE EXAMPLE 4

(a) Ethyl (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-butyrate

10 A solution of [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid (2.9g) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (3.7g) in dimethylformamide (about 40ml) was treated with diisopropylethylamine (10ml), followed after about 30 seconds by a solution of (R/S) ethyl 3-(2,3-dihydro-1H-indol-5-yl)butyrate [about 2.5g,

15 Reference Example 5(a)] in dimethylformamide (about 10ml). The resulting clear, dark brown solution was kept at room temperature for about one hour then evaporated to low bulk. The residue was partitioned between water and ethyl acetate and the organic layer was washed with dilute hydrochloric acid, then with aqueous sodium bicarbonate solution, then with brine, then dried and then evaporated. The residual brown gum was subjected to flash chromatography on 20 silica eluting with a mixture of ethyl acetate and petrol (3:2 to 3:1, v/v) to give the title compound (2.8g) as a light yellow, amorphous foam. MS(ES⁺) 552 (M-Na⁺).

(b) By proceeding in a similar manner to Reference Example 4(a) but coupling [4-(3-o-tolyl-ureido)-phenyl]-acetic acid with (R/S) ethyl 3-(2,3-dihydro-1H-indol-5-yl)butyrate there was 25 prepared ethyl (R/S) 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-butyrate as an off-white solid. MS(ES⁺) 500 (MH⁺), 522 (MNa⁺). MS(ES⁺) 498 (M⁺).

(c) By proceeding in a similar manner to Reference Example 4(a) but coupling [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid with dimethyl 2-(2,3-dihydro-1H-indol-5-ylmethyl)-30 pentanedioate (Reference Example 9) there was prepared dimethyl 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-2,3-dihydro-1H-indol-5-yl)-pentanedioate as an off-white foam. MS(ES⁺) 574 (MH⁺), 596 (MNa⁺).

(d) By proceeding in a similar manner to Reference Example 4(a) but coupling [4-(3-o-tolyl-ureido)-phenyl]-acetic acid with dimethyl 2-(2,3-dihydro-1H-indol-5-ylmethyl)-pentanedioate 35

(Reference Example 9) there was prepared dimethyl 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl]-pentanedioate as a white foam. MS(ES⁺) 566 (MNa⁺). MS(ES⁻) 542 (M⁻).

5 (e) By proceeding in a similar manner to Reference Example 4(a) but coupling [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid with ethyl (R/S) 3-(1,2,3,4-tetrahydro-quinolin-6-yl)butyrate [Reference Example 5(b)] there was prepared ethyl (R/S) 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-butyrate as a yellow gum. MS(ES⁺) 544 (MH⁺), 566 (MNa⁺). MS(ES⁻) 542 (M⁻).

10 10 (f) By proceeding in a similar manner to Reference Example 4(a) but coupling [4-(3-o-tolyl-ureido)-phenyl]-acetic acid with ethyl (R/S) 3-(1,2,3,4-tetrahydro-quinolin-6-yl)butyrate [Reference Example 5(b)] there was prepared ethyl (R/S) 3-(1-[(4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-butyrate.

15 15 (g) By proceeding in a similar manner to Reference Example 4(a) but coupling (2-o-tolylamino-benzoxazol-6-yl)-acetic acid with ethyl (R/S) 3-(1,2,3,4-tetrahydro-quinolin-6-yl)butyrate [Reference Example 5(b)] there was prepared ethyl (R/S) 3-[1-[(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-butyrate.

20 20 (h) By proceeding in a similar manner to Reference Example 4(a) but coupling [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid with dimethyl 3-(1,2,3,4-tetrahydro-quinolin-6-yl)-pentanedioate [Reference Example 9(b)] and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and petrol (3:1, v/v) there was prepared dimethyl 3-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-pentanedioate as an off-white foam. MS(ES⁺) 588 (MH⁺), 610 (MNa⁺). MS(ES⁻) 586 (M⁻).

25 25 (i) By proceeding in a similar manner to Reference Example 4(a) but coupling [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid with methyl (R) 4-[1-(1,2,3,4-tetrahydro-quinolin-6-yl)-2-methoxycarbonyl-ethylcarbamoyl]-butyrate [Reference Example 13(a)] and subjecting the product to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:19, v/v) there was prepared methyl (R) 4-[2-methoxycarbonyl-1-(1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethylcarbamoyl]-butyrate as a pale orange foam. MS(ES⁺) 659 (MH⁺), 681 (MNa⁺). MS(ES⁻) 658 (M⁻).

(i) By proceeding in a similar manner to Reference Example 4(a) but coupling [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid with (R) N-[2-methoxycarbonyl-1-(1,2,3,4-tetrahydro-quinolin-6-yl)-ethyl]-succinamate [Reference Example 13(b)] and subjecting the product to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:19, v/v) there was prepared methyl (R) N-[2-methoxycarbonyl-1-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethyl]-succinamate as a light orange foam. MS(ES⁺) 667 (MNa⁺).

5 10 (k) By proceeding in a similar manner to Reference Example 4(a) but coupling ethyl (R/S) 3-(1,2,3,4-tetrahydro-quinolin-6-yl)butyrate [Reference Example 5(b)] with (1-boc-2-o-tolylamino-1H-benzimidazol-5-yl)-acetic acid (Reference Example 22) and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (3:7, v/v), there was prepared ethyl (R/S) 3-[1-(2-o-tolylamino-3H-benzimidazol-5-yl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-butyric acid.

15 (l) By proceeding in a similar manner to Reference Example 4(a) but coupling [3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetic acid with (S) methyl 2-acetylamino-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate [Reference Example 19(b)] and subjecting the product to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:19, v/v) there was prepared methyl (S) 2-acetylamino-3-[1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate as an off-white foam. MS(ES⁺) 573 (MH⁺), MS(ES⁻) 572 (M⁻).

20 25 (m) By proceeding in a similar manner to Reference Example 4(a) but coupling (2-o-tolylamino-benzoxazol-6-yl)-acetic acid with (S) Methyl 2-(N-boc-amino)-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate (Reference Example 19) and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (1:9, v/v) there was prepared (S) methyl 2-(N-boc-amino)-3-[1-[2-o-tolylamino-benzoxazol-6-yl]-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate as a colourless gum.

30 35 (n) By proceeding in a similar manner to Reference Example 4(a) but coupling 2-chlorobenzoic acid with methyl (S) 2-(N-boc-amino)-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate (Reference Example 19) and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (15:85, v/v) there was

prepared methyl (S)-3-[1-(2-chloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-2-(N-boc-amino)-propionate as a colourless oil.

(o) By proceeding in a similar manner to Reference Example 4(a) but coupling (4-acetoxy-3-chloro-phenyl)-acetic acid with methyl (S) 2-(N-boc-amino)-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate (Reference Example 19) and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (15:85, v/v) there was prepared (S) methyl 3-[1-[(4-acetoxy-3-chloro-phenyl)-acetyl]-1,2,3,4-tetrahydro-quinolin-6-yl]-2-(N-boc-amino)-propionate as a colourless oil.

(p) By proceeding in a similar manner to Reference Example 4(a) but coupling 3-methoxy-4-(3-o-tolyl-ureido)-phenylacetic acid with ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-heptanoate [Reference Example 24(a)] and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (11:9, v/v) there was prepared ethyl (R/S) 3-[1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl]-heptanoate as a foam.

(q) By proceeding in a similar manner to Reference Example 4(a) but coupling 4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenylacetic acid with ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-heptanoate [Reference Example 24(a)] there was prepared ethyl (R/S) 3-[1-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl]-heptanoate as a white solid. MS (ES⁺) 606 (MNa⁺).

(r) By proceeding in a similar manner to Reference Example 4(a) but coupling 3-methoxy-4-(3-o-tolyl-ureido)-phenylacetic acid with ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-pentanoate [Reference Example 24(b)] and subjecting the product to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (99:1, v/v) there was prepared ethyl (R/S) 3-[1-[(3-methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl]-pentanoate as a glass.

(s) By proceeding in a similar manner to Reference Example 4(a) but coupling 4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenylacetic acid with ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-pentanoate [Reference Example 24(b)] there was prepared ethyl (R/S) 3-[1-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl]-pentanoate as a white solid. MS (ES⁺) 578 (MNa⁺).

(i) By proceeding in a similar manner to Reference Example 4(a) but coupling 3-methoxy-4-(3-o-tolyl-ureido)-phenylacetic acid with ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate [Reference Example 24(e)] and subjecting the product to flash chromatography on silica eluting with a mixture of pentane and ethyl acetate (1:1, v/v) there was prepared ethyl (R/S) 3-(1-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl)-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate as a foam.

(ii) By proceeding in a similar manner to Reference Example 4(a) but coupling 4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenylacetic acid with ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate [Reference Example 24(c)] there was prepared ethyl (R/S) 3-[(4-[(2,3-dihydro-indole-1-carbonyl)-amino]-3-methoxy-phenyl)-acetyl]-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate as an off-white solid. MS (ES⁺) 626 (MNa⁺).

REFERENCE EXAMPLE 5

15 (a) Ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)butyrate
 A solution of (R/S) ethyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)butyrate (3.1g, Reference Example 6) in dichloromethane (30ml), cooled in an ice bath, was treated with trifluoroacetic acid (30ml). After about 30 minutes the reaction mixture was evaporated and traces of trifluoroacetic acid were removed by chasing off with toluene (twice), to give the title compound as a dark viscous gum, which was used immediately without further purification.

20 (b) By proceeding in a similar manner as in reference Example 4(a) but using ethyl (R/S) 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)butyrate (Reference Example 11) there was prepared ethyl (R/S) 3-(1,2,3,4-tetrahydro-quinolin-6-yl)butyrate.

25 (c) By proceeding in a similar manner as in reference Example 4(a) but using (R/S) 4-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-tetrahydro-pyran-2-one (Reference Example 16) and carrying out the reaction at room temperature there was prepared (R/S) 4-(1,2,3,4-tetrahydro-quinolin-6-yl)-tetrahydro-pyran-2-one as a brown solid.

REFERENCE EXAMPLE 6

(R/S) Ethyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)butyrate

A mixture of ethyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)crotonate (11.4g, Reference Example 7) and ammonium formate (about 30g) in ethanol (about 200ml) was warmed in an oil-bath to 60°C. Palladium on charcoal (10%, about 1g) was added in one portion under a blanket of

nitrogen - effervescence began almost immediately. The mixture was stirred at about 60°C for about one hour, then cooled to room temperature and filtered through Celite. The filtrate was evaporated and the residue was partitioned between water and ethyl acetate. The organic layer was washed with water, then dried and then evaporated to give the title compound (11.1g) as a colourless, mobile oil.

REFERENCE EXAMPLE 7

(a) Ethyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)crotonate
A mixture of 1-boc-5-bromoindoline (15.0g, Reference Example 8), ethyl crotonate (8.6g), 10 palladium acetate (480mg), tris(o-tolyl)phosphine (1.6g) and triethylamine (10ml) in dimethylformamide (60ml) was stirred in a sealed vessel under an atmosphere of argon at about 100°C for about 4 hours. After cooling to room temperature the dark mass was poured onto hydrochloric acid (about 1L, 1M) and the product extracted into ethyl acetate. The combined extracts were washed with aqueous sodium bicarbonate solution, then with brine, then dried and 15 then evaporated. The residual light yellow oil was subjected to flash chromatography on silica eluting initially with a mixture of ethyl acetate and petrol (5:95, v/v) to remove high running impurities, then eluting with a mixture of ethyl acetate and petrol (1:9, v/v) to give the title compound (11.4g) as a colourless, mobile oil.

20 (b) By proceeding in a similar manner to Reference Example 7(a) but using methyl acrylate and carrying out the reaction at 80°C there was prepared methyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)acrylate as a light yellow solid. MS(ES⁺) 629 (2MNa⁺).

25 (c) By proceeding in a similar manner to Reference Example 7(a) but using 1-boc-6-iodo-1,2,3,4-tetrahydroquinoline (Reference Example 12) there was prepared ethyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)crotonate as a light yellow solid.

30 (d) By proceeding in a similar manner to Reference Example 7(a) but using 1-boc-6-iodo-1,2,3,4-tetrahydroquinoline (Reference Example 12) and methyl acrylate and carrying out the reaction at 80°C there was prepared methyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)acrylate as a light yellow powder.

REFERENCE EXAMPLE 81-boc-5-bromoindoline

5-bromoindoline (10g) was added in one portion to molten Boc-anhydride (11.6g) at 30-40°C. Immediate effervescence was followed by the formation of a solid cake which was triturated with 5 pentane to give the title compound (15g) as a white powder.

REFERENCE EXAMPLE 9(a) Dimethyl 2-(2,3-dihydro-1H-indol-5-ylmethyl)-pentanedioate

A mixture of dimethyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)-2-methoxycarbonyl-pentanedioate [530mg, Reference Example 10(a)] and concentrated hydrochloric acid (20ml) was stirred at reflux overnight then evaporated. The residual clear foam (370mg) was treated with methanol (20ml), then with concentrated sulphuric acid (10 drops). The resulting solution was stirred at reflux for 2 hours then evaporated. The residue was partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer and extracts were washed with brine, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and petrol (1:1, v/v) to give the title compound (150mg) as a clear oil. MS(ES⁺) 278 (MH⁺).

20 (b) By proceeding in a similar manner to Reference Example 9(a) but using ethyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-2-ethoxycarbonyl-pentanedioate [Reference Example 10(b)] there was prepared dimethyl 3-(1,2,3,4-tetrahydro-quinolin-6-yl)-pentanedioate as a colourless oil. MS(ES⁺) 292 (MH⁺), 314 (MNa⁺).

REFERENCE EXAMPLE 10(a) Dimethyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)-2-methoxycarbonyl-pentanedioate

A stirred solution of sodium (156mg) in methanol (15ml) was treated with dimethyl malonate (0.8ml) and after stirring for 15 minutes the mixture was then treated with a solution of methyl 3-(1-boc-2,3-dihydro-1H-indol-5-yl)acrylate [1.0g, reference Example 7(b)] in tetrahydrofuran (15ml). The mixture was stirred at reflux for 3 hours, then cooled to room temperature, then treated with water (2ml) and then evaporated. The residue was partitioned between ethyl acetate and water. The layers were separated and the aqueous layer was extracted with fresh ethyl acetate. The combined organic layer and extracts were washed with brine, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture

of ethyl acetate and petrol (15:85, v/v) to give the title compound (530mg) as a clear oil. MS(ES^+) 458 (MNa⁺). MS(ES^-) 434 (M⁻).

5 (b) By proceeding in a similar manner to Reference Example 10(a) but using methyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)acrylate [Reference Example 7(d)] there was prepared ethyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-2-ethoxycarbonyl-pentanedioate. MS(ES^+) 514 (MNa⁺). MS(ES^-) 490 (M⁻).

REFERENCE EXAMPLE 11

10 (a) Ethyl (R/S) 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)butyrate
A mixture of ethyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)crotonate [9g, Reference Example 7(c)] and 5% palladium on charcoal (2.5g) in ethanol (250ml) was hydrogenated at room temperature and pressure overnight. The spent catalyst was removed by filtration through Celite and the filtrate was evaporated to give the title compound (9.1g) as a colourless oil.

15 (b) By proceeding in a similar manner to Reference Example 11(a) but using E and Z ethyl 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-hept-2-enoate [Reference Example 26(a)] and carrying out the hydrogenation at 2bar pressure of hydrogen gas for 4.5hours there was prepared ethyl (R/S) 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-heptanoate as a white solid.

20 (c) By proceeding in a similar manner to Reference Example 11(a) but using E and Z ethyl 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-pent-2-enoate [Reference Example 26(b)] and carrying out the hydrogenation at 2bar pressure of hydrogen gas for 100 minutes there was prepared ethyl (R/S) 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-pentanoate as a white solid.

25 (d) By proceeding in a similar manner to Reference Example 11(a) but using E and Z ethyl 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-cinnamate [Reference Example 26(c)] and carrying out the hydrogenation at 2bar pressure of hydrogen gas for 120 minutes there was ethyl (R/S) 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate as a white solid.

REFERENCE EXAMPLE 12

1-Boc-6-iodo-1,2,3,4-tetrahydroquinoline

A solution of iodine monochloride (16.2g) in acetic acid (30ml) was added to a stirred solution of 1,2,3,4-tetrahydroquinoline (12.6ml) in acetic acid (125ml) at room temperature under nitrogen.

35 After stirring at room temperature for a further hour the dark mixture was poured onto water

(about 500ml) and the mixture was basified by the cautious addition of solid potassium carbonate. The aqueous layer was extracted with *tert*-butyl methyl ether, and this extract was washed successively with aqueous sodium thiosulphate solution, then with brine, then dried and then evaporated. The residual brown gum (22g) was treated with *boc* anhydride (44g) in 5 tetrahydrofuran (250ml). The mixture was stirred at reflux overnight then evaporated and the residue was partitioned between ethyl acetate and dilute hydrochloric acid. The organic layer was washed with brine, then dried and then evaporated. Crystallisation of the residue from heptane gave the title compound (15g) as a light yellow powder.

10 **REFERENCE EXAMPLE 13**

(a) **Methyl (R) 4-[1-(1,2,3,4-tetrahydro-quinolin-6-yl)-2-methoxycarbonyl-ethyl]carbamoyl-buturate**
 A stirred solution of methyl (R) 3-amino-3-(1-*boc*-1,2,3,4-tetrahydro-quinolin-6-yl)-propionate (1.7g, Reference Example 14) in tetrahydrofuran (50ml) was treated with glutaric anhydride. 15 After stirring for 4 hours the mixture was evaporated to dryness the residue was dissolved in methanol (40ml) and treated with conc. sulphuric acid (20 drops). This solution was stirred at reflux for 3 hours and then allowed to stand at room temperature overnight. After the addition of solid sodium bicarbonate (10g) the mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The aqueous layer 20 was extracted with fresh ethyl acetate. The combined organic layer and extracts were washed with brine, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with ethyl acetate to give the title compound (1.6g) as a yellow oil. MS(ES⁺) 363 (MH⁺), 385 (MNa⁺) MS(ES⁺) 361 (MH⁺).
 25 (b) By proceeding in a similar manner to Reference Example 13(a) but using succinic anhydride there was prepared (R) N-[2-methoxycarbonyl-1-(1,2,3,4-tetrahydro-quinolin-6-yl)-ethyl]-succinamate as a colourless oil. MS(ES⁺) 371 (MNa⁺).

REFERENCE EXAMPLE 14

30 **(R) Methyl 3-amino-3-(1-*boc*-1,2,3,4-tetrahydro-quinolin-6-yl)-propionate**
 A solution of methyl 3-[R]-[benzyl-({S}-1-phenyl-ethyl)-amino]-3-(1-*boc*-1,2,3,4-tetrahydro-35 quinolin-6-yl)-propionate (6.5g, Reference Example 15) in ethanol (100ml) was treated with 20% palladium hydroxide on charcoal (1.0g), acetic acid (3.6ml) and water (10ml) and the mixture was hydrogenated at room temperature overnight. The spent catalyst was removed by filtration through Celite and the filtrate was evaporated to low bulk. The residue was taken up in ether

and this solution was washed with aqueous sodium bicarbonate solution, and the layers separated. The aqueous layer was extracted twice with fresh ether and the combined ether extracts were washed with brine, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:9, v/v) to give the title compound (1.7g) as a clear oil which slowly crystallised on standing.

5 MS(ES⁺) 335 (MH⁺), 357 (MNa⁺), 669 (2MH⁺)

REFERENCE EXAMPLE 15

10 Methyl 3-(R)-[benzyl-[(S)-1-phenyl-ethyl]-amino]-3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-propionate

A solution of (S)-N-benzyl- α -methylbenzylamine (2.6ml) in anhydrous tetrahydrofuran (50ml), cooled to -70°C and under nitrogen, was treated dropwise with a solution of butyllithium in hexanes (5ml, 2.5M) over about 5 minutes to give a red solution. After stirring at -70°C for a further 40 minutes the mixture was treated dropwise with a solution of methyl 3-(1-boc-1,2,3,4-15 tetrahydro-quinolin-6-yl)acrylate [2.0g, Reference Example 7(d)] in tetrahydrofuran (20ml) over about 10 minutes. Stirring was continued at low temperature for a further 20 minutes and then the reaction mixture was allowed to warm to room temperature. The mixture was partitioned between ether and water, the layers separated, and the organic layer washed with water then with brine, then dried and then evaporated. The residue was subjected to flash chromatography 20 on silica eluting with a mixture of ethyl acetate and petrol (initially 1:9 and then 15:85, v/v) to give the title compound as a viscous, colourless oil, 1.5g.

REFERENCE EXAMPLE 16

25 (R/S) 4-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-tetrahydro-pyran-2-one

A mixture of 1-boc-6-iodo-1,2,3,4-tetrahydroquinoline (2.0g, Reference Example 12), 5,6-dihydro-pyran-2-one (1.1g), tetrakis(triphenylphosphine)palladium (0) and triethylamine (2.2g) 30 in dimethylformamide (5ml) was stirred at about 95°C in a sealed vessel under an atmosphere of nitrogen overnight. The reaction mixture was partitioned between ethyl acetate and dilute hydrochloric acid, the layers separated, and the organic layer washed with sodium bicarbonate solution, then dried, and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (2:3, v/v) to give the title compound as a brown oil, 1.2g.

REFERENCE EXAMPLE 17Methyl (R) 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-3-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionate

A solution of 5-methyl-isoxazole-3-carboxylic acid (65mg) in dimethylformamide (30ml) was treated successively with O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (190mg), diisopropylethylamine (1ml) and methyl (R) 3-amino-3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)-propionate (200mg, Reference Example 14). After standing at room temperature overnight the mixture was evaporated to low bulk and the residue partitioned between ethyl acetate and dilute hydrochloric acid. The layers were separated and the organic layer was washed with sodium carbonate solution, dried, and evaporated. The residue was purified by flash chromatography to give the title compound as an orange gum, 310mg.

REFERENCE EXAMPLE 18Methyl (S) 2-amino-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionate

A solution of methyl (S) 2-(N-boc-amino)-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate [500mg, Reference Example 19(a)] in tetrahydrofuran (20ml) was treated successively with triethylamine (360mg) and 2,6-dichlorobenzoyl chloride (380mg). The mixture was stirred at 40°C for 2 hours and then partitioned between ethyl acetate (100ml) and dilute hydrochloric acid (100ml). The organic phase was washed with sodium bicarbonate solution, then dried and then evaporated. The residue was dissolved in trifluoroacetic acid (2ml) and the clear solution was left at room temperature for 30 minutes then evaporated. The residue was partitioned between ethyl acetate and dilute hydrochloric acid. The organic phase was washed with sodium bicarbonate solution, then dried and then evaporated to give the title compound (200mg) as a colourless oil.

25

REFERENCE EXAMPLE 19(a) (S) Methyl 2-(N-boc-amino)-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate

A solution of methyl (S) 2-(N-boc-amino)-3-quinolin-6-yl-propionate [3.8g, Reference Example 20(a)] in ethanol (100ml) at 60°C was treated with ammonium formate (10g) and 10% palladium on charcoal (500mg). After stirring at 60°C further ammonium formate (about 5g) and palladium on charcoal (about 250mg) were added, and this was repeated at 30 minute intervals for a further 2 hours, at which time TLC analysis indicated the reaction was complete. After cooling to room temperature the mixture was filtered through Celite to remove spent catalyst, and the filtrate was evaporated. The residue was partitioned between ethyl acetate (200ml) and

sodium bicarbonate solution (200ml). The organic phase was dried and evaporated to give the title compound (3.8g) as a colourless oil which slowly crystallised on standing.

5 (b) By proceeding in a similar manner to Reference Example 19(a) but using methyl (S)-2-(acetylamino)-3-quinolin-6-yl-propionate [Reference Example 20(b)] and carrying out the reaction at reflux temperature for 2 hours there was prepared methyl (S)-2-acetylamino-3-(1,2,3,4-tetrahydro-quinolin-6-yl)-propionate as a colourless oil, MS(ES⁺) 277 (MH⁺), 299 (MNa⁺).

10 REFERENCE EXAMPLE 20

(a) Methyl (S)-2-(N-boc-amino)-3-quinolin-6-yl-propionate

A mixture of methyl (S)-2-amino-3-quinolin-6-yl-propionate (3.0g, Reference Example 21) and boc-anhydride (3.2g) in tetrahydrofuran (30ml) was stirred at reflux for 30 minutes. The reaction mixture was evaporated and the residue was triturated with pentane to give the title compound (3.8g) as a white powder.

15 (b) By proceeding in a similar manner to Reference Example 20(a) but using acetic anhydride there was prepared methyl (S)-2-(acetyl-amino)-3-quinolin-6-yl-propionate as a colourless oil which crystallised slowly on standing. MS(ES⁺) 273 (MH⁺), MS(ES⁺) 271 (M⁺).

20

REFERENCE EXAMPLE 21

Methyl (S)-2-amino-3-quinolin-6-yl-propionate

A solution of butyllithium in hexanes (13.4ml, 2.5M) was added dropwise to a stirred solution of (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (5.2g) in anhydrous tetrahydrofuran (80ml)

25 at -78°C under an atmosphere of nitrogen. After stirring at -78°C for 10 minutes this solution was treated with a solution of 6-(chloromethyl)quinoline [5.0g, prepared according to the procedure described by Mahiou, Belaid; Gleicher, Gerald Jay. J. Org. Chem. (1990), 55(14), 4466-9] in tetrahydrofuran (20ml). The resultant dark orange mixture was stirred at -78°C for 2 hours. The cold reaction mixture was poured onto a mixture of ethyl acetate (200ml) and brine (200ml). The organic phase was dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and dichloromethane (1:1, v/v) to give a colourless oil (6g). This material was treated with hydrochloric acid (250ml, 0.25M) and the resulting solution was allowed to stand at room temperature for one hour then evaporated. The residue was treated with water (30ml) and the solution basified by addition of concentrated ammonia (50ml). This mixture was extracted three times with dichloromethane (100ml). The

35

combined extracts were dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate to remove high running impurities and then with a mixture of methanol and ethyl acetate (1:1, v/v) to give the title compound (3.0g) as a colourless gum.

5

REFERENCE EXAMPLE 22

(1-Boc-2-o-tolylamino-1H-benzimidazol-5-yl)-acetic acid

Ethyl (R/S) (2-o-tolylamino-1H-benzimidazol-5-yl)-acetate (1.6g, Reference Example 23) was suspended in ethanol (30ml) and treated with sodium hydroxide solution (5ml, 1M). After 10 stirring at 40°C for 2 hours the mixture was evaporated. The residue was partitioned between dilute acetic acid (50ml) and dichloromethane (50ml) and the resulting white precipitate (650mg) was dissolved in acetonitrile (30ml) and the solution was then treated with Boc-anhydride (580mg) and dimethylaminopyridine (10mg). After standing at room temperature overnight the mixture was evaporated and the residue was partitioned between ethyl acetate and dilute acetic acid. The organic layer was dried and then evaporated. The residue was dissolved in methanol (2ml) and the solution was treated with ether. The resulting precipitate was collected by 15 filtration to the title compound (500mg) as a white powder.

REFERENCE EXAMPLE 23

Ethyl (R/S) (2-o-tolylamino-1H-benzimidazol-5-yl)-acetate

A solution of ethyl (3,4-diaminophenyl)acetate (4.1g) in ethanol (50ml) and treated with o-tolylisothiocyanate (3.1g). After standing at room temperature overnight the clear solution was evaporated to give a yellow gum which was treated with ethanol (70ml). The resulting solution was treated with diisopropylcarbodiimide (5.3g), and the mixture stirred at 55°C for 4 hours then evaporated. The residue was subjected to flash chromatography on silica eluting initially with ether and then with a mixture of methanol and ether (1:9, v/v), to give the title compound (4.1g) as a light yellow gum.

REFERENCE EXAMPLE 24

30 (a) Ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-heptanoate

A solution of R/S 3-(2,3-dihydro-1H-indol-5-yl)-heptanoic acid hydrochloride [4.13g, Reference Example 25(a)] in absolute ethanol (100mL) containing concentrated sulphuric acid (1.4mL) was stirred for 6 hours then allowed to stand overnight at room temperature. The mixture was concentrated to a low volume and the residue was partitioned between ethyl acetate (200mL) and 35 saturated aqueous sodium bicarbonate (200mL). The organic phase was washed with saturated aqueous sodium bicarbonate (50mL). The aqueous phases were further extracted with ethyl

acetate and the combined organic phases were dried over magnesium sulphate then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of pentane and ethyl acetate (2:1, v/v) to give the title compound (2.88g) as a pale yellow oil.

5 (b) By proceeding in a similar manner to Reference Example 24(a) but using R/S 3-(2,3-dihydro-1H-indol-5-yl)-pentanoic acid hydrochloride [Reference Example 25(b)] there was prepared ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-pentanoate as a light yellow oil.

(c) By proceeding in a similar manner to Reference Example 24(a) but using R/S 3-(2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionic acid hydrochloride [Reference Example 25(c)] there was prepared ethyl (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate as a light orange oil.

REFERENCE EXAMPLE 25

(a) (R/S) 3-(2,3-Dihydro-1H-indol-5-yl)-heptanoic acid hydrochloride
15 A suspension of ethyl (R/S) 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-heptanoate [3.95g, Reference Example 11(b)] in aqueous hydrochloric acid (120mL, 6M) was heated at 85°C for 7 hours. After cooling to room temperature the mixture was evaporated. The residue was treated with toluene and the solvent evaporated under reduced pressure (repeated twice more). Final drying in a dessicator afforded the title compound (4.13g) as an orange-brown oil. LC-MS: RT=3.36
20 minutes; M(ES⁺) 248 (MH⁺).

(b) By proceeding in a similar manner to Reference Example 25(a) but using ethyl (R/S) 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-pentanoate [Reference Example 11(c)] there was prepared (R/S) 3-(2,3-dihydro-1H-indol-5-yl)-pentanoic acid hydrochloride as a brown oil.

25 (c) By proceeding in a similar manner to Reference Example 25(a) but using ethyl (R/S) 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionate [Reference Example 11(d)] there was prepared R/S 3-(2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionic acid hydrochloride as a brown solid.

30

REFERENCE EXAMPLE 26

(a) E and Z Ethyl 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-hept-2-enone
Sodium hydride (1.09g, 60% dispersion in mineral oil) was suspended in tetrahydrofuran (150mL). The mixture was cooled in an ice-bath under a nitrogen atmosphere and triethyl phosphonoacetate (4.75mL) was added during 3 minutes. After 45 minutes a solution of 1-acetyl-

5-pentanoyl-2,3-dihydro-1H-indole [5.33g, Reference Example 27(a)] in tetrahydrofuran (50mL) was added dropwise over 50 minutes. After stirring for 15 minutes the reaction mixture was allowed to warm to room temperature, then heated on a steam bath for 20 hours under a nitrogen atmosphere. In a separate flask, sodium hydride (1.09g, 60% dispersion in mineral oil) was suspended in tetrahydrofuran (150mL). The mixture was cooled in an ice-bath under a nitrogen atmosphere, triethyl phosphonoacetate (4.75mL) was added during 3 minutes and the mixture was stirred for 70 minutes. This mixture was added by canula to the main reaction mixture with ice-bath cooling. The reaction mixture was then refluxed for 43 hours, then cooled, then concentrated to half volume and then partitioned between ethyl acetate and 0.33M aqueous hydrochloric acid. The organic phase was separated and the aqueous phase re-extracted with ethyl acetate. The combined organics were dried over magnesium sulphate then evaporated to give an orange-brown oil which was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, v/v) to give the title compound (4.3g).

(b) By proceeding in a similar manner to Reference Example 26(a) but using 1-acetyl-5-propanoyl-2,3-dihydro-1H-indole (Reference Example 27(b)) there was prepared E and Z ethyl 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-pent-2-enoate as a cream solid.

(c) By proceeding in a similar manner to Reference Example 26(a) but using 1-acetyl-5-benzoyl-2,3-dihydro-1H-indole (Reference Example 27(c)) there was prepared E and Z ethyl 3-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-cinnamate as a yellow solid.

REFERENCE EXAMPLE 27

(a) 1-acetyl-5-pentanoyl-2,3-dihydro-1H-indole
25 Pentanoyl chloride (10.8g) was added dropwise to a mixture of anhydrous aluminium chloride (28.2g) and 1-acetyl-2,3-dihydro-1H-indole (10g) in 1,2-dichloroethane (100mL) with mechanical stirring. The mixture was stirred at reflux for 16 hours, then cooled, then poured into ice-water. The mixture was extracted with dichloromethane. The extracts were washed with 1M aqueous sodium hydroxide, then dried over magnesium sulphate, then evaporated to give the title

30 compound (10.3g) as a dark gum.

(b) By proceeding in a similar manner to Reference Example 27(a) but using propionyl chloride and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (3:2, v/v) there was prepared 1-acetyl-5-propanoyl-2,3-dihydro-1H-indole as a cream-orange solid.

(c) By proceeding in a similar manner to Reference Example 27(a) but using benzoyl chloride and subjecting the product to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (3:2, v/v) there was prepared 1-acetyl-5-benzoyl-2,3-dihydro-1H-indole as a cream solid.

REFERENCE EXAMPLE 28

(R/S) 6-(2-Carboxy-1-methyl-ethyl)-3,4-dihydro-2H-quinoline-1-carboxylic acid 9H-fluoren-9-ylmethyl ester

10 A suspension of (R/S) 3-(1,2,3,4-tetrahydro-quinolin-6-yl)-butyric acid (2.6g) and sodium bicarbonate (2.2g) in acetone (40ml) and water (40ml) was treated with 2,5-dioxo-pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester (4.0g) and the resulting mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate evaporated to low bulk. The residue was treated with dilute hydrochloric acid and the resulting gummy precipitate was extracted into a mixture of tetrahydrofuran, ethyl acetate and dichloromethane. This solution was washed with brine, then dried and then evaporated to give the title compound (5.8g) as a light brown oil, which solidified on standing. MS (ES⁺) 464 (MNa⁺), MS(ES⁻) 440 (M⁻).

20 IN VITRO AND IN VIVO TEST PROCEDURES

1. Inhibitory effects of compounds on VLA4 dependent cell adhesion to Fibronectin and VCAM.

1.1 Metabolic labelling of RAMOS cells.

25 RAMOS cells (a pre-B cell line from ECACC, Porton Down, UK) are cultured in RPMI culture medium (Gibco, UK) supplemented with 5% foetal calf serum (FCS, Gibco, UK). Prior to assay the cells are suspended at a concentration of 0.5×10^6 cells/ml RPMI and labelled with 400 μ Ci/100mls of [³H]-methionine (Amersham, UK) for 18 hours at 37°C.

30 1.2 96 well plate preparation for adhesion assay.

Cytostar plates (Amersham, UK) were coated with 50 μ l/well of either 3 μ g/ml human soluble VCAM-1 (R&D Systems Ltd, UK) or 28.8 μ g/ml human tissue Fibronectin (Sigma, UK). In control non-specific binding wells 50 μ l phosphate buffered saline was added. The plates were then left to dry in an incubator at 25°C, overnight. The next day the plates were blocked with 35 200 μ l/well of Pucks buffer (Gibco, UK) supplemented with 1% BSA (Sigma, UK). The plates

were left at room temperature in the dark for 2 hours. The blocking buffer was then disposed of and the plates dried by inverting the plate and gently tapping it on a paper tissue. 50 μ l/well of 3.6% dimethyl sulphoxide in Pucks buffer supplemented with 5mM manganese chloride (to activate the integrin receptor Sigma, UK) and 0.2% BSA (Sigma, UK), was added to the

5 appropriate control test binding and non-specific binding assay wells in the plate. 50 μ l/well of the test compounds at the appropriate concentrations diluted in 3.6% dimethyl sulphoxide in Pucks buffer supplemented with 5mM manganese chloride and 0.2% BSA, was added to the test wells.

Metabolically labelled cells were suspended at 4×10^6 cells/ml in Pucks buffer that was

10 supplemented with manganese chloride and BSA as above. 50 μ l/well of cells in 3.6% dimethyl sulphoxide in Pucks buffer and supplements was added to all plate wells. The same procedure exists for plates coated with either VCAM-1 or fibronectin and data is determined for compound inhibition of cell binding to both substrates.

1.3 Performance of assay and data analysis.

15 The plates containing cells in control or compound test wells are incubated in the dark at room temperature for 1 hour.

The plates are then counted on a Wallac Microbeta scintillation counter (Wallac, UK) and the captured data processed in Microsoft Excel (Microsoft, US). The data was expressed as an IC50, namely the concentration of inhibitor at which 50% of control binding occurs. The

20 percentage binding is determined from the equation:

$$\{[(CT_B - C_{NS}) - (C_I - C_{NS})] / (CT_B - C_{NS})\} \times 100 = \% \text{ binding}$$

where CT_B are the counts bound to fibronectin (or VCAM-1) coated wells without inhibitor

25 present, C_{NS} are the counts present in wells without substrate, and C_I are the counts present in wells containing a cell adhesion inhibitor.

Compound data of this invention is expressed for IC_{50s} for inhibition of cell adhesion to both fibronectin and VCAM-1. Particular compounds of the invention inhibit cell adhesion to fibronectin and VCAM-1 with IC_{50s} in the range 100 micromolar to 0.1 nanomolar. Preferred

30 compounds of the invention inhibit cell adhesion to fibronectin and VCAM-1 with IC_{50s} in the range 10 nanomolar to 0.1 nanomolar.

2. Inhibition of antigen-induced airway inflammation in the mouse and rat.

2.1 Sensitization of the animals.

Rats (Brown Norway, Harland Olac, UK) are sensitized on days 0, 12 and 21 with ovalbumin (100 µg, intraperitoneally (i.p.), Sigma, UK) administered with aluminium hydroxide adjuvant (100mg, i.p., Sigma, UK) in saline (1ml, i.p.).

In addition mice (C57) are sensitized on days 0 and 12 with ovalbumin (10µg, i.p.) administered with aluminium hydroxide adjuvant (20mg, i.p.) in saline (0.2ml, i.p.).

10 2.2 Antigen challenge.

Rats are challenged on any one day between days 28-38, while mice are challenged on any one day between days 20-30.

The animals are challenged by exposure for 30 minutes (rats) or 1 hour (mice) to an aerosol of ovalbumin (10g / l) generated by an ultrasonic nebulizer (deVilbiss Ultraneb, US) and passed into an exposure chamber.

15 2.3 Treatment protocols.

Animals are treated as required before or after antigen challenge. The aqueous-soluble compounds of this invention can be prepared in water (for oral, p.o. dosing) or saline (for 20 intratracheal, i.t. dosing). Non-soluble compounds are prepared as suspensions by grinding and sonicating the solid in 0.5 % methyl cellulose / 0.2 % polysorbate 80 in water (for p.o. dosing, both Merek UK Ltd., UK) or saline (for i.t. dosing). Dose volumes are: for rats 1ml / kg, p.o. or 0.5mg / kg, i.t.; for mice 10ml / kg, p.o. or 1ml / kg, i.t.

25 2.4 Assessment of airway inflammation.

The cell accumulation in the lung is assessed 24 hours after challenge (rats) or 48-72 hours after challenge (mice). The animals are euthanized with sodium pentobarbitone (200mg/kg, i.p., Pasteur Merieux, France) and the trachea is immediately cannulated. Cells are recovered from the airway lumen by bronchoalveolar lavage (BAL) and from the lung tissue by enzymatic (collagenase, Sigma, UK) disaggregation as follows.

BAL is performed by flushing the airways with 2 aliquots (each 10 ml/kg) RPMI 1640 medium (Gibco, UK) containing 10 % fetal calf serum (FCS, Serotech Ltd., UK). The recovered BAL aliquots are pooled and cell counts made as described below.

Immediately after BAL, the lung vasculature is flushed with RPMI 1640 / FCS to remove the 30 blood pool of cells. The lung lobes are removed and cut into 0.5 mm pieces. Samples (rats: 400mg; mice: 150mg) of homogenous lung tissue are incubated in RPMI 1640 / FCS with

collagenase (20 U/ml for 2 hours, then 60 U/ml for 1 hour, 37°C) to disaggregate cells from the tissue. Recovered cells are washed in RPMI 1640 / FCS.

Counts of total leukocytes recovered from the airway lumen and the lung tissue are made with an automated cell counter (Cobas Argos, US). Differential counts of eosinophils, neutrophils and

5 mononuclear cells are made by light microscopy of cytocentrifuge preparations stained with Wright-Giemza stain (Sigma, UK). T cells are counted by flow cytometry (EPICS XL, Coulter Electronics, US) using fluophore-labelled antibodies against CD2 (a pan-T cell marker used to quantify total T cells), CD4, CD8 and CD25 (a marker of activated T cells). All antibodies were supplied by Serotec Ltd., UK.

10


2.5 Data analysis.

The cell data was expressed as mean cell numbers in unchallenged, challenged and vehicle treated, and challenged and compound treated groups, including the standard error of the means. Statistical analysis of the difference among treatment groups was evaluated using one-

15 way analysis of variance via the Mann-Whitney test. Where $p < 0.05$ no statistical significance existed.

CLAIMS

1. A compound of general formula (I):-



5

wherein:-

R¹ represents:

- (i) R³-Z³-;
- 10 (ii) R³-L²-R⁴-Z³-;
- (iii) R³-L³-Ar¹-L⁴-Z³-; or
- (iv) R³-L³-Ar¹-L²-R⁴-Z³-;

R² represents hydrogen, halogen, lower alkyl or lower alkoxy;

R³ represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroaryalkenyl, heteroaryalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

15 R⁴ represents an alkylene chain, an alkenylene chain, or an alkynylene chain;

R⁵ represents hydrogen or lower alkyl;

R⁶ represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl or 20 heteroarylalkyl;

R⁷ and R⁷a are each independently hydrogen or lower alkyl;

R⁸ represents hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R⁹ represents alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or alkyl substituted by aryl, 25 an acidic functional group, cycloalkyl, heteroaryl, heterocycloalkyl, -S(O)mR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵;

R¹⁰ represents hydrogen, R³ or alkyl substituted with alkoxy, cycloalkyl, hydroxy, mercapto, alkylthio or -NY⁴Y⁵;

R¹¹ and R¹³ are each independently selected from hydrogen or a group consisting amino acid side chains, an acidic functional group, R³, -C(=O)-R³, or -C(=O)-NY⁴Y⁵, or alkyl substituted by an acidic functional group or by R³, -NY⁴Y⁵, -NH-C(=O)-R³, -C(=O)-R⁴-NH₂, -C(=O)-Ar¹-NH₂, -C(=O)-R⁴-CO₂H, or -C(=O)-NY⁴Y⁵;

5 or R¹⁰ and R¹¹ or R¹⁰ and R¹² together with the atoms to which they attached form a 3- to 6-membered heterocycloalkyl ring;

R¹² represents C₁-6alkylene, optionally substituted by R³;

R¹⁴ represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

10 A¹ represents a straight chain C₁-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by -ZR⁶, -NY¹Y², -CO₂R⁶ or -C(=O)-NY¹Y²;

Ar¹ represents arylene or heteroaryldiyl;

L¹ represents:

15 (i) a direct bond;

(ii) an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, -S(O)_mR⁹, R³, -C(=O)-R³, -C(=O)-OR³, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹,

20 -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ or -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or by (b) alkyl substituted by an acidic functional group, or by S(O)_mR⁹, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵;

(iii) a -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p- linkage;

(iv) a -Z²-R¹²- linkage;

25 (v) a -C(=O)-CH₂-C(=O)- linkage;

(vi) a -R¹²-Z²-R¹²- linkage;

(vii) a -C(R⁴)(R¹³)-[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p- linkage; or

(viii) a -L⁵-L⁶-L⁷- linkage;

L^2 represents a $-NR^5-C(=Z)-NR^5-$, $-C(=Z)-NR^5-$, $-C(=O)-$, $-C(=Z)-O-$, $-NR^5-C(=Z)-$, $-Z-$, $-S(O)_m-$, $-NR^5-$, $-SO_2-NR^5-$, $-NR^5-SO_2-$, $-NR^5-C(=O)-O-$, $-O-C(=O)-$, or $-O-C(=O)-NR^5-$ linkage;

L^3 represents a heteroarylidiyl, $-NR^5-C(=Z)-NR^5-$, $-C(=Z)-NR^5-$, $-C(=Z)-O-$, $-NR^5-C(=Z)-$, $-Z-$, $-S(O)_m-$, $-NR^5-$, $-SO_2-NR^5-$, $-NR^5-SO_2-$, $-NR^5-C(=O)-O-$, $-O-C(=O)-$, or $-O-C(=O)-NR^5-$ linkage;

L^4 represents a direct bond, an alkylene, alkenylene or alkynylene chain;

L^5 and L^7 each independently represent a direct bond or an alkylene chain;

L^6 represents a cycloalkylene or heterocycloalkylene linkage;

10 Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group $-NY^1Y^2$ may form a cyclic amine;

Y^4 and Y^5 are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, $-NY^1Y^2$, or one or more $-CO_2R^8$ or $-C(=O)-NY^1Y^2$ groups; or

15 the group $-NY^4Y^5$ may form a 5- to 7-membered cyclic amine which (i) may be optionally substituted with one or more substituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5-, 6- or 7-membered cyclic acetal derivative thereof), R^{10} ; (ii) may also contain a further heteroatom selected from O, S, SO_2 , or NY^6 ; and (iii) may also be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system;

20 Y^6 represents hydrogen, alkyl, aryl, arylalkyl, $-C(=O)-R^{14}$, $-C(=O)-OR^{14}$ or $-SO_2R^{14}$;

Z is an oxygen or sulphur atom;

Z^1 is $C(R^7)(R^{7a})$, $C(=O)$ or $CH(OH)$;

Z^2 is O , $S(O)_n$, NR^5 , $SONR^5$, $C(=O)NR^5$ or $C(=O)$;

Z^3 is a direct bond, $C(=O)$, $OC(=O)$, $NR^5C(=O)$, or SO_2 ;

25 m is an integer 1 or 2;

n is zero or an integer 1 or 2;

p is zero or an integer 1 to 4; and

Y is carboxy (or an acid bioisostere);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs, but excluding compounds where an oxygen, nitrogen or sulphur atom is attached directly to a carbon carbon multiple bond of an alkenylene, alkynylene or cycloalkenylene residue.

2. A compound according to claim 1 in which R¹ represents a group R³-Z³, in which Z³ is C(=O) and R³ is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted arylalkyl.

5 3. A compound according to claim 2 in which R³ is phenyl or phenyl substituted by one or two of aryloxy, cyano, halo, lower alkoxy, lower alkyl, nitro or CF₃.

4. A compound according to claim 2 in which R³ is isoquinoliny, isoxazolyl, pyrazolopyrimidinyl, pyridyl, pyrimidinyl, quinoliny, thiazolyl and triazolyl, each optionally substituted by one or two of alkylcarbonyl, aryl, cyano, halo, lower alkoxy, lower alkyl, lower alkylsulphonyl, lower alkylthio, nitro or CF₃.

10 5. A compound according to claim 2 in which R³ is benzyl optionally substituted in the phenyl ring by one or two of halo, hydroxy or methoxy.

15 6. A compound according to claim 2 in which R³ is 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl or 2-phenoxyphenyl.

20 7. A compound according to claim 1 in which R¹ represents a group R³-L³-Ar¹-L⁴-Z³, in which Z³ is C(=O), L⁴ is a straight or branched C₁₋₆alkylene chain, Ar¹ is optionally substituted phenylene or optionally substituted heteroaryldiy, L³ is an -NH-C(=O)-NH- linkage and R³ is optionally substituted aryl or optionally substituted heteroaryl.

25 8. A compound according to claim 7 in which L⁴ is methylene, Ar¹ is optionally substituted p-phenylene and R³ is optionally substituted phenyl.

9. A compound according to claim 8 in which Ar¹ is p-phenylene or p-phenylene substituted in the 3-position by halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylthio, C₁₋₄alkylsulphonyl or C₁₋₄alkylsulphonyl and R³ is phenyl substituted in the 2-position by C₁₋₄alkyl.

10. A compound according to claim 1 in which R^1 represents a group $R^3-L^3-Ar^1-L^4-Z^3$ in which Z^3 is $C(=O)$, L^4 is a straight or branched C_{1-6} alkylene chain, Ar^1 is an optionally

substituted 8 to 10 membered bicyclic system  in which ring  is a 5 or 6

membered heterocyclic ring, ring  is a 5 or 6 membered heterocycle or a benzene ring

5 and the two rings are joined together by a carbon-carbon linkage or a carbon-nitrogen linkage, L^3 represents NH and R^3 is optionally substituted aryl.

11. A compound according to claim 10 in which L^4 is methylene and Ar^1 is optionally substituted benzoxazolyl or optionally substituted benzimidazolyl.

10

12. A compound according to claim 11 in which Ar^1 is benzoxazolyl or benzimidazolyl each optionally substituted by one or more groups selected from lower alkyl, lower alkoxy, amino, halogen, hydroxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl, and R^3 is phenyl substituted in the 2-position by lower alkyl, lower alkoxy, halo or di C_{1-4} alkylamino.

13. A compound according to claim 1 in which R^1 represents a group $R^3-L^3-Ar^1-L^4-Z^3$ in which Z^3 is $C(=O)$, L^4 is a straight or branched C_{1-6} alkylene chain, Ar^1 is optionally substituted phenylene or optionally substituted heteroaryldiyl, L^3 is $-C(=O)-NH-$ and R^3 is heterocycloalkyl.

20

14. A compound according to claim 13 in which L^4 is methylene and Ar^1 is optionally substituted p-phenylene.

15. A compound according to claim 14 in which Ar^1 is p-phenylene or p-phenylene substituted in the 3-position by halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulphinyl or C_{1-4} alkylsulphonyl and R^3 is indolinyli.

16. A compound according to any preceding claim in which R^2 is hydrogen.

17. A compound according to any preceding claim in which A¹ is an unsubstituted straight chain C₁₋₃alkylene linkage.

18. A compound according to claim 17 in which A¹ is methylene.

5

19. A compound according to claim 17 in which A¹ is ethylene.

20. A compound according to any preceding claim in which Z¹ is CH₂, CHO or C(=O).

10 21. A compound according to claim 20 in which Z¹ is CH₂.

22. A compound according to any preceding claim in which L¹ is an optionally substituted alkylene linkage.

15 23. A compound according to claim 22 in which L¹ is ethylene or propylene, each optionally substituted by lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ and -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵ or alkyl substituted by carboxy or an acid bioisostere, -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵ (wherein R³, R⁵, R⁸, R⁹, R¹⁰, R¹¹, Y⁴, Y⁵, Z and P are as defined in claim 1).

20

24. A compound according to claim 22 in which L¹ is a group  where R⁵ is hydrogen or lower alkyl and R¹⁵ is hydrogen or lower alkyl, or where R⁵ is hydrogen and R¹⁵ is aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵, -[C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)]_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy or an acid

25 bioisostere, or by -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵ (wherein R³, R⁵, R⁸, R⁹, R¹⁰, R¹¹, Y⁴, Y⁵, Z and P are as defined in claim 1).

25. A compound according to claim 24 in which L^1 is a group $-\text{CH}-\text{CH}_2-$ where R^{15}

represents hydrogen, lower alkyl, aryl, heteroaryl, $-\text{N}(R^8)\text{-C}(=O)\text{-R}^9$, $-\text{N}(R^8)\text{-C}(=O)\text{-OR}^9$, $-\text{N}(R^8)\text{-SO}_2\text{-R}^9$ or $-\text{NY}^4\text{Y}^5$, or alkyl substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵ (wherein R³, R⁸, R⁹, Y⁴ and Y⁵ are as defined in claim 1).

5

26. A compound according to claim 24 in which L^1 is a group $-\text{CH}-\text{CH}_2-$ where R^{15}

represents hydrogen, lower alkyl, aryl, heteroaryl, $-\text{N}(R^8)\text{-C}(=O)\text{-R}^9$, $-\text{N}(R^8)\text{-C}(=O)\text{-OR}^9$, $-\text{N}(R^8)\text{-SO}_2\text{-R}^9$ or $-\text{NY}^4\text{Y}^5$, or alkyl substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵ (wherein R³, R⁸, R⁹, Y⁴ and Y⁵ are as defined in claim 1).

10

27. A compound according to claim 22 in which L^1 is a group $-\text{CH}_2-\overset{\text{R}^5}{\underset{\text{R}^{15a}}{\underset{\text{C}}{\text{C}}}}-$ where R^5 is

hydrogen or lower alkyl and R^{15a} represents lower alkyl, or where R^5 is hydrogen and R^{15a} represents aryl, heteroaryl, $-\text{N}(R^8)\text{-C}(=O)\text{-R}^9$, $-\text{N}(R^8)\text{-C}(=O)\text{-OR}^9$, $-\text{N}(R^8)\text{-SO}_2\text{-R}^9$, $-\text{NY}^4\text{Y}^5$, $-\text{[C}(=O)\text{-N}(R^{10})\text{-C}(R^5)(R^{11})]_p\text{-C}(=O)\text{-NY}^4\text{Y}^5$, or alkyl substituted by carboxy or an acid

15 bioisostere, or by -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵ (wherein R³, R⁵, R⁸, R⁹, R¹⁰, R¹¹, Y⁴, Y⁵, Z and P are as defined in claim 1).

28. A compound according to claim 27 in which L^1 is a group $-\text{CH}_2-\overset{\text{R}^{15a}}{\underset{\text{CH}}{\text{C}}}-$ where R^{15a}

represents $-\text{N}(R^8)\text{-C}(=O)\text{-R}^9$ or $-\text{N}(R^8)\text{-SO}_2\text{-R}^9$ (wherein R⁸ and R⁹ are as defined in claim 1).

20


29. A compound according to claim 27 in which L^1 is a group $-\text{CH}_2-\overset{\text{R}^{15a}}{\underset{\text{CH}}{\text{C}}}-$ where R^{15a}

represents $-\text{N}(R^8)\text{-C}(=O)\text{-R}^9$ or $-\text{N}(R^8)\text{-SO}_2\text{-R}^9$ (wherein R⁸ and R⁹ are as defined in claim 1).

30. A compound according to any preceding claim in which Y represents carboxy.

31. A compound according to claim 1 having the formula (Ia):-

5




in which R², R³, A¹, Ar¹, L¹, L⁴, Y and Z¹ are as defined in any relevant preceding claim, and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and

10 solvates of such compounds and their N-oxides and prodrugs.

32. A compound according to claim 1 having the formula (Ib):-

15




in which R², R³, A¹, L², Y and Z¹ are as defined in any relevant preceding claim, X is NR⁵ or O,

Z⁴ represents a direct bond, NR⁵, O or S(O)_n (where R⁵ and n are as defined in any relevant preceding claim), and R is hydrogen or an aryl group substituent, and the corresponding


20 N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

33. A compound according to claim 1 having the formula(Ic):-



in which Ar¹, L⁴, A¹, R², L¹, Y and Z¹ are as defined in any relevant preceding claim, and the
 5 corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates
 of such compounds and their N-oxides and prodrugs.

34. A compound according to claim 1 having the formula (Id):-



10

in which R³, A¹, R², L¹, Y and Z¹ are as defined in any relevant preceding claim, and the
 corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates
 15 of such compounds and their N-oxides and prodrugs.

35. A compound according to claim 31 in which R³ is phenyl substituted in the 2-position by
 C₁₋₄alkyl.

20 36. A compound according to any one of claims 31, 33 and 35 in which Ar¹ is p-phenylene or
 p-phenylene substituted in the 3-position by halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylthio,
 C₁₋₄alkylsulphonyl or C₁₋₄alkylsulphonyl.

37. A compound according to claim 32 in which R³ is phenyl substituted in the 2-position by
 25 lower alkyl, lower alkoxy, halo or diC₁₋₄alkylamino.

38. A compound according to claim 32 or claim 37 in which Z^4 represents NH.

39. A compound according to any one of claims 32, 37 and 38 in which R represents hydrogen, halo, lower alkyl or lower alkoxy.

5

40. A compound according to any one of claims 31, 32, 33 and 35 to 39 in which L^4 is a straight or branched C_{1-4} alkylene chain.

41. A compound according to claim 40 in which L^4 is methylene.

10

42. A compound according to claim 34 in which R^3 is phenyl or phenyl substituted by one or two of aryloxy, cyano, halo, lower alkoxy, lower alkyl, nitro or CF_3 .

15

43. A compound according to claim 34 in which R^3 is benzyl optionally substituted in the phenyl ring by one or two of halo, hydroxy or methoxy.

20

44. A compound according to claim 34 in which R^3 is 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl or 2-phenoxyphenyl.

25

45. A compound according to any one of claims 31 to 44 in which A^1 is an unsubstituted straight chain C_{1-3} alkylene linkage.

46. A compound according to claim 45 in which A^1 is methylene.

47. A compound according to claim 45 in which A^1 is ethylene.

48. A compound according to any one of claims 31 to 47 in which Z^1 is CH_2 .

30

49. A compound according to any one of claims 31 to 48 in which R^2 is hydrogen.

50. A compound according to any one of claims 31 to 49 in which L^1 is an optionally substituted alkylene linkage.

51. A compound according to claim 50 in which L^1 is ethylene or propylene, each optionally substituted by lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵ and -{C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)_p-C(=O)-NY⁴Y⁵ or alkyl substituted by carboxy or an acid bioisostere, -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵ (wherein R³, R⁵, R⁸, R⁹, R¹⁰, R¹¹, Y⁴, Y⁵, Z and p are as defined in claim 1).

10 52. A compound according to claim 50 in which L^1 is a group $\begin{array}{c} R^5 \\ | \\ -C-CH_2- \\ | \\ R^{15} \end{array}$ where R⁵ is

hydrogen or lower alkyl and R¹⁵ is hydrogen or lower alkyl, or where R⁵ is hydrogen and R¹⁵ is aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, -NY⁴Y⁵, -{C(=O)-N(R¹⁰)-C(R⁵)(R¹¹)_p-C(=O)-NY⁴Y⁵, or alkyl substituted by carboxy or an acid bioisostere, or by -ZH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵ (wherein R³, R⁵, R⁸, R⁹, R¹⁰, R¹¹, Y⁴, Y⁵, Z and p are as defined in claim 1).

53. A compound according to claim 52 in which L^1 is a group $\begin{array}{c} CH-CH_2- \\ | \\ R^{15} \end{array}$ where R¹⁵

represents hydrogen, lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵ (wherein R³, R⁸, R⁹, Y⁴ and Y⁵ are as defined in claim 1).

20 54. A compound according to claim 52 in which L^1 is a group $\begin{array}{c} CH-CH_2- \\ | \\ R^{15} \end{array}$ where R¹⁵

represents hydrogen, lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵ (wherein R³, R⁸, R⁹, Y⁴ and Y⁵ are as defined in claim 1).

55. A compound according to claim 50 in which L^1 is a group $—CH_2—C(\overset{R^5}{\underset{R^{15a}}{\mid}})—$ where R^5 is

hydrogen or lower alkyl and R^{15a} represents lower alkyl, or where R^5 is hydrogen and R^{15a} represents aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, $-NY^4Y^5$, $-[C(=O)-N(R^{10})-C(R^5)(R^{11})]_p-C(=O)-NY^4Y^5$, or alkyl substituted by carboxy or an acid

5 bioisostere, or by $-ZR^3$, $-C(=O)-NY^4Y^5$ or $-NY^4Y^5$ (wherein R^3 , R^5 , R^8 , R^9 , R^{10} , R^{11} , Y^4 , Y^5 , Z and p are as defined in claim 1).

56. A compound according to claim 55 in which L^1 is a group $—CH_2—CH(\overset{R^{15a}}{\underset{R}{\mid}})—$ where R^{15a}

represents $-N(R^8)-C(=O)-R^9$ or $-N(R^8)-SO_2-R^9$ (wherein R^8 and R^9 are as defined in claim 1).

10

57. A compound according to claim 55 in which L^1 is a group $—CH_2—CH(\overset{R^{15a}}{\underset{R}{\mid}})—$ where R^{15a}

represents $-N(R^8)-C(=O)-R^9$ or $-N(R^8)-SO_2-R^9$ (wherein R^8 and R^9 are as defined in claim 1).

58. A compound according to any one of claims 31 to 57 in which Y represents carboxy.

15

59. A compound of formula (Ia) according to claim 31 in which R^2 is hydrogen, R^3 is a 2-substituted phenyl, A^1 is methylene or ethylene, Ar^1 is optionally substituted m- or p-phenylene or optionally substituted p-pyridinediyl, L^1 is a $—CH(\overset{R^{15}}{\underset{R^{15}}{\mid}})CH_2—$ [where R^{15} represents

hydrogen, lower alkyl, aryl, heteroaryl, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$ or $-NY^4Y^5$, or alkyl substituted by carboxy (or an acid bioisostere), $-OH$, $-OR^3$, $-C(=O)-NY^4Y^5$],

20 L^4 represents a straight or branched C_{1-6} alkylene chain, Y represents carboxy and Z^1

represents CH_2 ; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

60. A compound of formula (Ia) according to claim 31 in which R^2 is hydrogen, R^3 is a 2-

25 substituted phenyl, A^1 is methylene or ethylene, Ar^1 is optionally substituted m- or p-phenylene


or optionally substituted p-pyridinediyl, L¹ is a $-\text{CH}_2-\underset{\substack{| \\ \text{R}^{15a}}}{\text{CH}}-$ group [where R^{15a} represents

-N(R⁸)-C(=O)-R⁹, or -N(R⁸)-SO₂-R⁹], L⁴ represents a straight or branched C₁-alkylene chain, Y represents carboxy and Z¹ represents CH₂; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their

5 N-oxides and prodrugs.

61. A compound of formula (Ib) according to claim 32 in which R is hydrogen, chloro, methyl, ethyl or methoxy, R² is hydrogen, R³ is optionally substituted aryl, A¹ is methylene or ethylene, L¹ is a $-\text{CH}-\underset{\substack{| \\ \text{R}^{15}}}{\text{CH}}-$ group [where R¹⁵ represents hydrogen, lower alkyl, aryl,


10 heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -OH, -ZR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵], L⁴ is a straight or branched C₁-4alkylene chain, X is O, Y is carboxy, Z¹ is CH₂, Z⁴ is NH, and the



15 N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

62. A compound of formula (Ib) according to claim 32 in which R is hydrogen, chloro, methyl, ethyl or methoxy, R² is hydrogen, R³ is optionally substituted, A¹ is methylene or ethylene, L¹ is a $-\text{CH}_2-\underset{\substack{| \\ \text{R}^{15a}}}{\text{CH}}-$ group [where R^{15a} represents -N(R⁸)-C(=O)-R⁹ or -N(R⁸)-SO₂-R⁹], L⁴ is a straight or branched C₁-4alkylene chain, X is O, Y is carboxy, Z¹ is


20 CH₂, Z⁴ is NH, and the group $-\text{L}^4-\underset{\substack{| \\ \text{O}}}{\text{C}}-\text{L}^1-\text{Y}$ is attached at the ring 6 position;



and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

63. A compound of formula (Ib) according to claim 32 in which R² is hydrogen, R³ is 5 optionally substituted, A¹ is methylene or ethylene, L¹ is a $\text{---CH}_2\text{---CH}_2\text{---}$ group [where R¹⁵ $\overset{\text{15}}{\underset{\text{R}}{\text{---}}}$


represents hydrogen, lower alkyl, aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl substituted by carboxy (or an acid bioisostere), -OH, -OR³, -C(=O)-NY⁴Y⁵ or -NY⁴Y⁵], L⁴ is a straight or branched C₁₋₄alkylene chain, X is NR⁵, Y is



10 ring 5 or 6 position; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

64. A compound of formula (Ib) according to claim 32 in which R² is hydrogen, R³ is 5 optionally substituted aryl, A¹ is methylene or ethylene, L¹ is a $\text{---CH}_2\text{---CH}_2\text{---}$ group [where R^{15a} $\overset{\text{15a}}{\underset{\text{R}}{\text{---}}}$

15 R^{15a} represents -N(R⁸)-C(=O)-R⁹ or -N(R⁸)-SO₂-R⁹], L⁴ is a straight or branched C₁₋₄alkylene chain, X is NR⁵, Y is carboxy, Z¹ is CH₂, Z⁴ is NH, and the group



N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

20 65. A compound of formula (Ic) according to claim 33 in which R² is hydrogen, A¹ is methylene or ethylene, Ar¹ is optionally substituted m- or p-phenylene or optionally substituted

p-pyridinediyl, L¹ is a $\text{---CH}_2\text{---CH}_2\text{---}$ group [where R¹⁵ represents hydrogen, methyl, aryl,

₁₅

heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl

substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵], L⁴ is a straight or branched

C₁₋₄alkylene chain, Y is carboxy and Z¹ is CH₂; and the corresponding N-oxides, and their

5 prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs.

66. A compound of formula (Ic) according to claim 33 in which R² is hydrogen, A¹ is

methylene or ethylene, A¹ is optionally substituted m- or p-phenylene or optionally substituted

10 p-pyridinediyl, L¹ is a $\text{---CH}_2\text{---CH}_2\text{---}$ group [where R^{15a} represents -N(R⁸)-C(=O)-R⁹ or

_{15a}

-N(R⁸)-SO₂-R⁹], L⁴ is a straight or branched C₁₋₄alkylene chain, Y is carboxy and Z¹ is CH₂;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

15 67. A compound of formula (Id) according to claim 34 in which R² is hydrogen, R³ is
optionally substituted phenyl, optionally substituted heteroaryl or optionally substituted benzyl,
A¹ is methylene or ethylene, L¹ is a $\text{---CH}_2\text{---CH}_2\text{---}$ [where R¹⁵ represents hydrogen, methyl,

₁₅

aryl, heteroaryl, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹ or -NY⁴Y⁵, or alkyl

substituted by carboxy, -OH, -OR³ or -C(=O)-NY⁴Y⁵], Y is carboxy and Z¹ is CH₂; and the

20 corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

68. A compound of formula (Id) according to claim 34 in which R² is hydrogen, R³ is
optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted benzyl,


25 A¹ is methylene or ethylene, L¹ is a $\text{---CH}_2\text{---CH}_2\text{---}$ group [where R^{15a} represents

_{15a}


-N(R⁸)-C(=O)-R⁹ or -N(R⁸)-SO₂-R⁹], Y is carboxy and Z¹ is CH₂; and the corresponding

N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

69. A compound according to any one of claims 60, 62, 64, 66, and 68 in which L¹ is a group



70. A compound according to any one of claims 61, 63, 65 and 67 in which L¹ is a group



10 71. A compound according to claim 70 in which R¹⁵ represents hydrogen.

72. A compound according to claim 70 in which R¹⁵ represents lower alkyl.

15 73. A compound according to claim 70 in which R¹⁵ represents optionally substituted phenyl.

74. A compound according to claim 70 in which R¹⁵ represents -N(R⁸)-C(=O)-R⁹ where R⁸ is hydrogen or lower alkyl and R⁹ is lower alkyl, aryl, heteroaryl, alkyl substituted by alkoxy, alkyl substituted by carboxy or alkyl substituted by -NY⁴Y⁵.

20 75. A compound according to claim 70 in which R¹⁵ represents -N(R⁸)-C(=O)-OR⁹ where R⁸ is hydrogen or lower alkyl and R⁹ is lower alkyl or alkyl substituted by aryl.

76. A compound according to claim 70 in which R¹⁵ represents -N(R⁸)-SO₂-R⁹ where R⁸ is hydrogen or lower alkyl and R⁹ is lower alkyl, aryl, heteroaryl.

77. A compound according to claim 70 in which R¹⁵ represents -NY⁴Y⁵ where Y⁴ and Y⁵ represent hydrogen.

78. A compound according to claim 70 in which R^{15} represents $-NY^4Y^5$ where Y^4 is hydrogen and Y^5 is lower alkyl or alkyl substituted by aryl.

79. A compound according to claim 70 in which R^{15} represents $-NY^4Y^5$ where Y^4 and Y^5 represent alkyl substituted by aryl.


80. A compound according to claim 70 in which R^{15} represents lower alkyl substituted by carboxy.


10 81. A compound according to claim 70 in which R^{15} represents lower alkyl substituted by $-OH$.

82. A compound according to claim 70 in which R^{15} represents lower alkyl substituted by $-OR^3$.

15 83. A compound according to claim 70 in which R^{15} lower alkyl substituted by $-C(=O)-NY^4Y^5$.

84. A compound according to claim 70 in which R^{15} represents $-H$, $-NH_2$,





85. A compound according to claim 69 in which R^{15a} represents -N(R⁸)-C(=O)-R⁹ where R⁸ is hydrogen or lower alkyl and R⁹ is lower alkyl, aryl, heteroaryl, alkyl substituted by alkoxy, alkyl substituted by carboxy or alkyl substituted by -NY⁴Y⁵.

86. A compound according to claim 69 in which R^{15a} represents -N(R⁸)-C(=O)-R⁹ where R⁸ is hydrogen or lower alkyl and R⁹ is selected from 2-chlorophenyl, 5-chloro-2-cyanophenyl, 2-chloro-6-methylphenyl, 2,6-dichlorophenyl, 2,6-difluorophenyl, 4-fluoro-2-trifluoromethyl, 2-methyl-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2-nitrophenyl, 3-nitrophenyl and 2-phenoxyphenyl.

87. A compound according to claim 69 in which R^{15a} represents -N(R⁸)-C(=O)-R⁹ where R⁸ is hydrogen or lower alkyl and R⁹ is selected from quinolin-4-yl, isoquinolin-2-yl, 2,4-pyridin-3-yl, 2,6-dimethyl-4-trifluoromethylpyridin-3-yl, 4-trifluoromethylpyridin-3-yl, 2-phenyl-4-methyl-

1,2,3-triazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2,7-dimethylpyrazolo-[1,5-a]pyrimidin-6-yl, 2-isopropyl-4-methylthiazol-5-yl and 4-trifluoromethylpyrimidin-5-yl.

88. A compound according to claim 1 selected from:-

5 3-(1-{[3-methoxy-4-(3-[2-methylphenyl]-ureido)-phenyl]-acetyl}-1,2,3,4-tetrahydro-quinolin-6-yl)-propionic acid;

3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-2,3-dihydro-1H-indol-5-yl)-butyric acid;

3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-1,2,3,4-tetrahydro-quinolin-6-yl)-butyric acid;

10 3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-2,3-dihydro-1H-indol-5-yl)-pentanedioic acid;

3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-1,2,3,4-tetrahydro-quinolin-6-yl)-pentanedioic acid;

4-[2-carboxy-1-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-1,2,3,4-tetrahydro-quinolin-6-yl)-ethyl]carbamoyl]-butyric acid;

15 N-[2-carboxy-1-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-1,2,3,4-tetrahydro-quinolin-6-yl)-ethyl]-succinamic acid;

3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-1,2,3,4-tetrahydro-quinolin-6-yl)-3-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionic acid;

20 2-(2-chloro-6-methyl-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid;

2-(2,6-dichloro-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic acid;

3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-2,3-dihydro-1H-indol-5-yl)-3-phenyl-propionic acid;

25 3-(1-{[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-2,3-dihydro-1H-indol-5-yl)-pentanoic acid; and the corresponding N-oxide, and its prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

30 89. Intermediate compounds of formulae (IV), (IX) and (2).

90. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof; or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof, in association with a pharmaceutically acceptable carrier or excipient.

91. A compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof; or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof for use in therapy.

5 92. A compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof; or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

10 93. A composition according to claim 90 for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

15 94. A compound or composition according to claim 1 or 90 respectively for use in the treatment of inflammatory diseases.

95. A compound or composition according to claim 1 or 90 respectively for use in the treatment of asthma.

20 96. Use of a compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof; or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof in the manufacture of a medicament for the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

25 97. Use of a compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof; or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof in the manufacture of a medicament for the treatment of asthma.

30 98. A method for the treatment of a human or non-human animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof; or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof.

35

99. A compound as substantially herein before described with references to the Examples.

INTERNATIONAL SEARCH REPORT

Int'l. Application No.
PCT/GB 99/02819

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07D209/12	A61K31/395	C07D215/14	C07D405/04	C07D413/12
	C07D215/08	C07D401/12	C07D413/06		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 07716 A (THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY) 26 February 1998 (1998-02-26) * example LIV or page 32, scheme XV, compound 121; page 70, line 24 or page 31, scheme XIV, compound 113 *	1
X	STJEPAN KUKOLJA ET AL.: "Orally absorbable cephalosporin antibiotics. 2. Structure-activity studies of bicyclic glycine derivatives of 7-aminodeacetoxycephalosporanic acid." JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 12, - 1985 pages 1896-1903, XP002126291 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 * page 1897 and 1901: compound 22 *	1

-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general subject matter which is not considered to be of particular relevance

"E" earlier document not published on or after the International filing date

"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention can be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention can be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the International search

20 December 1999

Date of mailing of the International search report

11/01/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5018 Patentbox 2
NL-2280 RY Rijswijk
Tel: (+31-70) 340-2040, Tx: 81 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02819

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 042 298 A (MAY & BAKER LTD.) 23 December 1981 (1981-12-23) * page 106, example 96 *	1
X	CHEMICAL ABSTRACTS, vol. 127, no. 11, 15 September 1997 (1997-09-15) Columbus, Ohio, US; abstract no. 149061u, KOHNO, YASUSHI ET AL.: "Synthesis and antirheumatic activity of novel tetrahydro-6-quinolineacetic acid derivatives." XP002126292 abstract -& DATABASE CHEMICAL ABSTRACTS 'Online' CA 127:149061, XP002126293 compounds with RN 193292-76-1 and -74-9 & BIOORG. MED. CHEM. LETT., vol. 7, no. 12, - 1997 pages 1519-1524, _____	89
A	US 5 688 913 A (THOMAS S. ARRHENIUS ET AL.) 18 November 1997 (1997-11-18) column 4 -column 6 _____	1,90,92
A	EP 0 842 945 A (HOECHST AG) 20 May 1998 (1998-05-20) claims 1,20 _____	1,90,92

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/02819

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims No.: **98**
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 98
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. Claims No.: **1-89 (partly)**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims No.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims No.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims No.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 99 02819

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-89 (partly)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty of compounds of formula (I) as well as of intermediate compounds (claim 89). So many documents were retrieved that it is impossible to determine which parts of claim 1 may be said to define subject-matter for which protection might be legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of claim 1 and of claim 89 is impossible. Consequently, the search strategy has been further limited to compounds having the required activity, i.e. compounds " which modulate the interaction of the ligand VCAM-1 with its integrin receptor alpha4beta1 (VLA-4) ".

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/GB 99/02819

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9807716	A	26-02-1998	AU 4080597 A	06-03-1998
EP 42298	A	23-12-1981	AT 9329 T AU 539678 B AU 7186481 A CA 1149811 A DK 264281 A ES 503097 A ES 512704 A ES 512705 A ES 512706 A FI 811889 A GB 2078736 A,B GR 75701 A HK 92485 A HK 92684 A IE 52102 B IL 63110 A JP 57028048 A KR 8501470 B KR 8501550 B KR 8501549 B MY 97585 A MY 40986 A NZ 197441 A PH 16357 A SG 68984 G SG 73085 G US 4493943 A ZA 8104057 A	15-09-1984 11-10-1984 24-12-1981 12-07-1983 19-12-1981 01-10-1982 01-02-1983 01-02-1983 01-04-1983 19-12-1981 13-01-1982 02-08-1984 29-11-1985 30-11-1984 24-06-1987 31-10-1986 15-02-1982 10-10-1985 17-10-1985 17-10-1985 31-12-1985 31-12-1986 09-11-1984 05-09-1983 15-03-1985 02-05-1986 15-01-1985 28-07-1982
US 5688913	A	18-11-1997	AU 693143 B AU 1215695 A CA 2177840 A CN 1142832 A EP 0737204 A JP 9509146 T NZ 277206 A WO 9515973 A US 5821231 A US 5770573 A US 5936065 A	25-06-1998 27-06-1995 15-06-1995 12-02-1997 16-10-1996 16-09-1997 24-11-1997 15-06-1995 13-10-1998 23-06-1998 10-08-1999
EP 842945	A	20-05-1998	DE 19647381 A AU 4515597 A CA 2220777 A CN 1182746 A CZ 9703601 A HR 970604 A HU 9702036 A JP 10158298 A NO 975246 A NZ 329176 A PL 323129 A SK 152797 A	20-05-1998 21-05-1998 15-05-1998 27-05-1998 17-06-1998 31-08-1998 28-07-1998 16-06-1998 18-05-1998 29-03-1999 25-05-1998 03-06-1998